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INTERPERSONAL PSYCHOTHERAPY, 
MIRTAZAPINE AND DOPAMINE D2 RECEPTORS 
IN TREATMENT RESISTANT MAJOR DEPRESSION 
ELIZABETH ROBINSON 
Twenty DSM-IV major depressed patients who had not responded to at least one 
previous trial of antidepressant therapy at an adequate dose and duration agreed 
to participate in this study. They were randomly assigned to receive either 
mirtazapine (30-45mg) alone or in combination with 16 sessions of weekly 
Interpersonal psychotherapy (IPT). The patients were followed up naturalistically 
for one year, during this time the psychotherapy sessions were delivered 
monthly. Blinded clinician ratings and self ratings were obtained for depression 
(Hamilton Depression Scale (HamD), Beck Depression Inventory (BDI)), anxiety 
(Hamilton Anxiety Scale (HAS)), and social functioning (Social Adaptation Scale) 
at baseline, 6, 16, 26 and 52 weeks. 
1123 lodobenzamide Single Photon Computed Emission Tomography (IBZM 
SPECT) scans measured striatal dopamine D2 receptor activity at baseline and 
after 6 weeks of treatment. 
A two way repeated measures analysis of variance (ANOVA) detected significant 
effects measured by the HamD and HAS for time (p= 0.001; p= 0.001 
respectively), treatment (p= p= 0.007; p= 0.033) and the interaction between the 
two (p = 0.007; p = 0.044). Significant differences emerged between the two 
groups by six months and continued to one year follow up favouring the IPT 
group (HamD, p= 0.033; HAS, p= 0.003). The only significant effects for the BDI 
were for time (p= 0.001 ). There were no statistically significant effects measured 
by the SAS. 
A 3-way repeated measures ANOVA on the IBZM SPECT data detected a 
significant interaction between Time X Hemisphere, demonstrated by a higher 
IBZM uptake in the striatum in non-responders (p=0.013, agitated patients (p= 
0.045) and women (p= 0.012). The same interaction effects were noted in 
patients with a high level of resistant depression (p= 0.001 ). 
This preliminary study shows promising initial results for IPT in resistant 
depression. There is some evidence to support a role for dopamine in treatment 
resistant depression. 
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Chapter One - Introduction 
This chapter provides a summary of all of the chapters covered in this 
thesis. A review of current literature on treatment resistant depression 
(TRD}, interpersonal psychotherapy (IPT) for depression and the role of 
dopamine in depression, including an overview of functional brain 
imaging of dopamine receptors will be presented. This will lead on to a 
description of two parts of a clinical research trial. Firstly, the effects of 
IPT combined to the antidepressant mirtazapine are compared to 
mirtazapine alone in participants with treatment resistant depression. 
Secondly, there are functional brain imaging scans of the dopamine D2 
receptors in the above group, pre-treatment and 6 weeks post-treatment 
Treatment resistant depression (TRD) 
Depression is a debilitating illness and has a lifetime prevalence of 
around 17% (Kessler et al, 1994 ). Although many patients respond to 
antidepressant treatment there is a range of about 17% (Robbins et al, 
1991) to 50% (Hirshfield et al, 2002) of patients who do not respond to 
initial antidepressant treatment. This lack of response to treatment, or 
treatment resistance accounts for approximately one third of patients 
with major depressive disorder (Dinan, 1993; Burrows et al, 1994; Kleine 
et al, 2004). Despite a growing interest regarding treatment resistant 
depression in the scientific community, there is a lack of consensus in 
the literature regarding how best resistant depression should be defined. 
Numerous definitions have been suggested, most of which generally 
focus on antidepressant treatment and duration of therapy (Souery et al, 
1999). Literature reviewed in this chapter regarding treatment resistant 
depression includes patients who do not respond to treatment, partial 
responders or patients with chronic depression. Providing these patients 
are receiving antidepressant treatment at a therapeutic dose for an 
appropriate period of time and yet still remain symptomatic, they are to 
be considered resistant to treatment As some patients require multiple 
antidepressant medications pr combinations with neuroleptic medicati~n 
7 
while others respond after just two or three different antidepressants 
indicates a spectrum of non response or treatment resistance. The lack 
of an agreed definition regarding treatment resistant depression makes 
interpretation of research in this area difficult and reduces the 
generalisabilty of the finding~. 
The impact of Treatment resistant depression 
The economics of treatment resistant depression will be considered. 
Major depression has been found to be associated with increasing health 
and social care costs, however, costs for the employer of patients with 
treatment resistant depression have been found to be 3.5 times that of 
normal comparison employees, and double that of major depression 
(Greenberg et al, 2004). Furthermore, costs increase with increasing 
resistance to treatment (Russell et al, 2004). 
The personal impact on an' individual suffering from major depression 
cannot be underestimated. For example, suicide is a serious concern in 
major depression as around 15% of patients with major depression 
commit suicide (APA, 2004). Within the context of resistant depression, 
there is an increased preoccupation with suicidal ideation compared to 
patients with major depression (Papakostas et al, 2003a). Furthermore, 
there is an increased risk of suicide reported in partial responders 
(Fawcett, 1990) and an increased incidence of suicide and 
hospitalisations reported in chronic depression (Van Vulkenberg et al, 
1984; Coryell et al, 1988; Klein et al, 1988; 1998). 
Patients with treatment resistant depression have been found to have 
more problems relating to psychosocial adjustment (Petersen et al, 
2004), additionally, chronic depression is reported to be more 
psychosocially disabling than some medical conditions including arthritis, 
diabetes and hypertension (Hays et al, 1995). Indeed mild or moderate 
depression has been associated with work impairment (Petersen et al, 
2004). 
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Risk factors which contribute or increase the risk of resistant depression 
will be reviewed including family history (Nelsen and Dunner, 1995), 
psychotic depression (Lee and Murray, 1988; Aronson, 1988) initial slow 
responders to treatment, and poor or non responders (Boyer and 
Feigner, 1994; Neirneberg et al, 1995). Comorbid psychiatric disorders 
including anxiety and panic attacks (Dubovsky et al, 2005; Rosenbaum 
et al, 2001 ), double depression, that is major depression alongside 
dysthymic disorder (Keller and Shapiro, 1982) and personality disorders 
' . (DeBattista and Muella, 2001; Black et al, 1991; Papakostas et al, 
2003b) will be presented. Comorbid medical conditions are also 
reviewed including thyroid abnormalities (Prange et al, 1996), heart 
disease (Carney et al, 1993; Harnett, 1994), and urea and electrolyte 
imbalances (Franco-Bronson, 1996). 
Brain imaging in treatment resistant depression 
There are a small number of studies evaluating the functioning and 
structure of the brain in patients with treatment resistant depression. 
Three studies which used Single Photon Emission Computed 
Tomography (SPECT) fourtd increased hippocampal amygdala activity 
(Hornig et al, 1997), increased blood flow in the left dorsolateral 
prefrontal cortex post treatment (Zheng et al, 2000), and reduced blood 
flow bilaterally in the frontal regions of the brain (Conca et al, 2002). 
Structural changes as measured by Magnetic Resonance lmaging (MRI) 
scans demonstrate right striatal atrophy (Shah et al, 2002), changes in 
frontal lobe volumes (Coffey et al, 1993) and white (Steffens et al, 2001) 
and grey matter hyperintensities (Hickie et al, 1995). 
Treatment options in treatment resistant depression 
Treatment options which have been suggested and reviewed in the 
• 
literature· will be presented. There are a greater number of 
pharmacological approaches for treatment resistant depression reviewed 
in the literature than psychotherapy. Pharmacotherapy options include 
switching or combining antidepressant medications; alternatively another 
approach is to augment the antidepressant with a different agent 
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including the mood stabilisers lithium (Bauer, 2003) and lamotrigine 
(Barbosa et al, 2003), low dose atypical antipsychotic medication (Thase 
et al, 2004), thyroid hormone augmentation (Aronson et al, 1996), or 
pindolol (Artigas et al, 1994; Perez et al, 1997). There are also a small 
number of studies which evaluate the efficacy of biological treatments 
such as electroconvulsive therapy (ECT) (Sackheim et al, 1993), 
transcranial magnetic stimulation (TMS) (George et al, 1999) and vagus 
nerve stimulation (VNS) (Rush et al, 2000). 
The literature reviewing psychotherapy in treatment resistant depression 
is sparse. The use of a psychoeducational group (Antonuccio et al, 1984) 
' . . 
and cognitive behaviour therapy (CBT) has been useful in non 
responders (Fava et al, 1996; 1998; Barker et al, 1998). Positive results 
have been obtained in partial responders with Interpersonal 
Psychotherapy (IPT) (Scocco and Frank, 2002; Frank, 2000) and CBT 
(Fava et al, 1996; Paykel et al, 1999). Most of the literature published 
concerns psychotherapeutic approaches used in the management of 
chronic depression. The majority of the evidence suggests either IPT 
(Markowitz, 2003; Feijo de Mello, 2001; Browne et al, 2002); CBT (Thase 
et al 1997; Moore and Blackburn, 1997; Ravidran, 1999) or a more 
recently devised psychotherapy called Cognitive Behavioural Analysis 
System of Psychotherapy (GBASP) (Keller et al 2000) for this treatment 
group. Other psychotherapies including group psychotherapy 
(Hellerstein, 2001 ), Problem Solving Therapy (PST) and counselling are 
evaluated. A significant number of psychotherapy studies have involved 
open trials and been hampered by small numbers, a lack of a control 
condition, or a placebo. IPT has not been tested for tolerability, feasibility 
or efficacy in treatment resistant depression. 
There are limited data evaluating treatment approaches in resistant 
depression. Although there is a growing body of literature reviewing a 
pharmacological approach, there is a paucity of information relating to 
• 
the use of a psychotherapeutic approach in resistant depression. The 
efficacy of IPT in treatment resistant depression has not been evaluated. 
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The burden of resistant depression is great and has an impact on the 
sufferers' personal, work and social relations. Moreover, the risk of 
suicide, the economic implications and potential course of the disorder if 
untreated or inadequately treated cannot be ignored. Further research is 
needed to establish which treatments work for whom, taking into account 
the spectrum of treatment resistant depression. 
Interpersonal Psychotherapy 
Interpersonal Psychotherapy (IPT) is a manualised brief psychotherapy 
treatment which was developed initially to treat major depression 
(Kierman et al, 1984). In this chapter the author will provide an overview 
of IPT, describing the three phases of treatment; the initial, middle and 
the end phase and will provide an overview of the goals and strategies of 
treatment. The literature detailing the efficacy of IPT in depression during 
• 
acute, continuation and maintenance therapy across all age groups 
(DiMascio et al, 1979; Weissman et al, 1979; Elkin et al, 1989; Sloane et 
al, 1985; Rothrum et al, 1982; Mufson et al, 1999) will be reviewed. The 
use of IPT in patients with highly recurrent depressive episodes (Frank et 
al, 1989) and combined IPT and antidepressant medication (Kierman et 
al, 1974; Weissman et al, 1974; Reynolds et al, 1994) will also be 
evaluated. 
Adaptations of IPT will be presented including IPT as maintenance 
therapy (Frank et al, 1989), treatment for dysthymia (Markowitz, 1998a); 
depression and concurrent •medical conditions including heart disease 
(Miller, 2002; Stuart and Cole, 1996) and HIV positive patients 
(Markowitz et al, 1995) and IPT for post partum (O'Hara et al, 2000) 
and antepartum depression (Spinelli, 1997; Spinelli and Endicott, 2003). 
Additionally, the delivery of IPT either by telephone (Miller and 
Weissman, 2002) or as a group (MacKenzie and Grabovac, 2001; 
Levkovitz et al, 2001) will be outlined. Data from a small number of 
studies which have evaluated biological correlates of treatment with IPT 
in depression, involving functional neuroimaging studies (Martin et al, 
1'1 
2001; Brody et al, 1999; 2001) and sleep studies (Reynolds et al, 1997) 
will be reviewed. 
Dopamine hypothesis of depression 
The monoamines are chemical neurotransmitters which include 
serotonin, noradrenaline and dopamine, all of which have been 
implicated in at least subtending if not causing depression. A review of 
the evidence which supports the dopamine hypothesis of depression w.ill 
be presented, including areas of concentrations of dopamine in the brain 
and the three dopaminergic pathways by which dopamine is transmitted; 
the nigrostriatal pathway, the mesolimbic (mesocortica/ or 
mesocorticolimbic) pathway and the tubero-infundibular pathway. This 
chapter will then focus on various lines of evidence supporting the role of 
dopamine in depression; this includes changes in dopamine levels 
(Birkmayer and Riederer, 1975; Manji et al, 2001; Rajkowska, 2000) or 
its metabolite, homovanillic acid (HVA) (Traskman-Bandz et al, 1984) as 
well as alterations in the dopamine transporter system (DA T) (Weintraub 
et al, 2005) in the brain and in the cerebral spinal fluid of depressed 
• patients compared to controls. 
Additionally, further evidence for the role of dopamine in depression is 
outlined in terms of identifying the mechanism of action and alterations in 
dopamine function following treatment with either antidepressant 
medication (Arbuthnott, In Johnson et al, 1998; Johnson, In Fiegner and 
Boyer, 1991) or electroconvulsive therapy (ECT) (Puri and Hall, 2004). 
The introduction of Single Photon Emission Computed Tomography 
(SPECT) brain functional imaging scanning procedures using 
radiopharmaceuticals is a technological advance which allows in vivo 
assessment of brain neurotransmitters, blood flow and glucose 
metabolism. A brief introduction to the techniques of SPECT and a 
review of the literature of dopamine in depression will be presented. 
Dopamine function is assessed with the use of the radioligand 1123 
lodobenzamide (IBZM) which binds to the dopamine 02 I 03 receptors 
reflecting dopaminergic functioning. Although there is a paucity of 
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literature in this area, dopamine abnormalities demonstrated by 
increased (Shah et al, 1997; D'haenen and Bossyut, 1994) or decreased 
IBZM binding (Kiimke et al, 1999) have been identified in depression. 
Only two studies have assessed the sequential effects of antidepressant 
treatment either with an SSRI (Kiimke et al, 1999) or total sleep 
deprivation (Ebert et al, 1994 ), reduced initial IBZM uptake has been 
reported in treatment responders when compared to controls and 
nonresponders (Kiimke et al, 1999). The author will discuss limitations of 
previous studies including heterogeneity of patients studied, different 
scanning methods, different treatments and varying methods of 
interpreting the results. 
Thesis study 1: Interpersonal Psychotherapy for treatment resistant 
depression a parallel trial 
IPT has proven efficacy for major depression in all age groups (Eikin et 
al, 1989; Reynolds et al, 1996; Mufson and Fairbanks, 1996) and in 
dysthymic adults (Markowitz et al, 1998; Browne et al, 2002). There have 
been no clinical trials to date which have reviewed the efficacy of IPT in a 
resistant depressed population. This parallel group trial aimed to 
evaluate the effects of IPT combined with the antidepressant mirtazapine 
versus mirtazapine alone. 
Participants 
Following informed consent, twenty major depressed participants 
according to DSM IV criteria (American Psychiatric Association, 1994) 
who had not responded to at least six weeks of antidepressant therapy 
at an adequate dose were randomised to mirtazapine (30-45mg daily) 
alone or combined with 16 sessions of weekly IPT. They were then 
followed up naturalistically for one year; participants who were 
randomised to receive IPT continued to do so for one year at a monthly 
maintenance dose. 
Participants came from the Sunderland area and were recruited from 
GP's and psychiatrists from March 2000 to June 2001. Participants with 
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a concurrent diagnosis of dysthymia or anxiety disorders were included 
in the trial. However, participants with psychotic depression, or current 
alcohol/ drug abuse were excluded from the trial. 
Clinical measurements 
A blinded clinical rater obtained baseline measurements of depression 
and anxiety using the 21 item Hamilton Depression Scale (Hamilton, 
1960) and 14 item Hamilton Anxiety Scale (Hamilton, 1969); the rater 
also asked the participants to complete the Beck Depression Inventory 
(Beck, 1987) and Social Adaptation Scale (Weissman, 1976). These 
measurements were repeated at week 6, 16, 26 and 52. At baseline the 
author completed the Structured Clinical Interview (DSM-IV) and 
recorded details of previous depressive episodes including 
antidepressant treatment and response. 
Demographic details 
An equal number of males and females were recruited and were aged 
28-52 (mean 39.5, SO 7.24). Most of the participants had left school 
without any qualifications, and a large proportion of this group were 
randomly allocated to the IPT and mirtazapine group (9 vs. 5). There 
were only a minority of participants who had professional (n=2), or 
further education (n=2) qualifications; all of these participants were all 
assigned the mirtazapine only group. 
Nearly all (n=9/1 0) of the combined IPT and mirtazapine group were out 
of work, the remaining participant was employed in unskilled work; 
whereas only half of the mirtazapine only group were not working and 
most of the remaining participants (4/5) were in skilled employment. 
There were more divorcees in the combined group compared to the 
mirtazapine only group (4 vs. 1 ). 
Depression 
The duration of the current major depressive episode in the total group 
ranged from 2.5-42 months (mean 17.05, SO 12.05). The medication 
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only group had experienced eight months longer symptoms of 
depression during their current index episode (mean 21.05, SO 10.06 vs. 
mean 12.93, SO 12.05). The total number of months of depression over 
a lifetime in the total group ranged from 12 to more than 300 months and 
was 26 months longer in the combined IPT and mirtazapine group (mean 
67.8, SO 88.3 vs. mean 41.4, SO 21.62). From the total sample, 
• 
fourteen participants had a concurrent diagnosis of dysthymic disorder 
which was more heavily distributed in the combined group (8 vs. 4). The 
numbers of previously failed antidepressant treatments were similar in 
both groups (combined treatment, mean 2.6, SO 2.6 vs. monotherapy, 
mean 2.3, SO 1.15). Depression scores at baseline were similar in both 
groups with the Hamilton Depression Scale (mirtazapine plus IPT 29.7, 
SO 5.69 vs. mirtazapine 29.4, SO 4.03); and were slightly lower with the 
self rated Beck Depression Inventory with the mirtazapine only group 
(39.6, so 8.57 vs. 33.2, so 3.22) 
Interpersonal psychotherapy 
IPT was delivered as per manual for acute (Kierman et al, 1984) and 
maintenance treatment (Frank et al, 1989) by two research trained IPT 
therapists. Sixteen sessions of IPT (mean 11.3, range 7-17) were 
provided for the acute phase, followed by monthly IPT sessions (mean 
5.8, range 3-12) for reminder of the year. IPT sessions were audiotaped 
and monitored for adherence by two raters. There were only two out of a 
possible four problems areas addressed during either acute or 
maintenance sessions; role transition and role dispute, both of which are 
the most common areas of focus in IPT. There were no participants 
requiring therapy for interpersonal deficit or complicated bereavement. 
• 
Mirtazapine 
Mirtazapine is a "new" generation antidepressant which is classified as a 
noradrenergic and serotonergic antidepressant (NaSSA). Its principle 
action is to block the presynaptic alpha 2 receptors resulting in an 
increase in noradrenaline in synaptic clefts through the inhibition of the 
reuptake of noradrenaline. This also leads to an increase in stimulation 
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and release of serotonin (DeBoer et al, 1996). Additionally, animal 
studies show that mirtazapine increases extracellular dopamine and 
noradrenaline in the medial prefrontal cortex (Devoto et al, 2004; 
Nakayama et al, 2004; Millan et al, 2000). 
Participants were prescribed a daily dose of 30-45mg of mirtazapine. 
Compliance was monitored using the pharmacy returns. Taking into 
account the prescribed dose and medication returns the mean dose of 
both groups were 31.3mg in the mirtazapine and IPT group versus 
• 
34.7mg ih the mirtazapine only group. By today's standards these are 
relatively low/ moderate doses of mirtazapine, however this study took 
place in 2000/2001. Dosing schedules of the present day may be higher 
for patients who are resistant to treatment. 30mg of mirtazapine is 
efficacious for most depressed patients and we were not aiming to do a 
dose ranging study. 
Thesis study 2: Sequential dopamine 02 receptor mapping in 
treatment resistant depression 
1123- lodobenzamide (IBZM} is a radioligand which has a strong affinity 
for the neurotransmitter dopamine, specifically the subtype dopamine 02 
receptor. Following intravenous administration, the radioligand 
increasingly binds to the dopamine 02 receptor sites and emits a single 
photon of gamma radiation. This is detected using Single Photon 
Emission Computed Tomography (SPECT) imaging. These in vivo 
functional brain scans can give us some insight into the functional 
dopaminergic activity in depressed participants; this may be correlated to 
specific symptoms of depression or indeed response to antidepressant 
treatment. 
Design 
This design involves a parallel group study comparing IBZM SPECT 
before and after 6 weeks of treatment with mirtazapine alone or 
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mirtazapine plus Interpersonal Psychotherapy m treatment resistant 
depressed participants. 
Method 
The 20 participants in this study have already been described in the IPT 
trial. A further three participants had originally consented to the trial 
withdrew consent before the start of the trial for "personal reasons". 
This clinical trial comprising thesis studies 1 and 2 received ethical 
approval from Sunderland Ethics Committee in advance of the start of 
study. In addition, as per UK requirements, Professor David Williams, 
Chief Medical Physicist obtained the necessary consent from 
Administration of Radioactive Substances Committee (ARSAC) for the 
use of the IBZM SPECT sca'ns at the same time. Or Terry Featherstone, 
Consultant Neuroradiologist, was the ARSAC certificate holder. 
A thyroid blocking agent was given to the participant the day before each 
SPECT scan in order to protect the thyroid gland during the scanning 
procedure. 
Following a three day antidepressant washout phase, IBZM SPECT 
scans took place at week 0, before either treatment had started and after 
6 weeks of treatment with either mirtazapine alone or combined with I PT. 
Clinical ratings, as detailed in the psychotherapy trial (HamD, BDI, SA$, 
HAS) took place on the same day as scan one and within one day of the 
second scan. 
SPECT procedure - Quality control and performance tests 
A quality control programme was carried out by the medical physicists 
before any participants had entered the trial to establish sensitivity and 
uniformity of the scans. 
Scanning method 
Having received an intravenous injection of the IBZM radioligand the 
. 
participants had to wait for two hours before the IBZM SPECT scan 
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could be acquired. The results of the scans were analysed at the end of 
the trial. 
Results 
The results report any changes between the two groups in IBZM uptake. 
Additionally, functional dopaminergic changes were examined in relation 
to a number of clinical areas including: the level of treatment resistant 
depression, responders versus non responders, agitated participants 
versus non agitated participants and men versus women. 
Discussion 
Of the twenty three participants who agreed to participate in this trial only 
three withdrew their consent prior to the start of treatment. There were a 
further two participants, one in each group, who were not available for 
week 16 clinical assessments. For the statistical analysis this was 
identified as an intention to treat sample and the last observation was 
carried forward. Attrition to' IPT was highest; there were no drop outs 
from either group although three participants switched from mirtazapine 
to an alternative antidepressant medication due to intolerable side 
effects, after the second IBZM scan. 
There are certain limitations which restrict the generalisability of this 
study. The treatment provided during this trial took place at one research 
site. All of the participants came from the same area in the North East of 
England. Moreover, most of the participants studied came from a low 
socioeconomic class; particularly those participants randomised to IPT, 
most were out of work and had left school without any qualifications. 
There was no placebo or normal control comparison used in this study, 
although both mirtazapine and IPT have been shown to be effective in 
the treatment of depression. Additionally, a UK Ethics Committee would 
not grant approval for a placebo study of this treatment population or 
application of the treatments to normal controls. In addition, by UK 
standards it is unethical to irradiate the brains of normal subjects, for 
which an ARSAC certificate would not have been granted. 
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This study breaks boundaries in a number of ways: firstly, IPT has never 
been tested in treatment resistant depressed patients before; secondly, 
no researchers have previously examined the role of dopamine 02 
receptors in selected resistant depression nor is there any such work 
with particular regard to increasing levels of treatment resistance. Finally, 
it is very rare to see research which spans psychotherapy, medication 
and brain imaging to investigate the potential biological correlates of 
psychotherapy in such a difficult to treat patient group. 
Future research is needed to identify the treatment options which may be 
effective to accommodate the potential variability of treatment resistant 
depression. The use of IPT alongside a sequential pharmacological 
approach to increase potency of antidepressant medication after a given 
period of time is needed. This may provide critical information about 
which particular treatments benefit which particular patients at varying 
stages of resistant depression. Longer term treatment and follow up 
studies are also needed. Comparisons to an alternative psychotherapy, 
such as CBT combined with medication are an area for future work. 
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Chapter two'- Treatment Resistant 
Depression (TRIO) 
Definitions of treatment resistant depression 
Treatment resistant depression has captured the attention of researchers 
for two decades. However, despite 20 years of research and 
investigation, there is still no widely accepted definition which can be 
used for clinical and research purposes. Currently, neither the 
International Classification of Diseases 10 (I CD 10, 2003) or the 
Diagnostic and Statistical Manual for Mental Disorders IV Text Revision 
(DSM IV TR, 2000) have a djstinct classification of resistant depression. 
Fawcett and Kravitz (1985) were the first to conceptualise treatment 
resistant depression, and did so on the basis of the duration of the 
depressive illness, extent of the antidepressant treatment, and the use of 
augmentation strategies in order to improve depressive symptoms. 
Despite continued references over the next few years in the literature to 
"resistant depression" there was no consensus on how best to describe it 
(Nelson and Dunner, 1993), and no internationally agreed definition of 
either treatment resistance or non-response to treatment (Dinan et al, 
1993). Nelson and Dunner (1993) recognised this problem and 
suggested that a definition would help make future research more 
generalisable and verifiable. 
Having conducted a meta-analysis Fava and Davidson (1996) suggested 
the most simple definition of treatment resistance was a failure to 
achieve euthymia (that is a normal mood) with adequate antidepressant 
treatment and proposed a definition: "Treatment resistant depressed 
patients may be identified as those who fail to respond to a standard 
dose of antidepressants administered continuously for a minimum 
duration of 6 weeks." Resfi!archers over the next few years became 
interested in defining resistant depression; this prompted a review by 
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Sourey et al (1999) who highlighted that more than 15 definitions had 
been proposed. Fawcett and Kravitz (1985) conceptualised treatment 
resistant depression based on the duration of the illness, extent of 
treatment and the use of .augmentation strategies. Nierenberg et al 
(1990) suggests a model in which treatment resistant depression is an 
episode of major depression that persists despite any number of 
adequate antidepressant treatment within the current episode and in 
which the number of failed treatments is used as a measure of the 
degree of resistance. Sourey et al (1999) proposed a model which took 
into account the various stages, or levels of severity of treatment 
resistant depression, incorporating classifications at different levels of 
resistance. This started with a "non responder' (to one single class of 
antidepressants for 6-8 weeks), the next level of severity would be 
classified as "treatment resistant depression" where 2 or more 
• 
antidepressant trials have been tried, and the longer the period of time 
not responding the greater the level of treatment resistance. Finally, the 
authors suggested the term "chronic refractory depression" should be 
applied to those patients who have had several trials of antidepressants 
including augmentation strategies. 
The scientific community became increasingly aware of other areas for 
clarification; response, partial response and non-response were also 
necessary within the context of researching resistant depression 
(Neirenberg and DeCecco, 2001 ). For example, Thase and Rush (1995) 
argued that there is a spectr.um of patients' responses to antidepressant 
treatment. They proposed distinguishing between relative treatment 
resistance and refractoriness and classified antidepressant responders 
along a continuum of five stages; Stage 1 involves one adequate trial of 
a single antidepressant. The Stages that follow involve more complex 
treatment incorporating different classes of antidepressant medications 
culminating in Stage V which would involve multiple classes of 
antidepressants in addition to bilateral ECT (see table below for details of 
Stage 1-V). This staged approach has more recently been cited in some 
of the literature regarding identifying the degree of treatment resistance. 
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However, there are limitations in this conceptualisation as it excludes 
augmentation with mood stabilisers, antipsychotic medications, thyroxin, 
transcranial magnetic stimulation, vagus nerve stimulation and 
antidepressant psychotherapy. This may be due in part to the lack of 
substantial clinical trials supporting the efficacy of these treatments in 
TRD at this moment in time. Indeed, Pridmore and Turnier-Shea (2003) 
argued that the Thase - , Rush guidelines are useful for research 
purposes but have less routine clinical utility. 
An updated system for staging antidepressant resistance 
Stage I Failure of an adequate trial of one class of major antidepressant 
Stage 11 Failure of adequate trials of two distinctly different classes of 
antidepressants 
Stage Ill Stage Ill plus failure of a third class of antidepressant including a 
TCA 
Stage IV Stage Ill plus failure of an adequate trial of an MAO I 
Stage V Stage IV plus failure of an adequate course of ECT 
From: Thase ME. CNS Spectr. Vo/9, No 11.2004 
Despite these advances, at this moment there is no clear definition of 
resistant depression which is widely accepted in both a clinical and a 
research setting. As recently as 2004, Kleine reiterated this problem 
when identifying that despite 30% of patients being treatment resistant 
there was still no general consensus or definition in use. 
Although the most common approach has been to define resistance 
primarily by degrees of non response in order to detect levels of 
treatment resistance, Fagiolini and Kupfer in 2003 were interested in 
assessing if treatment resistant depression was a unique subtype of 
depression. They carried out a review addressing issues such as the 
clinical characteristics and course of the disorder, the neurobiological 
profile and the context and environment in which resistant depression 
develops. The authors concluded that although patients with resistant 
depression share a number of clinical, biological and environmental 
characteristics there is still a lack of available data, and the clinical 
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heterogeneity of the condition does not allow a classification of treatment 
resistant depression as a unique subtype. 
The concept of treatment resistant depression 
Researchers and clinicians alike agree with the concept of treatment 
resistant depression despite no universally accepted definition. There are 
common themes which emerge from suggested definitions which appear 
fundamental to the conceptualisation of resistant depression. These 
include potency of antidepressant medication, response to treatment and 
the overall time taken to achieve a remission or response. 
lt is essential that the antidepressant treatment prescribed to the patient 
is carefully assessed; dose and duration of pharmacotherapy is 
frequently highlighted as a starting point, this usually forms the focus of 
the first or second pharmacological intervention. Additionally, the number 
of strategies used to achieve remission of symptoms must have some 
relevance in determining the level of patients' resistance to treatment. If 
the treatment approaches have become more complex, such as the use 
of antidepressant and mood stabiliser combinations or electroconvulsive 
therapy (ECT), which is usually used in severe major depression, the 
patient may well be considered to be more resistant to treatment than 
those patients who may eventually respond after just 2 or 3 less complex 
antidepressant switching strategies. Following treatment algorithms that 
involve staged systematic approaches may give us some indication that 
patients may well be entering into the spectrum of resistant depression. 
When considering a response to treatment, there are a number of 
factors which need to be addressed. For instance, chronic depression, 
non responders, partial responders (Fawcett, 1994), and responders who 
immediately relapse without a sustained period of remission (Little et al 
1998) all fall short of a distinct period of wellness and therefore are not 
~ . 
considered "healthy". However, all of these patients can, to some degree 
be placed within a continuum of treatment resistance; they may not have 
responded, or indeed poorly responded to a given treatment regime. 
23 
Furthermore, the issue of how and what is measured in relation to a 
"response" needs to be addressed. Hamilton depression scores and 
. 
Beck Depression scores are routinely used in depression studies; 
response is usually accepted as a 40 - 50% reduction in scores. This 
may be misleading as "responders" may have demonstrated significant 
improvements in terms of a reduction in total depression scores, but may 
still actually be very symptomatic (Dyck, 1994). There have been similar 
concerns raised regarding the use of the Clinical Global Impression 
scales (Greenberg et al, 2004). Souery et al (1999) argued that 
measurements of social functioning should also be taken when 
considering a response to treatment. 
Some, but not all of the literature suggests that resistant depression 
needs to be graded based on the time taken to achieve a response or 
remission of symptoms. Clearly, all three factors contribute in some way 
to our understanding of how a patient will respond to treatment; and the 
level of non response. lt is unclear if a certain number of patients with 
depression will follow a chronic refractory course, and be truly "resistant" 
to any treatment. Evidently, there are distinct levels of response to 
treatment ranging from immediate positive and prolonged responders, 
poor or partial responders eventually leading to increasing levels or 
degrees of limited or no response. The range of the lack of response is 
currently given a general. term of "treatment resistance". For the 
. 
purposes of this thesis I will conceptualise treatment resistant depression 
as varying levels of treatment response (or non response) to treatment. 
Clearly, there is a spectrum of response on which patients can be placed 
when considering the potency of antidepressant treatment, including the 
number of trials used, the level of response and the time taken to 
achieve any clinically significant progress. 
Although the literature has included all patients across the difficult to 
treat spectrum it is hard to establish the true extent of the problem. 
Factors such as numerous definitions of treatment resistant depression, 
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the study of heterogeneous samples and the lack of prospective studies 
confound the situation further. Despite the growing literature relating to 
resistant depression, there is a need for longer term studies, reviewing 
different treatment approaches, using consistent definition and 
classification of the varying levels of resistant depression. 
As these mechanisms for classifying, measuring and monitoring 
response in the difficult to treat depressed population improve, we will 
begin to gain further insight into this debilitating condition including the 
prevalence rates for poor and partial responders and the efficacy of 
treatment options for all levels of treatment resistant depression. We may 
also demonstrate a number of patients who do not respond favourably to 
the current treatment approaches available. 
Some of the papers reviewed for this thesis have included a mix of 
patients who were either poor or non responders, or intolerant of 
antidepressant medication. Whilst the poor and non responders are to 
some degree treatment resistant; those patients who are "intolerant" 
cannot be considered resistant to treatment. lt is reasonable to assume 
that patients intolerant of medication would not have continued with 
pharmacotherapy at an adequate dose and duration; a fundamental 
criterion of resistant depression. 
Problems associated with a lack of an agreed definition for 
resistant depression 
Although there is an agreement amongst the scientific population that 
resistant depression exists, the lack of an agreed definition to date 
• 
makes research in this area difficult to interpret. One study may view a 
particular patient population as "resistant" whereas another study may 
use an altogether different definition. Research to date is clearly not 
generalisable. Further questions are raised when considering not just 
whether a patient is resistant to treatment, but also the potential extent of 
lack of response, (i.e. levels of resistance) as recently suggested by 
Thase and Rush (1995) stages 1-V. 
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As a result of multiple definitions of treatment resistant depression, 
clinical trials have used different criteria for the number and type of 
previously failed trials needed to establish a diagnosis of treatment 
resistant depression; thus systematic and meaningful interpretation of 
the results of the trials is extremely difficult (Fagiolini and Kupfer, 2003). 
Other factors which may confound the situation include patients who 
have been inappropriately diagnosed as "resistant to treatment" who may 
in fact have a "psuedoresistance" in that they might have been 
I 
inadequately treated or misdiagnosed (Kornstein and Schneider, 2001). 
Fava and Davidson (1996) also argued that a diagnosis of resistant 
depression might actually reflect the expectations or assumptions of a 
clinician regarding a patient's response rather than the true clinical 
picture. A systematic and structured method of evaluating treatment in 
addition to a definition of treatment resistant depression may help ease 
the problems identified, such as misdiagnosis or pessimistic clinicians' 
assumptions and expectations. Clinical outcome measures such as the 
Hamilton Depression Scale can be a critical part of monitoring objectively 
a response to treatment and aid appropriately timed interventions. 
Epidemiology and course of resistant depression 
Kessler et al (1994) identified major depressive disorder as the most 
prevalent psychiatric condition over the course of a lifetime (17.1 %) as 
well as over a 12 month period. Although, no study has systematically 
assessed the epidemiology of treatment resistant depression, there are 
estimates of levels of treatment resistance and response cited in the 
literature. Robbins et al (1991) identified that only 19%-37% of those who 
suffer from depression ever seek treatment; and at least 50% of those 
people who do begin treatment with an antidepressant do not respond 
(Hirschfield et al, 2002). Furthermore, as many as 30% of patients 
• 
suffering from major depression are resistant to antidepressant treatment 
(Dinan et al, 1993; Brodaty et al, 1993; Burrows et al, 1994; Kleine et al, 
2004). 
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lt has been argued that partial responders and chronic depression 
should be conceptualised as a form of resistant depression (Fawcett, 
. . 
1994). Fawcett (1994) suggests the definition of a partial responder 
should be symptomatic improvement between 25-50%, as measured by 
a depression rating scale. This could mean that if a patients BDI score 
was 40 at the start of treatment and dropped by 50% to 20, although 
defined as a "partial responder", the participant is still moderately 
depressed, according to conventional interpretation of BDI scores. 
Estimates of the incidence of partial response to antidepressant 
treatment vary in the literature. In a review Fawcett (1994) identified 
between 40-60% of patients with only a partial response to treatment. 
Fava,(1994) however, increased this figure having identified that 50-
60% of patients seen in clinical practice receiving adequate dose of 
antidepressants at an appropriate duration do not demonstrate an 
adequate response to treatment. Bellas et al (2002) estimated partial 
response as high as 60-75%. 
According to data from the Mental Health Collaborative Depression 
Study, about 20% of patients with a depressive disorder will develop a 
chronic course of illness (Keller and Hanks, 1984). A later review 
carried out by the same author found that 25% of patients follow a 
chronic course and 21% had still not recovered after 2 years (Keller et al, 
. . 
1994). In the same year Burrows et al (1994) reviewed 36 randomised 
controlled trials involving 3,679 patients identified that 28% of patients 
followed a chronic course. Elderly depressed patients were a particular 
risk as half of this group followed a chronic course. Nearly half, (46%) of 
the total subjects studied failed to respond to an antidepressant 
treatment of an adequate dose and duration. Of the 46%, 12-15% were 
partial responders and 19-34% were treatment resistant. lt is reasonable 
to hypothesise that this is a significant underestimation as most 
depression trials exclude previous non responders from entering the trial 
at baseline. A more recent review conducted by Michalakam in 2002 
identified that one third of all•cases become chronic. 
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Partial responders do not reach acceptable levels of well-being and 
continue to experience suicide risk, work impairment and distress 
(Thase, 2003). lt may be more appropriate when evaluating a patient's 
response to treatment, that depressive measures should consider the 
severity of the depression, i.e. mild, moderate or severe, rather than 
baseline scores and the 'percentage reduction after treatment. In 
addition, assessment of social functioning using the Social Assessment 
of Functioning Scale (SAS) for example, which takes into account social, 
work and leisure activities could help us appreciate more fully the clinical 
significance of response to treatment. 
Factors which may contribute to chronic depression and partial response 
are: inadequate treatment, persistent stress, neurotic personality and 
dysfunctional attitudes (Fawcett 1997). 
Economic costs of TRD 
The social, economic and personal burdens caused by depression are 
tremendous. Pharmacoeconomic studies of depression have 
demonstrated that increased treatment effectiveness is positively 
correlated with significant reductions in treatment costs (Simon et al, 
2000; Mitchell et al, 1997; Thompson et al, 1996) Those individuals with 
treatment resistant depression (TRD) have been found to be frequent 
users of health care services incurring significantly greater costs than 
those without resistant depression. (Simon et al, 2000). Greenberg and 
colleagues 2004 were keen to explore the economic implications of 
treatment resistant depression among employees and carried out a data 
claims analysis of employees of a large national US employer. This 
consisted of medical, pharmaceutical and disability forms from 1996-
1998, inclusive involving more than 100,000 enrolled beneficiaries. 
Having identified 1692 employees who had a medical or disability claim, 
180 employees were then identified as treatment resistant depressives 
after the authors applied a treatment algorithm. Direct and indirect costs 
to the employer were then compared with three groups: the TRD group, 
a depressed non-treatment resistant major depression group and a 
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random 1 0% sample with other types of claim used as a control. The 
results demonstrated substantial differences in average annual costs to 
the employer for each group. The annual direct and indirect costs of the 
control group were $4000. These costs increased by 50% in the 
depressed non-treatment resistant group. However, the treatment 
resistant group was by far the most expensive group with annual direct 
and indirect costs over 3.5 times that of the control condition. Not 
surprisingly the authors concluded that TRD produces a significant 
burden on an employer; they also identified that TRD employees are 
more likely to be treated for eo-morbid conditions and have higher 
medical and work costs across all conditions. Although this paper raises 
interesting findings, there are limitations to this research. Retrospective 
data gathered from medical, pharmaceutical and disability forms have 
restricted value; only a small piece of the jigsaw, which may in itself be 
out of context. Psychosocial factors, family history, compliance with 
medication and sub clinical or unidentified medical illness such as thyroid 
disease were not considered, all of which could have a significant effect 
on treatment resistant depression. Additionally, it is not clear what the 
relationship is between the treatment resistant depression and eo-morbid 
. . 
medical disorders. Have the medical disorders made the depression 
more difficult to treat, or vice versa? These questions have not been 
considered in this paper and warrant further study. 
Russell et al in 2004 wished to assess healthcare costs of patients with 
treatment resistant depression in terms of pharmaceutical and medical 
expenditures. The authors used a medical and prescription claims 
database covering 3.5 million enrolees from 1995-2000. 7,737 patients 
who were identified to have had 2 or more unsuccessful trials of 
antidepressants were identified as treatment resistant. In addition the 
number of antidepressant medication changes was used as a guideline 
that the TRD was increasing in severity. The results demonstrated that 
depression-related and general medical health care increased 
significantly as TRD increased in severity. There was greater health care 
cost associated with each additional antidepressant change. The authors 
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reported a maximum of eight changes in the medication regimes. The 
• 
mean total health care expenditure increased by 104% from $571/month 
to $1165/month when patients had moved from the second to their 
eighth antidepressant change. The total depression related healthcare 
costs increased by 176% from the second ($139/month) to the eighth 
medication regime change (P<0.05). 
Suicide risk 
Long term studies demonstrate the risk of suicide in depression is 15% 
and several symptoms including moderate alcohol abuse, anhedonia, 
psychic anxiety, panic attacks, diminished concentration and global 
insomnia are found to be significant predictors of suicide (Fawcett et al 
1990). Partial responders have been identified as a greater risk of 
suicide, in addition to a 50% chance of work impairment and a 65% 
chance of subjective stress associated with their interpersonal and family 
lives. (Fawcett, 1994). Several studies have shown that patients with 
chronic depression carry out a greater number of suicide attempts and 
hospitalisations (Van Vulkenberg, 1984; Coryell et al, 1988; Klein et al, 
1998). 
Papakostas et al, (2003a) were the first group to prospectively study the 
prevalence and impact of hopelessness and suicidal ideation in 89 
• 
patients with treatment resistant depression. Having identified suicidal 
ideation and hopelessness as a risk factor for suicide, the authors 
assessed these symptoms using items 3 and 30 of the 31 item Hamilton 
Depression Rating Scale at baseline and follow up. The patients then 
entered a six week trial of nortriptyline. More than half of the patients 
reported thoughts and wishes of death to self and significant 
hopelessness and one third reported significant suicidal ideas or 
gestures. The authors concluded that patients with TRD are more likely 
than not to report prominent suicidal ideation and hopelessness. Thase 
(2004) in a review supported the findings that resistant depressed 
patients are more likely to attempt suicide, and added they were more 
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likely to suffer greater morbidity and mortality from general medical 
conditions (Thase 2004). 
Psychosocial factors which affect treatment resistant depression 
• Several environmental factors have been related to both a positive and 
negative treatment outcome in depression. Psychosocial factors which 
have been found to be detrimental to a positive recovery include chronic 
stressors (Joyce and Paykel, 1989; Thase and Rush 1995), multiple loss 
events (Akistal, 1982), low socioeconomic status (Downing and Rickels, 
1973; Thase and Kupfer 1987), low levels of education (Keller et al1986; 
Scott et al 1994), a non-supportive social environment (Miller et al 1992; 
Akistal, 1982) or high levels of psychosocial impairment (Aipert and 
Lagomasino, 2001; Thase, 2003b). In addition, explicit family conflicts or 
even the absence of family support can also have a negative effect 
(Keitner, 1992; Moos, 1990~. Fava (1994) has suggested that mild or 
moderate use of alcohol can have a negative effect on antidepressant 
use and lead to treatment resistance. lt is difficult to ascertain if these 
psychosocial factors cause or maintain the depression, or develop as a 
result of the depression. 
Corey-Lisle et al in 2004 were interested in factors which related to a 
poorer outcome when treating depression and prospectively studied 601 
depressed patients in a naturalistic trial comparing SSRI treatment in 
Primary care. Significant predictors of non response included older age, 
diagnosis, worse physical functioning and lower energy level. 
Positive psychosocial factors have demonstrated a protective effect in 
resistant depression; living with a partner, higher education and a higher 
quality of life (Hirshfield et al, 1998), better family functioning (Keitner et 
al, 1992), lower family conflict, and adequate family support predicts a 
more favourable outcome (Moos et al, 1990). Better social adjustment at 
baseline predicted less severe depression in a three year naturalistic 
study at the Sydney Mood Disorders Unit (Brodaty et al, 1993). Marital 
status (i.e. being married) and contrary to an earlier study, (Akistal, 1999) 
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an early onset of depression favoured a positive response to treatment in 
resistant patients (Perlis et al, 2003). Moreover, positive life events have 
also been found to predict a better outcome (Paykel, 1992; Scott et al, 
1988) and higher satisfaction scores (Koivumma-Honkanen et al, 2001 ). 
Work and social impairment 
lt is without doubt that resistant depression has a major impact on the 
• 
sufferer's life which stretches beyond purely physical symptoms of 
depression. Chronic depression has been found to be associated with 
severe and pervasive functional impairment, to a greater degree than 
that seen in major depressive disorder; and has been found to be more 
psychosocially disabling than major depressive disorder (Hays et al, 
1995). In fact, chronic depression has been found to be more severe 
than in many chronic medical conditions such as arthritis, hypertension 
and diabetes (Hays et al, 1995). Patients who have a Hamilton 
depression score between 10-16, can be classified as having mild to 
moderate depressive symptoms. This is the average Hamilton 
depression score at end point to most antidepressant studies, and 
unfortunately these patients have been found to have a 45-50% 
probability of work impairment. (Petersen et al, 2004; Mintz et al, 1992; 
Fawcett, 1994). Impairment of work function can be demonstrated by 
absenteeism, poor work performance and/or significant interpersonal 
conflict, and has been shown to have a 65% probability of patients 
reporting subjective distress associated with their interpersonal and 
family lives (Fawcett, 1994). In addition, impairment of work function has 
been found to continue even after remission of depressive symptoms in 
about a third of patients (Mintz et al, 1992). Finally, Lim and colleagues 
(2000) identified that depression and generalised anxiety disorder were 
• 
both predictive of work impairment, which increases when the two 
conditions coexist. Furthermore, Lim and colleagues (2000) found that 
mental health sufferers exhibited extremely low treatment seeking 
behaviour which is an important predictor of poor work productivity. 
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The Global Burden of Disease Study was launched in 1992 with the aim 
to develop measures of the burden of disease. This resulted in two 
measures becoming widely accepted: disability adjusted life years 
(DAL Y's), which assesses the years of life lost to the disease, or the 
years lived with the disability due to the disease (YLD). These two 
measures were compared worldwide for 1 00 disorders and revealed a 
high burden of disease for depression. Neuropsychiatric conditions were 
found to be the world leaders in YLD, accounting for almost 30%. 
Moreover, unipolar major depression alone accounted for 11% of the 
global YLD's. Whilst the authors acknowledged that no separate 
disability assessments were. compiled for resistant depression, they 
argued that these patients are the most severely disabled depressed 
patients. The key reasons given for providing the high burden in this 
treatment group were the depressive recurrences, cycle acceleration and 
increasing severity of treatment resistant depression (Greden, 2001 ). 
Petersen et al (2004) were the first group to prospectively evaluate 
psychosocial functioning in 92 patients with resistant depression using 
the Longitudinal Interval Follow up Evaluation (LIFE) scale. This group of 
patients demonstrated poor social adjustment, a poor level of 
involvement in recreational,activities, mild impairment to enjoy sexual 
activities and mild to moderate impairment in work activities. 
Interestingly, the authors noted that in their sample there was a tendency 
for both the patients and the clinicians to assign more severe global 
impaired ratings than when comparing ratings for specific functional 
areas. The authors suggested this may be due to accumulative effects of 
depressive, social, interpersonal and work related symptoms affecting 
the global ratings. 
Gender 
In older literature, female gender is sometimes mentioned as a risk factor 
for treatment resistant depression; however there is little evidence to 
support this. As depression is more common in women than men, any 
sample of treatment resistant cases would naturally demonstrate a 
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preponderance of women because of the gender differences in the 
depression prevalence rates (Kessler et al 1993). Gender has not been 
found to have a positive correlation with poor response in initial treatment 
. . 
(Sotsky et al, 1991 ). Two studies have recently been published which 
have analysed different gender responses to the SSRI Sertraline and the 
TCA Imipramine. Women were found to respond better to Sertraline, and 
men to Imipramine. Pre-menopausal women responded better to the 
SSRI than post-menopausal women (Kornstein et al, 2000). 
Aetiology of treatment resistant depression 
Risk factors contributing to Treatment Resistant Depression 
There are many factors which increase the risk of developing a resistant 
depression which include the severity and type of depression, the 
number of previous episodes, chronic depression and being partial 
responders. Concomitant eo-morbid medical and psychiatric disorders 
can also increase resistance. Furthermore, psychosocial and 
environmental factors can be instrumental in contributing and a 
maintaining treatment resistant depression. 
Type of depression and the number of episodes 
Nelsen and Dunner (1995) found that patients with treatment resistant 
depression are more likely to have a history of affective disorder; 
moreover, there have been suggestions that a family history of affective 
disorder increases the risk of resistant depression (Akistal et al, 1981; 
Scott, 1988). However, these findings have not been confirmed in large 
well designed prospective studies (Kornstein and Schneider, 2001 ). 
Although patients cannot be identified as resistant to treatment when 
prescribed inadequate doses of antidepressant medication; they do 
however, increase the risk of developing a resistant depression the 
longer the duration of the depressive episode. Additionally, there is good 
evidence that the greater the number of depressive episodes the higher 
the risk of developing a resistant depression (Keller et al, 1986; Scott, 
1988; Akistal, 1981). Scott et al (1988) found that the number of previous 
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psychiatric hospital admissions contributes to chronic or resistant 
depression however; this has not been confirmed by any other studies 
(Judd, 1997; Black et al, 1991 ). In addition, patients who are severely 
depressed on the Hamilton depression scale have been found to be 
more likely to be treatment-resistant (Kornstein and Shneider, 2001 ). 
Psychotic depression which is often associated with severe depression 
has been found to worsen outcome in terms of response to treatment 
and subsequent resistance (Lee and Murray, 1988). As few as 17% of 
patients recover with antipsychotic treatment and remain well for 12 
months (Parker et al, 1991 ). Aronson (1998) found that a subgroup of 
late onset delusional depressed patients were more likely to become 
treatment resistant. Relapse or recurrence has been reported in 50-92% 
of psychotic depressed patients (Nelson and Bowers, 1978; Aronson et 
al, 1987; Aronson et al, 1988). The speed of response to antidepressant 
treatment in depressed patients can also provide an indication of future 
resistance. Non response or a poor response to treatment within the first 
2-6 weeks has been found in a number of studies to predict poor 
outcome (Boyer and Feigner, 1994; Neirenberg et al, 1995; Gasperini et 
al, 1992). A meta- analysis carried out by Boyner and Feigner (1994) 
found that those patients who had not responded by at least a 20% 
reduction in Hamilton depression scores in the first two weeks had only a 
33.7% chance of being a responder as determined by the 50% reduction 
in the Hamilton depression scores. 
Comorbid psychiatric disorders 
Both early onset and late onset of depression have been identified as 
risk factors for resistant depression (Akistal et al, 1981; 1998; Aronson et 
al1988). 
Early onset depression, before the age of 21 is correlated with higher 
rates of comorbid personality disorders, substance abuse and a greater 
family history of affective disorder; and has been associated with a 
chronic course, lower response rates and incomplete remission of 
symptoms (Akistal et al, 1981; 1999). In addition, late onset depression, 
35 
after 60 years has been associated with several factors which contribute 
to treatment resistance, including the increased likelihood of psychotic 
depression, comorbid medical conditions and dementia (Brown et al, 
1983; Brodaty et al, 1991 ). 
Comorbid psychiatric conditions have been linked with an increase in 
treatment resistance. Keller and Shapiro (1982) used the term "double 
depression" to describe where an episode of major depression is 
superimposed on dysthymic disorder. In a study of 101 subjects, 26% 
• had double depression. Relapse rates were higher in this group as well 
as slower rates of recovery compared to the single diagnosis of major 
depressive disorder (Keller and Shapiro, 1982). In a further study, Keller 
et al (1986) found that patients who have double depression can recover 
from major depression but take much longer to recover from the 
dysthymia. 
Anxious patients have a poorer prognosis (Fawcett, 1994) in terms of 
delayed or poor response to antidepressants, and greater severity of 
both the anxiety and impairment associated with depressive symptoms, 
makes the depression more refractory to treatment (Dubovsky et al, 
2005; Rudd et al, 1993, Rosenbaum et al, 2001 ). Additionally, those 
patients who have panic attacks alongside depression have a much 
worse outcome compared to a diagnosis of depression alone; both in 
terms of treatment outcome and the severity of the depression (Van 
Vulkenberg, 1984; Coryell et al, 1988). In addition there have been 
reports of higher rates of suicide, higher risk of recurrence and greater 
psychological and psychosocial impairment in patients with concomitant 
anxiety disorders (Aipert and Lagomasino, 2001; Thase 2003). 
Comorbid personality disorder 
• There is a wealth of literature reviewing the effects of concomitant 
personality disorder in addition to depression. The DSM IV TR (APA, 
2000) lists 1 0 specific personality disorder diagnosis as well as residual 
"not otherwise specified" category. lt defines personality disorders in 
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terms of habitual and enduring patterns of perception, cognition and 
behaviour that are relatively inflexible and maladaptive and lead to 
significant functional impairment and distress. The disorder must 
manifest itself by late adolescence or early adulthood and is not due to 
the consequence of another mental disorder, chronic intoxication, or a 
general medical condition such as a head injury. 
Most surveys indicate that depressed people have an increased rate of 
personality disorder and more pathological traits when compared with 
healthy controls (Farmer and Nelson-Gray, 1990; Charney et al, 1981 ). 
In fact, Fava (1994) has suggested that personality disorders are 
frequent in depression. In depressed outpatients the prevalence of 
• 
personality disorder is 30%-70% (Ainaes and Torgersen, 1990; Black et 
al, 1988; Charney et al, 1981; Davidson et al, 1985; Frank and Kupfer, 
1990; Kaye et al, 1994; Koenigsberg et al, 1985; Reich et al, 1987; 
Sanderson et al, 1992; Shea et al, 1990). In-patient samples have 
yielded the same prevalence rates with the most predominant diagnosis 
of borderline personality disorder (DeBattista and Mueller, 2001 ). 
A retrospective study carried out by Black et al ( 1991) studied 14 71 
depressed patients and found that a comorbid personality disorder was 
associated with a worse outcome. In a more recent prospective study 
Ezquiga et al (1998) fou111d a significant relationship between the 
presence of a comorbid personality disorder and non-response or a 
partial response. These findings have not been reproduced in 
subsequent studies (Fava 1994, 1996; Perry et al 1999). 
Shea et al (1990) found that patients diagnosed with personality disorder 
had a poorer response to tricyclic antidepressants than those without a 
personality disorder. This was reinforced by Papakostas et al (2003b) 
who prospectively examined 92 outpatients with treatment resistant 
depression and found that a presence of avoidant personality disorder 
predicted a poorer response to nortriptyline . 
• 
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Despite the references to personality disorder and depression in the 
literature, the issue of concomitant personality disorder in depression is 
controversial. Some researchers and clinicians believe that depressive 
symptoms can frequently be confused with those of a personality 
disorder, and often as the .patient recovers from their depression the 
apparent "personality disorder" also remits. Furthermore, research on the 
relationship between depression and personality disorder is 
compromised by a number of methodological factors (Akistal, 1983; 
Farmer and Nelsen-Gray, 1990). For example, personality disorder is a 
longitudinal construct which is developmental in origin and typically 
manifest by late adolescence. Patients however typically are assessed at 
one point in time; that is cross-sectionally. They can usually provide an 
accurate portrayal of their depressive symptoms; however descriptions of 
their habitual patterns and tendencies are often biased by a negative 
cognitive set. Their depressive state biases recall of past memories and 
• experiences in a negative way, as well as increasing the probability of 
negative recollections (Cohen et al, 1988). They are more likely to view 
themselves as weak, ineffective, lazy, unintelligent, undependable and 
unlovable (Thase, 1996). Under these conditions this can make the 
diagnosis of personality disorder extremely difficult. These problems 
were reinforced when in one study, Thase (2000), deferred formal 
assessment of personality until the depressed person had responded to 
successful antidepressant treatment. The number of comorbid 
personality disorders was reduced by 50%, indicating a very large 
misdiagnosis of affective disorder as personality disorder. 
From a scientific perspective, there are pitfalls in the relatively reliability 
of diagnoses many Axis 11 disorders (Loranger et al, 1991 ). Lower 
reliability represents a particular problem because it imposes an upper 
limit or constraint on the validity of the diagnosis. Furthermore, research 
sampling presents a concern: Many depression trials exclude patients 
with a serious Axis 11 comorbidity such as antisocial personality disorder 
or borderline personality disorder. Thus when investigators report the 
relationship of personality disorder and outcome using data from a 
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clinical trial, the study group may not be generalisable to the broader 
range of patients seen in clinical practice (Thase, 1996). 
Comorbid medical conditions 
Medical comorbidity represents another major factor of treatment 
resistance and can play a major role in inducing and maintaining 
treatment resistant depression, especially when the medical illness is 
irreversible (MacEwan and Renwick, 1988; Akistal, 1982). Undiagnosed 
medical illness has been found to lead to a non response, for example 
(Guscott and Goff, 1991; Wehr et al, 1988), only 40% of patients with a 
comorbid medical illness respond to treatment with antidepressant 
medication (Popkin et al, 1985). Most of the studies published are nearly 
20 years old and therefore have involved less choice of antidepressants. 
The antidepressants may not have been less efficacious but attrition 
rates may be higher due to intolerable side effects or drug interactions. 
Additionally, the tricyclic antidepressants have considerably cardiotoxic 
effects which may restrict clinical use in the medically depressed patient. 
Fava (1994) suggested that concomitant medical illness, even when 
. . 
treated, can lead to poor response and treatment resistance. This, 
however, was not supported by further work carried out by Perlis et al 
(2004) among 386 fluoxetine non-responders, and Papakostas et al 
(2003c) with 89 nonresponders. Perhaps newer forms of antidepressant 
treatment may have contributed to the different findings. 
Thyroid abnormalities in treatment resistant depression 
lt has been found that 5-10% of depressed patients present with thyroid 
dysfunctions (Prange, 1996). In addition to frank hypothyroidism, 
resistant depression is associated with two other abnormal thyroid 
profiles: elevated basal thyrotropin (TSH) levels alongside normal L-
triiodothyronine (T3) and thyroxine (T4) levels, or a normal basal TSH 
level with an exaggerated response to thyroid releasing hormone 
stimulation (Prange, 1996). Thyroid abnormalities including 
hypothyroidism, abnormal TSH, T3 and T4 can be detected by a simple 
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• blood test. Howland (1993) carried out a review of studies involving 
depression and thyroid disease and found that 52% of refractory 
depressed patients show evidence of sub-clinical hypothyroidism (range 
29%-100%). This estimate compares with a prevalence of 8% to 17% in 
unselected populations of depressed patients, demonstrating a 3-6 fold 
increase in prevalence rates. Howland et al (1993) in a review 
summarising research into resistant depression reported that nearly half 
of the patients who do not respond initially to treatment for depression 
have sub-clinical hypothyroidism. Exaggerated thyroid stimulating 
hormone (TSH) response to thyroid releasing hormone (TRH) has been 
found in cases of refractoi)C depression (Targum et al, 1984). In fact, 
Baruch et al (1985) found this response to be higher in treatment 
resistant depressed patients than responders to antidepressant 
treatment. A history of thyroid dysfunction was found to worsen outcome 
in treatment resistance in a number of studies (Scott et al, 1988; Hatterer 
et al, 1993; Phillips and Neirenberg, 1994), although there is one 
contradictory study (Fava et al, 1988). 
Myocardial infarction, ventricular arrhythmias and congestive heart 
failures have all been associated with the development of major 
depression (Carney et al, 1993; Harnett, 1994; Kuttner et al, 1990). 
Depression may inhibit recovery or even increase the risk of mortality 
from myocardial infarction (Fraser-Smith et al, 1993). Conversely, 
physical problems associated with heart disease may also cause a 
deterioration of depressive symptoms. 
Papakostas et al (2004a) identified an association between treatment 
resistance and low serum folate and low vitamin B 12 levels. The same 
group demonstrated that high serum cholesterol at baseline would be 
more likely to lead to a poor response to treatment. A second study 
confirmed the relationship between hypercholesterolaemia and poor 
outcome in the treatment of resistant depression (Papakostas et ~1. 
2003d; Sonawalla et al, 2002). 
40 
Pies (1994) found that uraemia (excess urea in the blood), 
hyponatraemia (low sodium concentrations in the blood), hypokaleamia 
(low potassium concentrations in the blood) are commonly associated 
• 
with depression (Franco- Bronson, 1996). Some patients who do not 
respond to antidepressant medication may on occasion have an occult 
malignancy (Franco-Bronson, 1996). Until this is identified and excised 
the medication for depression may not work (Pomara and Gershon, 
1984). 
Even assuming a medical diagnosis is correctly established, any 
medication subsequently used to treat general medical conditions may 
significantly confound the evaluation and management of treatment 
resistant depression: for example, glucocorticosteroids are associated 
with depression mania and delirium; antihypertensives at high levels in 
high use can also increase the risks of depression (Kornstein and 
Schneider, 2001 ). 
Finally, it is important to note that any chronic illness regardless of 
whether it is medical or psychiatric in origin is a considerable 
psychosocial stressor which can also increase and maintain the severity 
and duration of depressive symptoms or in fact delay response to 
treatment. 
Neuroimaging in treatment resistant depression 
• 
Neuroimaging has only recently provided evidence regarding changes or 
abnormalities in the brain structure and function of depressed patients. 
Most of the published data focuses on major depressive disorder with a 
paucity of studies reviewing treatment resistant depression. 
There are only three functional studies assessing treatment resistant 
depressed patients reviewing the changes in regional cerebral blood flow 
as measured by 99m Technetium-hexamethylpropalineamineoxime 
(HMPAO) Single Photon Emission Computed Tomography (SPECT). 
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Hornig and colleagues (1997) compared 8 resistant depressed patients 
with 13 major depressed patients and 16 controls. The TRD patients 
demonstrated significant increases in the hippocampus-amygdala activity 
compared to major depressed patients and the healthy controls. There 
were no differences in the HMPAO activity in any other brain region, or 
right/left symmetry between the groups. 
Five patients with treatment resistant depression were studies with 
HMPAO SPECT before and after treatment with Transcranial Magnetic 
Stimulation (TMS). Increases in the regional cerebral blood flow in the 
left dorsolateralprefronal cortex were found post treatment (Zheng et al, 
2000). 
Recently, a group of four resistant depressed patients were evaluated 
using HMPAO and simultaneous (18) F-fluorodeoxyglucose (to measure 
cerebral metabolism) following 10 sessions of repetitive Transcranial 
Magnetic Stimulation augm~nted to antidepressant medication. There 
were increased uptake of both radioisotopes bilaterally in the frontal 
regions and a decreased uptake in the left orbitofrontal cortex compared 
to controls (Conca et al, 2002). 
Structural imaging studies using Magnetic Resonance lmaging (MRI) 
have suggested a relationship between resistant depression and right 
frontostriatal atrophy (Shah et al, 2002), changes in the left hippocampus 
(Mervaala et al 2000; Shah et al, 2002), changes in the frontal lobe 
volumes (Coffey et al 1993), and the presence of subcortical gray matter 
hyperintensities (Steffens et al, 2001) and white matter hyperintensities 
• which are found to increase the more severely resistant the patient 
becomes (Hickie et al, 1995). 
Several studies involving mainly elderly depressed patients have 
suggested that pathologic vascular changes involving gray or white 
matter hyperintensities may play an important role in treatment non-
response (Steffens and Krishnan, 1998). Indeed, several authors 
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propose that vascular depression may be classified as a specific subtype 
of depression (Aiexopolous et al, 1997; Simpson et al, 1998; Soares and 
Mann, 1997; Steffens et al, 2001; Steffens and Krishnan, 1998). 
Some brain imaging studies have used picture caption pairs to 
manipulate a depressed subjects mood prior to and during brain scans. 
During one such study, Kumari and colleagues (2003) investigated 
neural abnormalities using functional magnetic resonance imaging (fMRI) 
in resistant depressed patients. Picture caption pairs were shown during 
the fMRI procedure to elucidate neural correlates of cognitive 
generations of affect in treatment resistant depression. The authors 
found differences between patients and controls; participants 
demonstrated a relative decrease response in the anterior cingulate 
(rostra! and right) with both negative and positive picture caption pairs 
and in the medial frontal gyrus and hippocampal (left) with positive 
picture pairs. An increase response was found in the inferior (right) and 
middle temporal gyri (left) with negative picture caption pairs and in the 
parahippocampal gyrus (right). Increased response was also found in the 
Inferior frontal gyrus subgenual cingulates (right) striatum (right) and 
brain stem (left) with po$itive picture caption pairs. The authors 
concluded that different brain regions appeared to activate during 
positive and negative affect disturbances in treatment resistant 
depression; reduced medial-middle prefrontal and hippocampal activity 
may have accounted for the positive affect disturbances, and temporal 
lobe hyperactivity for negative affect disturbances. 
lt is important to note that neuroimaging results are not always 
replicated, for which there may be several reasons. This may often 
reflect lack of homogeneity of clinical features, especially medication and 
organic factors of the study samples and there are often small sample 
• sizes. In addition, biological variables may be found in the same brain 
area but in extreme variation. This may be erroneous or due to 
pathoplasticity. As methodological and technical aspects of brain 
imaging research is refined and improved the possibility of identifying 
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neuroanatomical, functional or biochemical substrates of treatment 
resistance is not unrealistic .• 
Management of treatment resistant depression 
Initial assessment of treatment resistant depression 
Despite a lack of consensus in defining treatment resistant depression, 
there is agreement amongst clinicians and researchers regarding what 
an initial assessment should entail. The first step is simply to check the 
diagnosis and use of antidepressant medication in relation to 
compliance, therapeutic dose and duration of treatment (Flint, 2002; 
Thase, 2003b; Davidson et al, 1996; Nelson and Dunner, 1993). 
Although there are discrepancies in the literature regarding what an 
. . 
adequate dose or duration is, six weeks is thought to be a reasonable 
trial at therapeutic antidepressant levels (Nelson and Dunner, 1993). lt is 
a concern that the most common cause for initial failure is not in fact 
resistance but under-treatment due to inadequate therapeutic doses 
being prescribed from the outset (Thase 2003). 
The NICE guidelines (2004) define resistant depression as that which 
fails to respond to at least two antidepressants given sequentially for an 
adequate time. Furthermore the guideline suggests that a combination of 
pharmacological and psychological treatment may be effective in the 
case of chronic depression;. a hint that chronic depression may be 
considered part of the spectrum of resistant depression. 
If present, the issue of non-compliance needs to be evaluated and 
clinically managed. Intolerable side-effects have often led to non-
compliance (Nelsen and Dunner, 1995). lt is imperative that education 
about the depressive disorder, treating symptoms without side-effects 
and close monitoring during early weeks of treatment is maintained 
during the initial weeks of recovery. Researchers in some older scientific 
papers have suggested that plasma level monitoring may enhance 
compliance to antidepressant treatment (Davidson et al, 1996) and 
. . 
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improve response rates (Giassman et al, 1977). Whilst plasma 
monitoring may have provided some clinical value with the older tricyclic 
antidepressants, it has been found to have little value with the modern 
antidepressants such as the serotonin specific reuptake inhibitors or 
serotonin and noradrenaline reuptake inhibitors (Thase, 2003). 
Assessing clinical effects and possible side effects of antidepressant 
medication to maintain compliance and aid recovery is an important part 
of treatment. lt is important that the clinicians address any concerns the 
patient may have. 
Clinician's role in achieving compliance 
Despite the fact that there is broad agreement in scientific publications 
which outline compliance to medication as an important issue in 
managing resistant depression; surprisingly only one paper reflects 
specifically on the clinician's role in achieving compliance. Fawcett 
(1995) argued that compliance cannot be defined simply as the patient 
physically taking prescribed medication, but has proposed the term 
"adherence" which encompasses a broader clinical and behavioural 
context. Fawcett argues that responsibility should be placed on the 
clinician to form a therapeutic alliance using educational techniques to 
increase behavioural compliance to medication. Fawcett identified 
factors which may affect patient compliance to treatment. These include 
patient characteristics encompassing specific symptoms such as guilt, 
suspiciousness, or additional comorbid symptoms such as panic attacks, 
severe anxiety symptoms, and alcohol or drug abuse. These symptoms 
can confound the treatment progress both in terms of compliance and 
• 
clinical outcome. Medication characteristics can be assessed by a 
clinician proactively by providing psychoeducation regarding the patients' 
illness, the need for medication to aid recovery as well as dealing with 
any fears or concerns they may have regarding treatment. Finally, the 
expertise of the clinician is an area often overlooked, but is a crucial 
component in helping the patient achieve compliance leading to 
subsequent recovery. Fawcett argues that the interpersonal processes of 
the patient-doctor relationship are often down-played as medication 
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algorithms become the focus. Fawcett recommends that 
psychotherapeutic and psychopharmacological approaches need to be 
integrated in order to reduce the problems which lead to non-compliance. 
lt has also been found that side-effects and lack of therapeutic response 
are not always the cause of non-compliance in depressed patients 
(Biackwell et al, 1982). The landmark NIMH study compared 16 weeks of 
Imipramine, Interpersonal Psychotherapy and Cognitive Behaviour 
Therapy to placebo. The pr'oject designers anticipated many problems 
with compliance particularly with regard to the placebo group. In order to 
maximise compliance they provided the clinicians with training and a 
manual (Eikin et al, 1985). The drop-out rates were 27% for the placebo 
group, 23% for Imipramine and 25% and 27% for the two 
psychotherapies respectively after eight weeks of treatment. The authors 
found that systematic attention to the clinical process may have 
contributed to the retention and treatment outcomes. 
The clinicians have a role to ask the patient about their medication and 
deal with any concerns they,may have regarding their medication. Many 
authors have agreed that an accurate assessment of resistant 
depression would be helpful both in the clinical and research setting 
(Fava and Davidson, 1996; Burrows et al, 1994; Nelson, 2003; Thase, 
2004). Systematic reviews using the Hamilton Depression scale for 
example would provide additional help (Davidson et al 1996). In addition, 
a stepped care and systematic treatment approach will help clinicians 
achieve remission in resistant patients (NICE, 2004, Flint, 2002). 
In addition to monitoring and managing the patients' response to 
antidepressant medication the clinician needs to consider factors such as 
• thyroid problems (Thase, 2003; Howland, 1993; Franco-Bronson, 1996), 
substance abuse (Linoila, 1990), endocrine disturbances (Nelson and 
Dunner, 1993; Kornstein and Schneider, 2001 ), and mild head injury 
(Dinan and Mobayed, 1991). These factors can all confound effective 
antidepressant treatment. Furthermore, the clinician should assess 
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alcohol and illicit drug use (Thase 2003b; Linoila, 1990) and 
' . 
psychosocial stressors which may maintain both alcohol intake and 
depressive symptoms (Pridmore and Turnier-Shea, 2003; Linoila, 1990). 
Treatment options in resistant depression 
There are many different treatment options in resistant depression which 
comprise of pharmacological methods such as switching to another single 
antidepressant, combining two or more antidepressants, or augmenting 
another agent such as low dose antipsychotic or a mood stabiliser. 
Additionally, non-pharmacological approaches can be used and include 
both psychological treatments such as Interpersonal Psychotherapy, 
Cognitive Behavioural Th~rapy, and other biological or physfcal 
interventions such as Electroconvulsive therapy, Transcranialmagnetic 
Stimulation, and Vagus Nerve Stimulation (Kieine et al, 2004; Nelson, 
2003; Trivedi, 2003.) The latter two treatments have largely been used in 
a research setting. Indeed, transcranialmagnetic stimulation is only 
licensed as a treatment in Canada and Israel. However, there is little 
empirical evidence as yet to support any of these treatment strategies and 
a paucity of controlled studies to support their efficacy (Nelson 2003; 
Thase, 2004). 
Following a review of resistant depression, Kennedy and Lam (2003) 
recommended that a combination or augmentation strategy early in the 
treatment increases the likelihood of remission. Similarly, Blier and Ward 
(2002) suggested that combination therapy may provide a more time 
efficient approach to relieve depression rather than drug substitution. lt 
has frequently been suggested in the literature that the development of a 
treatment algorithm would be a positive step to effectively manage 
resistant depression (Aidie et al, 2003; Thase, 2004). There is clearly a 
need for more research needed to help us understand both the efficacy of 
particular treatment approach as well as gaining an understanding of 
which treatment will work for which patient. 
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Switching antidepressants 
Pharmacological action of antidepressants 
There are a range of pharmacological approaches used in treating 
depression; all of the current antidepressant medications target the 
neurotransmitter monoamine system which includes serotonin, 
noradrenaline and dopamine. The antidepressant drugs produce their 
effects by interacting with the drug receptors. Drugs that bind to receptors 
to initiate a response are called agonists. Drugs with no intrinsic 
pharmacological activity which produce effects by preventing an agonist 
initiating a response are called antagonists (Arbuthnott, 1990). 
The first two groups of antidepressants, the tricyclic antidepressants 
(TCA's) and the monoamine oxidase inhibitors (MAOI's) were developed 
in the late 1950's and are often referred to as the "classical 
antidepressants". The sele~tive serotonin reuptake inhibitors (SSRI's) 
followed in the late 1980's and grew out of a greater need for increased 
selectivity. More recently compounds with actions on both noradrenergic 
and serotonergic systems are being used to treat depression (Stahl, 
1999). 
The tricyclics are so called because of their three ringed structure. The 
therapeutic effects of the TCA's are due to the blockade of the reuptake of 
noradrenaline and serotonin, and to a lesser extent dopamine. The 
monoamine oxidase inhibitors (MAOI's) are defined by their ability to 
inhibit monoamine oxidase, an enzyme which usually acts to destroy 
noradrenaline, serotonin arid dopamine. Selective serotonin reuptake 
inhibitors (SSRI's) were introduced in the late 1980's and have become 
popular due to their better tolerance and side effect profile. The SSRI's 
rapidly block presynaptic serotonin (5HT) reuptake, this causes the 
presynaptic autoreceptors to down regulate and results in an increase in 
the net serotonin transmission (DeMontigny et al, 1981 ). The next group of 
antidepressants are known as atypical or novel antidepressants due to 
their unique pharmacology and mechanism of action. As they are quite 
diverse they need to be considered individually. Bupropion is a reuptake 
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inhibitor of noradrenaline and dopamine. Although widely available in the 
United States it does not currently have a licence in the United Kingdom. 
Trazodone acts as an antagonist at histaminergic and alpha 1-adrenergic 
receptors which results in the inhibition of serotonin. Nefazodone is a 
potent serotonin 5HT2 receptor agonist which inhibits both serotonin and 
noradrenalin. Mirtazapine is an agonist at several receptors (5HT2, 5HT3, 
H1 and presynaptic alpha-2) thus enhancing serotonin and noradrenaline 
release (DeBoer, 1996). Venlafaxine is a reuptake inhibitor of both 
noradrenaline and serotonin, at lower dosages serotonin reuptake 
inhibition is prominent, at moderate to high doses noradrenaline reuptake 
becomes more significant and at higher doses dopamine reuptake occurs 
(EIIingrod and Perry, 1994). 
Treatment approaches in resistant depression 
First line approaches to non or partial responders to antidepressant 
treatment are often to increase the dose or switch antidepressant 
medication. Thase and Rush (1997) suggested that a switch to 
antidepressants in the same class is less likely to be effective than a 
' 
switch to a different antidepressant class. Although clinicians tend to 
switch to a different class of antidepressant, some would argue that there 
are sufficient differences in the pharmacokinetics and secondary 
neurochemical effects to justify switching within the same antidepressant 
class (Gilmore et al, 2002). 
SSRI to SSR/ 
Thase and colleagues (1997b) studied 106 out patients with major 
depression who had a history of intolerance or non response to sertraline. 
Treatment was switched to fluoxetine (mean dose 37.2mg/day) and 
evaluated with the 28 item Hamilton Depression Scale throughout the 6 
week trial. 63% (n=67) of the 106 patients demonstrated a 50% reduction 
in their initial Hamilton depression scores. A limitation of this study is the 
inclusion of patients who were intolerant to medication; clearly this group 
cannot be considered resistant to treatment as they were unlikely to have 
received an adequate trial of antidepressant medication. Another study 
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• 
conducted by Zarate and colleagues (1 996) examined the response to 
sertraline after failure or intolerance to fluoxetine in 31 hospitalised 
patients with major depressive disorder. Uniquely this study carried out 
longer term evaluations of the efficacy of treatment. At discharge 42% 
(n=13) of the patients were responders. Seven months later at follow up 
only a disappointing 26% (n=8) were still to be judged responders. An 
open study evaluating the efficacy of a switch to another SSRI in 55 
depressed patients who had failed to respond to prior treatment was 
undertaken by Joffe and colleagues (1996). This is the only study to have 
purely evaluated non-responders and excluded intolerance to the current 
treatment. After 5 weeks 61% (n=28) of patients had a marked. or 
complete antidepressant response. 
SSR/ to tricyclic antidepressant 
There are limited data in the use tricyclic antidepressants following SSRI 
failure. The first small study (n=15) was a double blind cross over study 
switching patients who had failed on paroxetine to imipramine. Eleven 
(73%) of the patients responded (Peselow et al, 1989). Thase and 
colleagues (2002) carried out a larger study comparing imipramine and 
sertraline in chronic depression. After 12 weeks of treatment, 117 patients 
who failed initial treatment with sertraline crossed over, double blind to 
. . 
imipramine. In the intent to· treat sample 44% (n=52) of the patients 
responded to treatment. Although the switch to tricyclic antidepressants 
can be clinically effective, there are serious risks of cardiotoxic side-
effects, death after overdose and high levels of TCA toxicity when 
switching from fluoxetine or paroxetine which may restrict their use. 
SSRI to Venlafaxine 
Neirenberg et al ( 1994) reported on a sample of 84 resistant depressed 
patients who were given 12 weeks of treatment with venlafaxine (a 
serotonin and noradrenalin reuptake inhibitor (SNRI) which blocks the 
serotonin and noradrenalin reuptake pumps resulting in an antidepressant 
effect similar to that of the tricyclic antidepressants). About one third of the 
patients responded. In a later open label study in Canada, deMontigny 
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and colleagues (1999) studied 152 patients who had previously failed at 
least 1 previous antidepressant and switched treatment to venlafaxine. 
58% demonstrated at least 50% reduction in the Hamilton depression 
' scores. More recently Kaplan'(2002) reported an uncontrolled study ot'73 
patients who had not responded to SSRI treatment and were switched to 
venlafaxine. 87% (n=60) patients achieved full remission assessed by the 
Hamilton depression scale after 6-8 weeks of treatment with venlafaxine. 
In the same year Poirer and Boyer (1999) described a double blind open 
label study comparing venlafaxine and paroxetine in 122 patients who had 
failed two previous antidepressant trials. Venlafaxine was provided at 200-
300mg daily and paroxetine 30-40mg daily. The response rate was 52% 
(venlafaxine) versus 33% (paroxetine) (P<0.04) and remission was 
achieved in 42% of the venlafaxine patients versus 20% of the paroxetine 
patients (p<0.01 ). 
SSR/ to Bupropion 
Fava and colleagues (2003) carried out an open switch study for patients 
who were unresponsive to 20mg of fluoxetine. 29 patients who were 
refractory to 8-12 weeks of fluoxetine were prescribed bupropion SR (an 
antidepressant noradrenalin and dopamine reuptake inhibitor (NDRI) 
which is only available in the United States) for an 8 week trial. Completer 
(n=20) and intention to treat analysis (n=26) were carried out yielding 35% 
(n=7) responders and 40% (n=8) partial responders and 48.8% (n=9) non-
responders. 
SSR/ to Mirtazapine 
Thase (2000a) reported a double blind study involving a switch to 
mirtazapine (mean dose 30mg/day) or sertraline (mean dose 120mg/day) 
in 243 patients who had reported failure to citalopram, fluoxetine or 
paroxetine. Although reduction in depression scores were significantly 
better in the mirtazapine groups at weeks 3 and 4, there were no 
significant differences (remission rates 37% versus 29%) by the end of the 
8 week trial. 
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In an open pilot study 69 patients having failed a prospective double blind 
study using either sertraline, fluoxetine or paroxetine were switched to 
mirtazapine; 48% (n=33) responded to mirtazapine (Fava et al 2001 ). 
Combination strategies 
There are some patients who do not respond or respond poorly to a 
• 
staged approach of switching antidepressant medications resulting iri a 
pharmacological blockade of the different monoamine systems. The next 
step to increase the potency of the antidepressant treatment is to combine 
antidepressant pharmacotherapy. The rationale is to broaden the central 
nervous system effects by combining agents affecting different 
neurotransmitter systems. This can be done in various ways; the 
contemporary standard is to combine the relatively selective yet dissimilar 
antidepressants such as bupropion, a dopamine and noradrenaline 
reuptake inhibitor, venlafaxine, a noradrenaline and serotonin reuptake 
inhibitor or the 5HT2, 5HT3 and Histaminergic1 and alpha 2-autoreceptor 
mirtazapine which enhances. serotonin and noradrenaline to create a 
broader spectrum (Fredman et al, 2000). 
Pharmacokinetics describes the way the concentration of a drug is 
reached with in the tissues in the body and includes absorption, 
distribution, biotransformation and excretion. Pharmacodynamics 
describes the way the drug acts on the body; this includes the mechanism 
of action of the drugs and receptor sensitivity. Receptor sensitivity is 
influenced by complex regulatory homeostatic factors. Changes in 
receptor sensitivity mean that the same concentration of drug will produce 
a greater or lesser physiological response. Desensitisation or down 
• 
regulation occurs for example after prolonged stimulation of cells ·by 
agonists. Thus the cell becomes refractory to further stimulation. There is 
a rationale for a combination of two SSRI's to be used in treatment 
resistant depression due to the different pharmacokinetic and 
pharmacodynamic properties of the antidepressants (Fava, 2001; Bondolfi 
et al. 1996). 
52 
SSR/s and TCA 's 
The most extensively studied strategy is the combination of a TCA and 
SS RI. Nelson et al (2004) recently published a double blind replication 
study of 39 depressed in patients in which the combination of fluoxetine 
and desipramine was significantly more likely to result in remission of 
depressive symptoms than either drug alone (combination 58% vs. 
fluoxetine 7.1% or desipramine 0% (P.0.001). Combining two 
antidepressants are not always found to be more clinically efficacious than 
monotherapy; in 2 published studies Fava et al (1994, 2002) found that 
increasing the single dose ·of fluoxetine was more effective than· a 
combination of fluoxetine 20mg/day and desipramine 25-50mg/day. 
However, as the patients in the combined therapy group had a mean 
desipramine blood plasma level of 1 OOng/ml, it is likely that the dose of 
tricyclic antidepressant used in this study was too small (Nelson and Price, 
1995). Taylor and Prather (2003) examined the efficacy of nefazodone 
augmentation in resistant depression where the patients had marked 
anxiety symptoms. Eleven outpatients received nefazodone 50mg/day 
increased until an optimal dose was achieved. This was added to ongoing 
antidepressant treatment. Seven of the 11 patients achieved complete 
remission of their depressiv~ symptoms and 9/11 patients demonstrated 
complete remission of their anxiety symptoms. 
SSR/s and SSR/s 
SSRis vary in potency and specificity of serotonin reuptake inhibition in 
vitro, this provides the rational for trying this option in resistant depressed 
patients; augmenting another SSRI may increase the antidepressant 
potency without adding to the side effect burden (Lam et al 2002). 
However, there is more anecdotal evidence rather than well researched 
clinical trials reviewing the efficacy of this treatment (Fava, 2001 ). 
Bondolfi et al (1996) carried out an open trial of seven patients who had 
not responded to 40mg/day citalopram. 50-100mg of fluvoxamine was 
added which resulted in an 85.7% (N=6) response rate. The combination 
of medication was well tolerated with few side effects reported (nausea 
and slight tremor). 
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SSR/s and alpha agonists (Mirtazapinel Mianserin) 
' . 
Mirtazapine antagonises presynaptic alpha adrenoceptor activity which in 
turn enhances noradrenalin (via autoreceptor antagonism) and serotonin 
(via heteroreceptor antagonism) neurotransmission. lt has been 
postulated that its action may complement the action of SSRI and SNRI 
antidepressants (Kent, 2000). Positive antidepressant responses have 
been demonstrated in five studies combining an SSRI with either 
mianserin or mirtazapine. A pilot study of open label mirtazapine 
(30mg/day) combination to SSRis of 20 resistant depressed outpatients 
yielded a 55% response rate at week 4. (Carpenter et al, 1999). This 
finding was replicated in a double blind study carried out by the same 
researchers using 26 depre~sed patients who were randomised to either 
mirtazapine or placebo in addition to their primary antidepressant 
medication. A positive response was categorised as a 50% reduction in 
the Hamilton scores and was demonstrated by 64% of the mirtazapine 
group versus 20% in the placebo group. 45.4% of the mirtazapine group 
achieved remission versus 13.3% of the placebo group (Carpenter et al, 
2002). 
An open label study of mirtazapine augmented antidepressant treatment 
was conducted in Vancouver with 24 non-responding or partial responding 
depressed patients (Wan et al, 2003). Eight of the patients had previously 
. . 
been treated with ECT; there was a mean of 7 previous antidepressant 
trials and 1.5 augmentation strategies. The patients were receiving 
concomitant antidepressant medication. Symptomatic improvement (CGI ,:: 
2) was observed in 38% (n=9), and partial response observed in 38% 
(n=9) of the 24 patients who received an average of 14.1 months of 
mirtazapine treatment at a mean dose of 36.7mg/day. This study is limited 
by a number of factors including the small number of subjects, the open 
retrospective and uncontrolled design. 
Maes et al (1999) recruited 31 patients who were unresponsive to a prior 
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adequate trial of an antidepressant and randomly assigned them to 
treatment with either fluoxetine 20mg daily, fluoxetine 20mg plus pindolol 
7.5 mg/day or fluoxetine 20mg plus mianserin 60mg/day. Sixty percent of 
patients responded to fluoxetine plus mianserin compared to only 9% of 
the fluoxetine only group. 
A higher dose of mianserin (60mg) was assessed in a double blind 
randomised controlled trial involving 104 depressed patients who had not 
responded to 6 weeks of fluoxetine (Ferreri et al, 2001 ). The patients were 
switched to mianserin alone, mianserin plus fluoxetine, or continued on 
the fluoxetine. The combined group had significantly greater reductions in 
the Hamilton depression scores compared to the monotherapy groups. 
Additionally, response rates were greater in the combination groups 
(combined 63%, mianserin alone 49%, fluoxetine 37%). 
Augmentation strategies 
Augmentation strategies can be distinguished from combination strategies 
as they typically involve the addition of a drug which is not primary an 
antidepressant. The addition of the new medication does however have 
pharmacological properties which enhance the potency of the 
antidepressant. Improvement following antidepressant augmentation 
tends to occur after 3-4 weeks. Most studies which review the efficacy of 
treatment tend to focus on short term strategies with very little data 
available for longer term effects, including when the augmenting agent 
should be stopped (Fava, 2001 ). 
Lithium augmentation studies 
Although lithium is not as popular now as it was in the 1980's, it is the 
most extensively studied augmentation strategy (Bschor et al, 2003). Its 
therapeutic effects are thought to be due to serotonergic and 
noradrenergic mechanisms. This has been supported by animal models 
which demonstrate that lithium increases serotonin (5HT) transmission by 
reducing the activity of post synaptic serotonin. In contrast to the usual 
decrease in hypothalamo-pituitary adrenocortical (HPA) axis with tricyclic 
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antidepressants, lithium augmentation appears to demonstrate a marked 
increase in the adrenocorticotropic hormone (ACTH) cortisol response 
(Bschor et al, 2003). 
As early as 1981 DeMontigny found dramatic early response within 38 
hours when adding lithium to tricyclic antidepressants compared to 
placebo. When lithium was compared to ECT, both groups improved; 
however the lithium augmentation group demonstrated the quickest 
• 
improvement. 
Bauer (2003) reviewed the literature from January 1966-February 2003 
addressing the clinical evidence for lithium augmentation. 27 trials were 
reviewed: 13 open labelled trials, 1 0 double blind placebo controlled trials 
and 4 randomised comparative trials. The authors summarising the data 
from the open and controlled trials demonstrated approximately 50% of 
the patients responded to lithium augmentation within 2-6 weeks. 
The risk of toxicity, weight gain, and the need for blood monitoring may 
contribute to its current low -rate of clinical use (Fava, 2001; Salama and 
Shafey, 1989). At present, it remains unclear whether the antidepressant 
response to lithium augmentation is a result of synergistic effects or 
whether it is simply due to the antidepressant properties of the lithium 
itself. Randomised double blind studies controlling for the effect of lithium 
alone compared with combined lithium and antidepressant medication are 
still needed. 
SSRI and lamotrigine 
Negative findings were reported by Barbosa et al (2003) who compared 
the anticonvulsanUmood stabiliser lamotrigine versus placebo 
• 
augmentation to the antidepressant fluoxetine in 23 depressed patients. 
Eight were diagnosed with bipolar 11 disorder and 15 suffered major 
depressive disorder. The effect of lamotrigine was found to be statistically 
greater than placebo on the clinical global impression scale at end point. 
However, lamotrigine failed to distinguish from placebo on both the 
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clinician rated scales Hamilton depression scale and Montgomery and 
Asberg Depression Scale. The small sample size reduces the power of 
the study and increases the likelihood of an artefact accounting for the 
results. 
Thyroid hormone augmentation 
Thyroid hormones may enhance antidepressant response by two 
principle mechanisms: correcting suboptimal thyroid function and 
"priming" noradrenergic function (Joffe and Sokolov, 2000). Joffe et al 
(1993a) in a comparative study found that triiodothyronine (T3) to be as 
effective as lithium augmentation and better than placebo. A meta-
analysis carried out by Aronson et al (1996) demonstrated that T3 25-
50mcg augmentation has significant effects in approximately one half of 
the studies. 
Pfeffier and colleagues (2004) looked at the efficacy of high dose 
Lthyroxin treatment in 28 depressed patients who were resistant to at 
least 6 antidepressant strategies. Nearly 40% demonstrated a good 
outcome and 21% showed a very good outcome as measured on the 
Hamilton depression scale and the Clinical Global Impression scale. 
Antipsychotic medication augmentation 
Imipramine, the first tricyclic antidepressant was discovered during the 
search for alternatives to the antipsychotic chlorpromazine. This led to 
early clinical trials reviewing the efficacy of phenothiazines in the 
treatment of depression (Thase 2002a). 17 double blind trials of 
chlorpromazine or thioridazine were undertaken between 1960-1976 
involving nearly 17000 depressed patients. The phenothiazines were 
found to be better than placebo and as effective as tricyclic 
antidepressant medication but had significant increases in extra-
pyramidal side-effects which prevented their clinical use (Robertson and 
Trimble 1982). As the newer atypical antipsychotic medications have 
' reduced side-effects, investigators have turned their attention to examine 
their use in mood disorders. Zhang and colleagues (2000) suggested 
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that antidepressant effects of antipsychotic medication augmentation 
may be as a result of increased release of monoamines in the prefrontal 
cortex. The antidepressant response is enhanced by direct effects on 
agitation, insomnia and anxi~ty via blockade of the post synaptic 5-HT2 
receptor (Thase, 2002). 
Ostroff and Nelson (1999) reported on 8 depressed patients who had 
failed to respond to an SSRI alone. Every patient improved within one 
week of the addition of risperidone. A prospective open study of 36 non 
responsive depressed patients who received risperidone in addition to 
fluvoxamine was reported by Hirose and Ashby (2002). Thirty two of the 
36 (89%) patients responded (50% improvement) within 4 weeks. lt is 
worthy of note that only 5 of the patients used in this study had not 
responded to a previous trial of an antidepressant. 
Shelton et al (2003) conducted an 8 week double blind study with 28 
patients with recurrent unipolar depression who had failed to respond to 
an initial course of fluoxetine treatment. Patients were randomly 
assigned fluoxetine (52mg/day) and placebo, olanzapine (12.5mg/day) 
and placebo or a combination of fluoxetine and olanzapine (52mg/day 
and 13.5mg/day respectively). Results consistently favoured the group 
receiving the combined therapy, demonstrating a differential response as 
early as one week. 
Barbee et al (2004) carried out a retrospective chart review of 79 
• 
medication trials in 49 patients to determine the effectiveness of 
olanzapine, risperidone, quetiapine and ziprasidone as augmentation 
agents in treatment resistant major depression. The authors again 
assessed the patients Global Assessment of Functioning (GAF) in 
addition to Clinical Global Impression (CGI) at baseline and following 
treatment. The individual response rates were 57% for olanzapine, 50% 
risperidone, 33% quetiapine and 10% ziprasidone. Of all the 
antipsychotics studied, only the olanzapine was found to be statistically 
significant. 
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Papakostas and colleagues (2004) used ziprasidone with its strong 5HT 
(1A) agonist activity augmented to SSRI antidepressants in 20 
unresponsive patients. Of the 13 patients who completed the 8 week 
trial, 8 patients responded. The authors carried out an Intention to treat 
analysis and showed 50% responders as demonstrated by ~ 50% 
reduction in Hamilton depres,sion scores. 
In summary, there is little good quality evidence base for antipsychotic 
augmentation. Clinical experience and research suggest fairly good 
tolerability and safety and good coverage of hyper-arousal symptoms of 
depression including irritability, agitation and insomnia. The agent with 
the most proven efficacy is olanzapine (Thase, 2004), however there are 
currently trials underway and are close to completion which will inform 
the literature further. 
Pindolol Augmentation 
Pindolol augmentation is ra'rely used in the United States although is 
more popular in Europe and Canada. Pindolol is a beta-blocker which is 
also a potent antagonist of post-synaptic 5-HT autoreceptors. This 
blockade of the autoreceptors enhances the initial cellular effects of the 
SSRI's and thus may facilitate the antidepressant response (Artigas et al 
1994). 
Pindolol has been shown to quicken response to SSRI treatment in five 
studies (Perez et al, 1997; Tome et al, 1997; Zanardi et al, 1997; Bordet 
et al, 1998; Blier and Bergeron, 1998). Three further negative studies 
found no response (Moreno ~t al 1997) or difference to placebo (Perez et 
al, 1999; Berman et al, 1999). 
At present there has been little evidence (Thase 2004) to show its 
benefits in resistant depression or else negative results have been 
demonstrated (Maes et al, 1999; Berman et al, 1999). 
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Riluzole 
Glutamate is the most widely distributed excitatory transmitter in the 
central nervous system and has been implicated in depression 
(Tzshentke and Grunenthal, 2002; Sancora et al, 2003; Zarate et al, 
2004). Riluzole is a glutamate modulating agent which results in an 
antidepressant effect. 
Zarate et al in 2004 carried out an open labelled trial of riluzole (a 
glutamate modulating agent) in 19 patients with treatment resistant 
depression in order to determine the efficacy and safety of patients with 
. . 
recurrent major depression. 53% of all patients were classified as having 
stage two treatment resistance (failure of 2 adequate trials of two distinctly 
different antidepressant classes). After an average dose of 169mg daily a 
significant improvement in the depressive symptoms were noted. The 
authors concluded that riluzole may have some antidepressant properties 
in some patients. 
Sancora and colleagues (2004) reported case studies of two women with 
long standing treatment resistant major depression. Following the 
augmentation of riluzole, both women demonstrated a significant reduction 
in their Hamilton Depression scores after one week (21-5, 34-22 
respectively). After six weeks the scores reduced further to 1 and 7. This 
small data yields promising results regarding the efficacy of riluzole in 
highly resistant depressed women. Further studies are needed to confirm 
this initial data. 
Psychotherapy 
Although there is considerable evidence for short term psychotherapies 
such as IPT and CBT in acute phase treatment of major depression 
(Segal et al, 2001 ), there is a paucity of information published regarding 
the efficacy of psychotherapy in resistant depression. Currently there is 
. . 
no literature which demonstrates any specific study of psychotherapy in 
treatment resistant depression; however, there are a small number of 
studies assessing psychotherapy in partial responders and chronic 
60 
depression. Past reviews of the literature have found that although 
psychotherapy does appear to ameliorate symptoms of chronic 
depression, the majority of. previous trials are hampered by small, 
idiosyncratic samples, open designs, different outcome measures and 
other methodological limitations making any general conclusions difficult 
(Mason et al, 1993; Markowitz, 1996). Until recently, no large systematic 
clinical trials of psychotherapy have been performed. 
With regard to treatment resistant depression, there is one case study of 
a depressed patient who had not experienced a remission despite 
numerous trials of antidepressant medications in addition to ECT 
(Cooper and Hedges, 1994). Intensive CBT was provided (39 sessions 
over 8 months). Improvements in the depression was noted by a drop in 
• 
the BDI score to 1 0 from 46 at the start of treatment, which was 
maintained at 12 month follow up (Cooper and Hedges, 1994). 
In the absence of studies for treatment resistant depression, the 
available studies on non and partial responders, dysthymia alone or in 
addition to major depression will now be reviewed. Although these 
cannot directly address the efficacy of psychotherapy in treatment 
resistant depression; these studies address samples of patients that may 
overlap with treatment resistant depression as defined earlier in this 
chapter. Non and partial responders and chronic depression all remain 
symptomatic to some degree despite adequate treatment. As previously 
discussed this falls into the spectrum of resistant depression. We know 
from the literature available these patients at a particular point in time lie 
at the mild end of the spectrum of difficult to treat depression. What is not 
known however, is the course of these particular patients' depression 
over time. Some of the patients, following a depression trial may not 
continue to respond or only partially respond to increasing trials of potent 
antidepressants, this then would lead to a progression further into the 
spectrum of increasing treatment resistance. 
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Psychotherapy treatment in non responders 
Cognitive behavioural therapy 
Five depressed patients who had not responded to an "adequate trial" of 
antidepressant medication were provided 20 sessions of CBT, by a 
trained and experienced therapist over 16 weeks. 20% of the patients 
demonstrated a complete• improvement and the mean Hamilton 
depression scores fell from 22.8 to 7 .4. There were no statistical tests 
published in this paper (Fennel and Teasdale, 1982). 
A small study of 12 patients who were "unresponsive to antidepressant 
medication" was carried out by Harpin et al (1982). Patients were 
equally assigned to CBT (26-36 sessions) or to a waiting list control 
condition. There was a statistically significant difference in the 
depression scores in favour of the CBT group (P=0.05), and 30% of the 
group were considered responders. The Hamilton depression scores fell 
from 26 to 16.3 in the CBT group versus 24.7 to 23.3 in the control 
• 
condition. The CBT in this study was carried out by a single therapist, a 
51h year undergraduate psychology student, not the best design for a 
treatment resistant depression study. 
A slightly larger open study of non responsive (3 months of 
antidepressant medication at an adequate dose) was carried out by 
Mirabei-Sarron et al (1993). Twenty one of the 25 patients recruited to 
the study completed the 3 months CBT. The Hamilton depression scores 
demonstrated an improvement in depressive symptoms from moderate 
(21) to mild (1 0.3). Although the patients did not experience a total 
remission of symptoms the 'Ciepressive symptoms remained mild (1 0.3) 
at 12 month follow up. 
Five patients who received group CBT were compared to the same 
number using a self help management programme. (Bristow and Bright, 
1995) 16-20 sessions were. provided over 16-20 weeks and Hamilton 
depression scores were taken at baseline, post treatment and at 6 and 
12 month follow up. There was an improvement in depression scores 
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following treatment with no differences between groups. Improvements 
gained during treatment were maintained at 6 and 12 months. Although 
some patients in this study were non responders, the authors also 
included subjects who had refused antidepressant treatment, or were 
intolerant. This limits the findings of this small study. 
Twenty patients who had not responded to 6 weeks of an adequate dose 
of an antidepressant were randomly assigned to CBT plus 
antidepressant medication or medication alone. Fifteen sessions of CBT 
was provided. There were similar reductions in the Hamilton depression 
scores post treatment with no significant differences between groups 
(Barker et al, 1998). 
F ava et al ( 1997) reported an open trial of CBT in 19 patients who had 
not responded to at least two trials of antidepressant medication at an 
adequate dose. Sixteen patients completed the trial. The CBT was 
provided by a trained and experienced CBT therapist for 15 sessions, 
antidepressant medication was stopped in 8 out of 12 of the patients who 
were responding to CBT treatment. The Clinical Interview for Depression 
' measured depressive symptoms pre and post treatment. The mean 
scores fell to 31.4 from 54.1 and were clinically significant (P<0.001 ). 
Twelve of the patients were in remission by the end of the trial and only 
one of these had relapsed at 2 year follow up. 
Other psychotherapies 
Ten patients who had not responded to a 6 week trial of a therapeutic 
dose of an antidepressant were given an open trial of a 
psychoeducational group treatment. 12 two hour sessions were 
administered over eight weeks by an experienced therapist. The 
improvements in the BDI , scores after treatment were statistically 
significant (p<0.005) and improvement in depressive symptoms was 
maintained at 9 month follow evaluations (p<0.05) (Antonuccio et al, 
1984). 
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The literature on psychotherapy treatment in patients non responsive to 
antidepressant treatment is .sparse. There are just six CBT studies 
involving 91 patients. There are three open studies, two comparative 
studies and one waiting list controlled trial. There has been no difference 
in CBT compared to the comparison treatment (Bristow and Bright, 
1995). The CBT sessions have ranged from 15-36. Most of the studies 
have evaluated CBT in the short term and demonstrate improvements in 
depressive symptoms which have been maintained at one year (Bristow 
and Bright, 1995; Mirabei-Sarron, 2003) and two year follow up (Fava et 
al, 2003). 
A single open study of a psychoeducational group yielded a significant 
. . 
reduction in the Beck Depression Inventory scores which was maintained 
after 9 months, however a lack of control group or comparator therapy 
limit these findings. 
There have been no studies evaluating the efficacy of IPT in patients 
who have not responded to antidepressant medication. 
Psychotherapy treatment in partial responders 
Interpersonal Psychotherapy 
A single report of a case series of 5 elderly depressed patients who 
received IPT augmented to SSRI treatment was reported by Scocco and 
Frank 2002. The authors were unable to establish the adequacy of 
previous pharmacological treatments received before the trial, therefore 
patients were prescribed either citalopram (20mg) or sertraline (50mg); 
both medications were doubled after 3 weeks as the Hamilton scores 
taken at baseline were not reduced by 50%. After 6 weeks the patients 
started 16-20 sessions of IPT. The mean pre-treatment Hamilton 
depression scores had dropped from 21 to 15 after medication, and to 4 
at the end of combined IPT and pharmacotherapy treatment. All patients 
were in remission post treatment. The lack of control and small number 
of patients limit this study. Furthermore, every patient was in fact 
. 
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responding, although slowly in some cases, to their current moderate 
dose of a single antidepressant. 
Two separate but methodologically similar studies were compared by 
Frank and colleagues (2000~ .in order to ascertain the sequential effects 
of treatment in highly recurrent depressed women. In one study the 
women were assigned treatment with IPT combined with the 
antidepressant imipramine (n=180); in the second study women were 
treated with IPT initially and if not responding adequately received either 
fluoxetine or sertraline in addition (n=159). Response rates of the 
combined group were similar to that of other studies (66%); interestingly, 
of the women who needed antidepressant medication following a poor or 
non-response, 79% responded, which was statistically significant 
(P<0.02). 
Cognitive behaviour therapy 
Fava and colleagues (1996) wished to examine the usefulness of CBT in 
treating residual symptoms of depression in patients who did not fully 
respond to antidepressant medication. In this study 40 patients were 
randomly assigned to CBT or clinical management. Antidepressant 
medication was gradually tapered by 25mg amitriptyline each week and 
stopped. After 2 years there was a lower rate of relapse in the CBT 
group (15% vs. 35%); at four years the relapse rates between the 2 
groups became statistically significant (35% vs. 70%) in favour of the 
CBT group (Fava, 1996). The follow up assessment at 6 years did not 
yield significant differences ~n the relapse rates between the 2 groups 
(CBT, 50% relapse; CM 75%). 
Paykel and colleagues (1999) observed a significant relapse prevention 
effects in a 2 centre study of incompletely remitted patients (n=158) who 
were randomly assigned to clinical management (CM) alone or combined 
with CBT. This study differed from Fava's study (1994) in that both 
groups continued to receive antidepressant medication, (mean dose 
equivalent to 125mg amitriptyline/33mg fluoxetine), additionally 15% of 
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the subjects were receiving lithium augmentation (there was no 
difference in lithium patients in both groups). Patients were very mildly 
depressed at baseline, the mean Hamilton depression scores were 12.2 
(SD2.9) for the control group and 12.1 (SD2.7) for the CBT group. 
Furthermore, the symptoms of depression had been experienced for a 
limited period of time (2-18 months duration). The cumulative relapse 
rate (residual symptoms for 2 months plus Hamilton ~14) at 68 weeks 
was reduced significantly from 47% in the CM group to 29% in the CBT 
group. In addition CBT also increased full remission rates at 20 weeks 
(24% vs. 11 %), but this effect was relatively small and not associated 
with significant improvement in depression symptom ratings. 
In a later paper, reporting the same study the authors suggest that CBT, 
although more costly, was more effective than intensive treatment alone 
(Scott et al, 2003). They also report the use of CBT in chronic 
depression despite the mean duration of the depressive episode being 
13/14 months for each treatment group. This diagnosis however, falls 
short of the DSM IV or ICD 10 criteria for chronic depression. 
In summary, there have been four studies evaluating IPT and CBT which 
have included 542 partially responding depressed patients. A small case 
series of elderly partial responders who received 16-20 sessions of IPT 
augmented to their antidepressant medication demonstrated 
improvements in all patients. The small sample size, lack of comparison 
groups and non blind ratings limit these findings. Nevertheless, this does 
provide an indication of the feasibility and tolerability of IPT in this patient 
group. The efficacy of the sequential effects of medication added to IPT 
was assessed in a comparison of two clinical trials (Frank et al, 2000). 
Superior response rates were obtained with patients who received IP.T 
initially followed by antidepressant medication only if patients were not 
responding. lt was surprising that during this study the initial lower dose 
of sequential treatment provided better response rates than the higher 
dose of combined IPT and medication from the start of treatment. 
Patients who had not reduced Hamilton depression scores by at least 
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33% during the sequential treatment approach, had the dose of IPT 
doubled to twice weekly; if, after a further 4 weeks the Hamilton scores 
had not fallen by 50% either fluoxetine or sertraline was added. As 
patients were promptly treated with potent antidepressant therapy quickly 
during this trial, this may have contributed to the positive outcome. 
Further, the use of different antidepressant medication may have also led 
to superior results. 
Currently there are no other published data which review sequential 
effects of psychotherapy treatment in resistant depression; although 
there is one trial involving CBT is currently underway (Fava et al, 2003).· 
The two CBT randomised trials compare CBT to clinical management; 
one of the studies involved the concomitant use of an antidepressant 
(Paykel et al, 1999). Relapse rates for the CBT were found to be lower 
than the clinical management condition post treatment and at 68 week 
follow up (Paykel et al, 1999) and 2 and 4 year follow up (Fava et al, 
1996). 
Chronic depression 
Interpersonal Psychotherapy 
• 
IPT has been specifically adapted as a treatment for dysthymia (IPT-D) 
and has been manualised (Markowitz 1998). A fifth problem area has 
been introduced whereby the therapy itself becomes an iatrogenic role 
transition; that is a transition from chronic illness to a healthy state. The 
IPT therapist works with the patient to help mourn the loss of the old role 
(dysthymia) and gain mastery of the new (healthy) role. During this 
phase the therapist may spend also of time detoxifying and normalising 
feelings. There are a limited number of studies of IPT in chronic 
depression; not all studies have used the modified version of the therapy. 
One of the first published revi~ws of IPT in dysthymia was the analysis of 
a subgroup of 65 patients who were diagnosed with early onset chronic 
depression from the NIMH Treatment of Depression Collaborative 
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Research Programme (Agosti and Ocepek-Welikson, 1997). This study, 
which recruited 239 patients, had four treatment cells which provided 16 
weeks of IPT, CBT, imipramine plus clinical management and placebo 
' plus clinical management. The authors found that post treatment scores 
of depression were not found to be any different between groups to the 
placebo and clinical management condition. 
Cornell University Medical College reported pilot data on three small 
series of subjects totalling 17 patients, who were treated with an open 
trial of up to 16 sessions of IPT-0, (without medication). All of the 
patients met the OSM criteria for early onset dysthymic disorder and 
nearly half had double depression (i.e. major depression superimposed 
on dysthymia; Keller and Shapiro, 1982). Seven of the patients had been 
non responsive to antidepressant treatment. None of the patients 
deteriorated and 11 (65%) remitted (final Hamilton depression score >8), 
the average Hamilton depression scores fell from 21.5 (S04.4) to 7.4 
(S04.7) (Markowitz, 1994). Of the sample reported above, 7 patients had 
previously failed a trial of treatment with the tricyclic antidepressant 
desipramine (Mason et al 1993). 
Following on from the pilot data, the same researchers at Cornell have 
conducted 3 further controlled trials; the final results have not yet been 
published. The first study addressed early onset dysthymic patients and 
compared 16 weeks of IPT -0, sertraline, a Brief Supportive 
' Psychotherapy (BSP, used as an active control) and combined sertraline 
and IPT-0. Improved patients are entered into a continuation phase 
where IPT patients are seen for biweekly or bimonthly sessions. Non 
responders are crossed over to alternative treatment cells. A second 
study included patients with double depression who were randomly 
assigned IPT-0 or BSP for 16 weeks. There is a 6 month continuation 
phase although there is no cross over design to this study. The third 
study recruited dysthymic patients with comorbid alcohol abuse. This 
study involves random assignment to 16 weeks of IPT-0 or BSP both in 
addition to attending Alcoholics Anonymous. All three studies are now 
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complete and data analyses are underway. Preliminary results suggest 
no statistical difference between groups; IPT-D appears to be equally 
effective to pharmacotherapy and to a relatively active control condition 
(Markowitz, 2003). There is no published data available on these three 
studies regarding the numbers of subjects recruited and the trial design . 
• Feijo de Mello and colleagues (2001) wished to assess the applicability 
of IPT augmented to antidepressant medication in Brazilian dysthymic 
patients of a lower socioeconomic background. Thirty five dysthymic 
patients were randomly assigned to IPT and moclobemide (n=16) or 
moclobemide alone (n=19). This study included an acute and 
maintenance phase totalling 48 weeks. Moclobemide was provided at 
300-600mg daily and I PT was provided acutely as 16 weekly sessions, 
followed by monthly maintenance sessions. Blinded ratings of 
depression (HamD, Montgomery and Asberg Depression Rating Scale 
(MADRS)), quality of life (Quality of Life Enjoyment and Satisfaction 
Questionnaire) and global functioning (Global Assessment of 
Functioning) were performed at baseline, 12, 24, and 48 weeks. Six 
patients (37.5%) dropped out of the IPT and eleven (57.9%) dropped out 
of the medication only group. Both treatment groups improved on all 
measures over time, particularly between baseline and 12 weeks 
(p<0.0001 ); there was a non significant trend for the combined IPT and 
medication group. One single therapist provided the modified version of 
IPT-D for this study. The small sample size limits the generalisabilty of 
the findings. 
A large study was undertaken in Canada (Browne et al, 2002) comparing 
• IPT and sertraline alone or in combination with 707 dysthymic primary 
care patients. Ethical restrictions prevented the use of a placebo 
condition. Sertraline (50-200mg) and IPT (up to 12 sessions, mean 1 0) 
were provided within the first 6 months of acute treatment followed by an 
18 month naturalistic follow up. Blinded assessments of depression and 
social functioning (MADRS, SAS) were performed at baseline, 6, 18 and 
24 month follow up. Costs of treatment including the counsellors time, 
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antidepressant medication and health and social care use was collected 
at the same time. 586 subjects (83%) were available for the six month 
assessments and demonstrated significant difference in response (40% 
reduction in MADRS scores) rates: 59.7% in sertraline alone, 57.5% in 
sertraline and IPT and 46.6% in IPT group (P<0.025). At 2 years, 525 
(74%) were available for follow up and no differences in the depressive 
symptom reductions were found in sertraline alone (13.2.:!:_11.0) or 
combined group (13.6.±1 0.9). However, both of these treatments were 
more effective than IPT alone (1 0.2.±_11.0) in symptom reduction 
(p<0.02). At six months, there was no statistically significant difference in 
health and social service costs between groups; however, compared to 
sertraline alone both IPT groups used less of the other health and social 
care costs. After 2 years, there was a statistically significant difference 
among the groups in the total per person 2 year costs ($7866 sertraline, 
$7386 sertraline and I PT, $5657 I PT; p<0.001 ). 
As the focus of this study was to assess the effects of augmenting 
sertraline with IPT, patients were not prohibited from receiving alternate 
treatments during the 18 month follow up phase which included 
antidepressant medication, the numbers of patients who received 
• 
alternate· treatments were small (n=3 sertraline group, n=6 combined 
group, n=9 IPT group). lt is worthy to note that the IPT used in this study 
was not the adapted IPT-0 for dysthymia; additionally the number of 
sessions fell below the recommended number for acute treatment of 
major depressive disorder, or indeed the recommended dose of up to 18 
sessions for dysthymia (Markowitz, 1998). There is a great deal of 
evidence in the literature which supports the use of more potent 
antidepressant treatment in chronic depression. Providing IPT at such a 
low dose (1 0 sessions for acute treatment and no maintenance sessions) 
when sertraline was continued at a higher dose and continued 
throughout maintenance t>hase may not have provided a fair 
comparison. 
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Cognitive behaviour therapy 
A small open study of 6 female inpatients was carried out by Miller and 
• 
colleagues (1985). All patients were deemed as drug resistant (to a 3 
week trial of antidepressants) and four of the group were also dysthymic. 
Treatment involved hospital intervention, pharmacotherapy (based on 
clinical need) and either CBT (n=3) or social skills training (SST, n=3). 
Both psychotherapies provided an intensive programme; the patients 
were seen 5/7 days for the first week and then sessions were reduced to 
weekly for 16 weeks. The mean BDI scores fell from 25.7 in the CBT 
group to 9.3 (P=0.07) and 22 to 8 in the SST group (p= 0.08). Four of the 
women were in remission at the end of the treatment and 2 were partial 
responders (801~17). 
Thase and colleagues (1994b) were interested in differential response to 
CBT in 84 patients who were diagnosed with either major depressive 
disorder or double depression. The authors found that after a time limited 
course of CBT remission rates were greater in the major depressed 
group (55% vs. 27%) and concluded that more intensive CBT or 
alternate treatment methods may be necessary in patients with double 
depression. 
Moore and Blackburn (1997) compared CBT (n=7) to antidepressant 
medication (n=6) in chronically depressed outpatients. 15-30 sessions of 
. . 
CBT were provided over a 12 month period. Four of the CBT and 5 of 
the medication group completed treatment and were available for follow 
up evaluations. There was a statistically significant difference of the CBT 
group compared to the medication only group (P<0.01) as measured by 
the pre and post treatment Hamilton depression scores. 
Ninety seven patients diagnosed with primary dysthymia were compared 
with group CBT, sertraline, or both active treatments combined against a 
placebo for 12 weeks (Ravindran et al, 1999). The response rates were 
significantly higher for the combined group (71 %) and sertraline group 
(55%) compared with the GBT alone or the placebo. The group CB.T 
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alone was no different to the placebo. Although the addition of CBT to 
medication did not have a statistically significant effect in relation to 
response rates, it was found to augment the effects of the sertraline with 
regard to functional changes. 
Other psychotherapies 
Waring and collaborators (1988) reported preliminary data from a 
randomised study reviewing the effectiveness of combined marital 
therapy and antidepressant medication (doxepin) in the treatment of 
dysthymic women. After 10 weeks of combined treatment, the dysthymic 
women showed statistically significant improvement on all depression 
measurements and intimacy scale compared to placebo. 
A 36 week randomised pilot study reviewed the effects of combining 
group psychotherapy and fluoxetine in 40 patients with dysthymia versus 
fluoxetine alone. All patients,who had received 8 weeks of fluoxetine and 
had shown more than 40% decrease in their baseline Hamilton 
depression sores were randomly assigned to medication alone or 
medication plus 16 weeks of group psychotherapy. After 24 weeks at 
termination 89% (16/19) of the combined group responded to treatment 
(Hamilton depression score <50%) versus 76% (13/17) of the fluoxetine 
only patients. Remission was defined as no longer meeting the DSM IV 
criteria for dysthymia plus a "0" score on item 1 of the Hamilton 
depression scale. At termination 82% (14/16) and 63% (10/16) of 
medication only subjects were in remission, and at follow up, 31% (4/13) 
and 50% (6/12), respectively, were in remission. There were no 
statistically significant differences between groups (Hellerstein et al, 
2001 ). 
Keller and colleagues (2000) designed a psychotherapy which is 
incorporates techniques and strategies from IPT and CBT, Cognitive 
Behavioural Analysis System of Psychotherapy (CBASP) specifically as 
a treatment for dysthymia (McCullough 2000). A pilot study of 1 0 early 
and late onset dysthymic patients (McCullough, 1991) demonstrated the 
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feasibility and efficacy of the CBASP therapy. After treatment all patients 
met the termination criteria and 9 out of 10 achieved remission which 
was sustained at 2 year follow up. This led to a large randomised 
controlled trial. This multi-centre study recruited a total of 681 patients 
with chronic major depressive disorder, double depression that is major 
depression superimposed on dysthymic disorder or recurrent depression 
with incomplete remission. They were randomised to 12 weeks of 
CBASP monotherapy (16-20 sessions, patients were seen twice a week 
for the first 4 weeks which eould be extended to 8 weeks if the patient 
was not adequately performing a learned social problem-solving 
procedure), nefazodone therapy (maximum dose of 600mg daily) or 
combination treatment. The study also included a 4 month 
continuation/maintenance phase. Results from the acute study indicated 
that nefazodone produced quicker results initially and was more 
efficacious than CBASP alone during the first 4 weeks of treatment. By 
the end of the 12 weeks however, both appeared to be equally effective, 
completer analysis of the 519 subjects demonstrated response rates of 
52% for CBASP and 55% for the nefazodone and 85% combined 
nefazodone and CBASP (p<0.001 for both comparisons). Remission 
• 
rates showed similar trends (CBASP, 33%; nefazodone, 29%; combined 
treatment, 48%) and psychosocial outcome was significantly superior in 
the combined group (Hirschfield et al 2000). 
Barrett and colleagues (2001) examined the effects of 11 weeks of 
treatment with paroxetine, Problem Solving Treatment (PST) or placebo 
(pill plus clinical management) in 241 primary care patients with either 
dysthymia (n=127) or mild depression (n=114). 191 (73%) of subjects 
completed all treatment visits. For the dysthymia, remission rates, 
defined by the authors as a Hamilton depression score of 6 or below, 
were significantly higher for ~he paroxetine (80%) and PST groups (57%) 
compared to placebo (44%) (p < 0.008). The remission rates were high 
for the mild depression group (64%) with no statistical difference 
between treatment groups (60.7% paroxetine group, 65.5% PST group, 
65.6 placebo group). 
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A parallel study was conducted in patients over the age of 60 (n=415) by 
. ' 
Williams and colleagues (2000). The subjects included 211 dysthymic 
patients and 204 patients with minor depression. 311 (74.9%) of patients 
completed all visits. After 11 weeks of treatment the paroxetine group 
demonstrated the greatest improvement in depressive symptoms 
compared to placebo (p<0.004); although no differences were found 
between the PST and placebo the psychotherapy group demonstrated 
the more rapid symptoms improvement during the latter weeks 
compared to placebo (p<0.001 ). Mental health functioning was found to 
improve with paroxetine in the dysthymic group (p<0.03) but not the PST 
group compared to placebo. Both the medication and PST groups 
improved mental health functioning in patients with minor depression as 
measured by the Medical Outcomes Study Short-Form (SF-36). 
A UK study carried out by Simpson and colleagues (2000) examined the 
effects of counselling added to usual GP care in 181 primary care 
patients with chronic depression and/or anxiety. Patients in the 
experimental condition were compared to a treatment as usual (TAU) 
control group. Beck depression Inventory scores were taken at baseline, 
6 months and 12 months follow up. Comprehensive cost measurements 
were taken. There was an improvement in the BDI scores over time, 
although there were no significant differences between the groups . 
• 
Fewer ofthe experimental group were still "cases" on the BDI (>14) than 
controls at 6 and 12 months; this difference disappeared at 36 months 
(Corney and Simpson, 2005). The cost burden to GP practices was 
significantly higher in the counselling group. One key limiting factor of 
this study is the authors idiosyncratic definition of chronic depression; a 
BDI score of~ 14 alongside symptoms of mild depression for at least 6 
months. This does not fulfil the ICD 1 0 or DSM IV criteria for chronic 
depression. 
Despite the limited literature available there are promising data emerging 
which suggest a role for psychotherapy in treatment resistant depression 
(Thase 1997b, 1997c). The most effective treatment appears to suggest 
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a combination of pharmacotherapy and psychotherapy, including IPT, 
which may be beneficial in chronic or severe depression as well as 
preventing a relapse (Hollon et al, 2005; Hegerl et al, 2004). Clearly, 
there is a gap in the evidence base in this difficult to treat population; it 
' . 
has been argued that more trials of psychological treatments in resistant 
depression are needed (McPherson et al, 2005; NICE guidelines, 2004). 
Electroconvulsive therapy (ECT) 
Electroconvulsive therapy (ECT) was introduced in 1938 by Cerletti and 
Bini and has been used ever since. However, with the development of 
antidepressant medication its use has become less frequent. lt does 
form an essential treatment of severe or treatment resistant depression 
(Husain et al, 2004). Many comparisons of the two forms of therapy have 
been carried out in order to define better their relative clinical indications 
and our understanding of the mechanisms of action (Brandon et al, 1984; 
Gregory et al, 1985; Greenblat et al, 1964; Sackheim et al, 1987). 
ECT involves the application of electrical stimulation of the brain by 
passing a current through two electrodes placed in contact with the 
scalp. This can be administered bilaterally, on one side of the head, or 
unilaterally, on both sides of the head. ECT does not produce any 
structural changes of brain matter as assessed by sophisticated 
neuroimaging (Scott, 1995) and does not lead to neuronal death 
(Devand et al, 1994 ). Unilateral ECT has been found to cause less short 
term cognitive impairment (Sackheim et al, 1993). ECT is commonly 
' 
used for a treatment for depression after antidepressants have been tried 
unsuccessfully. A study of 100 medication resistant depressed patients 
conducted by Prudic et al (1996) found the response rates after one 
week of treatment was 63.1% which decreased to 47.7% after cessation 
of the ECT. Although the response rates were found to be lower in 
medication resistant depressed patients in the United States, this has not 
been supported in other areas where similar responses are reported in 
medication-resistant patients and non medication-resistant patients (van 
de Broek et al, 2004; Husain et al, 2004; Pluijms et al, 2002). 
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Vagus Nerve Stimulation (VNS) 
Vagus Nerve Stimulation (VNS) involves the implantation of a generator 
that stimulates the vagus nerve which is effective in reducing seizure 
activity. Vagus nerve stimulation is known to affect a variety of 
neurotransmitters including noradrenalin, serotonin, GABA and 
glutamate, and is thought to affect multiple areas of the brain which are 
implicated in mood disorders (George et al 2000). A recent pilot study of 
' 30 patients with treatment resistant depression reported a 40% response 
rate after 1 0 weeks of vagus nerve stimulation (Rush et al 2000). Several 
tests of neurological function showed improvements in this group 
(Sackheim et al, 2001 a). After an additional 9 months of vagus nerve 
stimulation, response rate was sustained and the remission rate 
significantly increased (Marangell et al, 2001 ). 
An open pilot study of 60 treatment resistant patients was reported by 
Sackheim and collaborators (2001 b). Patients had not responded to at 
least 2 trials of antidepressant treatments. Concomitant antidepressant 
medication was permitted ~hroughout the trial (at the same dose or 
decreased dose). After 1 0 weeks of VNS treatment 59 patients 
completed the ratings. There was a 30.5% response rate on the 
Hamilton depression scale and 37.5% for the Clinical Global Impression 
-Improvement score. The authors found that patients who had not 
previously received ECT were 3.5 times more likely to respond. 
Furthermore, none of the 13 patients who had not previously responded 
to 7 trials of antidepressant medication responded compared to 39.1% 
the remaining patients (p<0.005) suggesting increasing levels of 
treatment resistance are less likely to respond to VNS. A one year 
naturalistic study of treatment resistant depressed patients was 
' 
conducted by George et al (2005). Patients received VNS plus treatment 
as usual (TAU, which could include increasing doses of antidepressant 
medication and ECT if needed) (n=205) and were compared with TAU 
alone (n=124). The combined group was associated with a greater 
improvement each month as measured by the 30 Item Inventory of 
Symptomatology - Self Report (IDS-SR (30)) (P<0.001 ). There was a 
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significantly superior response rate in favour of the VNS as compared to 
the TAU group (27% vs. 13%; P < 0.01). Twelve months of VNS was 
well tolerated and the authors suggested a role for VNS in longer 
treatment of resistant depression (Rush et al, 2005). 
Transcranial Magnetic Stimulation (TMS) 
Transcranial Magnetic Stimulation (TMS) is a brain stimulation device 
which delivers a time varying current through a coil close the head in 
order to stimulate the brain of a conscious patient. lt stimulates the 
cortex by creating a time varying magnetic field over the surface of the 
head, depolarising the underlying superficial neurons which induces 
electrical currents in the brain (George et al, 1 999). lt is hypothesized 
that TMS produces behavioural effects solely through the production of 
electrical currents in the cortex of the brain (Wassermann, 1996). 
There have only been a handful of studies reviewing the efficacy of TMS 
in resistant depression which have involved mostly open trials and only a 
small number have compared the active TMS to a sham (placebo) 
condition. Fitzgerald and colleagues (2003) in Australia compared high 
frequency left TMS (HFL-TMS) with low frequency right TMS (LFR-TMS) 
against a sham condition in 60 treatment resistant depressed patients. 
. ' 
There was no distinction between HFL-TMS and LFR-TMS treatments 
and both were significantly better than the sham group (p<0.005). 
An open trial of 1 0 medication resistant patients received repetitive TMS 
(rTMS) augmented to antidepressant therapy (Huang et al, 2005). After 
two weeks there were significant reductions in the Hamilton depression 
and Beck Depression Inventory scores (48% and 28% respectively). 
Although three patients did not improve, 5 were considered responders 
(decrease of at least 50% in Hamilton depression scores) and were in 
remission (Hamilton< 8). 
A randomised controlled trial compared 15 sessions of TMS to the same 
number of sham treatments (Avery et al, 2005). Of the 68 medication 
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resistant depressed patients a superior response was obtained in favour 
of the TMS group (11/35; 30.6%) versus 6.1% (2/33) which was clinically 
significant (P.0.008). Furthermore, 7/35 (20%) achieved a remission with 
• 
the active treatment compared to the 3% (1/33) of the sham group. 
A comparison of rTMS to ECT in 40 severe and resistant depressed 
patients was conducted in Israel by Grunhaus and collaborators (2003). 
Patients were randomly assigned treatment with ECT or rTMS for 4 
weeks. Overall, 58% (23/40) of the patients improved (Hamilton 
depression score reductions > 50%) with no significant differences 
between treatment groups (response rate ECT, 12/20; rTMS 11/20). 
Whilst there have been positive results regarding the efficacy of TMS in 
resistant depression (Kaufman et al, 2004), there have been a small 
number of negative findings where active TMS at both high and low dose 
(Minuissi et al, 2005) have been no different to the sham condition (Loo 
et al, 2003). 
TMS is a relatively newcomer to treatment and is largely still only used 
as a research intervention. lt is only available as a clinical option Canada 
and Israel. 
Studies in progress 
Although there are data supporting certain approaches, efficacy of a 
broad range of clinical treatments tend to rely on anecdotal evidence and 
• 
we have yet to achieve a firm scientific foundation from which to base 
our clinical practice. Researchers in the United States have started to 
address this concern and have developed a large clinical trial with the 
aim to evaluate a staged treatment approach for varying levels of 
treatment resistance (Tamminga, 2003; Wisniewski et al, 2003). 
Recruitment has started for a multi-site, prospective randomised clinical 
trial of 4000 depressed out patients. There are four levels of treatment 
options being evaluated, entailing various randomised treatment options 
at each level. This will be the first and only study of its kind to 
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systematically evaluate a staged approach to manage treatment 
resistant depression. Patients who continue to demonstrate an 
unsatisfactory response at each stage progress on to the next level. The 
first level is treatment with citalopram. The second level treatments 
involve a switch or an augmentation category (Switch options: sertraline, 
bupropion, venlafaxine and cognitive therapy. Augmentation options: 
bupropion, buspirone and cognitive therapy). At this stage the cognitive 
therapy poor responders can be given venlafaxine or bupropion in 
addition. The third level also has a switch or augment option (switch to 
mirtazapine or nortriptyline; or augment lithium or thyroid hormone to the 
primary antidepressant). The final level involves one of two switch 
options (1) tranylcypromine or 2) venlafaxine and mirtazapine). The 
patients will be followed up for a twelve month naturalistic study. 
Although complex, the unique design of the study will allow 
generalisabilty to a large set of patients (Rush et al 2004; Fava, 2003b). 
Future directions in treatment resistant depression studies 
Clearly, resistant depression is a common problem which has only 
recently attracted scientific investigation; we are just beginning to 
understand clinically relevant and meaningful information. Yet, we still 
need to gain further insight into the spectrum of resistant depression, the 
efficacy of specific treatment approaches and which treatment 
approaches suit which particular patients. Moreover, there are limited 
data on the efficacy of any psychotherapy as a treatment for resistant 
depression, and no research has been conducted evaluating IPT in this 
treatment group. Indeed, the National Institute for Clinical Excellence 
(NICE, 2004) recommend . that adequately powered randomised 
controlled trials are carried out to compare true efficacy of different 
psychological models including IPT, CBT and behaviour therapy in 
resistant depression. 
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Chapter three- Interpersonal Psychotherapy 
(I PT) for depression 
History and origins of IPT 
The interpersonal approach has a long history dating back from the work 
of Adolf Meyer (1957) and Harry Stack Sullivan (1965). Meyer argued 
that mental disorders developed as a result of an individual's attempt to 
adapt to his or her environment. He was the first psychiatrist to introduce 
a psychobiological approach where he recommended that psychiatric 
I ' 
evaluation included consideration of social and cultural factors. Sullivan 
extended this theory further, suggesting that interpersonal relationships 
could be connected to psychiatric disorders. Rather than focusing 
exclusively on the mind, the brain or indeed society, he proposed that 
psychiatric assessment should involve the scientific study of people and 
the processes between people, that is, "interpersonal relations". 
Sullivans' approach has been applied to therapeutics within psychiatry; 
for example an interpersonal modification of intensive psychodynamic 
psychotherapy was proposed for schizophrenia (From-Reichmenn et al 
1960) and for manic depressive young people (Cohen et al 1954 ). 
In a related approach, Bowlby's attachment theory (1969) proposed that 
humans have an innate tendency to seek attachments which lead to 
individual satisfaction and thus contribute to survival of the species. 
Humans generally develop attachment bonds with few people such as a 
spouse, friend or member of the family (Henderson 1978). Bowlby 
argues that individuals are happiest when there are clear attachments; 
conversely, they are vulnerable to develop a depression when there is a 
disruption in attachments. 
The consideration and assessment of interpersonal and social factors in 
• 
understanding and treating depression has developed from work carried 
out by founders of the interpersonal approach. Mabel Cohen and 
colleagues ( 1954) led the first group in applying the interpersonal ideas 
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specifically to depression. A group of 12 manic depressive patients were 
studied, all of whom had experienced disrupted interpersonal 
• 
relationships during childhood. Early family experiences were found to be 
reflected in their adult life, demonstrated by interpersonal and 
dependency problems. 
Using an interpersonal approach the focus of observation and 
therapeutic intervention is the primary social group; particularly the 
individual's closest relationship such as the spouse or partner, family 
members, friends, work and wider community relationships. The 
relationship between psychopathology and social roles can be viewed in 
2 ways: disturbances in social roles can contribute to clinical pathology, 
and mental illness can lead to a reduced capacity to perform a social 
role. 
There is empirical evidence which supports the focal areas of treatment 
in IPT. Complicated bereavement has been shown to lead to depression 
(Walker et al, 1977; Maddison and Walker, 1967; Maddison, 1968). In 
addition, marital disputes (Paykel et al, 1969; Pearlin and Leiberman, 
1977) and the life changes encompassed by interpersonal role 
transitions (Overholser and Adams, 1977) are stressors which can also 
contribute to a depressive illness. This is especially the case when there 
is an absence of social supports. In contrast, intimate relationships, 
and/or having someone to talk to as a confident have been shown to 
have a positive and protective effect against depression (Henderson, 
1977; 1978; 1980; Brown-Harris and Copeland, 1977). Frank (1973) 
stressed that helping that patient achieve a mastery of current 
interpersonal situations is an important component of psychotherapy. 
A group of researchers from the New Haven Boston Collaborative 
Depression Research Project drew on these theoretical approaches and 
tested variants of Interpersonal Psychotherapy in several clinical trials 
(Kierman et al, 197 4; Weissman et al, 197 4, Weissman et al, 1979; 
DiMascio et al, 1979). lt tqok over 15 years for the above group to 
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develop IPT in its current form. A manual of IPT originally developed for 
research purposes to train therapists in the concepts and techniques of 
IPT was published to aid application of IPT in a clinical and research 
setting (Kierman et al, 1984 ). 
Structure of a course of IPT 
Interpersonal Psychotherapy is a brief psychotherapy which can be 
provided as acute treatment for major depressive disorder. The 50 
minute sessions are provided weekly for up to 16 weeks and involve 
three phases of treatment: an initial, middle and an end phase. 
The Initial Phase 
The initial phase of Interpersonal Psychotherapy (IPT) has a dual focus, 
to reduce depressive symptoms and to deal with the social and 
interpersonal problems associated with the depression. lt takes up to 
three sessions; during this time the therapist provides an overview of the 
• 
therapy and thus sets a framework for treatment. The IPT therapist 
starts with a comprehensive psychiatric history and a diagnosis of 
depression is made using the standard DSM IV TR criteria (APA 2000). 
Once confirmed, the patient is explicitly told that they have a diagnosis of 
depression; the therapist reinforces they suffer from a treatable medical 
illness. This "sick role" (Parsons, 1951) excuses the patient from 
overwhelming social obligations, helps to ease guilt often associated with 
depression and reinforces what treatment is needed to help the patient 
get better. The sick role is used as a therapeutic rather than regressive 
mechanism. The therapist outlines that although the patient does not 
have full control over their Hlness, they can take full control over what 
they can do to bring about a remission. This helps to provide hope for the 
future that things will improve. At the start of treatment the therapist 
obtains a baseline measurement of the severity of the patients' 
depression by using the Hamilton depression rating scale. Suicidal 
intention is assessed, as is the need for concomitant antidepressant 
medication. The therapist regularly evaluates the depressive symptoms 
using this scale throughout treatment to monitor progress. 
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As part of the history, the IPT therapist gathers an Interpersonal 
Inventory. This is a review of the patients social and interpersonal 
functioning and comprises of an in-depth assessment of the quality of 
relationships in the patient's life, both past and present. Details of 
significant relationships are explored, including frequency of contact, 
expectations of both parties in the relationship and whether their 
expectations are realised, any changes the patient feels they would like 
to make, levels of satisfaction or dissatisfaction with the relationship, 
benefits and drawbacks including any overt or covert disagreements. 
Changes which have occurred in the relationships or interpersonal 
situation are examined in relation to the onset of the depressive episode. 
This could include significant events such as bereavement, promotion, 
demotion, children leaving home or increased marital disharmony. 
At the end of the initial phase the therapist offers an interpersonal 
formulation (Markowitz and Swartz, 1997). Here a link is made between 
the onset and maintenance of the current depressive episode and the 
patient's social and interpersonal situation. This framework includes four 
• 
potential problem areas: bereavement, role-transitions, role-disputes and 
interpersonal deficits. The therapist seeks to reach an agreement with 
the patient regarding this potential problem area. Once established, a 
treatment contract is set for both therapist and the patient; hence the 
focus for the middle phase is agreed. 
The Middle Phase 
The middle phase of IPT, which usually lasts between sessions 3-14, 
forms the main focus treatment. Here one or two of potentially four 
problems areas are identified with the patient and clearly-defined 
treatment strategies as outlined in the treatment manual are used 
(Kierman et al, 1984). The aim is for the therapist to work with the patient 
to reduce depressive symptoms caused and maintained by interpersonal 
problems. The four interpersonal problem areas are as follows: 
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Complicated bereavement 
The patient has experience'd a death of a loved one and for various 
reasons may not have grieved appropriately which leads to ongoing 
symptoms of depression. 
Role dispute 
The patient may be in open dispute or disagreement with an individual or 
group of individuals which could include friends, family or 
employee/employer relationships. This conflict may be contributing to 
current symptoms of depression. 
Role transition 
This is a broad area and could involve a change in role such as a 
promotion, demotion, having a baby, leaving home, moving house, 
separation or divorce or even receiving a diagnosis of a medical illness. 
The new role could cause or maintain depressive symptoms. 
Interpersonal deficit 
There are some individuals who have very few, if any, interpersonal 
relationships. The lack of fulfilling or rewarding social relationships in 
itself may be a contributing factor to continuing depressive symptoms 
Once the IPT therapist has' identified the problem area, he or she will 
work through the strategies highlighted in the manual in order to reduce 
depressive symptoms. In the case of a complicated bereavement 
following the death of a loved one, the therapist focuses the sessions on 
the facilitation of mourning and gradually helps the patient move forward, 
encouraging the patient to find new activities and relationships in order to 
help compensate their loss. 
Strategies which the IPT therapist employs in the case of a role dispute 
include helping the patient to explore the relationship, particularly the 
nature of the dispute and options to resolve it. In the cases where the 
' . 
84 
dispute cannot be resolved the patient may conclude that the relationship 
has reached an impasse and seek to end the relationship and replace it. 
When dealing with a role transition, the IPT therapist encourages the 
patient to mourn the loss of the old role; exploring with the patient the 
strengths and weaknesses. The therapist then helps a patient adapt to 
the new role by recognising both positive aspects of this role. 
The residual fourth problem area identifies the patient as significantly 
lacking in social skills resulting in problems initiating or sustaining 
relationships. The IPT therapist encourages the patient to build 
relationships with others and reflects to the patient improvement in social 
skills. 
Every depressed patient will meet the criteria for at least one of the four 
• 
problem areas and the problem area may in fact change in the course of 
the treatment. This most notably occurs when Interpersonal 
Psychotherapy is provided as a maintenance treatment. The patient 
may have several related problem areas and may work on more than 
one, or select the most salient area. 
The End Phase 
The final phase of IPT typically is provided over last 2-3 weeks of 
treatment. During this time the therapist encourages the patient to 
recognise and consolidate therapeutic gains, and to develop ways of 
identifying and countering depressive symptoms should they arise in the 
future. The use of prophylactic antidepressant treatment, which could 
include psychotherapy and/or antidepressant medication, is also 
discussed. 
IPT sessions focus on "here and now" problems rather than childhood or 
developmental issues. Sessions typically start with the question, "How 
have things been since we last met?" This allows the patient and 
therapist to focus on recent interpersonal events and its impact on the 
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patient's current mood. The IPT therapist takes an active, non neutral, 
supportive and hopeful stance. 
As in the case of other psychotherapies, IPT employs similar techniques 
including the use of a supportive encouraging therapeutic stance and a 
non-judgemental positive regard. However, there are distinct differences 
unique to IPT such as the use of strategies used to deal with specific 
problem areas. 
IPT for varying phases of treatment 
Researchers have become increasingly aware of the importance of 
distinguishing between varying stages of treatment. Phases of treatment 
have been split into acute, continuation and maintenance therapy which 
has helped us to gain more insight into optimal dose and duration of 
antidepressant treatment at a given point in an individuals treatment 
programme. Nevertheless, this is a relatively new area and there are 
limited data available incorporating this approach. There are some more 
recent IPT studies which address the efficacy of IPT at varying stages of 
• 
treatment which are reported below. In addition, the application of IPT 
has also been assessed for different aged populations in depressive 
disorder. The findings are presented below. 
Clinical trials of IPT as an acute treatment for adults 
The efficacy of IPT was first reviewed during a 16 week randomised 
control trial which compared IPT and amitriptyline alone or in 
combination against a non-scheduled control treatment in 81 depressed 
out patients (DiMascio et al, 1997; Weissman et al, 1979). IPT was 
administered weekly by a trained therapist who was encouraged to 
adhere to a treatment manuaL Amitriptyline was provided at a daily dose 
of 1 00-200mg. The therapeutic dose recommended in the British 
National Formulary (2003) is 75-200mg per day. The patients in the non-
scheduled treatment condition were allocated a psychiatrist. Although 
there were no scheduled treatment sessions routinely arranged, patients 
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were told they could telephone to arrange a 50 minute session if they 
were in distress. This was limited to a maximum of one session per 
month. 
Although the antidepressant effects of IPT were slower to start than in 
the case of the amitriptyline (2 weeks versus 4 weeks) by the end of the 
16 week trial both active treatment groups were found to be equally 
effective. Interestingly, combined IPT and amitriptyline was more 
effective than both monotherapies; this may be due in part to the 
preferential effects of each single treatment. IPT was found to target 
mood, suicidal ideation, apathy and reduced interest; whereas the initial 
effects of amitriptyline was on neurovegetative symptoms of depression 
including somatic symptoms, sleep and appetite disturbances. 
(DiMascio et al, 1979). Improvements in social functioning were the 
same in each treatment group after 16 weeks. The non scheduled 
treatment group had a worse overall outcome. 
The National Institute for Mental Health Treatment of Depression 
Collaborative Research Program (NIMH TDCRP) which started in May 
1982 (Eikin et al, 1985) carried out an enterprising and original study 
involving 250 depressed out patients. There were a number of innovative 
• 
and unique aspects to this study; it was the first head to head 
comparison of IPT and CBT, and was the first multisite psychotherapy 
trial where both psychotherapies were tested in a neutral setting 
(Pittsburgh, Washington and Oklahoma). In addition, it was the first time 
both psychotherapies were tested outside of their original area of 
development. 
The study involved 4 randomly allocated treatment groups: IPT (n=61 ), 
CBT (n=59), Imipramine plus Clinical Management (IMI-CM) (n=57), 
Placebo plus Clinical Management (PLA-CM) (n=62). Each treatment 
group during this trial had a detailed manual which described the 
theoretical rationale to each approach, an outline of the techniques to be 
employed and suggestions for how to deal with specific problems. IPT 
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and CBT sessions were audiotaped and monitored by independent 
raters using a specifically developed psychotherapy rating scale 
(Collaborative Study Psychotherapy Rating Scale, Hollon et al, 1987) . 
• Pharmacotherapy sessions were 45-50 minutes duration at baseline arid 
20-30 minutes for each subsequent session. The average dose for 
imipramine treatment was 185mg; (the British National Formulary 
recommended dose is 75-200mg each day). "Clinical Management" was 
added to imipramine and placebo and was also manualised in an attempt 
to prevent the pharmacotherapists from administering psychotherapy. 
During this trial the pharmacotherapists were allowed to review 
depressive symptoms, monitor side effects and provide a biochemical 
explanation for the patients' progress. This could be done in a warm 
supportive manner. These treatment sessions were taped and monitored 
for treatment adherence (Hjll et al, 1992). Depression was measured 
using the Beck Depression Inventory (BDI) and blinded ratings using the 
17 Item Hamilton Depression Scale. Additionally, the general level of 
functioning was rated using the Global Assessment of Functioning. 
Treatment lasted 16 weeks and most subjects completed at least 12 
treatment sessions over 15 weeks. Eleven patients dropped out of the 
study before treatment started. About a further third (32%) cohort were 
withdrawn or dropped out before the end of the trial, having completed 
less than 15 weeks of treatment or 12 sessions). 25% of this cohort was 
due to "negative reasons" such as non-compliance, side effects, or 
• dissatisfaction with treatment. Surprisingly, only 9% of the sample were 
symptomatic failures. There were positive results in all treatment groups 
yielding a significant reduction in depressive symptoms at the end of the 
16 week treatment (P<0.001 ). Primary analysis of the data included 
subjects with a range of mild to severe depression; there were no 
differences in the pre-treatment scores of all of the groups. The results 
demonstrated that imipramine had the best response, placebo the worst 
and the psychotherapies were in the middle. Of the 239 patients who 
completed the treatment, imipramine and clinical management was 
found to be statistically significant to placebo (p<0.01) with a trend in 
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favour of IPT (p<0.018) and CBT (p<0.019). There were no significant 
differences in recovery rates (Hamilton depression score <7) between 
the active treatments (I M I-CM 57%, IPT 55%, CBT 51% and PLA-CM 
21%). 
Secondary analysis separated patients who had severe depressive 
' symptoms (44%) at baseline (Hamilton depression score ~20) from 
those who were mildly depressed (Hamilton depression scores ~19); this 
produced superior recovery rates for IPT and imipramine in the more 
severe depressed and functionally impaired group (P=0.017; Brunden 
corrected, p= 0.1; p=0.017, Brunden corrected p = 0.1 repectively). 
Imipramine plus CM produced the most rapid response to treatment with 
a supenor efficacy compared to placebo. IPT was comparable to 
imipramine plus CM in several areas and showed a mean outcome 
superior to placebo plus CM. 
The efficacy data from this, study was reanalysed by Klein and Ross 
(1993). Similar results were found with imipramine being superior to 
psychotherapy and the psychotherapies somewhat superior to placebo. 
When the patient group having a cut off score of 30 on the Beck 
Depression Inventory (moderate to severe depression), CBT was found 
to be relatively inferior to I PT. 
On first examination it is disappointing that neither psychotherapy 
treatments were found to be more effective than placebo in the primary 
analysis. However, it must be stressed that during this trial the placebo 
with the added clinical management arm was neither "inactive" nor a "no 
treatment" condition. Patient's' in this condition were seen initially for 50 
minutes for the first session, followed by 20-30 minutes each week by an 
experienced psychiatrist who reviewed depressive symptoms, side-
effects and social functioning. They could be supportive and 
encouraging. This amount of contact provided to the patient in addition to 
supportive and sympathetic attention to reviewing depressive symptoms 
and side effects must be acknowledged as something more than a 
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placebo, which may have provided enhanced antidepressant effects. A 
waiting list control may have provided a more suitable placebo control for 
this study. Twenty-eight therapists were taped and monitored using a 
Collaborative Study Psychotherapy Rating Scale (Hollon et al, 1987) 
and were found to be adherent. 
A naturalistic follow up study was carried out by Shea et al (1992) who 
studied the course of depressive symptoms following the 16 weeks of 
treatment using IPT, CBT, imipramine plus clinical management (CM), or 
placebo plus Clinical Management (PLA-CM). Ratings were completed at 
6, 12 and 18 months after completion of the trial. The patients who 
participated in this study demonstrated the same percent recovery rates 
as shown at the end of the 16 week period of acute treatment (30%, 
14/46, CBT; 26%, 14/53, IPT; 19%, 9/48, IMI-CM; 20%, 10/51, CM). 
Relapse rates at the end of the 18 month follow up period were 36% for 
the CBT, 33% for the IPT, 50% for imipramine plus clinical management 
and 33% for the placebo plus clinical management. This was an early 
indication that active antidepressant treatment is needed to manage 
depressive symptoms in the longer term. 
Clinical trials of IPT as an acute treatment in the elderly 
IPT was first used with elderly patients in the early 1980's as an addition 
to a 6 week medication trial. The initial aim was to increase compliance 
as well as provide some active treatment in the placebo group 
(Rothbrum et al, 1982; Sholomskas et al, 1983). Eighteen patients aged 
68-85 were randomised to 6 weeks of weekly 30-50 minute IPT sessions 
augmented to imipramine, alprazolam or placebo. Eleven patients (61 %) 
completed the trial and demonstrated a positive response to treatment, 
which was evident from week 2 of the trial and continued for the duration 
of the protocol. One patient (6%) deteriorated and 6 (33%) dropped out 
of the study due to side-effects, treatment refusal or illness. The mean 
Hamilton depression scores fell from 20.9 at baseline to 7.2 post 
treatment. The authors reported that the patients showed good 
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compliance with medication and tolerated the combined treatment very 
well. 
The first clinical trial of IPT alone compared to antidepressant medication 
was performed by Sloane et al (1985). Fifty-five elderly depressed 
patients were randomised to receive IPT, nortriptyline (NT) or placebo for 
6 weeks. All three groups demonstrated significant improvements in 
mood as measured on the BDI and Hamilton depression scale (p= 
0.005). IPT was found to be as effective as nortriptyline. There was a 
significant difference in attrition rates between the groups (p<0.005); 
none of the IPT patients failed to complete the first 6 weeks, whereas 
8/18 of the NT group and 4/18 of the placebo dropped out of the study by 
this time. 
Reynolds has adapted IPT to deal with both uncomplicated bereavement 
as well as complicated bereavement which is an area most commonly 
experienced by elderly patients. The authors carried out a randomised 
study to establish the efficacy of IPT and nortriptyline as a monotherapy 
or combined compared to placebo in 80 subjects over the age of 50 who 
had bereavement related depressive illness. The combined group 
achieved the highest rates of remission (69%) (Hamilton depression 
score of 7 or below.) Nortriptyline alone achieved remission (56%), IPT 
and placebo (29%) and placebo and medication clinic (45%). 
' Additionally, the combined group was associated with the highest rate of 
treatment completion and the lowest attrition rates. The authors failed to 
detect an effect of IPT which may be due to a small treatment size or due 
to the research protocol restrictions which meant that the researchers 
had to break the blind treatment if patients had not responded after 8 
weeks. In addition, the supportive medication clinic may have had an 
antidepressant effect on the placebo group (Reynolds et al, 1999a). 
Clinical trials of IPT as an acute treatment for adolescents 
Interpersonal Psychotherapy has been modified to treat adolescent 
depression (I PT -A) (Moreau et al, 1991) and addresses common 
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developmental issues such as separation from parents, peer pressure, 
development of interpersonal relationships and the initial experience of 
death of a loved one. Because of its frequent occurrence, a fifth problem 
area addressing issues around single parent families was added as a 
focus during the intermediate stage (Mufson et al, 1993). There is a 
. . 
published manual available for IPT for adolescents (Mufson et al, 1993). 
IPT was first tested as a monotherapy with adolescents in a 12 week 
open feasibility study involving 14 depressed adolescents. At the end of 
the treatment all patients had significantly reduced depression scores 
and none met the DSM Ill R criteria for major depression. In addition, 
social functioning had significantly improved (Mufson et al, 1994). Ten of 
the 14 patients agreed to clinical assessments as part of a naturalistic 1 
year follow up study. Only one of the ten patients reported a second 
major depressive episode (this subject had dropped out of the original 
study after 4 weeks). The remaining subjects demonstrated th~t 
improvements in social functioning (p<0.001) and few depressive 
symptoms (p<0.001) during the following year compared to baseline 
scores. There had been a significant number of negative life events 
occurred throughout the year in a number of cases there had been no 
reported hospitalisations, suicide attempts or pregnancies. Additionally, 
all patients had been attending school regularly (Mufson and Fairbanks, 
1996). 
Rossello and Bernal (1999) were the first to publish results on a 
randomised controlled trial comparing IPT and CBT to a waiting list 
control (WL). 71 patients with major depression, dysthymia or both aged 
13-18 were randomly allocated IPT (n=22), CBT (n=25) or WL (n=24 ). 
Most of the patients met the criteria for double depression (I PT n=21, 
CBT n=16, WL n=17) Self-rated measures of depression, social 
adjustment, self esteem and family involvement were recorded at 
baseline, post treatment and 3 month follow up. The IPT used in this trial 
was based on the original manual (Kierman et al 1984) and not the 
specifically adapted IPT-A (Mufson et al, 1993). IPT (p<0.002) and CBT 
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(p<0.015) significantly reduced depressive symptoms compared to the 
control condition. Furthermore IPT was more effective than CBT 
compared to placebo in increasing self esteem (p<0.001) and social 
adaption (p<0.003). 
Mufson and colleagues (1999) reported the efficacy of IPT-A in a 12 
week clinical trial of 48 depressed adolescents (ages 12-18) randomly 
assigned to either IPT-A (n=24) or to a Clinical Monitoring (CM) condition 
(n=24) which involved montnly 30 minute sessions reviewing symptoms 
and functioning with an option for further sessions. A blinded clinical rater 
assessed symptoms of depression, global functioning, social functioning 
and problem solving skills every two weeks until the end of the trial. Self 
ratings by the patients of depression and social functioning were 
completed at the same time. 32 of the 48 patients completed the 
protocol. Significant decreases in the Hamilton depression scores 
became apparent after week 12 and continued to termination for the IPT-
A group (p<0.01) However, no differences were noted in the Beck 
depression scores between groups. 75% of the IPT-A group met the 
recovery Criteria (HamD < 7) compared to 46% of the control group. At 
. . 
termination 13 (27%) of patients still met the criteria for major depressive 
episodes, of these patients 10 were in the CM group and only 3 in the 
IPT-A group. At the end of the study the IPT-A group were significantly 
less depressed (p<0.001) demonstrated significant improvements in 
functioning overall (p<0.02), with friends (p<0.02), dating (p<0.02) and 
problem solving (p<0.05) compared to the clinical management group. 
Then~ was a high attrition of the CM group (56% vs. 12% IPT-A-group). 
Similar to the NIMH Elkin study (1989), the CM in this study was more 
than a placebo condition which was deemed by the authors to be an 
ethically acceptable treatment. The adolescents who participated in this 
study were largely female, l:atin American and "older" (mean age 15:7 
and 15.9 for each treatment group). Psychotic illness, obsessive 
compulsive disorder, substance abuse all excluded entry into the trial 
and therefore would reduce generalisabilty of the findings. 
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Santor and Kusumakar (20Q1) carried out a 12 week open trial of IPT for 
25 adolescents with moderate to severe mood disorders which had 
lasted several months (mean 8 months). Uniquely, not all of the 
therapists in this trial had used IPT previously, however they were well 
supervised. The majority of patients showed improvement on the 
Hamilton Depression Scale, the Montgomery and Asberg Rating Scale, 
The Beck Depression Inventory, the Children's Global Assessment of 
Functioning. Eighty percent met the remission criteria on the BDI and 
84% remitted on the Hamilton Depression Scale. The authors noted in 
addition to confirming the efficacy of IPT for adolescents in this small 
group, IPT also demonstrated that limited training alongside careful 
supervision in this cohort had been an effective approach. 
Clinical trials of IPT as a maintenance treatment in adults 
Psychotherapy can be a useful alternative for patients who may not wish 
to take or indeed tolerate antidepressant medication including pregnant 
or nursing mothers, or those awaiting major surgery, for example. 
Maintenance Interpersonal Psychotherapy (I PT -M) has a role when 
dealing with social or interpersonal consequences or triggers of 
depression (Weissman 1994). Frank and others (1989; 1990b; 1991a) 
were the first to research and demonstrate the efficacy of any 
antidepressant maintenancE( psychotherapy. However, Klerman and 
collaborators reported a maintenance phase of IPT in an early study 
(Kierman et al, 1974). 
Although in 197 4 IPT had not been clearly developed to its current form, 
Klerman and colleagues were the first to study psychotherapy alone or 
combined with amitriptyline in 150 patients aged 25-60 following an 
acute phase of treatment of 4-6 weeks of 1 00-200mg amitriptyline. 
Responders progressed to what the authors called a maintenance phase 
although today this would be considered a continuation phase. The 
patients were allocated to one of six possible options: amitriptyline, 
placebo or no pill, all of thes'e treatments were augmented to either high 
interpersonal contact (one hour per week session with experienced 
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social worker focusing on the patients' current problems and 
interpersonal relations) or low interpersonal contact (maximum of 15 
minutes a month with a psychiatrist reviewing symptoms, side effects 
and rating depression). 
The amitriptyline group (high and low interpersonal contact) yielded the 
lowest relapse rates; 12.5% and 12% respectively. This was closely 
followed by the no pill and weekly psychotherapy group (16.7%). The 
placebo group in the high and low interpersonal contact conditions 
showed higher relapse rates (28%, 30.8%) and the no pill and monthly 
15 minute interpersonal contact (virtually no treatment) had the highest 
relapse rates (36%). Blinded raters used the Social Adjustment Scale 
(SAS) one month after maintenance treatment started and after 2, 4 and 
8 months. There were 1 06 patients available at follow up. Although no 
• 
treatment effects were noted after four months, numerous differences 
were noted between the high contact and low contact groups at month 
eight. High contact psychotherapy (44%) was found to improve the 
patients' social adjustment, family relations, work performance, improve 
communication, and reduce friction compared to the low contact group 
(28%). There were no drug treatment effects on the patients' social 
adjustment. Combined IPT and amitriptyline demonstrated the greatest 
efficacy in preventing relapse and improving social functioning (Kierman 
et al, 1974, Weissman et al, 1974). Although the effects of 
psychotherapy in preventing relapse were suggested, it was not found to 
be statistically significant. 
Maintenance Therapies in Recurrent Depression Study (MTRD) 
Researchers led by Ellen Frank in Pittsburgh were interested to see if 
IPT could be adapted as a maintenance treatment and used successfully 
with prophylactic benefits in highly recurrent major depressed patients. A 
sophisticated study known as The Maintenance Therapies in Recurrent 
Depression Study (MTRD) (Frank et al, 1989) recruited 128 patients 
aged between 21-65 who had had at least three previous major 
depressive episodes (the last episode not exceeding 2.5 years before 
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index episode). Patients with major depression who had a Hamilton 
Score of at least 15 and minimum Raskin Score of 7 met the inclusion 
criteria of the trial. 
Patients with double depression (eo-morbid dysthymic disorder) were 
excluded from the trial. At the start of treatment patients underwent a 2 
week drug washout peribd and received biological (sleep and 
neuroendocrine) and psychosocial (social adjustments and social 
supports) assessments. Patients were then treated during the acute 
phase with a combination of IPT (weekly for 12 weeks reduced to 
fortnightly for 8 weeks) and imipramine (150-300mg). When depression 
scores dropped to below 7 on the Hamilton Scale and below 5 on the 
Raskin Scale for three consecutive weeks the patients entered 17 weeks 
of a continuation phase. This prolonged and maintained the patients' 
recovery from depression, and ensured a clear remission of depressive 
symptoms. At the end of the 17 weeks the patients were randomised to 
one of five treatment cells for the maintenance phase of treatment lasting 
' 
three years: Monthly maintenance IPT (IPT-M); Imipramine and monthly 
IPT (IMI-IPT-M), monthly IPT and placebo (IPT-M-PLA); IMI and 
Medication Clinic (IMI-MC); and placebo and medication clinic (PLA-MC). 
Biological and psychological assessments were carried out at baseline, 
at the end of the acute and continuation phase. Depression was 
measured by an experienced blinded rater throughout the trial. 
A variant of IPT was developed specifically for this study. Sessions were 
planned monthly and therapists were encouraged to employ 
interpersonal strategies in order to prevent a relapse. A longer time 
frame would allow the patientand therapist to shift focus among the four 
problem areas. There was no work done to establish a reasonable 
"dose" of IPT-M, and it must be noted that monthly IPT is significantly 
less than the weekly acute dose. Imipramine however, was administered 
at high acute doses, at a mean dose of 21 Omg/day. 
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The course of the illness and early recurrences were reported (Frank et 
al, 1989) in 7 4 patients who had been randomised to no active 
medication during the maintenance phase. lt is not surprising in this high 
risk group that 44 of 74 patients relapsed during the three year period, 8 
dropped out or were noncompliant and only 22 of 74 remained well. 50% 
of the medication clinic group had relapsed by 21 weeks in contrast to 61 
weeks for the IPT-M group. Only IPT-M was found to significantly extend 
survival time (p<0.02). Interestingly the authors found no correlation 
between initial severity of depression and treatment outcome; this was 
thought to be due in part t'o the 20 weeks continuation phase where 
patients remained on high doses of imipramine and frequent IPT-M 
psychotherapy sessions. Gender, age of onset, length of depressive 
episode all did not predict survival time. 
In 1990 Frank and collaborators reported the results of the study in total. 
230 patients had entered the study, 73 of whom failed to reach 
continuation treatment, and 128 out of 157 patients completed the 
continuation phase. Dropouts were due to relapse, intolerable side 
effects, non-compliance or a secondary diagnosis of psychotic disorder. 
The patients were randomly assigned to the treatment cells as follows: 
' IPT-M, n=26; IPT-M -PLA, n=26; IPT-M -IMI, n= 25; IMI-MC, n=28; MC-
PLA, n=23. There were no significant differences in the treatment groups 
regarding age, gender, number of previous depressive episodes or 
illness duration. Although the entry criterion was a minimum of 3 major 
depressive episodes the mean number of episodes was 7, suggesting an 
extremely high risk for a future relapse. Only 22 (17%) failed to complete 
the 3 year study. Survival analysis revealed that high dose Imipramine 
(average dose 215mg) was found to effectively provide protection 
against a recurrence and IPT-M greatly extended survival time (p 
<0.05); the overall effect of the I PT-M occurred regardless of whether it 
was combined with medicaNon or not. The mean survival time starting 
with the best treatment group and ending with the worst were as follows: 
IPT-M + IMI 131 weeks (sd10); IMI + MC 124 weeks (sd13); IPT-M 82 
(sd13); IPT-M + PLA 74 (sd12); PLA +MC 45 weeks (sd11). The groups 
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were ranked in the same order with respect to survivors after one year 
(IPT-M +IMI 84%; IMI+MC 60.7%; IPT-M 46.2%; IPT-M+PLA 46.2% and 
I 
finally PLA + MC 21.7%) and maintained their positions after 3 years (IMI 
60%; IMI+MC 46.4%; IPT-M30.8%; IPT-M+PLA 19.2%; PLA+MC 8.7%). 
Twenty of 28 patients who had completed the 3 year study and remained 
well on active medication agreed to an additional 2 years comparison of 
imipramine versus placebo (Kupfer et al, 1992). Patients who were 
receiving maintenance IPT-M would continue to do so (n=13). Twelve 
patients completed the 2 years, 7 of which had a depressive recurrence. 
1 patient was withdrawn. The high dose imipramine group yielded the 
best survival results (82%, p<0.001) and not surprisingly the recurrence 
rates for the placebo group was 11 times greater than that of the 
imipramine group. lt is worthy of note that 78% of the placebo survivors 
had continued to receive I PT-M and 11% of the placebo survivors did 
not; promising results for the antidepressant potency of IPT in this high 
risk group of patients. 
Researchers of the MTRD study were eager to evaluate the quality of the 
therapy provided during the trial (Frank et al 1991 ). Blinded raters 
reviewed 7 -minute segments at the beginning of each session using a 27 
item Psychotherapy Rating Scale which was designed to ascertain 
interpersonal interventions (the focus of IPT-M) or somatic interventions 
I (which would be a primary focus during medication visits). Blind raters 
using psychometrically sound instruments were found to discriminate 
between the two maintenance conditions (p<0.0001 ). Furthermore, 
subjects receiving IPT-M could be divided into groups providing a high 
and a low interpersonal focus. Interestingly, there were significant 
differences in the survival rates of these two groups. Low interpersonal 
focus during psychotherapy sessions resulted in a median of 18.1 weeks 
to recurrence, whereas the high interpersonal focus (i.e. more specific 
interpersonal approach) demonstrated 101.7 weeks to a recurrence 
(p<0.0001 ). Given the history of response and duration of being well 
between episodes, the lower interpersonal focus group survived for the 
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same period of time as previously. In sharp contrast, the higher 
specificity group survived more than four times longer than expected. 
Clinical trials of IPT during continuation/maintenance phases in the 
elderly 
Psychotherapy research for depression in late life was identified a priority 
by a National Institute of Mental Health conference, U.S. in 1990 
(Reynolds et al, 1992). This led to a sophisticated long term study led by 
Reynolds and collaborators similar in design to the Maintenance of 
Recurrent Depression Study which was conducted at the same research 
centre, the Depression Prevention Clinic, Pittsburgh. This group carried 
out a rigorous study with a large sample size evaluating the efficacy of 
IPT in old age depression. (Reynolds et al, 1992; 1994; 1996a; 1996b; 
1997; 1999a; 1999b) Although primarily a maintenance study this 
encompassed treatment during acute and continuation phases. 
Overview of Maintenance Treatment Late Life Depression Study 
The Maintenance of Therapies in Late Life Depression (MTLLD) study 
was designed to compare 4 treatment maintenance therapies in 
prolonging recovery and preventing a recurrence of major depression in 
recurrent elderly depressives. Acute, continuation and maintenance 
phases of treatment were studied; outcome measures included 
depressive symptoms, global functioning and social functioning. The 
study recruited 187 depressed elderly subjects. During the acute phase 
of the trial patients received an open trial of nortriptyline (titrated to 
achieve blood levels of 80-120ng/ml) and at least 12 weekly IPT 
sessions. Patients who did not demonstrate a minimum of 50% reduction 
in the Hamilton depression scores by 8 weeks were provided additional 
antidepressant, mood stabilising or tranquilising medication until 
remission of depressive symptoms. Concomitant medication 
administered at the acute phase was then withdrawn for the continuation 
phase. Patients who were in remission (3 weeks of a Hamilton 
Depression Score of 10 or below), progressed to the 16 week 
continuation phase. IPT was then reduced to fortnightly for the first 8 
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weeks and then to 3-weekly for the remaining period. Sustained remitters 
at this point were then randomly assigned to one of four treatment 
conditions and followed up for 3 years: Combined IPT and nortriptyline 
(IPT-NT); IPT and placebo (IPT-PLA); nortriptyline and medication clinic 
(NT -MC) (medication clinic was a 15 minutes review by a psychiatrist of 
symptoms and side effects); placebo and medication clinic (PLA-MC). 
Preliminary results reported during the acute and continuation phase 
• 
After two years of the study Reynolds and colleagues (1992) reported 
preliminary results an open trial of weekly IPT and nortriptyline during 
acute and continuation phase. 
73 patients aged 60-80 (mean 67.5) were initially enrolled in the study. 
Twelve patients (16.4%) withdrew consent or dropped out before the 
treatment started. One patient died and another withdrew consent 
during the continuation phase. 61 subjects of the original cohort 
completed the acute phase; and 59 (80.8%) of the subjects who entered 
the study completed both the acute and continuation phases. 48 (78.7%) 
subjects responded fully to combined IPT and nortriptyline, three patients 
showed a partial response (Hamilton depression score 11-14) and 10 
patients were found to be nonresponders. There were no differences 
detected in response when comparing early onset (~.60) major 
depressive disorder to late (<60) onset (70% vs. 64.2% respectively). 
There were low attrition rates from the trial (16.4%). During the 16 week 
continuation phase the clinic/psychotherapy visits were decreased to 
fortnightly for half of the phase, and then to 3 weekly for the remaining 
period. Five of the 51 (9.8%) patients who had responded to the acute 
phase relapsed but were successfully restabilised. lt is not surprising that 
the 10 nonresponders during the acute phase remained as depressed 
. . 
during the continuation phase. Six out of 25 patients (24%) of patients 
assigned to placebo-maintenance condition relapsed during the double 
blind discontinuation of nortriptyline. None of the patients assigned to 
continue nortriptyline relapsed during the 4-6 week transition period. 
Additionally, global functioning as measured on the Global Assessment 
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of Functioning (GAF) Scale (jemonstrated a steady improvement from a 
baseline GAF score of 76.6 at the start and 82.3 and end of continuation 
phase of treatment. lt is debatable whether this is a meaningful 
difference on a semi-objective scale. 
In the next paper, Reynolds and collaborators (1994) reported 32 
patients (mean age 66.8) who had relapsed following treatment with 
placebo during the maintenance phase of the study. They had a pre-trial 
median of four major depressive episodes and were re-treated with an 
open trial of nortriptyline and IPT within 2 weeks of the onset of the 
subsequent episode. Two P.atients withdrew from treatment and 27/30 
(90%) achieved remission; however 3/30 failed to remit and required 
further treatment intervention. The protocol required that the subjects 
were monitored closely, thus an early diagnosis of the subsequent major 
depressive episode was made alongside prompt antidepressant 
intervention; as a result this group of 27 responders to IPT and 
nortriptyline were not as depressed or as functionally impaired at the 
start of the subsequent episode compared to the index episode. This 
prompt intervention for the subsequent episode demonstrated 
significantly reduced time to remission (8.1 weeks versus 13.3 weeks 
respectively; p <0.01 ). Twenty-two of 27 (81 %) subjects demonstrated a 
shorter time to remission dtaring treatment of the subsequent episode; 
whereas only 5/27 (19%) took longer. Furthermore, there was a 
significant difference in total episode length between the index episode 
(41.5 weeks) and subsequent episode (9.9 weeks) (p<0.0001 ). The 
remission rates and time to remission in this study were comparable to 
non geriatric patients studied from the same site (Kupfer et al, 1989). 
Clearly, this is promising data supporting the efficacy for a combination 
of IPT and nortriptyline in recurrent depression, particularly as an early 
intervention. 
Opdyke and colleagues (1996) found in that in 105 patients who received 
l . 
combined nortriptyline and IPT, situational depression at baseline was 
associated with higher levels of residual depressive symptoms; whereas 
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the level of chronic medical burden, personality and social support were 
not. 
The pattern of response in depression and functioning during the 
continuation phase in the same subjects by the same authors was 
reported (Odpyke et al, 1996/7). Fourteen subjects were excluded from 
the analysis, 11 subjects had suffered a major depressive relapse during 
the initial continuation phase (Reynolds et al 1996b) and three had 
entered the continuation phase as a partial responder. Ten patients 
(19.5%) received concomitant adjunctive pharmacotherapy which was 
stopped when remission was achieved in order to progress to the 
maintenance phase. Due to a positive response to acute phase 
treatment, symptoms of depression at the start of the continuation phase 
were low (mean Hamilton score 7, 80=2.3), and patients continued to 
• demonstrate moderate improvements in depression scores by the end of 
the continuation phase (mean Hamilton score 5, SD=3; P>0.04). The 
authors were interested to identify which depressive symptoms which 
were present and persistent throughout the continuation phase. The 
greatest variability was observed with depressed mood, apathy, anxiety 
and anergia. Moderate resolution of symptoms was evident with 
insomnia, guilt and reduced libido. An excellent resolution of retardation, 
agitation, hypochondriasis, and suicidality, loss of insight, reduced 
appetite and weight loss was seen during the continuation phase. 
Additionally, the GAF scores demonstrated a significant improvement in 
the scores from the start to the end of the continuation phase (p=0.001 ). 
The mean GAF score at the end of treatment was 81.8 which indicated 
only a mildly impaired level of functioning. 
Findings from the MTLLD study 
180 patients were successfully recruited to the MTLLD, study of whom 
140 (78%) responded (Hamilton score~ 1 0) to a combination of IPT and 
nortriptyline during the acute phase therapy. Nineteen patients were 
nonresponders and a further 21 dropped out of the study mainly due to 
side effects and non-compliance; two subjects reported finding the IPT 
102 
too traumatic. By the end of the continuation phase 124 I 140 patients 
had maintained a remission of their depressive symptoms. Recurrence 
rates over the three year maintenance study were as follows: 
nortriptyline plus IPT 20% (95%CI, 4%-36%), nortriptyline plus 
medication clinic 43% (95% Cl, 25%-61 %), IPT plus placebo 63% (95% 
Cl, 45%-83%), and medication clinic plus placebo 90% (95% Cl, 79%-
1 00%). Combined treatment with IPT and nortriptyline was superior to 
. . 
IPT and· placebo (p<0.01) and showed a trend for superiority over 
nortriptyline monotherapy (p<0.06). 
Having completed the acute and continuation phase, the researchers 
found they could split the patients (n=140) into 4 different categories of 
response: delayed responders; sustained responders; mixed responders 
without a sustained improvement and prolonged non-responders. The 
groups were then randomised to three years of maintenance therapy 
with IPT and nortriptyline alone or in combination against a placebo. 
Each group was compared on subsequent recovery rates and time to a 
depressive recurrence. The authors found that the initial response profile 
predicted ultimate recovery rates: Rapid initial responders, within 4-5 
weeks, showed significant maintenance treatment effects (p<0.001) and 
lower recurrence risk with either combined or monotherapy relative to 
placebo. Either IPT or nortriptyline alone as a maintenance treatment 
appeared equally effective in the rapid responder group. Combined 
therapy, which was marginally better than monotherapy, was the only 
treatment which was superior to placebo with initial mixed responders 
(p<0.006). For delayed responders (more than 6 weeks), combined 
therapy was the only treatment superior to placebo (p<0.024). Prolonged 
non-responders did not benefit from maintenance treatment (Dew et al, 
• 
2001 ). 
The effects of age was evaluated in two sets of analyses; firstly, the 
effects of treatment with increasing age, and secondly, the age of onset 
of the first depressive episode and treatment outcome. The speed of 
response, remission and recurrence was reviewed in the two subgroups 
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of elders, 60-69 (n=113) and 70+ (n=67). Although no differences in time 
to remission, relapse or recovery was evident between the two 
subgroups, the "older" group (70+) showed significantly higher 
recurrence rates during the first year of maintenance treatment 
(p>0.0005). This was statistically detectable at 70 years and could 
predict poorer outcome at the age of 75 (p<0.007). The older group 
reported greater impaired subjective sleep quality and a higher incidence 
of medical comorbidity as well as a more frequent focus on 
bereavement, loss and role transition (Reynolds et al, 1997) which are all 
factors likely to increase the risk of depression. 
The data of 187 subjects was analysed in order to examine the effects of 
age at onset of first depressive episode in relation to treatment outcome 
and course. Early onset depressives (n=129, aged 59 or younger) were 
compared to late onset (n=58, age 60+) depressed subjects. Although 
there were no differences in absolute rates of remission, recovery and 
relapses were found between the groups; the early onset group took 
significantly longer to achieve remission (12.9 weeks) compared to the 
late onset group (7.3 weeks). In addition, a higher proportion of early 
onset 22.5%, (n=29) versus 1.7% (n=1) reported a history of suicide 
attempts which was statistically significant (p<0.0006) (Reynolds et al, 
1998). 
Analysis of clinical variables which correlated with depression free 
symptoms during the maintenance phase was conducted by Taylor and 
colleagues (1999). Patients with baseline Hamilton Scores of ~19 (n=6/9) 
were found to benefit most from IPT-M; conversely, Hamilton scores of 
over 19 (n=14/16) demonstrated greater relapse rates (p<0.01 ). In 
addition, the number of previous depressive episodes, chronic medical 
burden, time to remission and social support measures were not 
associated with an increased risk of a recurrence. However, these 
• 
results should be viewed with caution due to the small sample size of 
highly selected patients during this study. 
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Ageing populations bring about similar common problems; conjugal 
bereavement being one of the most frequent. The incidence of major 
depressive disorder is higher than the general population, at around 15-
30% following the death of a spouse within the first year of the loss 
(Zisook, 1991 ). Reynolds and collaborators (1999) were keen to examine 
the effects of nortriptyline and IPT alone or combined compared to 
placebo in 80 patients who had bereavement related major depression. 
Depression was measured using the Hamilton Depression scale and 
grief symptoms were measured using the Texas Revised Inventory of 
Grief. The combined IPT and nortriptyline group demonstrated the best 
remission rates (69%, n=11) followed by the nortriptyline only group 
(56%, n=14); then medication visits and placebo (29%, n=10) and finally 
IPT-PLA (29%, n=5). Additionally, the combined group showed the 
lowest attrition rates. As the authors suspected there was a significant 
effect of combined IPT and NT over placebo, however, no differences 
were found between IPT and PLA-MC. The authors concluded that this 
may be due to a number of factors: the small sample size may not have 
provided sufficient statistical power. Furthermore, the protocol dictated 
that the blind treatment is broken for patients who have not 
demonstrated 50% reduction in the Hamilton scores after 8 weeks; this 
may have discriminated against the IPT group. Furthermore, as was the 
case of the clinical management treatment used in the Elkin trial (1989) 
the supportive medication visit may also be considered a treatment with 
beneficial effects. 
There were no differential effects of the four treatment conditions on 
bereavement as assessed by the Texas Revised Inventory for Grief. 
This in itself may reflect the need for more time for the patient to resolve 
the grief, as bereavement alone is not a pathological condition but a 
normal response. 
Miller and colleagues (2003) examined the recurrence rates of 
depression in elderly depressed patients who were treated up to 3 years 
with pill placebo and either monthly IPT, or monthly clinical management 
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in addition. The authors were specifically interested to see if a different 
focal area in IPT would have a significant clinical effect. The authors 
found that patients with a focus on role conflict who were treated with 
maintenance-IPT survived for 3 years without a recurrence compared to 
the placebo/ clinical management group. The median time to recurrence 
was 68.3 weeks for the IPT patients versus 16.3 weeks for the patients 
• 
receiving clinical management. The authors found no differential for 
subjects with an IPT focus on role transition or complicated 
bereavement. 
MTLLD 2 study 
Extending further the MTLLD study the same researchers have started to 
attempt to ascertain how the "old-old" (by which they meant patients over 
70 years) will respond to IPT, paroxetine alone (mean 22.4mg/day), or in 
combination when compared to placebo. Patients over the age of 70 are 
being recruited to the MTLLD 2 study, which differs slightly from the 
original study in that subjects are not required to have had a previous 
episode of depression, and also may suffer from mild to moderate 
cognitive impairment (mini mental state scores of 18 or above). Miller 
and colleagues (2001) reported the preliminary findings on 70 subjects 
who have entered the trial and completed at least 10 sessions of I PT. At 
baseline, the researchers have noted there are no differences in the 
depressive severity between groups. Not surprisingly, the older patients 
(70+) have generally shown the greatest cognitive dysfunction and 
demonstrated worse physical activities of daily living compared to the 60-
70 age group. IPT therapists report a progressive decline in their ability 
to engage (p<0.003), allow the patient to focus (p<0.001 ), and recall 
• (p<0.0001) as patients demonstrate increasing cognitive impairment. 
Despite these findings, there have been no differences identified 
between the cognitively impaired and unimpaired group in the rates of 
remission and time to remission for the combined group. The IPT 
therapists for this group have adapted IPT to regularly involve and 
include family members and caregivers in reviewing symptoms and 
reinforcing options and strategies for change in between sessions. This 
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is an ambitious study which clearly breaks new ground into helping us 
understand the value of the efficacy of IPT in an older population. lt also 
allows further evaluation of the adaptability and versatility of IPT with two 
main areas: the application of IPT in depressed patients with mild 
cognitive impairment, and the involvement of family and carers with IPT 
in this challenging group. 
Treatment resistant depression- a single study reported 
Scocco and Frank (2002) reported progress of a group of five depressed 
• 
elderly patients who received IPT augmented to SSRI antidepressant 
treatment (sertraline or citalopram) having responded poorly to 6 weeks 
of an SSRI alone. All patients received 16-20 IPT sessions and achieved 
remission. All of the patients of this open study were classified as 
"difficult" cases and were referred to the author as the treating 
psychiatrist. Every patient had failed to respond to at least one previous 
adequate trial of an antidepressant, although the documentation of other 
antidepressant trials was not available in the notes, hence the level of 
treatment resistance was not established. Further restrictions of this 
open trial meant that patients could only start treatment subject to the 
psychiatrist availability to • provide IPT sessions. As a result all 
participants were asked to sign a contract to agree to attend the 
sessions. lt also appears that the author, who was the treating 
psychiatrist, and IPT therapist carried out the Hamilton Depression 
ratings. All of these factors may have seriously biased the results of this 
small case series. 
Evidently, IPT is a well tolerated and efficacious intervention for the 
elderly depressed population, and has been found to be readily 
adaptable to their needs without major modifications (Miller et al, 1998). 
Furthermore, elderly patients have demonstrated they can work as 
partners in psychotherapy, learn from psychoeducational components of 
IPT as well as modify interpersonal interactions with others (Miller, 
1998). Hartman and Lazurus (1992) support this approach arguing that 
elderly patients do benefit from a structured therapeutic relationship 
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where a therapist allows the patient to recognise and master problems 
which contribute to their depression . 
• 
Moreover, during combined treatment IPT, through encouragement and 
extensive psychoeducation has supported good compliance with the 
pharmacotherapy resulting in increased potency of the antidepressant 
intervention (Wolfson et al, 1997; Miller et al, 2001 ). This phenomenon 
can readily be applied to the rationale for using IPT in the resistant 
depressed population; clearly an area which needs more potent 
treatment and intervention. 
Although both IPT and CBT have the largest evidence base for their 
clinical use in old age depression (Arean and Cook, 2002), more 
research is needed, notably in the frail elderly population (Karel and 
Hinrichsen (2000). lt is interesting that only one study has attempted to 
assess the value of IPT in the treatment of a small number of poor 
responders (Scocco and Frank, 2002). The data from this open trial is 
limited: there is no available information on the number of previous 
episodes of depression, or indeed previous antidepressant therapy or 
response. Furthermore, the clinical ratings were not blind and were 
conducted by the IPT therapist/author. Despite these limitations, this 
study does still provide initial preliminary data on the tolerability and 
feasibility of IPT in poor responders. There have been no published 
• 
reports on the efficacy of IPT in resistant depression in any other age 
group. 
Summary of acute and maintenance trials of IPT across all age 
groups 
1200 depressed patients, including adolescents, adults the elderly 
patients have been studied in 15 trials, 9 of which were randomised 
controlled trials. Most of the studies have focused on treatment outcome, 
with IPT demonstrating efficacy in acutely reducing depressive 
symptoms across all age groups (Eikin et al, 1989; Sloane et al, 1985; 
Reynolds et al, 1996; Mufsol'l ~tal, 1999). IPT can be used a an effective 
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treatment in severe depression (Thase, 1997b; Sotsky et al, 1991) 
although combined IPT and antidepressant medication is the better 
option for severely depressed adult patients (Kierman et al, 197 4) and in 
delayed responder elderly patients (Reynolds et al, 1999). Continuation 
and maintenance studies have also demonstrated the efficacy of IPT 
• (Kierman et al, 1974; Frank et al, 1989). IPT alone or in combination has 
been shown to significantly increase the survival time of highly recurrent 
depressed elderly (Miller et al, 2003), and adult patients (Kupfer et al, 
1992), and with adults has been correlated to the therapist maintaining a 
specific a focus on interpersonal issues during treatment (Frank et al, 
1991 ). Miller and colleagues (2003) found that depressed elderly patients 
with the focus of role disputes increased the survival time to a recurrence 
four-fold compared to placebo. Furthermore, the earlier the 
antidepressant interventions during a depressive relapse, the quicker the 
response (Kupfer et al, 1989; Reynolds et al, 1994). Feske et al (1998) 
found that the longer the duration of the index episode of depression, the 
less likely an early response is seen with IPT alone. There have been no 
studies to specifically address the dosage of IPT when delivered at the 
acute, or continuation phases of treatment. Benefits of improved social 
functioning following treatment in addition to reducing depressive 
symptoms is reported in the literature (Mufson et al, 1994; Klerman et al, 
1974) which have been sustained after one year of follow up (Mufson 
and Fairbanks, 1996). 
Clinical management, clinical monitoring (Eikin et al, 1989; Mufson et al, 
1999) and supportive medication visit (Reynolds et al, 1994; 1996) have 
been used as a placebo i'n studies which have been noted by the 
researchers to be more effective than a placebo control. The numbers 
involved in each study have varied greatly ranging from an open study of 
5 to a randomised controlled trial of 187 patients. The larger studies have 
included a number of different treatment cells with about 16-26 patients 
in each cell. 
109 
The attrition to IPT is generally lower than antidepressant medication 
(Sioane et al, 1985; Reynolds et al, 1999); furthermore, researchers from 
previous trials have argued that IPT has been found to improve 
compliance to pharmacotherapy (Wolfson et al, 1997; Miller et al 2001 ), 
both of these factors may be important in the role of IPT in treatment 
resistant depression. lt is possible that the results of IPT trials have more 
power than medication with less attrition taking into account Intention-to-
Treat analysis. This warrants thorough meta-analysis beyond the scope 
of this study. 
Interpersonal Psychotherapy for various types of 
depression 
Recurrent depression 
The efficacy of IPT as a maintenance treatment (IPT-M) was established 
and initially reported in a group of adult major depressives (Kupfer, 1989; 
Frank et al, 1991 ). Frank and colleagues (2000) were interested to see if 
a sequential treatment approach using IPT followed by an antidepressant 
in poorly responding patients would have a different impact on treatment 
• 
than if IPT and antidepressant medication was provided from the outset. 
In two separate but methodologically similar studies involving women 
with DSM IV recurrent major depressive disorder, Frank and colleagues 
(2000) compared IPT alone as an initial treatment and only non-remitting 
patients received pharmacotherapy in addition (fluoxetine or sertraline) 
(Buysse et al, 1997; 1998; 1999) to IPT and pharmacotherapy 
(imipramine) provided at the outset (Frank et al, 1990). Patients who 
started in the IPT group alone who had not demonstrated a minimum 
Hamilton depression symptom reduction of 33% after 4 weeks had the 
dose of IPT increased to twice weekly for a further 4 weeks. If this did not 
yield a 50% reduction in scores, treatment with fluoxetine or sertraline 
prescribed according to clinical need was initiated. The group which had 
combined treatment at the outset (n=180) had a remission rate of 66%, 
whereas the women in the second cohort who were treated with IPT 
alone, and if there was no improvement received pharmacotherapy in 
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addition (n=159) demonstrated a remission rate of 79%. This was 
significantly greater than the initial combined group (p=0.02). The IPT 
only group was found to be slower in its onset of action. There were 
differences in the studies which may have contributed to the discrepant 
results; there were slightly higher doses of IPT used in the sequential 
treatment group. Additionally, there were different classes of 
antidepressant medication used in both studies. However, similar 
remission rates (78%) have been reported in a separate study using a 
mixed sex cohort treated with IPT followed by fluoxetine or imipramine 
(Thase et al, 1997). A sequential treatment approach may be interesting 
strategy which is attractive to women particularly in the child bearing and 
breast feeding years. 
Although the studies reported below are maintenance studies reported 
earlier, one common factor not previously explored was that both studies 
provided treatment for highly recurrent depressed patients. Reynolds and 
colleagues (1996) were eager to compare the temporal course, 
remission and response rates in the elderly group (n=148, mean age 
67.9) against the midlife (n=214, mean age 38.5) recurrent depressives. 
They analysed the data from the Maintenance Treatments for Recurrent 
Depression Study (Frank et al 1991) and the Maintenance Treatment in 
Late Life Depression study .(Reynolds 1996). Patients were treated 
acutely and during the continuation phase with an open trial of IPT and 
tricyclic antidepressants (imipramine for the midlife patients and 
nortriptyline for the elderly patients). 78.4% (n=116) of the elderly and 
69.6% (n=149) midlife patients remitted during the acute phase. There 
were similar low attrition rates for both groups (12.2%, n=18 elderly, 
11.2%, n=24 midlife patients). Although both groups demonstrated 
significant responses to treatment (p<0.001) the elderly patients were 
slower to show a reduction in Hamilton depression scores. Furthermore 
a greater proportion of elderly subjects (15.5%, n=18/116) relapsed 
during the continuation phase compared to midlife patients (6.7%, 
• 
n=1 0/149). These relapses were seen earlier in the elderly patients 
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compared to their younger counterparts (7 .4 weeks versus 16.6 weeks). 
Despite the slower response to treatment, and earlier relapse rates there 
were no significant differences in recovery rates (elderly=66.2% versus 
57% midlife patients). Although there were many similarities in both trials 
there were also notable differences: IPT had been adapted slightly for 
use in the elderly population. Two different tricyclic antidepressants were 
used, imipramine for midlife patients and nortriptyline for the elderly 
patients, each with its unique proportion of serotoninergic and 
noradrenergic mechanisms. Elderly patients had a greater number of 
comorbid medical conditions compared to the midlife patients. 
Dysthymia 
Dysthymic disorder, or chronic depression is a prevalent disorder, 6% of 
the population develop dysthymia during their lifetime (American 
' Psychiatric Association, 2005). Markowitz (1995) identified a need for a 
psychotherapeutic treatment for the disorder for those patients unable or 
unwilling to take medications; hence Interpersonal Psychotherapy was 
adapted as a treatment for dysthymic disorder (Markowitz, 1998). Initial 
pilot data was obtained through three small series of subjects at Cornell 
University Hospital, New York. Mason and colleagues (1993) treated 9 
dysthymic subjects with an open trial of IPT; 5 of whom had not 
responded to the antidepressant desipramine and the remaining 4 had 
refused antidepressant medication. All of the subjects were long term 
dysthymia sufferers with the mean duration of the disorder of 22.4 years. 
Twelve sessions of IPT were provided and the Hamilton depression 
scores fell from 19.4 pre treatment to 7.4 post treatment. This response 
equalled that of the desipramine only subjects. Markowitz (1992b) 
treated 2 dysthymic patients with 12 and 16 sessions of IPT. The 
Hamilton scores fell from 20.5 to 5 post treatment. In order to test the 
applicability of IPT in dysthymia a further 2 therapists provided IPT 
treatment to 6 more patients resulting in a drop of the Hamilton scores to 
8.5 from 20.8 at the start of treatment. 
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Browne et al (2002) explored the long term effects of IPT for dysthymic 
disorder on depressive symptoms, social and medical costs in primary 
care patients in Canada. They randomised 707 adults aged 18-74 years 
who were diagnosed with DSM IV dysthymic disorder with or without 
past and/or current major depressive disorder to receive either sertraline 
(50-1 OOmg), IPT alone (1 0 sessions) or both treatments combined. All 
patients received 6 months acute phase treatment and were followed up 
with an 18 months longitudinal study. Depression was assessed by a 
rater, blind to the treatment condition using the Montgomery and Asberg 
Rating Scale (MADRS) at six months and twice during the 18 month 
follow up period. Treatment costs and subjects' use of other health and 
social services were also investigated. At six months 586 subjects 
completed the MADRS. Responders were identified by the authors as 
those who demonstrated a 40% reduction in the depression scores. 
60.2% of the sertraline group, 46.6% IPT alone and 57.7% of the 
combined group responded. There was no statistically significant 
difference between the sertraline alone or combined group in depressive 
• 
symptoms reduction. There was however a significant difference 
between groups in the costs for health and social service use, with the 
IPT group having the lowest costs (total costs per person: sertraline only, 
$7866; sertraline and IPT, $7386; IPT only, $5657. p = 0.001). Over the 
long term all three treatments were effective in treating dysthymia, the 
most efficacious treatment was either sertraline alone or in combination 
with IPT. The combined group also demonstrated $480 per person less 
per year on health and social care costs compared to the sertraline 
group. 
DeMello et al in Brazil (2001.) compared outcomes of 35 outpatients with 
dysthymic disorder who received either moclobemide antidepressant, a 
reversible monoamine oxidase inhibitor, with routine clinical 
management (n=19) or in combination with IPT (n=16). Depression 
scores were assessed at baseline and week 12, 24 and 48 by trained 
raters. Despite the low numbers of patients, both treatment groups 
showed a significant improvement at each measurement (p=0.047 vs. 
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p=0.043 respectively). There was a non-significant trend towards lower 
scores on the Hamilton depression scores and Montgomery and Asberg 
Rating Scale for the moclobemide and IPT group, which provides 
interesting pilot data. A larger study with greater power may provide 
substantial evidence of differential treatment outcomes. 
Medical conditions and depression 
The prevalence of depression in medically ill patients is around 6-8% 
(Reiger et al 1993). The subsequent economic burden, increased social 
and vocational disabilities is well established (Greenberg et al, 1990; 
• 
Wells et al, 1989; Weissman et al, 1997). There have been a number of 
studies evaluating IPT for depressed patients with concurrent medical 
conditions. 
Although there have not been any epidemiological studies demonstrating 
the prevalence rates for depression in those patients who are HIV 
positive; there is some evidence which demonstrates depression can 
occur (Markowitz et al 1994). Colleagues at Cornell University, including 
Gerald Klerman carried out the first efficacy study during the late 1980's. 
During this pilot open trial, 23 depressed HIV positive patients received 
. . 
16 weeks of IPT. Twenty (87%) subjects responded with a remission of 
depressive symptoms by the end of treatment. The authors reported that 
specific aspects of IPT worked particularly well with HIV positive 
depressed patients, including: the here and now framework, an 
interpersonal focus, grief, role transitions and an option for change. 
Patients benefited from learning to act out their reasonable fantasies to 
regain a quality of life. The structure of IPT was helpful for the therapist 
(Markowitz et al, 1992). 
A National Institute of Mental Health (NIMH) funded study; based on the 
. . 
NIMH Treatment of Depression Collaborative Research Programme 
(Eikin et al, 1989) was undertaken by the same researchers at Cornell. 
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This was the first controlled study of psychotherapy for 32 depressed 
HIV positive patients. 101 depressed HIV positive patients were 
randomly assigned to receive either IPT (n=24), CBT (n=27), supportive 
psychotherapy (SP) (n=24), or imipramine plus supportive 
psychotherapy (IMI-SP) (n=26). Each treatment was manualised and 
monitored for adherence using audio or video tapes (Markowitz et al, 
1994b). 
Preliminary data from the IPT (n=16) and supportive psychotherapy 
group (N=16) demonstrated that patients who were randomised to IPT 
yielded clinically and significantly superior results which was evident from 
week 8 and maintained to week 16. Mean Hamilton scores fell from 19.5 
at baseline to 5.8 post treatment for the IPT group versus 20.7 to 11.9 for 
the SP group. This suggested increased antidepressant potency of IPT 
for this cohort of patients (Markowitz et al, 1995). The final results 
presented data on all four treatment groups; IPT (n=24), supportive 
psychotherapy with imipramine (n=26), supportive psychotherapy (n=24) 
and CBT (n=27) showed similar reductions in Hamilton depression 
scores for each treatment. Pre to post treatment completer analysis 
mean Hamilton depression scores fell from 19.6 to 6.5 in the IPT group 
and 20.8-9.6 in the supportive psychotherapy with imipramine group. The 
supportive psychotherapy and CBT performed less well with a reduction 
in Hamilton scores of 20.3-11.7 and 20.4-12.9 respectively. Intention to 
• 
treat analysis demonstrated that Imipramine and supportive 
psychotherapy and IPT were both superior to CBT (p<0.05). Although 
supportive psychotherapy had the third best results they were not 
significantly different. 
A direct association between post myocardial infarction (MI) and social 
isolation and life stress has been found (Case et al 1992). 27% of 
patients who have suffered an Ml develop major depression (Scheifer et 
al, 1989). There have been two reported case studies of IPT in heart 
disease. Miller (2002) reported a case of a 67 year old man who 
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developed major depression following a cardiac transplant. IPT was 
added to paroxetine to help the patient address his preconceived 
expectations of the transplant, reintroduce his social contact and reduce 
his depressive symptoms. Stuart and Cole (1996) in Iowa report a case 
history of a depressed 57 year old man following his myocardial 
infarction. He was successfully treated with paroxetine and Interpersonal 
Psychotherapy. IPT using the strategies suggested in the manual for role 
dispute and role transition was found specifically to target interpersonal 
conflicts and grief and loss associated with his Ml in addition to reducing 
his depressive symptoms. The depression scores fell from HamD 20, 
Beck Depression Inventory 29 at the start of treatment to 3 and 2 
respectively at termination. 
IPT for ante partum/postpartum depression 
1 0-12% of pregnant women develop a major or a minor depression 
(Spinelli, 1997); with similar prevalence rates reported for post partum 
• 
women (O'Hara and Swain, 1996). This causes great personal suffering, 
additionally; there is good evidence to suggest that mother-infant 
bonding is impaired by maternal depression (Downey et al, 1990). 
Furthermore, subsequent development of infants has negative 
consequences during social relationships. Women during pregnancy and 
breast feeding may express natural concerns about the effects of 
pharmacological treatments for depression for their developing foetus or 
baby. 
A treatment manual has been developed for ante partum depression 
(Spinelli, 1997); the basic approach of IPT is the same, although the 
content relates to the pregnancy. This role transition allows the mother to 
evaluate her feelings regarding parenthood, her relationship with her 
spouse and physical changes in her body. A fifth area of "complicated 
pregnancy" has been added. 
Spinelli (1997) reported on an open pilot study using IPT to treat 13 
depressed pregnant women. At the end of 16 weeks of treatment, all of 
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the patients had responded positively as measured by a clinician rated 
and patient rated depression scales. The mean depression scores 
dropped from 22.1 to 3.9 on the Hamilton depression scale and 21.8 to 
8.9 on the Beck depression Inventory. All subjects met the criteria for 
recovery post treatment and none of the ten women available for review 
at 3 months post partum reported any depressive symptoms. Based on 
this study the authors carried out a randomised controlled trial whereby 
50 subjects were entered into a 16 trial assigned to receive either IPT or 
a didactic parenting educati~n programme (Spinelli and Endicott, 2003). 
Depression was measured with the Hamilton depression scale, Beck 
Depression Inventory and Edinburgh Postnatal Depression scale 
(EPDS). IPT demonstrated a statistically significant advantage over the 
parenting education programme demonstrated by reductions on all mood 
scores; (EPDS 11.8% vs. 33.3%; BDI 52.4% vs. 23.5%; HamD 52.4% 
vs. 29.4% (p<0.001 )). The authors reported a significant correlation of 
the mother's improved mood with her ability to interact with the infant. 
Zlotnick and colleagues (2001) reported on an open pilot study which 
attempted to use IPT provided in a group format for four sessions 
• 
compared to treatment as usual in 37 pregnant women who had at least 
one risk factor for depression. Of the 35 women who completed the 
study within 3 months of the birth 6 (33%) of the treatment as usual 
group had developed post partum depression compared with none of the 
17 women in the IPT group. 
Swartz (1997) report the case of a depressed HIV positive woman who 
received four months of I PT. The areas of dispute (with the baby's father) 
and transition, regarding both pregnancy and HIV infection were the 
prime focus of IPT. Her Hamilton Depression Scores fell from 18 at the 
start of treatment to 2 as she worked through therapy and regained 
mastery over a difficult situation. 
An unpublished treatment manual is available for post partum depression 
which was used in the following study. The researchers reviewed the 
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efficacy of IPT compared to a waiting list condition in 120 women with 
' DSM IV post partum depression. The average duration of major 
depression in this study was 7 months (apart from 3 chronic depressed 
women with a mean duration of over 2.5 years). Subjects were randomly 
assigned to 12 weeks of Interpersonal Psychotherapy or to a waiting list 
condition (WLC). Depression was measured by an unblinded clinician 
using the Hamilton Depression Scale (HDS) or self rated by the patients 
using the Beck Depression Inventory (BDI) at baseline and 4 weekly. 
Additionally, social functioning and post partum adjustment were also 
assessed. 99 subjects completed the study; dropout rates (20% for IPT 
and 15% for the WLC group respectively were not statistically 
significant.) Significantly greater improvements in depression scores, 
social functioning and post partum adjustment were noted in the IPT 
group both on the HDS and the BDI compared to the waiting list control 
group. A significantly greater proportion of women (37%) versus (13.7%) 
who received I PT recovered from their depressive episode with a 
Hamilton score of 6 or lower. Furthermore, social adjustment revealed 
significant differences favouring the IPT group (p<0.009). Post partum 
adjustment demonstrated significant effects of IPT group at week 8 
which continued to the end of the trial (p<0.001 ). Although Hamilton 
scores are usually blind for a study of this type, the authors gave 
practical reasons for this not being the case. They believed this would 
help women in the WLC develop a relationship with the rater which 
would allow compliance with the trial. lt is significant that there was a 
strong significant correlation found between the results of the Hamilton 
Depression scores and the Beck Depression Inventory (O'Hara et al, 
2000). 
Klier and colleagues (2001) in Austria also carried out group IPT for 17 
women diagnosed with post partum depressive disorder. There were 
significant reductions in mean scores on the Hamilton depression scale 
which fell from 19.7 at baseline to 8 post treatment. Six month follow up 
evaluation revealed continua.tion of the positive treatment effect. 
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IPT demonstrates promising results as a treatment for ante partum and 
postpartum depression. The areas of role transition and role dispute are 
the most common focal areas for attention during therapy. Clearly, an 
advantage of antidepressant treatment without the use of medication is 
of tremendous value to pregnant or breast feeding women. Although 
women studied to date have not been resistant to treatment, there have 
been a small number of patients from the studies who were chronically 
depressed (O'Hara et al, 2000); it has been suggested that chronic 
depression is a form of treatment resistance (Fawcett 1994) and falls 
within the spectrum of "difficult to treat" category. Based on this limited 
data it is reasonable to test the efficacy of IPT for resistant depression 
with the general population. If successful, further work is warranted with 
this treatment population, which may help to reduce the risk of 
developing a treatment resistance and increasing the quality of 
relationship between the mother and baby at a critical period of time . 
• 
Summary of IPT for chronic, recurrent, postpartum, antepartum 
depression and depression with concurrent medical conditions 
The efficacy of IPT in 1413 patients with either recurrent depression or 
dysthymia has been reviewed. This has involved 8 studies, 3 of which 
were randomised controlled trials (Frank et al, 1991; Reynolds et al, 
1996; Browne et al, 2001 ), and 2 were parallel group studies (Frank et al 
2000, De Mello et al, 2001 ). IPT has been shown to be effective in 
recurrent depression. Despite the fact that recovery rates are the same 
in adult and elderly patients, the latter group tend to demonstrate a 
• 
slower response to treatment ·and relapse earlier (Reynolds et al, 1996). 
One interesting study starts to demonstrate how a staged approach to 
treatment has had positive benefits for depressed women with recurrent 
depression. During this study, Frank and colleagues (2000) initially 
compared IPT as a monotherapy, with imipramine added later to poor 
responders, to IPT combined with antidepressant medication. lt was not 
surprising that initially, combination therapy yielded superior results. 
However, when an antidepressant medication was added to IPT at a 
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later date for the poor responders in the group, this resulted in higher 
recovery rates (79% vs. 66%) compared to those who received 
combination therapy from the start. Although IPT as a monotherapy is 
less potent and slower to demonstrate its antidepressant effects; 
augmentation of an antidepressant at a later date led to greater recovery 
rates. Clearly, more research is needed to explore the value of a 
sequential approach when treating depression, and whether it would 
benefit patients to start with either psychotherapy or pharmacotherapy .. 
IPT is an effective treatment for dysthymic disorder (Markowitz, 1998; 
DeMello et al 2001; Browne et al, 2002). Although combined IPT and 
sertraline was as effective as sertraline alone in the large dysthymia 
study (Browne et al, 2002) when treating depressive symptoms; low 
dose IPT alone or combined with sertraline led to a significant reduction 
in the use of health care costs. This has been the only study to report the 
economic effects of IPT. There have not been any studies reviewing the 
efficacy of IPT in treatment resistant depression. 
There are less data available on the efficacy of IPT as a treatment for 
depression in the medically ill. Eight trials including just one randomised 
controlled trial and 3 case studies have been presented involving 396 
patients. Most of the literature concerns the treatment of depressed HIV 
positive patients. IPT has been shown to be an effective antidepressant 
treatment and the specific goals and strategies have been reported to fit 
well for this group of patients. For example, as part of a role transition, a 
common focal area in this group of patients, therapists would encourage 
the patients to "live out their fantasy", which helped to frame their 
situation in a more positive way and improved depressive symptoms. In 
contrast, however, the treatment approach of challenging negative 
cognitions in CBT was more difficult, particularly when patients had just 
received a diagnosis of HIV positive. The model of CBT appears to be 
disadvantaged with this treatment group. Additionally, the authors also 
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acknowledged the time limit of IPT worked well with HIV positive patients 
(Markowitz et al, 1992; Markowitz et al, 1995). 
For postpartum and antepartum depression IPT has demonstrated 
efficacy as an antidepressant and has been well tolerated (Spinelli et al, 
1997; Spinelli and Endicott, 2003; O'Hara et al, 2001 ). Furthermore, it 
has also been found to improve social adjustment (O'Hara et al, 2001) 
and has helped to improve mother and infant interaction in postpartum 
women (Spinelli and Endicott, 2003). Group IPT has been evaluated in 2 
open trials involving antepartum and postpartum depression (Ziotnick et 
. . 
al, 2001; Klier et al, 2001 ). During these small trials it has been effective 
and has been shown to prevent a depressive recurrence in the short 
term (Ziotnick et al, 2001 ). 
Delivery of ~nterpersonal Psychotherapy 
Interpersonal Psychotherapy by telephone 
Accessibility of treatment for individuals who have depression may 
become problematic; time constraints, financial limitations and demands 
for childcare (Miranda et al 1996) can prevent a patient obtaining 
appropriate treatment which may increase the risk and incidence of 
treatment resistant depression. With this in mind, Miller and Weissman 
(2002) developed the concept that IPT could be delivered over the 
telephone. They conducted a 12 week study of IPT which was delivered 
over the telephone (IPT-T). 30 women with a life time history of 
recurrent major depression were randomly assigned to equal groups of 
either IPT-T or no treatment. A blind rater carried out assessments of the 
depression and social functioning scores at baseline and after 12 weeks. 
The IPT-T group showed significant improvement in depression scores 
(p<0.02), global functioning scores (p<0.02) and social adjustment 
(p<0.02). Although a small study, this demonstrates the versatility and 
adaptability of IPT. This may help us manage major depression more 
. . . 
effectively, preventing the incidence of treatment resistant depression by 
adding IPT to the antidepressant therapy armamentarium. 
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IPT in groups 
Group psychotherapy is a popular type of treatment which may have the 
added benefits of being cos~-effective and also provides an ideal foru~ 
for social support and an opportunity to develop and practise social skills. 
There have been minor adaptations for IPT to be used in a group setting 
(IPT-G) and there is a published treatment manual, (Wilfey et al 2000). 
The group members have separate individual interviews where the 
therapist assesses and confirms the diagnosis, completes the 
interpersonal inventory and agrees a treatment contract. The group 
therapy sessions are 50% longer, 90 minutes in duration. 
MacKenzie and Grabovac (2001) reported on a case study of IPT 
delivered in a group setting in Vancouver. Eight depressed patients who 
had received extensive adequate trials of antidepressant 
pharmacotherapy attended 14 ninety minute group session of IPT. The 
Beck Depression Inventory was completed by the patients at the start of 
treatment, during the middle phase and at the end of treatment, followed 
by 4 month after the end of therapy. Most (6/8) of the patients were 
severely depressed and had a comorbid diagnosis of dysthymic disorder. 
Five of the patients demonstrated a marked reduction in their depression 
scores, which was maintained at 4 month follow up. The authors found 
IPT-G to be helpful in its broad application to clinical practice. 
Levovitz and colleagues (2061) in Tel Aviv evaluated the effectiveness of 
IPT in groups for patients who had suffered moderate to severe 
depressive disorder and responded to acute treatment with 
antidepressant medication. After acute treatment the patients were split 
into two groups: IPT-G (n=7) and a continuation of the standard 
treatment (n=7). The group IPT comprised of 18 weekly sessions lasting 
90 minutes. The depression was assessed five times (HamD and Clinical 
Global impression scale) during treatment, and 6 months after 
termination. In addition to the rater being blind to the treatment condition, 
the author reported that the group therapists and the patients were also 
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blind to the fact the study was being completed. Although an interesting 
finding, consent and ethical approval are required from most research 
studies. The IPT-G demonstrated significant improvements in recovery 
rates by 6 months (86% vs. 29%; p<.0.01 ). 
Biological correlates of response to IPT 
Brain functional imaging studies 
Our understanding of the biology of depression has increased 
dramatically over the past 4-5 decades. We have gained awareness into 
the effectiveness of IPT in depression for various age groups and types 
of illness. Furthermore, we have started to understand specific potent 
effects of the treatment, including purity of IPT important for 
standardising intervention for biological investigation (Frank et al, 1991) 
and combined pharmacotherapy and IPT (Kierman et al 1984; Frank et 
al, 1991, Reynolds et al 1996). Technological advances have allowed 
scientists to study brains in vivo during depressed states and following 
' ' 
recovery with treatment. There is evidence that there are functional brain 
changes in depressed patients compared to controls. Abnormalities, 
usually demonstrated as areas of hypoperfusion have been shown in 
depressed patients compared to controls, including: frontal and temporal 
cortices (Sackheim et al, 1990; Mayberg et al, 1992, Austin et al, 1992), 
the left dorsolateral prefrontal cortex (Dolan et al 1992, Martin 1995}, and 
the cluster of cingulate gyrus, anterior parietal regions and the caudate in 
the basal ganglia (Mayberg et al, 1994). There are 2 recent studies 
which have extended our understanding of IPT to include the 
physiological response of the brain to treatment which correlated with an 
improvement in clinical symptoms of depression. 
In a Single Photon Emission Computed Tomography (SPECT) study 
Martin and colleagues (2001) reported functional changes in blood flow 
scans in 28 depressed outpatients who were randomly treated with either 
venlafaxine or IPT. Brain scans were performed at baseline and after 6 
weeks; depression was measured using the Hamilton depression scale 
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on the same day of the scan. Both treatment groups demonstrated 
significant improvements in depression scores. There were functional 
brain changes with both treatment groups. The venlafaxine group 
showed right posterior temporal and right basal ganglia activation 
(p<0.01) while the IPT group had limbic right central cingulate and right 
basal ganglia activation (p<0.01 ). 
In a similar study, Brody and colleagues (2001) conducted a brain 
metabolism study which used Positron Emission Tomography (PET) to 
measure. glucose uptake to , compare 24 depressed outpatients who 
selected treatment with either weekly IPT or paroxetine and 16 normal 
control subjects. Brain scans were taken at baseline and after 12 weeks 
of treatment. At baseline patients with major depression demonstrated 
higher normalised metabolism in the prefrontal cortex, caudate and 
thalamus and lower metabolism in the temporal lobe. Both treatment 
groups demonstrated an improvement in the clinical scores as measured 
by the Hamilton depression scale (61.4% reduction for paroxetine and 
38% IPT group). Both groups showed decreases in the prefrontal cortex 
(bilaterally in the paroxetine treated group and on the right in IPT treated 
patient), left anterior cing4late gyrus metabolism and increases in 
normalised left temporal lobe metabolism. The results from this study 
should be viewed with caution as only one patient had IPT and two 
scans in sequence though. 
Sleep studies 
A number of studies have been undertaken to understand the 
relationship between neurobiological correlates of depression and 
subsequent response to treatment. Abnormalities in all night sleep 
electroencephalogram (EEG) studies have been found to be more 
common among depressed patients compared to controls (Benca et al, 
1992, Knowles and Maclea" ,1990). Specific abnormalities such as delta 
wave proportion (Kupfer et al, 1990) and rapid eye movement (REM) 
latency around dream sleep (Giles et al 1987) have been associated with 
a recurrence of a major depressive episode. Some studies have shown 
124 
that specific patterns of change in sleep EEGs during early drug 
treatment correlate with ulti[llate clinical response (Kupfer et al, 1981, 
Reynolds et al 1991 ). lt has been argued that antidepressant medication 
has helped to "normalise" some of the depressive sleep changes 
(Buysse et al, 1996). Furthermore, patients with reduced REM latency 
have responded poorly to placebo and favourably to antidepressant 
medication in both uncontrolled (Akistal et al, 1980; Svenson et al, 1981) 
and controlled studies (Rush et al, 1985; Rush et al, 1989; Zammit et al, 
1988). We know that serotonin has a major involvement in depression 
aetiology; it is also crucial in sleep neurochemistry. 
Correlates of psychotherapy response help us to understand better the 
biological underpinnings and effects of psychological treatments. 
Moreover, if differential predictors of response can be established, the 
most clinically appropriate and cost effective treatment can be planned. 
Thase and collaborators (1997d) wished to establish the relationship 
between abnormal sleep profiles and response to IPT. They classified 91 
depressed patients into those with a normal sleep profile (n=50) and 
those with an abnormal sleep profile (n=41) after monitoring sleep for 2 
nights for sleep efficiency, REM latency and REM density. Patients who 
did not respond to IPT alone received antidepressant medication as an 
augmentation to psychother~py. These responders were also compared 
in the analysis. The patients with abnormal sleep profiles had 
significantly poorer outcomes in depression, poorer attrition rates and 
less remission compared to patients who had normal sleep profiles. 
Reynolds and colleagues (1997) examined the outcomes of 47 elderly 
patients who had recovered from a major depressive episode and 
remained well with monthly IPT, after discontinuation of antidepressant 
medication. Subjective sleep quality was assessed using the Pittsburgh 
Sleep Quality Index. Of the patients who reported good subjective sleep 
quality, 90% IPT group remained well after one year. Whereas five (31 %) 
of the patients assigned to medication clinic had remained well for this 
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period. Impaired subjective sleep quality yielded less favourable results; 
33% of the IPT -M group and 17% of the medication clinic group were 
well after one year. 
Buysse et al (1992) examin~d the longitudinal EEG sleep studies in 1.9 
depressed patients who were treated with IPT. Sleep measurements 
were taken at baseline and shortly into recovery. The baseline 
assessments revealed no abnormal findings. Automated measures of 
delta-sleep and REM activity showed small state related changes, with 
delta activity increasing from baseline to remission and automated REM 
measures decreasing. Strong baseline-remission correlations were noted 
for most sleep measures including slow wave sleep, phasic REM activity 
and automated delta wave counts. 
In the same study reported later Buysse and colleagues, (1999b) 
compared EEG sleep measures of patients who remitted with 
psychotherapy to those who did not remit. 111 women with recurrent 
major depression received weekly Interpersonal Psychotherapy; pre and 
post psychiatric measurements and sleep assessments were taken by a 
rater other than the patients' therapist. Clinical symptoms and sleep 
measures were compared between 62 remitters and 49 nonremitters. 
Treatment nonremitters had significantly elevated phasic REM. The 
authors could correctly identify 68.3% of nonremitters and 68.5% of 
remitters using linear discriminant function analysis of subjective sleep 
quality and REM activity. 
Later the same group (Buysse et al, 2001) carried out sleep studies to 
examine the correlates of remission and recovery in depressed patients 
receiving IPT alone or combined with fluoxetine. The authors used sleep 
electroencephalogram (EEG) power spectra of NREM and REM sleep as 
well as observed phasic REM as quantitative measures of sleep at 
baseline and post treatment. 130 women were studied; 23 patients 
recovered with IPT alone and 23 recovered with the combination 
therapy. IPT nonremitters had increased phasic REM compared to 
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remitters, but no significant differences in EEG power spectra. IPT and 
fluoxetine recoverers but not IPT recoverers showed increases in phasic 
REM and REM percentage from baseline to recovery. In non-REM sleep, 
the combined group showed a decrease in the alpha power from 
baseline to recovery, while IPT alone showed a slight increase. 
This study was limited as there was no control group. There was no 
proof of a specific EEG effect from IPT although the authors claimed IPT 
. . 
slightly increased EEG wave strength (alpha power). This happens 
anyway in recovery. The same team in 1992 with IPT alone showed a 
slight increase in slow delta wave power. The authors suggested that an 
abnormal sleep profile may reflect a more marked disturbance in the 
central nervous system arousal that warrants pharmacotherapy. 
Summary of biological correlates of IPT 
Research in depression has led to a greater understanding of its 
biological basis: disturbances in monoamine neurotransmitters serotonin, 
noradrenaline and dopamine are widely reported. Furthermore, 
functional and structural brain scans including MRI, SPECT, PET and 
fMRI have yielded abnormalities in depressed patients compared to 
controls. There is a paucity of literature which evaluates the biological 
correlates of IPT in depression. Only 2 functional brain studies have 
been reported, one SPECT and one PET study, and just three sleep 
studies. There have been no studies examining biological correlates of 
treatment resistant depression in IPT. 
Both functional brain imaging studies assessed patients with a major 
depressive disorder. Abnormalities in depression pre-treatment were 
seen to normalise with IPT t~eatment in both studies (Martin et al, 2001; 
Brody et al, 2001 ), although one study reported data on a single patient 
(Brody et al, 2001 ). Interestingly, this included different brain areas 
(limbic right central cingulate) to those which changed with 
antidepressant medication. 
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There are sleep disturbances in depression (Benca et al, 1992) including 
an abnormal delta ratio (Kupfer et al, 1990) and abnormal REM latency 
around dream sleep (Giles et al, 1987). Early changes in sleep have 
been found to predict a good response to antidepressant medication 
(Kupfer et al, 1981; Reynolds et al, 1997). Good sleep at baseline 
appears to predict a positive outcome with IPT, whereas poor sleepers 
appear to do less well with IPT (Reynolds et al, 1997; Buysse et al, 
2001). The dose of the IPT received by remitters versus nonremitters 
reported by Buysse et al (2001) is unclear. Low dose IPT (monthly 
sessions) was effective in preventing a recurrence in a maintenanQe 
study (Reynolds et al, 1997) for good sleepers, but not poor sleepers. 
The question which may need to be addressed is the potency of the 
antidepressant therapy, including pharmacotherapy or indeed a higher 
dose of IPT. 
Effects on social adjustment 
Depression has been found to have a significant negative effect on 
psychosocial functioning (Jarrett and Rush, 1994). To complicate matters 
further, depression often occurs within a psychosocial context which may 
in itself confound antidepre~sant treatment. Psychotherapy can play .a 
crucial role to help address psychosocial contexts and provide treatment 
tailored to patients' individual needs, increase engagement and help 
make depression less difficult to treat. 
Weissman and colleagues (1974) were the first to assess the treatment 
effects on the social functioning in depressed patients. 106 patients were 
treated acutely with amitriptyline and then randomly assigned 
amitriptyline, placebo or no medication with either high contact weekly 
psychotherapy treatment or low contact (basic symptom review). Social 
adjustment was measured using the Social Adjustment Scale (SAS) 
following one month of acut'e treatment, and then at 2, 4 and 8 month 
intervals. There were substantial differences in the percentage 
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improvements in the social functioning in the psychotherapy group (44%) 
compared to the low contact medication group (28%). The 
psychotherapy patients demonstrated significantly less impaired work 
performance, interpersonal •friction and anxious rumination. However, 
these differences did not emerge until 8 months of treatment. 
In a much later study, Lenze and colleagues (2002) studied depressed 
elders to assess the impact of IPT and nortriptyline (NT) in doses 
sufficient to produce a steady blood level of 80/120ng/ml together or 
alone against a placebo condition during maintenance treatment. 
Following successful acute and continuation treatment, patients were 
randomised to one of the four treatment conditions for 3 years. The 
authors were interested in assessing the social functioning of those 
subjects who remained in recovery with active treatments for one year of 
• 
maintenance therapy (IPT and NT n=18; NT n=18; IPT n=13). The mean 
scores on the Social Adjustment Scale (SAS) improved with the 
combined group, but declined with both monotherapies (P<0.01 ). The 
authors found that a decline in social functioning during maintenance 
treatment predicted future recurrences. Only one (5.3%) of the 19 
subjects who maintained the SAS scores during the first year had a 
depressive recurrence in the following 2 years; in contrast 5 of 19 
(26.3%) subjects who had a decline in SAS scores during the initial year 
suffered a depressive relapse before the end of the trial. 
Combined therapy was found to enhance the length and quality of 
recovery. In contrast to Weissman's (1974) study, gains in social 
adjustment were maintained rather that improved during maintenance 
therapy. O'Hara et al (2000) in his study of post partum depressed 
women found IPT led to improvements in social adjustment. 
Therapist adherence in IPT 
Psychotherapy research requires us to investigate differential 
psychological therapies, just as we would with different medicines in 
head to head pharmacotherapy studies. lt is also helpful to establish and 
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identify what are the specific potent effects of the psychotherapy, just as 
with pharmacodynamics and dose ranging studies with medication trials. 
There are three studies outlining the adherence monitoring used in the 
NIMH TDCRP study (2 applied to the study itself and the scale used in a 
separate IPT trial). Two of the studies demonstrated adherence, another 
provides qualitative detail of the different psychotherapeutic approaches. 
There is one conflicting stud~. 
Hill and collaborators (1992) used the Collaborative Study 
Psychotherapy Rating Scale (CSPRS) to monitor the adherence of 
therapists from the NIMH TDCRP. Four sessions from each of the 180 
patients were rated. This included one from the initial and end phase of 
treatment, and 2 sessions from the middle phase of therapy. The authors 
found that cognitive behavioural therapists increased scores on the CBT 
scale after the first session and stayed at a high level and were more 
directive in the middle and than the initial or later sessions. Clinical 
management (CM) therapists had higher CM scores during the initial 
• 
phase than any other phase.· IPT therapists and CBT therapists scored 
higher CM scores for the first session than any other session. This was 
not inappropriate given there is an overlap of all therapies at the initial 
phase when obtaining a psychiatric history, depressive symptoms, 
suicidal ideation and general functioning. Therapists were found to 
exhibit more behaviour appropriate to their own respective treatment 
approaches than any other treatment approach. The CSPRS was found 
to discriminate between the three treatments. High interrater reliability 
and consistency was found during analysis of the psychometric 
properties. 
Markowitz et al (2000) published results using the same adherence 
monitoring techniques from the NIMH study to assess level of therapist 
adherence in a randomised controlled trial of 56 HIV positive depressed 
patients treated with either I PT, CBT or supportive psychotherapy alone 
or with imipramine. The therapists were certified in the manualised 
treatments. Blind independent raters randomly selected taped sessions 
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and used an adaptation of the NIMH scale. Adherence scores were 
given for the individual therapies as well as for therapist interventions. All 
therapists were found to be adherent with high inter-rater reliability (0.89-
0.99) and the scale discriminated each of the four treatments (p<0.0001) 
with each therapy scoring highest in its own scale. Facilitative comments 
were found to vary by intervention but did not predict treatment outcome. 
This study shows that both therapists and adherence monitors can be 
trained to deliver specified treatments. This is an important approach to 
investigate consistency based effectiveness in psychotherapy. 
Albon and Jones in 2002 in a later analysis examined the transcripts of 
the NIMH treatment of Depression Research Programme which 
compared IPT, CBT, imipramine and placebo plus clinical management 
in 239 depressed outpatients. 
The authors hypothesised that the process and technique of IPT and 
CBT would overlap and be responsible for patient change. Prototypes of 
the ideal regimes of IPT and CBT were developed by expert therapists 
using the Psychotherapy Q-Set, an instrument designed to provide a 
standard language for describing treatment processes. Ratings of 
• 
sessions (n=35, IPT, n= 29, CBT) identified higher correlations with the 
CBT prototype than IPT in both treatment groups (p<0.001) and a 
moderate correlation between Q-set ratings and the IPT prototype 
(p<0.001 ). The authors suggested that in the NIMH trial there were no 
separate and distinct psychotherapy treatments provided, and that 
common characteristics, which were supportive in nature were 
associated with a positive outcome with both psychotherapies. The small 
numbers used in this study and others monitored limit these findings. 
The application of this rating instrument would be helpful, particularly in 
studies which identify high specificity and purity of the therapy provided. 
A case for IPT in Treatment resistant depression 
IPT has come a long way since Meyer's initial psychobiological 
approach, which accounts for social and cultural aspects of the 
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individuals' life. In addition, Sullivan's interpersonal approach brought 
further change to the way psychiatry has continued to work, 
encompassing a holistic approach which addresses physical, 
psychological, social and interpersonal factors. IPT is a useful treatment 
which provides psychoeducation about the patients' depression, which is 
regularly and systematically reviewed through the use of validated 
depression rating scales. Reassurance is a strong component of 
treatment and is provided regularly to the patient. These factors in 
combination may in fact help to increase compliance and subsequent 
response to potent antidepressant treatment and thus reduce the factors 
which are known to increase the likelihood of a resistant depression. 
Meyer made the connection between a psychiatric illness and the 
environment; proposing that mental illness was the result of the patients' 
ability to adapt to a changing environment. IPT explicitly links 
environmental and interpersonal factors within the context of the patients 
depression, and through the use of problem areas with clearly defined 
strategies, the IPT therapist helps the patient resolve these issues which 
subsequently alleviates their depressive symptoms. In a recent study 
evaluating the specific components of IPT which were considered to 
have an antidepressant effect, the resolution of problem areas during IPT 
correlated significantly with reduced Hamilton depression scores 
(Markowitz et al, 2006). Althpugh IPT deals with depression in the "here 
and now" the therapy also allows the patient to understand long term 
management of their depression; an important factor in treatment 
resistant depression. Psychoeducation in depression, duration of 
antidepressant treatment required for each episode and what steps to be 
taken in the event of a recurrence are dealt with during therapy. The 
strong interpersonal focus during treatment has been shown to have a 
protective effect against future episodes, even in those patients who 
have a high risk of a recurrence (Frank et al, 1989; 1991 a; 1991 b; Kupfer 
et al, 1992). Furthermore, the better the quality of even low dose IPT 
(monthly IPT, IPT-M), the longer the patient remains in remission, 
regardless of whether the patient is receiving antidepressant medication 
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in addition (Kupfer et al, 1992; Frank et al, 1991 b). This study involved 
more complex patients who had had at least seven previous episodes of 
major depression. lt is reasonable to assume the specific antidepressant 
components of IPT which involve maintaining a high interpersonal focus 
would have similar beneficial antidepressant effects in resistant 
depression. 
Frank (1973) argued that mastery of interpersonal situations is important 
in psychotherapy and should be targeted. Social psychiatric research 
into the effects of reduced social contact or support on depression is well 
established (Brown and Harris, 1979; Paykel et al, 1971 ). One aim of IPT 
is to increase the social contact and support network available to the 
patient, using specific treatment strategies which support this. Again this 
may be considered a vital component of IPT which may help to have a 
protective effect on depression - both in terms of maintaining a euthymic 
• 
mood, or preventing the development of a future recurrence (Frank et al 
1991 ), or indeed a resistant depression. 
Although there are limited data on the clinicians' role with respect to 
helping the patient achieve compliance, it is apparent that this is an ideal 
area which could help improve the potential treatment outcome; which is 
critical in a treatment resistant depressed population. IPT is one 
psychotherapy which sits comfortably with both the medical model of 
depression (i.e. that depression is a treatable medical illness), as well as 
utilising a psychological and interpersonal approach. Indeed, patients 
with treatment resistant depression are a difficult to treat group and 
would need treatment with medication in addition to antidepressant 
psychotherapy. The IPT therapist synthesises these approaches in a 
practical way to aid the patients understanding of the context of their 
depressive episode, and what steps can be taken to allow the patient to 
get better. The clear aim of therapy is to reduce depressive symptoms 
and increase social and interpersonal functioning. If patients do not 
respond or only partially respond to antidepressant treatment, as is the 
case in treatment resistant depression, the IPT therapist addresses 
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issues in a pragmatic way and from a holistic perspective. Medication, 
interpersonal and social issues are all evaluated. If medication changes 
are needed they are encouraged, additionally, interpersonal events 
occurring in the patients life which contribute to the current depression or 
which may lead to vulnerability to future episodes are addressed. This 
may help reduce the risk of a future recurrence (Frank et al, 1991 ). This 
practical and systematic approach ensures potent antidepressant 
treatment is provided and 'may reduce the likelihood of the patient 
becoming resistant to treatment. Many authors (Pridmore and Shea, 
2003; Thase, 2003;), when reviewing treatment resistant depression 
repast under-treatment of depression and have classified this as 
psuedoresistance rather than treatment resistance (Kornstein and 
Schneider, 2001 ). IPT in treatment resistance depression which uses a 
medical model of depression in addition to a psychological approach 
may help prevent the incidences of psuedoresistance and help with the 
practical management of treatment resistance. 
As with any psychotherapeutic approach, extra time and support is given 
. . 
to the patient. Similarly, the psychotherapist obtains supervision which 
helps the IPT therapist adhere to the goals of treatment. 
Throughout the course of Interpersonal Psychotherapy treatment, weekly 
reviews of the patient's depression take place. Formal assessments of 
the depression are done using the Hamilton Depression Scale, a well 
established measure, at baseline and regularly throughout treatment. 
This may have a number of substantial advantages. lt can help the 
patient feel that their depression is being carefully assessed, managed 
and monitored throughout the course of treatment. This can instil 
confidence in both the therapist and the treatment. The rationale for the 
provision of a diagnosis of depression when assigning the sick role to the 
patient is not just to ease any guilt or blame they may feel; but also to 
provide hope to the patient that things will get better. The optimism 
provided in IPT during therapy in resistant depression may offer a key 
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component to help the patient understand their situation and continue to 
work in treatment to get better. 
For example, one patient, who received IPT as part of this study, had 
received a number of antidepressant trials in complex cocktails prior to 
her entering the study. She was clearly resistant to treatment. Although 
her depression scores improved throughout treatment, she did not reach 
a sustained period of euthymic mood. At the end of treatment she told 
the therapist, "Thank you for being so supportive. I truly believe I could 
not have coped over this past year. I think I would have probably killed 
myself." There were many times that the therapist found resistant 
depression difficult to manage; it is difficult to maintain an optimistic 
approach when the gains obtained are so slow to arrive. However, one 
factor specific to IPT which may have helped this particular patient and 
others with a resistant depression is the approach where the therapist 
encourages the patient to blame their illness and not themselves through 
the course of recovery. 
This has also been effective when using IPT in dysthymic patients. The 
structure of having this as part of the therapy prevents the therapist 
giving up, and allows them to provide realistic optimism that the patients' 
' . 
situation can improve. The therapist can reinforce to the patient that they 
cannot blame themselves for a reduced level of social or interpersonal 
functioning when they are suffering from a debilitating illness such as 
resistant depression. This can help prevent the patient from losing hope 
and continue to engage and comply with treatment. In dysthymia the IPT 
therapist encourages the patient to view the transition from dysthymia to 
euthymia as an iatrogenic role transition (Markowitz, 1998). As patients 
have suffered chronic periods of debilitating depression they often lack 
confidence in trying out new social or interpersonal roles and activities, 
which are often overwhelming. The IPT therapist is active in 
acknowledging these fears, and encouraging new activities thus 
reinforcing their potential antidepressant benefits. 
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Psychoeducation, a fundamental concept of IPT, should include a 
realistic overview of treatments offered for resistant depression. A 
diagnosis of treatment resis,tant depression brings the need for potent 
antidepressant therapy, which may involve high doses of antidepressant 
medication, or combination or augmentations strategies with additional 
pharmacological agents. Within the framework of IPT this is a significant 
role transition. Occasionally patients can complain that medication; either 
as a monotherapy or as part of a complex combination of 
antidepressants, mood stabilisers and low dose antipsychotics is 
overwhelming. Although this prospect is not the most desirable; it may be 
the most clinically appropriate option for the patient to consider. These 
issues can be addressed using the goals and strategies identified for role 
transition in IPT. Furthermore, psychoeducation allows the therapist to 
reinforce that the patient witH resistant depression represents one third of 
depressed patients, reinforcing the medical classification of treatment 
resistant depression and preventing the patient from blaming 
themselves; this is a reasonable clinical approach and patients need the 
support to make this transition. Similarly the IPT therapist can draw 
similarities by comparing patients who have diabetes, heart disease or 
cancer for instance may need long term pharmacotherapy which is 
necessary to their recovery. Patients in these conditions all face a 
transition when accepting long term or life long prophylactic medication 
of any sort, and this is not an easy transition. There are however 
fundamental differences in that a cancer sufferer may be more willing to 
• 
accept the need for treatment than a depressed patient. Accepting the 
sick role and a medical model in IPT is a fundamental component in 
resistant depression which may help to reinforce the rationale and need 
for medical treatment with the aim of optimising treatment outcome. 
In addition to improvements in the patients' depression, the IPT therapist 
will also reflect and reinforce social and interpersonal gains throughout 
treatment. Frequently, patients who suffer from depression 
underestimate their achievements and this can help the patient to 
recognise some aspects of their progress. 
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lt is essential that the IPT therapist should maintain an optimistic 
approach to treatment, particularly in the case of difficult to treat 
depression. This is very similar to using IPT in chronic depression, when 
there can be a limited or a slower response to treatment. The strategy of 
the therapist being encouraged to blame the illness rather than the 
• 
individual in chronic depression (Markowitz, 1998) is transferable to 
dealing with patients with resistant depression, and provides the 
structure for the therapist to deal more confidently with the patient during 
sessions. For example, IPT therapists are encouraged to treat a number 
of patients with a major depressive disorder initially before attempting to 
use IPT as a treatment for dysthymia. This is because the therapist 
should gain confidence and competence in their skills in IPT before 
working with a more difficult and demanding illness such as dysthymia. 
Treating resistant depression would be likely to present very similar 
challenges to the therapist and it is reasonable to apply the same training 
restrictions. 
Although IPT has never been evaluated for treatment resistant 
depression prior to this study, efficacy of IPT in major depression in 
adults, adolescents and old age has been well established (Kierman et 
al, 1974; Weissman et al, 1979; Mufson et al, 1999; Reynolds et al, 
1996; 1997). Patients with increasing levels of complexity have also 
been successfully treated with IPT, including highly recurrent depression 
(Frank et al, 1991) and dysthymic disorder (Markowitz, 1998). Having 
originated from psychiatry and psychotherapy researchers, initial studies 
of IPT have predominantly consisted of efficacy studies. Despite this, a 
• 
small amount of the literature has evaluated specific components of IPT 
which has been suggested to contribute its antidepressant effects. 
Studies involving highly recurrent depression have demonstrated that the 
greater quality of IPT i.e. the more specific an interpersonal focus, the 
longer the antidepressant effects (Frank et al, 1991; Kupfer et al, 1992); 
furthermore, these effects have been maintained at long term follow up 
(Spanier et al, 1996). Researchers at the same site having identified that 
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patients with abnormal sleep are vulnerable to further episodes, have 
also found that high quality IPT during monthly maintenance sessions 
extends the period of wellness in recurrent depressives for an extra year 
compared to patients who received lower quality of IPT according to 
objective ratings (Spanier et al, 1996), which suggests that a high 
treatment specificity of IPT is of significant prophylactic benefit. Using the 
data from the IPT training programme for the NIMH Treatment of 
Depression Collaborative Research Programme (TRDCP), high scores 
on therapist competence in conducting IPT have been positively 
• 
correlated with treatment outcome (Rounsaville et al, 1987; O'Malley et 
al, 1988). Finally, in a recent study of dysthymic patients researchers in 
New York reported that clinicians and patients in separate ratings were 
both in agreement with the problem areas chosen during IPT sessions; 
and critically, resolution of these problem areas during therapy correlated 
significantly with a reduction in Hamilton depression scores (p= 0.0001 ). 
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Chapter four- The dopamone hypotlhesns of 
depression 
The monoamine hypothesis of depression 
The monoamine hypothesis of depression predicts that the underlying 
pathophysiological basis of depression is at least in part, depletion in the 
levels of the serotonin, noradrenaline and dopamine monoamines in the 
central nervous system (CNS). This hypothesized pathophysiology 
appears to be supported by the mechanism of action of antidepressant 
medications which mediate levels of neurotransmitters in the brain. 
These include serotonin, noradrenaline and dopamine, and all have been 
shown to be effective in the treatment of depressive symptoms. Intensive 
investigation has failed to find convincing evidence in at least some 
medicines affecting each of the neurotransmitters singularly for a primary 
dysfunction in the monoamine system. Since noradrenaline, dopamine 
and serotonin all have reciprocal interactions, it is virtually impossible to 
act on a specific neuronal element without affecting a cascade in the 
other two systems (Tremblay and Blier, 2006). The brain does not 
function on the basis of passive isolated pathways. The monoamine 
depletion paradigm reproduces the clinical syndrome of depression, thus 
allowing a more direct method using animal models for investigating the 
role of monoamines. Results from these studies have shown 
• 
antidepressant responses being transiently reversed. Interestingly, 
monoamine depletion does not worsen symptoms in depressed patients 
not taking medication, or cause depression in healthy volunteers with no 
depressive illness. This strongly suggests a transmitter receptor 
interactional process in any pathology. lt appears that antidepressants 
appear to require intact monoamine systems to reach a therapeutic 
effect (Delgado 2000). 
Dopamine system 
Since the initial dopamine hypothesis of depression was suggested by Randrup 
and colleagues (1975), multiple lines of investigation have explored the role of 
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the dopaminergic systems in depression. Dopamine dysfunction is now 
recognized as playing a major role in a wide range of psychiatric disorders. 
Dopamine is a neurotransmitter which acts in the brain and spinal cord. The 
effects of dopamine in the central nervous system (CNS) were initially 
considered to be mediated tty 2 receptor subtypes, D1 and D2. The 02 
receptors are localized both presynaptically and postsynaptically; the 
presynaptic receptors function as inhibitory autoreceptors (Andersen et al, 
1990). D1 receptors are important in the prefrontal cortex subtending working 
memory, planning and sorting tasks (Abi Dargham, 1998). Developments in 
genetic cloning have assisted with the identification of a further 3 types of 
dopamine receptor subtypes; D3, D4 and D5, all of which are localized in the 
limbic system (Sokoleff et al, 1990; Sunahara et al, 1991; Van Tol et al, 1991 ). 
There are different membrane protein characteristics of D2/D3 and D1/D4/D5. 
The dopaminergic systems in the brain arise from groups of cells in the 
midbrain and hypothalamus (van den Pol et al, 1996). Concentrations of 
dopamine producing cells which consist of a number of nuclear masses lying 
within the cerebral hemisphere are collectively known as the basal ganglia; the 
major components of which include the caudate nucleus, putamen, nucleus 
acumbens, substantia nigra, sub thalamic nucleus and globus pallidus. 
Groupings of the basal ganglia are as follows: striatum (caudate + putamen + 
nucleus acumbens), the corpus striatum (striatum + globus pallidus), and the 
lentiform nucleus (putamen and globus pallidus) (Crossman and Neary, 2002). 
Although large, the striatum is scarcely even visible to the naked eye at post 
mortem, with the appearance of its surrounding white matter. 
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Diagram of basal ganglia 
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There are three pathways' by which dopamine is transmitted; the 
nigrostriatal pathway extends from the substantia nigra to one of the 
basal ganglia called the caudate, these neurons contain 70% of brain 
dopamine and are involved with sensory stimulation and movement; the 
mesolimbic (mesocortical or mesocorticolimbic) pathway projects from 
the ventral tegmentum to the mesolimbic forebrain (anterior cingulate, 
amygdala, hippocampus) and is associated with cognitive, motivation, 
reward and emotional behaviour (Roth et al, 1987); the third tubero-
infundibular pathway is concerned with the neuronal control of the 
hypothalamic-pituitary endocrine system (Kapur and Mann, 1992). The 
diagram above shows these .three dopaminergic pathways. 
The role of dopamine in depression 
The role of dopamine in depression has been studied from various 
perspectives; a summary of the results from animal and human models 
will be presented. Studies using animal models of depression are 
correlated with dopamine dysfunction. Human studies involve depressed 
patients compared to healthy controls and include altered concentrations 
of the dopamine metabolite homovanillic acid (HVA) in cerebral spinal 
fluid, plasma or urine. There are abnormalities in the dopamine 
demonstrated by in vivo functional imaging studies, the dopamine 
transporter system and post'mortem studies. Further support is obtained 
from studies of Parkinson's disease which is associated with dopamine 
dysfunction as well as a higher incidence of depression (Carlton, 1997) 
not seen in other similarly debilitating illnesses. Finally, antidepressant 
therapies which have a direct effect on the dopaminergic system 
including medication and ECT have a therapeutic effect, which support 
the role of dopamine in depression. 
Animal studies 
Clinical symptoms of depression in humans including depressed mood 
and anhedonia make it diffic,ult to establish the validity of animal mode!s 
as a representation of human conditions (Willner et al, 1984). To help us 
link animal to human models, three approaches investigating the role of 
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dopamine in depression have been used: firstly, alterations in the 
dopamine system in animal models of depression are assessed; 
secondly, the role of dopamine in behaviours assumed to have relevance 
to human depression sucli as motivation and. reward seeking are 
examined; finally the effects of drugs on the dopamine system in animal 
models of depression are evaluated (Willner, 1995; Porsolt, 2000; Lucki, 
2001). 
"Learned helplessness" is a commonly used animal model of depression 
wherein animals exposed to stressful, inescapable situations exhibit 
decreased spontaneous activity, decreased effort to escape and a 
variety of somatic changes. Treatment with antidepressants has been 
shown to reverse the occurrences of learned helplessness in these 
situations (Sherman et al, J 982). Dopamine depletion in the caudate 
nucleus and nucleus acumbens occurs in animals with "learned 
helplessness" (Anisman et al, 1979a; Anisman et al, 1979b). 
Furthermore, prior treatment with a dopamine agonist prevents the 
development of the learned helplessness state (Anisman et al, 1979a; 
Anisman et al, 1979b). 
"Behavioural despair" or the "forced swim test" is another model in which 
rats are forced to swim in a confined space. After initial attempts to 
escape they assume an immobile posture. Antidepressants exert anti-
immobility effects; dopamine agonists augment the anti-immobility effects 
and dopamine antagonists r~verse it (Borsini and Meli, 1990). This has 
been found to be the most effective test for predicting the efficacy of new 
medications (Nestler et al, 2002). Healthy dopamine function in the 
striatum has been clearly shown to be central to learning new motor 
tasks progressively in primates. 
Another approach is based on the assumption that depression involves a 
neurobiological alteration in the central reward seeking, motivation, and 
environmental responsivity mechanisms which leads to anhedonia, 
social isolation, and psychomotor retardation, all core symptoms of 
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depression (Wise, 1989; Willner, 1991 ). Studies have investigated the 
role of the mesolimbic dopaminergic system in the maintenance of the 
reward response. One method used by researchers involves the use of 
drug self administration paradigms. They have shown that self 
administration of drugs possesses reinforcing properties such as 
nicotine, cocaine and psychostimulants which are associated with an 
increase in firing of dopamihergic neurons in the mesolimbic pathway. 
There is considerable electrophysiological and biochemical data in 
animal studies whereby the serotonin receptor subtype 5HT-2C agonists 
decrease the 5HT-2C levels resulting in an enhanced mesolimbic 
dopaminergic function (DiMatteo et al, 2002). Recent animal studies 
carried out by Alex and colleagues (2005) support growing evidence 
which indicates the 5HT -2C receptors inhibit nigrostriatal dopaminergic 
transmission. Furthermore, chronic treatment with antidepressant drugs 
produces a variety of changes in dopaminergic neurotransmission 
including increased sensitization of 02 like receptors in the mesolimbic 
dopaminergic system (Will11er et al, 2005), and receptors within the 
nucleus acumbens (Willner et al, 1997). Although these studies implicate 
the involvement of dopamine in specific behaviours, it is unclear what the 
exact role of dopamine in human depression is, and whether it is primary 
or secondary in causation (Willner, 1991; Wise, 1989; Dailly et al, 2004). 
Human studies of depression 
The most consistent finding in human studies is decreased turnover of 
dopamine in patients with depressive disorders. Lower levels of 
homovanillic acid (HVA), a major metabolite of dopamine has been found 
in the cerebral spinal fluid (CSF) of depressed patients. Most studies 
report this decrease in the CSF HVA of patients with depression (Lambert 
et al, 2000; Traskman-Bandz et al, 1984), which is more pronounced in a 
subgroup of patients with psychomotor retardation (Papeschi and 
McCiure, 1971; van Praag and Korf, 1971; Randrup et al, 1975). However, 
two later studies have failed to replicate these findings or have found 
increased CSF HVA in depressed patients (Jimmerson, 1987; 
Vestergaard et al, 1978). Although there is considerable evidence that 
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CSF HVA may be lower in depression, again it is not clear whether this is 
a primary abnormality or whether it is secondary to psychomotor 
retardation (Kapur and Mann, 1992). 
Post mortem studies 
Biochemical human post mortem studies on depressed patients indicate 
an unspecified deficiency of neurotransmitters in several brain areas. 
Birkmayer and Riederer, (1975) reported decreased concentrations of 
striatal dopamine in depressed subjects which was correlated to a 
reported loss of drive shown~ in subjects before death. 
More recently, post mortem studies use ligands to map dopamine 
receptors including 01, 02/03 and the dopamine transport system which 
have yielded important results. Dopamine transporter enzymes have been 
consistently shown to be abnormal in Parkinson's disease, a condition 
with a very high incidence of depression. Klimek and colleagues (2002) 
compared the brains of depressed subjects to normal controls and found 
no differences in 01 receptor binding. However, depressed patients were 
noted to demonstrate higher 02/03 binding in the basal, central, 
amygdaloid nuclei, additionally a reduced binding in the dopamine 
transport system was found, in the basal and central amygdaloid nuclei 
compared to controls; providing further evidence that major depression 
may be associated with a deficiency of mesolimbic dopamine. 
IBZM SPECT studies 
1123-lodobenzamide (IBZM) is a radioligand with a high affinity for 
dopamine 02 receptors (Kung et al, 1989; Kung et al, 1990; Brucke et al, 
1991 ). There has been only a very small number of functional dopamine 
02 neuroimaging studies attempted or published in depression, and 
none with psychotherapy 
Positron Emission Computed Tomography (PET) study of bipolar 
patients 
Suhara and colleagues (1992) used carbon labelled 11 C-SCH23390 (a 
radio-labelled dopamine 01 drug) to measure dopamine 01 binding in a 
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PET study of 10 bipolar mood disorder patients, who were compared to 
21 control subjects. Only three patients were depressed at the time of 
scanning (Hamilton depression scores were 34, 18 and 1 0), one patient 
was manic and the remaining 6 bipolar patients were euthymic. There 
were significantly lower binding of the ligand in the frontal cortex of the 
patients, regardless of their thymic state when compared to normal 
controls, and no significant differences in the binding potentials in the 
striatum were found between patients and controls. There were no 
differences in the binding potentials of patients with or without current 
symptoms. This study is seriously flawed for a number of reasons: The 
small sample size of 10 patients initially is further confounded by the fact 
that only 4/10 (40%) of the patients were clinically symptomatic. The 
60% of the patients who were asymptomatic could have been considered 
a psychiatric control group. Furthermore, there was a significant 
heterogeneity in the remaining four patients; the depressed patients 
symptoms ranged from mild, moderate to severe and there was only one 
manic patient studied using PET. These data are wholly inadequate to 
provide any statistically significant or clinically meaningful data. 
Reduction of 02/3 in right striatum after total sleep deprivation 
(TSD) 
Ebert et al (1994) studied 10 patients and 5 controls, all of whom had 
past psychiatric histories. T,he patients all were male, and depressed, 
with a DSM Ill R (APA, 1987) diagnosis of melancholic type depression 
with bipolar 11 course. The patients were rated using the Hamilton 
Depression scale (HAM-D), in addition the Clinical Global Impression 
Scale (CGI) of the severity of depression was also completed at 
baseline. All patients underwent 2 185Mbq 123 1-(s)-2-Hydroxy-N-(11-
Ethyl-2-pirrolidinyiMethyl) Benzamide (1-123J IBZM) SPECT scans, 
before and after total sleep deprivation treatment (TSD), an old 
antidepressant treatment of proven efficacy, generally used in Europe 
now only for drug-free research to minimize pharmacodynamic 
confounding variables. The patients also continued to take 75mg twice 
daily of the antidepressant 'amitriptyline. The authors found that after 
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sleep there were no difference between responders, non-responders and 
controls. However after total sleep deprivation the relative basal ganglia 
IBZM occupancy decreased in responders; this was significant on the 
right (p<0.02) and with a trend towards significance on the left (p<0.06). 
The authors hypothesised that the positive total sleep deprivation 
response in the subgroup of patient responders is connected to an 
increase in the dopaminergic response. That is, the IBZM ligand is 
competing with endogenous dopamine for receptor occupancy; the 
lowered relative dopamine D2 occupancy in responders after total sleep 
deprivation may reflect a change in dopamine release with TSD 
responders compared to non-responders. An alternative explanation of 
these results is that there may be post synaptic changes such that TSD 
may reduce D2 receptor densities in responders owing to enhanced 
dopamine release. TSD may change the D2 receptor agonist binding 
from a low to a high affinity state in responders. 
As all patients were medicated during this study, this may have 
increased the expected differences in the dopaminergic system between 
responders and non-responders. Furthermore, the fact that the controls 
had a past psychiatric history is also a confounding variable. 
High 02/03 density characteristics depressed in patients 
A cross sectional analysis with IBZM in depression was conducted by 
D'haenen and Bossyut (1994) in 21 DSM Ill R major depression cases (4 
males, 17 females, aged 21-61, mean age 40.5), who were compared to 
• 
11 controls (3 males, 8 females, aged 30-56, mean age 41 ). The scans 
were done 90 minutes post injection, measuring striatocerebellar ratios. 
Depression scores were assessed using the Hamilton Depression Scale 
by the same rater within 5 days of the scan; although patients were 
moderately depressed (mean Hamilton score 21.7, SD 5.04), the range 
of the severity of depression was from 11 (mild) to 32 (severe). The drug 
washout period was from 7 to over 21 days. Both the left and the right 
basal ganglia/cerebellar IBZM uptake ratio was higher in patients than 
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controls (left 1.93 (0.30) vs. 1.75 (0.18); right 1.95 (0.26) vs. 1.73 (0.17) 
which was statistically significant (p<0.025). The washout period did not 
affect the results. Retardation and Hamilton depression symptoms had 
no specific 02 correlates. Age had no 02 effect. The results suggest 
that patients either had more 02 receptors or a stronger affinity between 
receptor and ligand or both. Further, high receptor counts may reflect low 
dopamine turnover. 
Decreased IBZM binding in treatment responders 
Ebert and colleagues (1996) performed IBZM SPECT on 10 medicated 
and 10 unmedicated depressed patients and compared them to 10 
controls. Ten patients who were initially unmedicated received a second 
IBZM SPECT scan following 3 weeks of antidepressant medication. 
Patients were severely depressed at baseline with mean Hamilton 
depression scores of 26 (SO 3.6). A regional activity index (RAI) (ratio of 
counts per voxel) of the basal ganglia was compared with all of the 
counts per voxel in 36 brain regions. There were no correlations in IBZM 
uptake with age. No differences were found in patients and controls in 
striatal IBZM uptake. Four patients with psychomotor retardation 
demonstrated statistically significant higher right basal ganglia IBZM 
uptake and showed a non significant increase in IBZM binding on the left 
side, when compared to non psychomotor-retarded depressed patients 
and normal controls. Of the ten patients who were scanned in sequence 
before and during antidepressant treatment, there were an equal number 
of responders and non responders (Hamilton 10.3 (SO 3) vs. 20.2 
(802.8)). IBZM uptake decreased in responders after antidepressant 
therapy and remained unchanged or increased in nonresponders 
(p<0.05). 
• 
Progressive increase in 02/03 with treatment response 
Methodologically and in terms of clinical relevance to our study the 
project of Larisch et al (1997) is the most important study. Thirteen 
major depressed patients as per OSM IV (APA, 1994) who had not 
responded to tricyclic antidepressant treatment were scanned using 
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IBZM SPECT before and after treatment with SSRI therapy. All patients 
underwent a one week washout period before the first scan. 
All subjects were given 2 x 1-123 IBZM scans, before and after six weeks 
of antidepressant treatment with a serotonin specific reuptake inhibitor 
(SSRI) (30-50mg paroxetine or 60mg fluoxetine). The IBZM has an 
affinity for both the low and the high affinity states of the 02/03 receptor. 
The data acquisitions after the SPECT scans were taken 90 minutes 
after injecting the radioligand. SPECT and MRI were eo-registered with 
the Computerised Brain Atlas (CBA). Individual patients' striata were 
drawn on the individual SPECT slices; between patients there was high 
• 
variability in terms of size and position of the striatum. The authors 
selected the cerebellum rather than the frontal cortex as a reference 
region because 02 and 03 are present in frontal cortex and the anterior 
cingulate gyrus. Responders were defined as showing a greater than 
80% Hamilton depression score reduction and a CGI of "very much 
improved". This 80% improvement criterion is considered a stringent 
measure. 
02/03 binding and depressive symptom changes were analysed with 
Spearman's rank order correlation. The mean Hamilton depression 
scores of all of the patients dropped from 28 (SD 5) at baseline to 11 (SD 
1 0) after treatment, which was clinically significant (p< 0.001 ). The mean 
treatment duration was 40 (SD 9) days and ranged from 21-54 days of 
SSRI therapy between scans. The second scan was performed 
prematurely at week 3, 4 and 5 in three unresponsive patients. The 
control subjects and patients did not differ in age, gender or IBZM 
binding. Responders and non responders showed no differences in age, 
gender or severity of depression at the start of treatment. Four patients 
demonstrated an 80% reduction in their Hamilton depression scores, a 
further three patients demonstrated a partial response (60-80% drop in 
Hamilton depression scores) and 6 patients did not respond. The authors 
• 
found a significant difference· in IBZM binding between responders and 
nonresponders; IBZM binding increased in the SSRI responders in the 
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anterior cingulate gyrus and the striatum. Furthermore, there was a 
significant linear correlation between IBZM binding and clinical response 
as measured by the Hamilton depression scale in the left (p<0.04) and 
right (p<0.05) striatum 
The same group reported an extension of this study in which 2 additional 
patients were recruited to the trial and were compared to 17 normal 
controls in order to establish if there were differences between the two 
groups in the baseline IBZM binding ratios (Kiimke et al 1999). 
IBZM striatal binding in the control group was significantly correlated to 
age (p<0.01 ); linear regression analysis revealed a decline of 
striatum/cerebellar ratio of 0.092/decade. In the depressed group the age 
dependant reduction of IBZM striatal binding was lower per decade 
• (0.036/decade), but was not statistically significant. After age correction 
at baseline, responders had a lower IBZM binding compared to non-
responders and controls (p<0.05). Furthermore, there was a significant 
correlation between change of IBZM binding values and the percent 
change of depressive symptomatology. The authors suggested that 
reduced dopamine densities in the striatum underlie depressive 
symptoms, which may indicate a good response to pharmacological 
modulation of the serotonergic system. This was further supported by 
correlations with the intra-individual change of striatal binding and 
improvements in depression as measured on the Hamilton depression 
scale. 
Helpfully Klimke's group (1999) recorded that no patients had ever 
received neuroleptic medication, and their tricyclic prescriptions had 
tended to be over a long period (62-443 days of treatment). Although the 
authors identified that the patients had not responded to one previous 
trial of a tricyclic antidepressant, no further details were provided. 
Responders had lower baseline binding ratios than controls and non-
responders. 02/03 density did not reduce more in responders as per 
Ebert's findings. The authors suggested that these findings may be due 
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to reduced D2 receptor densities in the striatum and that this may 
underlie depressive symptoms. 
This is a rigorous study involving a non-psychiatric control group (n=17) 
and a homogeneous group (n=15) of depressed patients who had failed 
at least one previous trial of tricyclic antidepressants. The patients 
studied during this trial w~re severely depressed (mean Hamilton 
Depression score 28.5). IBZM SPECT scans were conducted at baseline 
and after 6 weeks of treatment with an SSRI, although no differences 
were noted between patients and controls, increased IBZM binding was 
noted in patients who responded to SSRI treatment, and interestingly 
IBZM binding was found to correlate linearly with percentage 
improvements on the Hamilton Depression scale. The authors suggested 
that this may reflect an increase in density and/or affinity for the striatal 
dopamine D2 receptors. Changes in D2/3 densities in the striatum in 
responders have been reported (Ebert et al, 1994; Larisch et al, 1997; 
Klimke et al, 1999) and may reflect plasticity of receptors to increase or 
' decrease in those who recover, and not to change or decrease in 
patients who remain resistant to treatment. Non-responders showed no 
change or a reduction in the IBZM binding in Klimke's work. Inter-study 
result variability due to camera type and region of interest method were 
discussed but the authors found the non-responder results unexpected 
and difficult to explain. Changes in the regional cerebral blood flow 
particularly in the striatum may have influenced the results. 
A suggestion of high 02/03 in depression 
Shah et al (1997) studied 15 depressed patients 2 of whom were bipolar, 
8 of whom were on antidepFessants, 3 on benzodiazepines and 4 were 
drug free. They were compared to 15 healthy matched controls in a 
cross sectional study with a single scan using a whole slice of the brain 
as a reference region. lt also included a neuropsychological battery of 
cognitive tests for memory, verbal fluency and motor function. 
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Depressed patients showed higher right striatal D2 density than controls. 
In both patients and controls, women had greater D2/D3 in the striatum. 
There were no significant differences between medicated and 
unmedicated patients, but there was a larger effect size in medicated 
patients for higher binding. There was no significant effect due to 
retardation as measured on the Hamilton depression score, or any 
measured depressive clinical subtype or severity group. These 
investigators had hoped to find neurotic/psychotic D2 correlates but did 
not. A strong negative correlation between D2/D3 density and suicidality 
was not explained by sex differences. The authors suggest it is possible 
that suicidal patients had experienced high dopamine release due to 
stress, then down regulated their receptors. 
The small numbers of patients studied during this trial are further 
hampered by the homogeneity of the group; two patients were diagnosed 
with bipolar disorder and patients were studies with or without 
melancholic and/or psychotic features, which may seriously confound the 
results. 
Dopamine Transporter Sys,tem (OAT) in depression 
Dopamine transporters (DAT) are monoamine transporters which are 
responsible for the homoeostasis of dopamine pools at nerve endings 
(lveston, 2006). Animal studies have shown that administration of 
antidepressants, irrespective of pharmacological class produce changes 
in the DAT binding affinity. This has led scientists to test the hypothesis 
that dopamine transporter function may play a crucial role in the 
pathophysiology of depression (Brunswick et al, 2003). 
Functional imaging studies using PET and SPECT allow in vivo 
exploration of these transporters and have found higher binding of the 
radioligand to DAT in the ba'sal ganglia in depressed patients compared 
to controls (Brunswick et al, 2003; Laassonen-Balk et al, 1999). 
Dopamine Transporter System (OAT) in depression in Parkinson's 
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disease 
Parkinson's disease is an idiopathic disorder characterized by rigidity, 
akinesia and tremor and is associated with degeneration of the 
nigrostriatal dopaminergic system, and loss of projections of the midbrain 
limbic and cortical projections (Cummings 1985). The role of dopamine in 
Parkinson's disease is clearly established. The incidence of depression 
in Parkinson's disease is more than ten times greater than that of healthy 
controls (40-50% vs. 3-4%), and as other similarly debilitating illnesses 
do not have an increased prevalence of depression, this cannot solely 
be attributed to the disabling effects of the illness. As depression often 
occurs before the motor symptoms of Parkinson's disease emerge 
(Mayeux, 1990), and there is no relationship between the severity of 
• Parkinson's disease and depression (Cummings, 1985; Mayeux, 1990), 
a neurobiological contribution to the pathogenesis of depression in 
Parkinson's disease is likely (Carlton 1997). However, a direct 
relationship between dopamine and depression in Parkinson's disease 
has previously been harder to establish; depression in Parkinson's 
disease does not correlate with CSF HVA levels; antidepressants often 
improve mood without a change in the motor component of the disease, 
ECT however, improves both (Andersen et al, 1980; Cummings et al, 
1985; Mayeux, 1990). This has led to a SPECT study of the dopamine 
transporters in Parkinson's disease. 
A SPECT study imaging the dopamine transporter (OAT) with labelled 
beta-CIT (2beta-carbomethoxy-3-beta (4-iodophenyl-tropane) was 
conducted on 76 patients with Parkinson's disease and compared with 46 
age matched healthy volunteers. Specifically, the authors were interested 
in correlations between patients with symptoms of depression and anxiety 
and OAT availability. The presence of depression in Parkinson's disease 
was significantly associated with diminished left anterior putamen OAT 
availability reflecting lower dopamine turnover (Weintraub et al, 2005). 
Conversely, OAT density was found to be higher among Parkinson's 
disease patients compared to controls in both sides of the basal ganglia 
• 
when imaged using 1231-labelled beta-CIT (2beta-carbomethoxy-3-beta 
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(4-iodophenyl-tropane) SPECT. The authors hypothesized that 
upregulation of the OAT in Parkinson's disease may be a primary 
alteration which leads to lower intrapsychic dopamine concentration and to 
lower neural transmission subtending depression in those Parkinson's 
disease patients who get it. •. 
Thus it appears that although dopamine degeneration may be a link in 
the causal chain of depression, it may not solely be responsible for the 
mood alterations seen in Parkinson's disease. 
Brain Reward System 
Psychostimulants such as amphetamine cause euphoria in normal 
volunteers. Amphetamine promotes the release of noradrenaline and 
dopamine from nerve terminals and inhibits their reuptake. The 
behavioural effects of amphetamine have been shown to be mediated by 
• the dopaminergic system (Randrup et al, 1975; Willner, 1983a). 
Central dopaminergic neurotransmission has multiple actions at each level 
of the mesolimbic reward pathway. The role of dopamine in the reward 
process has long been believed to be associated with the ability to 
experience pleasure; dysfunction of the dopamine transmission in the 
reward circuit is associated with symptoms such as anhedonia, apathy 
and dysphoria, all common symptoms of depression (Bressen and Crippa, 
2005). The state of the brain reward system can be assessed in major 
depression using dextroamphetamine, which provokes the release of 
dopamine within the mesolimbic system, and producing measurable 
behavioural changes, including rewarding effects of euphoria. 
Hypersensitive symptom responses have been found in depressed 
patients compared to controls which are positively correlated to the 
severity of the depression (Tremblay et al, 2002). Although outside the 
scope of Tremblay's study, patients who take amphetamine become more 
mentally ill as a rule in clinical experience. There is a large body of 
literature on psychotic deterioration with amphetamine with strong 
evidence for dendrite damage after dopamine release. 
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Following a single blind administration of dextroamphetamine to stimulate 
the brain reward system, subjects with major depression demonstrated a 
hypersensitive response to the reward system activating effects of 
dextroamphetamine compared to controls (p=0.01 ). Functional MRI 
showed altered brain activation in the ventrolateral prefrontal cortex, 
orbitofrontal cortex, the caudate and the putamen (Tremblay et al, 2005). 
Parsey and colleagues in New York (2001) with the use of IBZM SPECT 
imaging, wished to assess the density of 02/03 receptor availability in 
non-psychotic unmedicated unipolar patients during depression in 
relation to amphetamine induced dopamine release. 9 depressed 
subjects and 10 healthy matched controls were studied. There were no 
differences in the IBZM uptake ratios when comparing patients and 
controls. This study was seriously flawed by an absence of baseline 
symptom characterization and absence of analysis of any specific 
dopamine related symptoms e.g. a completely non agitated or 
psychomotor retarded group may putatively have shown no 02 
pathology in any event. Am'phetamine reduced 02/03 similarly in both 
patients and controls. This suggested that stimulant induced dopamine 
release is not altered in depression. Whilst this could reflect a lack of 
baseline 02/03 pathology in depression, it may be explained by the 
depressed state still remaining responsive to amphetamine, a very 
powerful drug which releases dopamine with clinical effects for anyone 
who takes it. This study would probably not have received ethical 
approval in Britain. 
Growth hormone response to apomorphine stimulation test 
The tuberoinfundibular dopaminergic system has neuroendocrine 
• 
functions, stimulating the release of growth hormone (GH) and inhibiting 
the release of prolactin. Thus baseline levels of thee hormones have been 
examined as potential markers of dopaminergic function in mood 
disorders, and their responses to dopamine agonists have been used to 
evaluate dopamine receptor responsiveness. The sensitivity of central 
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dopamine receptors can be' assessed with growth hormone response to 
the dopamine agonist apomorphine. Depressed patients have 
demonstrated a reduced sensitivity of central dopamine receptors 
compared to control subjects. Affective flattening has been associated 
with both dopamine receptor sensitivity and psychomotor slowing (Healy 
and McKeon, 2000). 
Studies with growth hormone have been inconclusive. Baseline levels of 
GH have been reported to be increased (Mendlewicz et al, 1985), normal, 
(Mitchell et al, 1991; Lechin et al, 1985) or decreased (Price et al, 1991) in 
depression. Additionally, bl~nted GH responses to apomorphine have 
reported a difference between major and minor depressives (Pitchot et al, 
1992; Ansseau et al, 1987). 
Abnormal prolactin levels have frequently been reported in depressed 
patients, but there is no consistency on the direction of change; low, 
normal and high levels have been reported in different studies (O'Keane 
and Dinan, 1991; Sher et al, 2003; Joyce et al, 1985). Studies have 
reported a decrease in prolactin levels in patients with seasonal affective 
disorder (SAD) which was present in winter when patients were 
depressed and summer during euthymia (Levitan et al, 1998; Depue et 
al, 1989; 1990). 
Antidepressant effects of dopaminergic agents 
Antidepressants whose primary mode of action is on the dopaminergic 
system provides further evidence for the role of dopamine in depression. 
The dopamine agonist bromocriptine which has been used in the 
treatment of Parkinson's disease has been shown to have 
antidepressant efficacy equivalent to that of tricyclic antidepressants 
(Theohar et al, 1981; Wells and Marken, 1989). Another dopamine 
agonist, piribedil has been shown to have antidepressant qualities 
(Mouret et al, 1987). The antipsychotic medications olanzapine, sulpiride 
' ' ' 
and amisulpride enhance dopamine function (Del Zombo et al, 1990; 
Standish-Barry et al, 1983; Dailly et al, 2004) and all have been shown to 
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have antidepressant properties. Furthermore, amisulpride the 02/03 
antagonist is licensed in France as an antidepressant medication in 
dysthymia. The 02 antagonist flupenthixol is licensed in the UK for 
depression. 
Nomifensine a dopamine reuptake inhibitor, which in clinical trials has 
proven antidepressant efficacy equivalent to TCA'S (Forest et al, 1977; 
Grof et al, 1977; McCielland et al, 1977; Kinney et el, 1985). lt has been 
shown to increase dopamine release in the striatum of rat brains 
(Butcher et al, 1991 ). lt has a specific effect on patients with 
psychomotor retardation, and greater efficacy in patients with lower CSF 
HVA levels. This antidepressant is no longer marketed as it causes 
haemolytic anaemia, an unrelated effect of its dopaminergic actions. 
Bupropioh, a dopamine reuptake inhibitor has been studied extensively 
in clinical trials and found to be superior to placebo and as effective as 
standard antidepressants (Settle 1989; Zung, 1983). Rat studies have 
shown dopamine concentrations are found to rise in the striatum and the 
nucleus acumbens and no alterations to the noradrenaline or serotonin 
levels (Nomikos, 1989). Alpha-amineptine, an antidepressant recently 
introduced in Europe selectively inhibits the reuptake of dopamine (Ceci 
et al, 1986; Bonnet et al, 1980). Large scale double blind studies have 
demonstrated the antidepressant efficacy of alpha-amineptine (Kemali, 
1989; Mendis et al, 1989) early results suggest a preferential response 
in patients with psychomotorr~tarded depression (Rampello et al, 1991 ). 
The antidepressant mirtazapine has been shown to increase extracellular 
noradrenaline and dopamine in the medial prefrontal cortex. This is 
thought to occur when the mirtazapine inhibits the alpha (2)-
adrenoreceptors which produces a eo-release of noradrenalin and 
dopamine (Oevoto et al, 2004). 
A research group in Wales (Willner et al, 2005) administered a low dose 
of sulpiride, a dopamine 02 antagonist to 8 depressed patients who had 
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responded to treatment with an SSRI (citalopram, fluoxetine or 
paroxetine) compared to 10 age matched normal controls (Willner et al, 
2005). Mood and psychomotor effects were measured. The control group 
reported an increase in their general feelings of well-being and the 
depressed group demonstrated a reinstatement of their depressed state. 
This data is consistent with the hypothesis that sensitization of the 02 
receptors may be central to ttle action of SSRI's. 
Electroconvulsive therapy (ECT) 
ECT is a powerful tool with which to investigate the biochemical effects 
that accompany antidepressant response. Animal models of depression 
show that show that chronic treatment with ECT increases dopaminergic 
activity in the nigrostriatal and mesolimbic pathways (Nomikos et al, 
1991; Gulati et al, 1987; Willner, 1983). 
The effect of dopaminergic activity was evaluated following treatment 
with ECT using prolactin and growth hormone responses. Of the studies 
' of growth hormone release in response to an apomorphine challenge, 
only one, Costain et al, (1982) out of three found evidence of enhanced 
dopaminergic function after ECT (Balldin et al, 1982; Christie et al, 1982; 
Costain et al, 1982). One study (Zis et al, 1992) of prolactin release 
found evidence to suggest increased dopaminergic transmission after a 
clinically successful course of ECT whereas two did not (Balldin et al, 
1982; Christie et al, 1982). 
Summary 
Animal and human studies have suggested there are abnormalities in 
dopamine in depression including: depleted levels of striatal dopamine. as 
found in post mortem studies, functional neuroimaging studies, reductions 
in the dopamine transporter system and reduced levels of the dopamine 
metabolite, homovanillic acid (HVA). Additionally, the mechanism of action 
of antidepressant treatments including both pharmacotherapy and 
Electroconvulsive therapy has been found to enhance dopaminergic 
function. Pharmacological probes such as dextroamphetamine and 
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apomorphine which stimulate the release of dopamine have demonstrated 
increased sensitivity of dopamine receptors which have been correlated to 
a depressed state, in particular psychomotor slowing. Furthermore, 
antidepressant medication which acts specifically on the serotonergic 
system appears to have an indirect effect on the dopaminergic system. 
Although not all of the evidence is consistent, there is an indication that 
abnormalities of dopamine in depression exist. There is a great need for 
further exploratory research in studies of improving methodological rigor to 
examine the role of dopamine in depression; this should include various 
types of depression, different treatment modalities and include various 
levels of response to treatment. Correlations of dopamine function to 
particular depressive symptoms should also be explored. Functional 
neuroimaging techniques are one mechanism which will allow us to the 
opportunity still to try to answer some of these questions. 
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Chapter Five - The effects of Interpersonal 
Psychotherapy a~gmented to mirtazapine in 
treatment resistant depressed participants 
Design 
The author wished to assess the effect of Interpersonal Psychotherapy 
augmented to the antidepressant mirtazapine in the treatment of resistant 
depression. This was a parallel group study where participants were randomly 
assigned to mirtazapine alone (30-45mg daily) or mirtazapine (30-45mg daily) 
plus 16 sessions of weekly Interpersonal Psychotherapy. The participants were 
then followed up naturalistically for one year; during this time those participants 
who had received weekly IPT continued to receive IPT administered as a 
monthly maintenance treatment. All participants could continue their 
antidepressant medication durir"lg this time. 
Participants used self rating scales to measure their depression (Beck 
Depression Inventory, Beck 1961) and social functioning (Social Adaptation 
Scale, Weissman, 1976), and clinician rated measurements of depression 
(Hamilton Depression Scale, Hamilton, 1960) and anxiety (Hamilton Anxiety 
Scale, Hamilton, 1969) were administered by a blind rater at baseline, 6 
weeks, 16 weeks, 6 months and after one year. The Annett scale (Annett, 
1970) of handedness will also was administered at baseline in order to 
establish if patients were left or right handed. 
Method 
Twenty three depressed participants who had not responded to at least six 
weeks of an antidepressant medication at an adequate dose were randomised 
using the sealed envelope technique to receive either mirtazapine alone (30-
45mg daily) or combined with 16 weekly sessions of Interpersonal 
Psychotherapy (IPT). Three participants who had originally consented to the 
trial withdrew their consent following randomisation before treatment had 
started (2 participants were allocated to the IPT and mirtazapine group and one 
was allocated to the mirtazapine only group). As this study included functional 
brain scans of the dopamine D2 receptor using IBZM SPECT (and previous 
IBZM dopamine D2 receptor SPECT studies have found increased dopamine 
receptor binding in woman compared to men, (Shah et al 1997)); the author 
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controlled for this confounding variable by randomising an equal number of 
men and women into both treatment groups. 
At baseline, comorbid conditions, demographic information and details of the 
depressive episodes were taken for each participant, which included the 
number of previous depressive episodes, the total number of months 
depressed during lifetime and the previous number of failed antidepressant 
treatments. This allowed an assessment of the level of treatment resistance for 
each particular participant. Information regarding the participants' depression 
history was retrospectively obtained from the medical notes and through 
verification with the participant. At times, however, there was limited clinical 
information in the medical notes and participants could not always remember 
details of timing, duration or treatments for depression. Where this was the 
case, the author has reported only the known facts (i.e. the period of time the 
participant had definitely been suffering from a depressive episode). Therefore, 
for this study, restraints of retrospective data collection led to an 
underestimation of the number of depressive episodes suffered and 
• 
subsequent treatment received for each participant. Details of the participants' 
diagnosis and depression are listed in the table below. The shaded area of 
each table throughout this thesis represents the combined IPT and mirtazapine 
group, the clear area denotes the mirtazapine only group. 
Depression 
Details of the participants' depression, past and current episodes are presented 
below. 
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Table C5-1 shows the parlicipant characteristics of depression 
Participant 
ID number 
Sex Previous 
major 
depressive 
episodes 
Total 
months 
depressed 
Duration of Previous 
current failed I 
episode poor 
treatments 
* Note: Where > sign is shown the participant reported a greater number of depressive 
episodes, or months depressed, however specific dates could not be ascertained from 
the medical records. 
There were three participants who withdrew their consent post randomisation 
but before starting treatment in the study, the details of which are listed below. 
ID number 009 ~"Personal reasons". 
ID number 013 -"Personal reasons". 
ID number 014- No reason given. 
Number of previous depressive episodes 
The number of previous major depressive episodes in the total group of 
20 participants in the study ranged from 0-5 (mean=1.75; SD=1.4). The 
number of previous major depressive episodes in the combined IPT and 
mirtazapine group ranged from 0-3, with a mean number of 2 depressive 
episodes (SD=1. 1"5). Two of the partieipar~ts who were randomised to the 
combined treatment group had no previous episodes of depression and 
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were experiencing their first, depressive episode. The range of previous 
episodes of major depression in the mirtazapine only group was 0-5 with 
the mean number of 1.5 (SD=1.65). Four participants of the mirtazapine 
group had not had a previous major depressive episode and were 
experiencing their first episode at trial entry. Small to moderate effect 
sizes (0.35, Cl 0.14-0.84) were detected in relation to the group 
differences regarding the number of previous major depressive episodes. 
Duration of the current (index) depressive episode 
The author then examined the duration of the current depressive episode 
for which the participant sought help. The total group ranged from 2.5 to 
42 months (mean=17.09; SIJ=12.05). The combined group had a range 
of 3-36 months (mean duration=12.93; SD=10.06). The mirtazapine only 
group had reported the duration of current depressive episodes for 2.5 to 
42 months with a mean score of 21.05; SD= 12.05. The difference 
between the two treatment groups was demonstrated with medium to 
large effect sizes (0.73, Cl 0.24-1.22) 
The total number of months depressed 
The total number of months depressed during the participant's lifetime 
ranged from 12 to more than 300 months (mean=54.6; SD=63.9) for the 
whole study sample. The medication only group had been depressed for 
' . 
12 to 84 months (mean=41.4; SD=21.62). The combined IPT and 
mirtazapine group had experienced depressive symptoms over a longer 
period of time, this ranged from 18 to >300 months (mean=67 .8; 
SD=88.13). The difference between the two groups was demonstrated 
with moderate effect sizes (0.44; Cl 0.08-0.9). 
There were no significant differences between the two groups at baseline 
regarding duration of total or current episode of depression, and the total 
number of previous depressive episodes, although the small sample 
sizes limit these findings. 
Number of different antidepressant treatments 
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The number of previous antidepressant medications including mood stabilisers 
was retrospectively gathered from the medical notes and are listed in the table 
below. 
Table C5-2 shows the participant's antidepressant treatment prior 
to study entry [ n.b. this table occupies pages164-5] 
Participants Medication Start date End date Response 
Seroxat ?dose ?.03.94 ?03.95 Poor 
Fluoxetlne 20mg ?.03.95 ?.04.95 Poor 
Fluoxeline 40mg 7.4.95 12.07.95 Poor 
Nefazodone 200mg 12.0795 31.07.95 Poor 
Seroxat 20mg 31 .07.95 21.09.95 Poor 
F01 Seroxat 30mg 21 .09.95 24.07.96 Poor 
Citalopram 20mg 24.07.96 09.08.96 Poor 
Cltalopram 40mg 09.08.96 
!'I 
12.08.98 Fair 
Ven/afaxine 75mg 12.08.98 ?.09.98 Poor 
Cltalopram 20mg 22.12.99 28.01 .99 Poor 
Mirtazapine 15mg 28.01.99 29.01.99 Not known 
Citalopram 40mg 17.03.00 2,9.04.00 Poor 
Imipramine ? dose ? ? Poor 
Dothiepin ? dose ? ?.94 Poor 
F05 Fluoxetine 20mg ? ?.07.94 Poor 
Seroxat 20mg ?.07.94 ?.10.95 Fair 
Venlafaxine 37.5mg ?.10.95 ?.03.96 Poor 
Seroxat ? dose ?.?.97 ?,06.99 Poor 
Venlafaxine ? dose ?.06.99 ?.12.99 Poor 
Citalopram 60mg ?.12.99 ?.04.00 Poor 
Dothiepin ? dos£1 ?.10.98 ?.08.99 Poor 
F11 Fluoxetine 20mg ?.10.99 ?.09.00 Poor 
Venlafaxine 75mg ?.09.00 ?.12.00 Poor 
Fluoxetine 40mg ?.04.00 ?.01.01 Poor 
F12 Unknown unknown unknown Poor 
antidepressant x 2 
F21 Fluoxetine 20mg ?.11 .00 31 .01 .01 Poor 
Venlafaxine 75mg 31.01 ~001 ?.05.01 Poor 
M04 Citalopram 20mg 26.11 .97 4.01 .98 Poor 
Cltalopram 40mg 04.01.98 15.09.98 Fair 
Mirtazapine 30mg 15.09.98 17.09.98 Not known 
Cita/opram 60mg 15.12.99 09.02.99 Good 
Venlafaxine 225mg 09.02.99 24.03.99 Poor 
Mirtazapine 30mg 24.03.99 26.03.99 Not known 
Venlafaxine 225mg 25.06.99 02.04.00 Poor 
M06 Sertraline 50mg ?.02.98 ?.11.99 Poor 
Dothiepin 75mg ?.11.99 ?.12.99 Poor 
Dothiepin 150mg ?.12.99 
ii 
?.02.99 Fair 
Ven/afaxine 150mg ?.02.99 ?.03.00 Fair 
M15 Paroxetine 50mg ?.03.95 ?.09.95 Poor 
Lofepramine 210mg ?.09,95 ?.02.97 Fair 
M16 Amitriptyline 100mg ?.02.99 ?.05.99 Poor 
Citalopram 20-60mg ?.02.00 ?.06.00 Poor 
Citalopram 30mg, ?.09.00 ?.02.01 Poor 
M23 Seroxat 20mg 15.09.99 ?.11 .99 Poor 
Sertraline 150mg 07.04.00 ?.05.01 Fair 
Sertraline 100mg 11.02.00 07.04.00 Poor 
Sertraline 50mg 18.01 .00 11 .02.00 Poor 
Venlafaxine 75mg 15.12.99 18.01.00 Poor 
F03 Venlafaxine 75mg ?.12.98 ?.06.99 Poor 
Venlafaxine 150mg ?.06.99 ?.02.00 Poor 
F10 Seroxat 30mg ?.05.98 ?.12.00 Poor 
F17 Citalopram ?dose ?. ?.98 ?98-3 months No response 
Paroxetine ?dose ?.?.98 ?98-3 months No response 
Dothiepin 75mg ??98 ?98 18months No response 
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F19 Clomipramine 100mg ?.01.97 ?.07.97 Poor 
. Clomipramine 150mg ?.07.97 ? .. 10.97 Poor 
Citalopram 20mg ?.10.97 ? .. 12.97 Poor 
Citalopram 40mg ?.12.97 ?.03.98 Poor 
Paroxetine 40mg ?.03.98 ?.11.00 Fair 
Venlafaxine 75mg ?.01.01 ?.02.01 Poor 
Reboxetine 8mg ?.02.01 ?.04.01 Fair 
Dothiepin ?dose Unknown .07.95 Unknown 
Trazodone 150mg .07.95 .07.97 Poor 
Fluoxetine 20mg .01.97 .03.97 Poor 
Dothiepin 150mg. .04.97 .05.97 Good 
F20 Venlafaxine 75mg .06.97 .07.97 Fair 
Venlafaxine 150mg .06.97 .07.97 Fair 
Serlraline 50mg .07.97 .05.98 Fair 
Sertraline 150mg .02.99 .05.99 Poor 
Seroxat 20mg .05.99 .11.99 Poor 
Venlafaxine 150mg .11.99 .03.00 Poor 
Venlafaxine 225mg .03.00 .04.01 Poor 
Dothiepin ? dose .04.91 .05.91 Poor 
MOB Paroxetine? dose 26.10.99 17.01.00 Poor 
Venlafaxine ?dose 18.01.00 14.02.00 Poor 
Citalopram ?dose 15.02.00 05.06.00 Poor 
Trazodone ? dose 06.06.00 04.07.00 Poor 
Fluoxetine 20mg .06.95 .06.95 No response 
Fluoxetine 40mg 06.95 .07.95 No response 
Clomipramine 150mg .07.95 .06.96 Good 
Clomipramine 200mg .02.96 .06.96 Good 
Lithium 400mg .03.96 .03.96 Good 
Dutonin 200mg .02.96 .04.96 Side effects 
Lithium BOOmg .06.96 .10.96 Poor 
Lithium 600mg ' .10.96 .12.96 Fair 
Lithium 1 OOOmg .07.97 .02.99 Poor 
M07 Venlafaxine 75mg .02.99 .03.99 Side effects 
Mirtazapine 30mg .03.99 .05.99 Non compliant 
Mirlazapine 45mg .05.99 .06.99 Non compliant 
Lithium 1 OOOmg .05.99 .08.99 No response 
Lithium 800mg .08.99 .11.99 Fair 
Citalopram 20mg .06.99 .08.99 Fair 
Citalopram 60mg .08.99 .10.99 Fair 
Epi/im chrono 1 OOOmg .11.99 .03.00 Fair 
Reboxetine 8mg .11.99 .03.00 Fair 
Fluoxetine 40mg .11.99 .03.00 Fair 
Lofepramine 140mg .05.00 .10.00 Fair 
M18 Fluoxetine 20mg .12.00 .02.01 Poor 
Venlafaxine 75mg .02.01 .04.01 Poor 
• Sertraline 50mg 05.06.00 27.06.00 Poor 
M22 Reboxetine Bmg 27.06.00 29.09.00 Poor 
Venlafaxine 75mg 29.09.00 15.05.01 Poor 
M24 Fluoxetine 20mg ?.12.00 ?.06.01 Poor 
Venlafaxine 75 mg ?.02.00 ?.12.00 Poor 
* Participant ID number F19 comment recorded in notes pre 1997 "numerous 
antidepressants" however no specific medication was documented. 
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All of the known antidepressant treatments were recorded in the table above. In 
order to establish the number of previous failed antidepressant treatments the 
author excluded some of this data which identified responses to treatment as 
"good", "fair" or "unknown". Furthermore, participants who were non-compliant 
to a particular trial of medication, or had experienced side effects were also 
excluded. Although all data from the medical records were included in the 
above table, not all the data represented a failed antidepressant trial. All of the 
data excluded from the analysis, which could not be confidently identified as a 
failed trial were recorded on the above table in italics. 
Antidepressant medication which was explicitly prescribed at a therapeutic 
dose for at least 6 weeks was ~ncluded as a single treatment, increases in the 
dose of antidepressant medication within the first six weeks was recorded as a 
single treatment. Medication which was increased after 6 weeks, due to poor 
response was recorded as a separate treatment. This was because the 
increased dose was assumed to be a change in the management of non or 
poor responding depression. There were only four participants for which this 
was the case, one in the IPT and mirtazapine group (F01) and the remaining 
three in the mirtazapine only group (F03, F19 and F20). Lithium which was 
provided to augment the effects of the antidepressant was also included in the 
data as an antidepressant treatment. 
Taking all of the above into account the range of failed antidepressant 
' treatment for the total study sample ranged from 1-6 (mean 2.45: SO 1.35). Ttie 
range of failed antidepressant treatment for the combined group was 1-6 (mean 
2.6; SO 1.57). The range of failed antidepressant treatments in the mirtazapine 
only group was 1-5 with a similar mean score of 2.3 (SO 1.15). 
As this data was gathered retrospectively, and factors which could not be 
confirmed were excluded, this represents an underestimation of the likely 
number of previous treatments for the sample of participants used in this study. 
Assessment of treatment resistant depression 
Treatment resistant depression (TRO) was first conceptualised over 2 decades 
ago by Fawcett and Kravitz, ~1985) who took into account the length of the 
depressive episode, the number of antidepressant treatments and the use of 
augmentation strategies to help improve the depression. Although there have 
been as many as 15 alternate definitions of TRO proposed (Sourey et al, 1999), 
166 
none have been widely accepted and used in clinical or research settings 
(Kieine, 2004) . For the purposes of this study the author accepted a minimum 
' definition . of treatment resistance; a lack of a clinical response to an 
antidepressant at an adequate dose and duration. 
Clearly, participants recruited to this study demonstrate a spectrum of non 
response or poor response to treatment. In order to identify these participants 
and then to establish increasing levels of non-response or resistance to 
treatment, the author identified factors which may help with this process. The 
number of previous failed antidepressant treatments, the duration of the current 
episode as well as the chronicity of depressive symptoms in a lifetime were 
considered appropriate clinical markers of non-response and treatment 
resistance. This data is recorded in the table below. 
Table CS-3 shows the participant's severity of treatment resistant 
depression 
A B c 
Total no. of failed Duration of Chronicity of A A A 
Participant antidepressant current depression B B c 
ID treatments episode .:::_12 .:::_30 c 
.:::_3 
F01 6 
-
40 X 
F05 3 12 >132 X X X 
F11 
- 12 38 
F21 
-
36 48 
M04 3 
- -
MOB 
-
21 >aoo 
' 
M16 3 12 >36 X X X 
M23 3 18 
-
X 
F03 - 12 >42 
F10 - 36 36 
F17 - 30 30 
F19 3 24 60 X X X 
F20 5 12 84 X X X 
M08 - >12 >18 
MO? 3 - >60 X 
M18 - 12 -
M22 - 42 42 
M24 - 30 30 
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The sample of participants recruited did demonstrate a spectrum of treatment 
resistance. Only 2 participants did not score highly on any of the above items 
(chronicity, duration or severity of the depression) and their level of TRD status 
could be considered as mild at that point in time. Both of these patients were 
randomised to the IPT and mirtazapine group (Pt ID: F12 and M15). 
There were 5 participants who had only had one clear previous failed 
antidepressant treatment before the trial, three were in the IPT and mirtazapine 
group (F12, M06, M15) and two were in the mirtazapine only group (F10, MOB). 
Four participants, two in the IPT and mirtazapine group (F05, M16) and two in 
the mirtazapine only group (F19, F20) scored highly in all three areas of 
chronicity of depression, long duration of current episode and more than two 
failed antidepressant treatments. 
Patients diagnosis and comorbiditv 
The author conducted an assessment using the Diagnostic and Statistical 
• 
Manual for Mental Disorders IV Structured Clinical Interview (DSM IV SCI) at 
baseline which formerly assessed psychiatric diagnosis at the start of the study. 
The participants' diagnosis including comorbid anxiety disorders are listed in 
the table below. 
Key: 
MDE Major depressive episode 
MDER Major depressive episode - recurrent 
DD Dysthymic disorder (chronic longer term depression) 
PA Panic disorder with agoraphobia 
P Panic disorder without agoraphobia 
GAD Generalised anxiety disorder 
168 
Table C5-4 shows the participant's diagnosis including comorbid 
anxiety disorders 
Participants MDE MDER DD PA p GAD 
F01 X X 
F05 X X X 
F11 X 
F12 X X X 
F21 X X X 
M04 X X 
M06 X X X 
M15 X 
M16. X X X 
M23 X X 
F03 X X X 
F10 X X 
F17 X X 
F19 X X 
F20 X X X 
M08 X X 
M07 X 
M18 X 
M22 X X 
M24 X 
There was twice the number of participants diagnosed with double depression, 
that is, dysthymia superimpos~d on major depressive disorder in the IPT and 
mirtazapine group. There was an equal distribution of anxiety disorders (panic 
disorder with or without agoraphobia and generalised anxiety disorder) 
throughout both treatment groups. 
Table C5-5 demonstrates a summary of the types of diagnosis of 
participant's in each group 
Diagnoses IPT and mirtazapine mirtazapine 
Single diagnosis of 
depression 11, 15 07,18,24 
Double depression - major 
depressive disorder and 1, 4, 23 10, 22 
dysthymia 
Double depression and 
• panic . 05, 06, 12, 16 
Double depression and 
generalised anxiety 21 03,20 
disorder 
Major depression and 08, 17, 19 
panic 
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Table C5-6 shows the number of additional DSM IV diagnoses in each 
treatment group 
Number of diagnosis Combined group Mirtazapine only 
1 diagnosis 2 3 
2 diagnoses 3 5 
3 diagnoses 5 2 
The author documented the number of additional psychiatric diagnoses for 
each participant. The tables (C5-5 and C5-6) below demonstrates that there 
were a greater number of participants in the combined IPT and mirtazapine 
group (n=5, n=2) who had major depression plus 2 additional comorbid 
diagnoses. 
Demographic data 
Demographic data was collected by the author at baseline and is detailed 
below. 
Handedness 
All of the subjects apart from one female in the psychotherapy group (F015) 
were right handed. 
Age 
The age range of the total patient group studied was 28-52 (mean= 39.5, 
SD=7.24) . The age range of the combined group was 32-52 years (mean=40.7; 
SD=6.43) and the range of the mirtazapine only group was 28-50 (mean=38.3; 
SD=8.12). 
Gender 
There were an equal number of men and women randomly assigned to both 
treatment groups. 
Table C5-7 shows the educational background of participant's in each 
group 
Schooling Combined group Mirtazapine group 
Left school no exams 9 5 
Year 11 0 1 
Sixth form 1 2 
2 year college 0 0 
4 year college 0 2 
Graduate/ professional 0 0 
school 
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Most of the combined IPT and mirtazapine group (n=9) and half of the 
mirtazapine only group had left school without any exams. Only one participant 
in the IPT and mirtazapine group had been educated to A' level. A greater 
proportion of the mirtazapine qnly group were educated to either A level (n=2) 
or degree level (n=2) . 
Table C5-8 shows the occupation of participant's in each group 
Combined group Mirtazapine only 
Unemployed 6 4 
Unskilled work 1 1 
Semi-skilled work 0 1 
Skilled work 0 2 
Professional work 0 1 
Off sick 2 1 
Retired early 1 0 
Nine of the participants in the combined IPT and mirtazapine group were not 
working , the only participant Who did work was undertaking unskilled work, 
whereas five of the participants in the mirtazapine only group were in 
employment (3/5 were undertaking skilled or professional employment, one was 
carrying out skilled work and only one of the participants were carrying out 
unskilled work) . Four participants in the mirtazapine only group were 
unemployed and one was on sick leave from work. 
Table C5-9 shows the social contacts of participant's in each group 
Combined group Mirtazapine only 
No social contacts 1 1 
Minimal social contacts with 7 5 
relatives 
Small number of friends 
• 
2 14. 4 
There was a relatively even spread of the reported use and availabi lity of social 
contacts in both treatment groups. 
Table C5-10 shows the marital status of participant's in each group 
Combined group Mirtazapine only 
Married 5 6 
Widowed 0 0 
Divorced or annulled 4 1 
Never married 1 3 
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There were similar numbers of married participants in the two treatment groups 
and a higher number of divorcees in the combined IPT and mirtazapine group 
Table C5-11 shows the alcohol and drug use of participant's in each 
group 
Combined group Mirtazapine only 
No alcohol 3 5 
No drugs 
' 
10 9 
Occasional < 5 units per week 0 3 
Regular >1 0 units/week 4 1 
>20 units/week 2 1 
>30 units/week 1 0 
Occasional cannabis use 0 1 
The combined IPT and mirtazapine group demonstrated a higher general 
alcohol intake per week. 
Interventions 
Sample selection 
Participants were recruited from psychiatrists and General Practitioners in 
Sunderland from October 2000 to June 2001 . All participants were white 
Caucasian. The severity of depression was measured at baseline using the 
Hamilton Depression Rating Scale (Hamilton, 1960), and a minimum score of 
18 was necessary to enter the study. In order to obtain a homogeneous sample 
and minimise confounding variables exclusions to the study included drug and 
alcohol abuse, Parkinson's disease, or previous head injuries. 
Interpersonal Psychotherapy 
The Interpersonal Psychotherapy was delivered as per manual (Kierman et al 
1984) by two trained IPT therapists. During the acute phase of treatment 
participants were offered 16 weekly sessions of IPT. The frequency of the IPT 
sessions was reduced to monthly between week 16 and week 52. Weekly 
meetings for supervision took place between the therapists to minimise drift. 
' Permission to tape each psychotherapy session was requested from each 
participant; the psychotherapy sessions were then rated using the National 
Institute Mental Health (NI M H) Adherence Rating Scale at the end of the trial. 
IPT therapists 
There were 2 Interpersonal Psychotherapists for this study , one male (PC) and 
one female (ER) . Both therapists were experienced psychiatric nurses and IPT 
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therapists and had received training in IPT to research level. The author of the 
study (ER) had received her initial IPT training from Professor JC Markowitz, 
Director of Psychotherapy Research, Cornell University, New York. He himself 
had been trained, and supervised by Gerald Klerman, the originator of 
Interpersonal Psychotherapy. Professor Markowitz also conducted research 
using IPT with Gerald Klerman. 
As the author was a research therapist for a previous I PT depression study 
(Martin et al 2001) she had already obtained the necessary training, supervision 
and experience for research validation for an Interpersonal Psychotherapy trial. 
Supervision received by the au~hor, prior to this first trial, had been provided by 
Kathleen Clougherty M.S.W., a psychiatric social worker from New York. Ms 
Clougherty is a highly experienced IPT therapist, trained by Klerman, and has 
published research and provided IPT as an IPT research therapist involving 
depressed HIV positive patients (Markowitz et al, 1995). Research validation 
requires that the therapist achieves three cases of successfully delivered IPT 
according to the model. During this validation every IPT session was 
audiotaped and sent to New York where the supervising therapist would listen 
to the tapes and provide telephone supervision between each therapy session. 
A small number of sessions were also supervised face to face. The author 
achieved the necessary level for the provision of IPT in a research environment 
and was found to adhere to the, model. 
Following an introductory course from Professor Markowitz the male therapist 
(PC) had each session of three cases supervised by (ER) before he started 
providing Interpersonal Psychotherapy for this study. Both therapists at 
the start of the trial had achieved adherence to the model of 
Interpersonal Psychotherapy (Kierman 1984). 
IPT therapy raters 
Two trained IPT therapists were used in this study to rate the 
psychotherapy sessions. The author, (ER) rated all of the sessions which 
were delivered by IPT therapist (PC). A second rater, a Consultant 
Psychiatrist (SDM) was also .a trained IPT therapist who received his 
initial training from Prof JC Markowitz, and had seen a number of IPT 
cases. In order to establish rater agreement both of the raters listened to 
173 
an IPT case together (not any of the participants used for this trial) and 
rated the IPT session using t}le NIMH adherence monitoring rating scale. 
Mirtazapine 
Mirtazapine was prescribed at a starting dose of 30mg each day, and if 
necessary could be increased to a maximum of 45mg daily. Medication 
was prescribed by one of two research psychiatrists who were working 
on this trial; a research registrar (ST) or a Consultant Psychiatrist (SDM). 
Antidepressant trial medication was prescribed at the start of treatment, 
week 3 and week 6. At each medication review the prescribing 
psychiatrist was instructed to review depressive symptoms, assess for 
any adverse events and issue a prescription and to avoid any 
psychoth~rapeutic interventions. This review would take no longer than 
20 minutes. After 16 weeks the participants were provided a prescription 
for their antidepressant which could be obtained from an external 
pharmacy. After 16 weeks it was the responsibility of the participant to 
obtain further medication from their GP or treating psychiatrist. 
A research pharmacist (JH) was responsible for the dispensing and 
return of the trial medication, she would make a note of any medication 
returns in order to monitor compliance. Adverse events were noted at 
each visit. 
Clinical ratings 
Measurements of depression, anxiety and social functioning of each 
participant were taken at baseline and repeated after six weeks of active 
treatment; this would provide an indication of early responders to 
treatment, additionally it would provide the data to assess any clinical 
correlates with the dopamine 02 receptor brain imaging scans which 
were performed at week 0 and again at week 6. Clinical measurements 
were repeated at week 16, the end of the acute phase of IPT and then at 
6 months and 12 month follow up in order to establish longer term 
efficacy of the two treatment conditions. The rating scales used for this 
project were the clinician ra'ted Hamilton Depression Scale (1960) and 
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Hamilton Anxiety Scale (1969) which were administered by a blinded 
rater. Following the clinical ratings the rater supplied the Beck 
Depression Inventory (Beck, 1961) and the Social Adaptation Scale 
(Weissman and Bothwell, 1976) which are participant rating forms for 
depression and social functioning. The ratings occurred five times over 
the period of the study: weeks 0, 6, 16, 26 and 52. 
As the author randomised the treatment groups and was an IPT 
therapist, blinded ratings were carried out by two experienced psychiatric 
nurses who had been qualified for a minimum of 18 years. Both nurses 
were unaware of the treatment each participant received and did not 
work in the same department where the research was undertaken. 
Participants were advised not to tell the raters what treatment they were 
receiving. This ensured they remained blind to treatment for the duration 
of the trial. 
Each nurse received training on the respective rating scales and carried 
out role play under supervision of the author. They then watched the 
video tape of a patient and scored it using relevant clinical rating scales 
to establish inter-rater reliability. At the appropriate time point the nurse 
rater completed the Hamilton Depression Scale and Hamilton Anxiety 
Scale, and at the same time she asked subjects to complete the self 
rating depression scale (Beck Depression Inventory) and Social Adaption 
Scale (SAS). 
Safety issues 
In the case of major relapse or possible increases in suicidality all 
participants were given the contact details of the author or her deputy in 
the case of deterioration, for the duration of the trial. This was in addition 
to usual access to psychiatric support services and the participants GP. 
Results 
The results from the study are presented below including changes in clinical 
scores relating to the participants depression, anxiety and social functioning. 
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This is followed by dose data for each arm. For the Interpersonal 
Psychotherapy intervention dose and adherence monitoring are reported and 
then the dose, compliance and adverse events related to the use of 
mirtazapine. 
Clinical ratings 
The results for the clinical measurements of depression, anxiety and social 
functioning for the participants individually and as a group are reported at the 
• 
five time points (Week 0, week 6, week 16, week 26, and week 52). Of the total 
clinical data presented only two ratings at week 16 were not carried out, this 
was because the participants did not attend for the assessment interview. 
There was one participant in each treatment group (M16 and F17). For the 
purposes of statistical analysis the last observation (week 6) was carried 
forward in both of these cases. 
Table C5-12 below shows the individual participants Hamilton Depression 
scores at baseline and over the year at week 6, week 16, week 26 and week 
52. The "X" signifies ratings which could not be obtained. The shaded area 
represents the combined IPT and mirtazapine treatment, and the clear area 
shows the mirtazapine only group. None of the IPT and mirtazapine group 
deteriorated as measured by the Hamilton Depression Scale on every point in 
time. Eight of the ten participants in the mirtazapine only group deteriorated as 
demonstrated by an increase in their Hamilton scores in 13/40 measurements. 
A 40% reduction in Hamilton depression scores is an accepted minimum level 
of a Hamilton depression score which demonstrates a response to treatment; 
there were 27/40 occasions when there was at least a 40% reduction in the 
Hamilton depression scores in the combined IPT and mirtazapine group 
compared to 10/40 occasions in the mirtazapine only group; this is indicated on 
the table below by an asterisk. 
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Table CS-12 shows the total scores of the participants Hamilton 
depression scores at baseline and after week 6, week 16, week 26 and 
week 52 
Participants WeekO WeekS Week 16 Week 26 Week 52 
F01 28 27 17* 14* 14* 
F05 27 15* 18 12* 23 
F11 34 19* 21 14* 11* 
F12 30 18* 21 17* 13* 
F21 27 18 12* 15* 13* 
M04 34 18* 8* 10* 24 
MOo 28 
• 
21 23 t6* 8* 
M15 32 12* 23 14* 8* 
M16 39 31 X 14* 8* 
M23 18 17 9* 8* 7* 
F03 31 21 31 33 19 
F10 34 24 43 35 26 
F17 28 27 X 15* 18 
F19 28 24 8* 14* 31 
F20 32 33 22 18* 37 
MOB 29 34 31 33 27 
• 
MO? 28 28 32 10 24 
M18 34 12* 3* 17* 27 
M22 30 35 30 32 28 
M24 20 12* 11* 10* 22 
* demonstrates at least a 40% reductton m the Hamtlton depresston scores from the 
baseline measurement. 
Table C5-13 shows the mean Hamilton Depression scores for both 
treatment groups and the total groups at baseline and for the time 
periods over the year. A score of 26 signifies severe depression on the 
• 
Hamilton · Depression scale. The mean scores of the each treatment 
group and the total group demonstrates severe depression. The combined IPT 
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group showed a gradual reduction in the mean Hamilton scores from week 6 
(moderate depression) to week 52 (mild depression) . The mirtazapine only 
group in contrast remained the upper end of moderately depressed throughout 
• 
the rating periods. 
Table CS-13 shows the mean scores (SD) for the Hamilton depression 
scale at Week 0, week 6, week 16, week 26 and week 52 
Week 0 Week 6 Week 16 Week 26 Week 52 
Total group 29.5 (4.77) 22.3 (7.40) 21.4( 11.21) 17.5 (8.47) 19.4 (8.79) 
IPT and mirtazapine 29.7 (5.69) 19.6 (5.58) 17.5 (5.85) 13.4 (2.71) 12.9 (6.19) 
mirtazapine 29.4 (4.03) 25 ( 8.26) 25.4 (14 .02) 21 .7 (10.28) 25.9 (5.62) 
*Note that on the above table there were data sets missing at week 16 for two subjects 
therefore the last observation was carried forward to calculate the mean scores. 
The data was analysed from the Hamilton depression scores using a two way 
repeated measures analysis of variance (ANOVA) . These analyses permitted 
the evaluation of effects of time, treatment and the interaction between 
treatment by time on the Hamilton depression scores. 
Mauchly's test indicated that the assumption of sphericity had been violated for 
the effects of time (Chi squared (9) = 18.12, P=0.035. Therefore the degrees of 
freedom were corrected using the Huynh-Feldt estimates of sphericity (epsilon 
= 0.776) . There was a significant effect of time F (3.1, 55 .8) = 10.5, p= 0.001 
and treatment F (1 , 18) = 9.36, p= 0.007. Critical ly, there was a significa[lt 
interaction effect between treatment and time F (3.1 , 55.8) = 2.9, p = 0.041 . To 
explore the interaction, pairwise comparisons were conducted at each time 
point and showed significant improvements on depression scores from baseline 
to weeks 6, p =0.003; week 16, p =0.009; week 26, p = 0.001 ; week 52 , p 
=0.001) . 
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Table CS-14 shows a graph of the Hamilton depression scores at baseline 
and weeks 6, 16, 26 and 52 
Hamilton Depression Scale Scores for Combined Treatment vs. Mirtazaplne at 
Baseline, 6, 16, 26 and 52 weeks 
I- c ombined -Mirtazapine I 
Baseline Week6 Week1 6 Week 26 Week 52 
The between group differences demonstrated significant differences in 
the two treatment groups F (1 , 18) = 9.36, p = 0.007 . Subsequent t tests 
revealed statistically significant differences between the groups which 
emerged by week 26 t = -2.47, df 10.25, p= 0.033 and week 52, t =-
4.95, df 17.87, p = 0.001 (Bonferroni corrected) . 
Table C5-15 below shows the individual participants Beck Depression 
Inventory scores at baseline and over the year at week 6, week 16, week 
26 and week 52 . The "X" signifies ratings which could not be obtained . 
The shaded area represents the combined IPT and mirtazapine 
treatment, and the clear area shows the mirtazapine only group. Five of 
• the ten participants in the IPT and mirtazapine group deteriorated at 
some point (7 out of a total of 40 measurements) in their treatment and 
six of the mirtazapine only group deteriorated 1 0 out of a total of 40 
measurements. 
There were 19/40 occasions when there was at least a 40% reduction in 
the Beck Depression scores in the combined IPT and mirtazapine group 
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compared to 4/40 occasions in the mirtazapine only group; this is 
indicated on the table below by an asterisk. 
Table CS- 15 shows the total scores of the participants Beck 
Depression Inventory depression scores at baseline and after week 
6, week 16, week 26 and week 52. 
Participants WeekO WeekS Week 16 Week 26 Week 52 
F01 31 34 21 26 16* 
F05 46 35 27* 26* 28* 
~ 
F11 54 ' 27* 32* 38 30* . 
F12 31 18* 36 18* 23 
F21 41 33 18* 23* 21* 
M04 40 30 22* 4* 50 
M06 37 44 42 43 34 
M15 51 30* 37 35 24* 
M16 36 39 X 17* 23* 
M23 29 20 18 17* 16 
F03 34 40 39 37 33 
F10 30 41 49 27 22 
F17 35 34 X 30 28 
F19 34 • 24 15* 30 33 
F20 35 44 30 25 38 
M08 32 31 32 29 43 
MO? 30 29 35 30 25 
M18 29 22 6* 17 14* 
M22 40 47 25* 33 33 
M24 33 25 22 22 31 
* demonstrates at least a 40% reduction m the BD/ scores from the base/me 
measurement. 
Table CS-16 shows the mean Beck Depression scores for both treatment 
groups and the total group at baseline and for weeks 6, 16, 26, and 52. A score 
of 40 signifies extreme depression on the Beck depression Inventory and 31 + 
• 
signifies severe depression. The mean scores of the each treatment group and 
the total group demonstrates severe depression. The combined IPT group 
showed a gradual reduction in the mean Beck Depression Inventory scores 
from week 6 (bordering moderate depression) to week 26 (moderate 
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depression) , there was a slight increase in the scores at week 52 (middle of 
moderately depressed category) . The mirtazapine only group in contrast 
remained at the low end of the severely depressed category for 2 out of 4 of the 
ratings (weeks 6 and 16) and remained the upper end of moderately depressed 
for the last two clinical rating periods (Week 26 and 52) 
Table C5-16 shows the mean scores (50) for the Beck Depression 
Inventory at Week 0. week 6, week 16. week 26 and week 52 
WeekO WeekS Week 16 Week 26 Week 52 
Total group 36.4 (7 .1 0) 32 .3 (8 .33) 29.6 (11 .33) 26.3 (9.05) 28.2 (9 .10) 
IPT and mirtazapine 39.6 (8.57) 31 .0 (7.96) 29.0(8.91) 24.7 (11 .62) 26.5 
(10.02) 
mirtazapine 33.2 ( 3.22) 33.7 (8 .89) 30.2 (13.83) 28 (5 .64) 30 (823) 
• 
*Note that on the above table there were data sets m1ssmg at week 16 for two 
participants therefore the last observation was carried forward to calculate the mean 
scores. 
The data was analysed from the Beck Depression Inventory scores using a two 
way repeated measures analysis of variance. These analyses permitted the 
evaluation of effects of time, treatment and the interaction between treatment 
by time on the Beck Depression Inventory scores. 
Using a repeated measures ANOVA there was only a significant effect detected 
for time F (4, 15) = 11.46, p= 0.001 . However, there were no significant 
differences noted between treatment groups (F (1 , 18) = 0.039, p = 0.845) or in 
the time X group interaction (F t4, 72) = 1.55, p= 0.196). 
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Table CS- 17 shows a graph of the Beck Depression Inventory scores at 
baseline and weeks 6, 16, 26 and 52 
Beck depression inventory scores for combined 
I 
treatment vs. mirtazapine at baseline, 6, 16, 26 and 
52 weeks 
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Table CS-18 below shows the individual participants Hamilton Anxiety scores at 
baseline and over the year at week 6, week 16, week 26 and week 52. The "x" 
signifies ratings which could not be obtained . Two of the ten participants in the 
IPT and mirtazapine group demonstrated increased anxiety at some point in 
their treatment (3 out of a total of 40 measurements) and 4 of the mirtazapine 
only group deteriorated (9 out of a total of 40 measurements) . 
There were 25/40 occasions when there was at least a 40% reduction in the 
Hamilton Anxiety scores in the combined IPT and mirtazapine group compared 
to 12/40 occasions in the mirtazapine only group; this is indicated on the table 
below by an asterisk. 
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Table C5-18 shows the total scores of the participants Hamilton Anxiety 
scores (HAS) at baseline and after week 6, week 16, week 26 and week 52 
Participants WeekO WeekS Week 16 Week 26 Week 52 
F01 17 17 26 19 7* 
F05 32 18* 19* 13* 27 
F11 29 19 18 9* 7* 
' 
, 
F12 25 17 18 13* 11* 
F21 20 25 20 13 12* 
M04 38 18* 9* 4* 17* 
M06 36 20* 19* 10* 13* 
M15 31 4* 14* 6* 4* 
M16 29 ' 25 X 14* 9* 
M23 13 8 8 5* 5* 
F03 24 16 34 25 14* 
F10 23 
' 
15 39 28 24 
F17 29 27 X 18 14* 
F19 29 17* 13* 16* 28 
F20 35 33 26 23 32 
M08 29 24 24 27 20 
M07 24 21 25 13* 17 
M18 23 11* 4* 17 11 * 
M22 24 31 27 26 19 
M24 19 10* 8* 8* 16 
• 
* demonstrates at least a 40% reductton tn the HAS scores from the base/me 
measurement. 
Table C5-19 below shows the mean Hamilton Anxiety scores for both 
treatment groups and the total group at baseline and for weeks 6, 16, 26, 
and 52. There are no published cut scores for the interpretation of the 
Hamilton Anxiety scores. The author therefore examined the percentage 
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reduction in the mean scores relative to the baseline measurement. The 
combined IPT and mirtazapine group reduced by 37% and 39% at weeks 
6 and 16 respectively, and demonstrated greater reductions signifying 
improvements in anxiety symptoms at the longer term follow ups of 26 
and 52 weeks (61% and 59% respectively) . The mirtazapine only group 
showed a 21% reduction in scores after 6 weeks, however this 
improvement was not sustained as the mean scores showed just 8% 
reduction at week 16. The greatest reduction in the Hamilton Anxiety 
scores in the mirtazapine only group were at week 26 (33%) and this score was 
reduced slightly at week 52 (25!Yo) . 
Table C5- 19 shows the mean scores (SO) for the Hamilton anxiety scale 
at baseline and after week 6, week 16, week 26 and week 52. Plus percent 
changes in reductions in HAS scores from baseline measurements 
(brackets) 
WeekO WeekS Week 16 Week 26 Week 52 
Total group 26.4 (6.46) 18.8 (7 .38) 20.2 (9.93) 15.3 (7.45) 15.3 (7.82) 
IPT and mirtazapine 27 (8.16) 17.1 (6.60) 16.5 (5.38) 10.6 (4.69) 11 .2 (6.81) 
(37%) (39%) (61%) (59%) 
} 
mirtazapine 25.9 (4.55) 20.5 (8 .06) 23.9 (12.02) 20.1 (6.71) 19.5 (6.70) 
(21 %) (8%) (33%) (25%) 
*Note that on the above table there were data sets missing at week 16 for two 
participants therefore the last observation was carried forward to calculate the mean 
scores. 
The data was analysed from the Hamilton anxiety scores using a two way 
repeated measures analysis of variance. These analyses permitted the 
evaluation of effects of time, treatment and the interaction between treatment 
by time on the Hamilton depression scores. 
There was a significant effect of time, F (4, 72) = 12.16, p= 0.001 and treatment 
F (1 , 18) = 5.34, p= 0.033. Critically, there was a significant interaction effect 
between treatment and time f (4, 72) = 2.56, p = 0.044. To explore the 
interaction, pairwise comparisons were conducted at each time point and 
showed significant improvements on anxiety scores from baseline to weeks 6, p 
=0.004; week 26, p = 0.001 ; week 52, p =0.001) . 
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Table CS-20 shows a graph of the Hamilton anxiety scores at baseline and 
weeks 6, 16, 26 and 52 
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In order to explore the differences between the treatment groups, t tests were 
conducted and revealed statistically significant differences between the groups 
which emerged by week 26 t = -3.67, df 18, p= 0.002 and week 52, t = -2.75, df 
18, p = 0.013 (Bonferroni corrected) . 
Table CS-21 below reports the total scores for the individual participants for 
Social Adaption Scores for each treatment group. The normal range for this 
scale is 35-52 . There was one participant in each group which fell within the 
normal range for social adaptation at the start of treatment. For most of the time 
the participants in both groups feU below the normal range, this occurred slightly 
more often in the IPT and mirtazapine group (38/40 vs. 34/40) . The double 
asterisk has marked those participants who were within the normal range 
according to this scale. 
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Table CS-21 shows the total scores of the participants Social Adaption 
scores at baseline and after week 6, week 16, week 26 and week 52 
Participants WeekO WeekS Week 16 Week 26 Week 52 
F01 36** 31 31 34 48** 
FOS 13 21 34 15 15 
F11 16 ' 26 31 26 27 
F12 27 32 24 28 17 
F21 16 20 20 13 15 
M04 30 24 30 47** 28 
M06 19 21 12 5 25 
M15 18 14 24 23 24 
M16 30 28 XX 25 26 
M23 20 31 25 25 29 
F03 20 14 19 23 19 
F10 35 34 17 30 28 
F17 17 22 XX 12 10 
F19 19 17 32 18 18 
F20 30 19 24 24 16 
M08 17 24 24 11 24 
M07 35** 35** 33 35** 31 
M18 32 44** 52** 36** 38** 
M22 13 9 9 9 8 
M24 24 25 24 28 27 
** denotes the normal range for the soc1al adaptation scores 
Table CS-22 below shows the mean Social Adaptation Scores for both 
treatment groups and the total group at baseline and for weeks 6, 16, 26, and 
52. Both treatment groups have similar mean scores at baseline which 
continue throughout treatment. All of the mean scores at each time point fall 
below the normal range (35) . , 
Table C5-22 shows the mean scores (SD) for the Social Adaption 
Scores at baseline and after week 6, week 16, week 26 and week 52 
WeekO WeekS Week 16 Week 26 Week 52 
Total group 23.3 (7.76) 24.5 (8.38) 25.8 (9.59) 23.3 (10.51) 23.6 (9.42) 
IPT and mlrtazaplne 22.5 (7.66) 24.8 (5.86) 25.7 (6.8) 24.1 (11 .62) 25.4 (9.56) 
mirtazapine 24.2 (8.17) 24.3 (10.67) 26 (12.21) 22.6 (9.84) 21.9 (9.45) 
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The data was analysed from the Social Adaptation scores using a two way 
repeated measures analysis of variance. These analyses permitted the 
evaluation of effects of time, treatment and the interaction between treatment 
by time on the Social Adaptation Scores. There were no significant effects for 
time (F (4, 72) = 1.2, p= 0.30) , treatment (F (1 , 18) = 0.013, p= 0.91 ), or the 
interaction between time and treatment (F ( 4, 72) = 0.16, p = 0. 96) . 
Table CS-23 shows a graph of the Social Adaptation scores at baseline 
and weeks 6, 16, 26 and 52 . 
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Interpersonal Psychotherapy 
The Interpersonal Psychotherapy provided in this study was carried out by two 
research trained IPT therapists. The author (ER) provided IPT for 7 participants, 
and the IPT therapist (PC) provided IPT for three of the participants. The author 
recorded the number of IPT sessions received by each participant, including the 
period of time the psychotherapy was delivered (encompassing acute and 
maintenance phases of treatment) . This information provides an indication of 
the dose of IPT each participant received during the acute and maintenance 
phases of treatment. The problem area which was the focus during acute and 
maintenance therapy was also noted in each participant. 
At the start of treatment participants were asked if the acute Interpersonal 
Psychotherapy sessions could be audiotaped for the purpose of monitoring 
adherence to the model of IPT. Four of the participants agreed to have their 
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• 
sessions taped; two participants from each therapist. Out of a possible 43 
acute phase IPT sessions, 22 (49%) were actually taped; this was due to 
technical difficulties. Due to the limited number of tapes available to monitor for 
the purposes of adherence, every tape was rated. 
Dose of Interpersonal Psychotherapy treatment 
The author planned to use the established doses of acute IPT (up to 16 weekly 
sessions) followed by monthly IPT maintenance sessions (Eikin et al 1989, 
Frank et al 1991). Table C5-24 below shows the number of IPT sessions each 
participant received during acute and maintenance treatment, including which 
therapist provided the IPT. During the first 6 weeks 50% of participants had 
received the full dose of 6 weekly sessions, 40% received a moderate/full dose 
of 4-5 sessions. One participant (10%) had attended for just 2 sessions of IPT 
in the first 6 weeks of treatment. 
During the maintenance IPT therapy 30% of the participants received an 
optimum dose, 30% received a moderate and a further 30% received a low 
dose of psychotherapy treatment. One participant (021) received 12 IPT 
sessions over a period of 10 months; this was due to psychotherapy sessions 
being tapered from weekly, during the acute phase treatment to fortnightly 
before receiving monthly maintenance IPT sessions . 
. . 
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Table CS-24 shows the number of /PT sessions the participant received 
during the first six weeks, and acute and maintenance phases 
Early 16 week Maintenance IPT delivered 
Acute phase 'Acute phase phaseiPT over total year 
IPT IPT 
Participant Total number of Number of Number of Total number of 
ID number sessions from sessions/ number sessions! number /PT 
weeks 0-6 of weeks of months sessions/months 
001 6 16/16 7/6 23/12 
005 6 17/22 7/6 24/12 
*011 6 12112 7n 19/9.5 
*012 4 , 1,~3/16 3/4 s,1~/8.5 
021 5 10/10 12/10 22/12 
• 004 6 12/15 5/6 17/12 
006 6 8/8 5/5 13/9 
*015 4 10/15 4/3 14n 
016 2 7/6 3/6 10/9 
023 4 8/14 5/9 13/11 
*The shaded area above represented the sessions provided by the therapist PC, the 
clear areas are those provided by the author (ER) . 
Table C5-25 reports the mean number of completed IPT sessions during early 
acute, acute and maintenance, phases of treatment. Each phase of treatment 
fell slightly below the optimum mean dose of IPT treatment; however the 
therapy provided could be still considered a reasonable therapeutic dose. 
Table CS-25 shows the mean number of /PT completed by week 6, during 
acute and maintenance treatment phases and after one vear (Optimum 
dose in brackets) 
Weeks 0-6 Acute IPT Maintenance TotaiiPT over 12 months 
IPT 
Mean 4.9 (6) 11.3 (16) 5.8 (8) 17.1 (24) 
Range 2-6 7-17 3-12 10-24 
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There was clearly a broad range in the dose of IPT administered during all 
phases of treatment. Only half of the group received the optimum dose of 6 IPT 
sessions after the initial six weeks; a further 4 participants received a moderate 
dose (4-5 sessions) of IPT and only one participant received an extremely low 
dose (2 sessions) of IPT for this period . 
The mean number of IPT sessions (11 .3) received by the total group during the 
acute phase would represent a r:noderate dose. Only two of these participants 
received the optimum dose as specified in the manual (Kierman et al 1984); a 
further five participants received moderate doses (1 0-13 sessions) and three 
participants received low dose IPT (7 or 8 sessions). The maintenance phase of 
treatment reflected the broadest range (3-12) of I PT sessions which were 
delivered over 3-10 months. Taking into account the time period for which the 
IPT maintenance sessions were delivered, the majority of participants (n=9) 
received an optimum dose of treatment. The remaining 2 participants received 
IPT at half of the current established maintenance dose (participants M16; 
M23). 
Table C5-26 shows the mean number of /PT sessions delivered (total /PT 
group) and the total time (months) of therapy 
Therapist PC,7N=3 @ ER, N=7 
Mean number of acute IPT sessions 11.7 i'i 11 .1 
Mean number of maintenance IPT sessions 
" 
4.6 £ 6.3 
Mean number of total IPT sessions 16.3 d 17.4 
(acute and maintenance) 
I@ 
Mean time in months IPT provided 8.3 11 
~ 
Range of time in months the IPT was provided 7-9.5 9-12 
' 
There were few differences between therapists in the number of acute 
Interpersonal Psychotherapy sessions provided to each participant. On 
average, therapist (ER) provided slightly more of the total (1) and maintenance 
(2) IPT sessions than the therapist (PC); however, these sessions were 
delivered over a longer period of time (11 vs. 8.3) months. 
Interpersonal Psychotherapy problem areas 
The problem areas agreed with the therapist and participant were recorded for 
both phases of treatment. 
Table C5-27 demonstrates the problem area which was the focus of 
treatment 
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Participant IPT Acute focal area IPT -M focal area 
001 Dispute, transition Dispute transition 
005 Transition Transition 
011 Dispute, transition Transition 
012 Dispute Transition 
021 Transition , dispute Transition , dispute 
004 Tcansition Transition 
006 Dispute, transition Dispute, transition 
015 Transition Transition 
016 Transition Transition 
023 Transition Transition 
There were no participants whose depression was classified as having 
apparently been caused or maintained by two of the four problem areas; 
namely, complicated bereavement or interpersonal deficit. 
IPT therapist adherence monltoring 
Only the acute phase sessions of the IPT were rated encompassing the initial 
and middle phases of both treatments. Both raters (ER, and SDM) 
independently listened to the complete IPT session which was to be rated . The 
author (ER) rated the sessions delivered by the therapist (PC) and rater SDM 
separately rated the sessions provided by ER. The rating scale allowed the 
rater to assess if particular treatment strategies for IPT were employed . 
Furthermore, the level of competence achieved by each therapist was 
assessed as well as the level of difficulty for each participant during the 
session. 
Initial phase of IPT -adherence monitoring 
The tasks of the initial sessions of IPT are listed in the table below. These form 
the NIMH adherence monitoring assessment of the initial phase of treatment as 
used in the Elkin study (1989) . This part of the assessment allows the rater to 
establish whether the task has been performed. There are no ratings for the 
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quality of the intervention at this stage of the treatment. A score of "1" indicates 
. . 
the tasks have been achieved ·and a score of "2" indicates that during the 
session rated the task had not been performed. 
Table C5-28 shows the tasks of the initial sessions on the NIMH 
adherence rating form 
Tasks- Initial session(s) 
A Inquire re: chief complaint and depressive symptoms 
B History of current depressive episode and treatment if any 
c Brief social history 
D Inquiry re : patients expectation of psychotherapy 
E Explanation of IPT and it's basic assumptions 
F Translation of chief compliant (depressive symptoms) into interpersonal context 
G Reassurance of patient re : positive prognosis 
H Explanation of IPT techniques 
I Contract setting Re: administrative details , ie length of sessions, frequency , duration of 
treatment , appointment times, ,etc 
J Interpersonal Inventory (detailed review of patient's important relationships) 
K Feedback to patient Re : therapist general understanding of the patients interpersonal 
difficulties (IPT problem areas) 
L Contract setting Re : treatment goals 
M Explanation of therapist and patient tasks in working toward treatment goals 
Table C5-29 shows the results of the therapist adherence monitoring for 
the initial sessions 
Therapist A B c D E F G H I J K L M 
Participants Session I Rater 
F011 1 PC/ER 1 1 1 2 2 2 1 2 2 1 2 2 2 
F011 2 PC/ER 1 1 1 2 1 2 1 2 2 1 1 2 2 
F012 1 PC/ER 1 1 1 2 1 2 1 1 2 1 2 2 2 
F012 2 PC/ER 2 2 2 2 1 1 1 1 2 1 2 2 2 
M023 1 ER/SDM 1 1 1 1 1 1 1 1 2 1 2 1 1 
F021 1 ER/SDM 1 1 1 1 1 1 1 1 2 1 1 2 '2 
F021 2 ER/SDM 1 1 1 1 1 1 1 1 2 1 1 1 1 
Four participants, treated by both therapists were rated for adherence to the 
initial phase of IPT. Although the IPT manual highlights that the initial phase 
may spread to 3 sessions, only the first 2 were rated . From a possible 91 
responses, nearly two thirds (n=57) of the strategies were achieved (13 tasks 
involving 7 psychotherapy sessions) during the sessions rated . Of the 
remaining third (n=34) of the strategies not observed during the rated period , 
the most common was "item I" - ("Contract setting Re: administrative details, 
i.e. length of sessions, frequency, duration of treatment, appointment times, 
etc'') . Neither therapist fulfilled this criterion for any of the participants. However, 
this activity would have been likely to have taken place before the subject 
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started their IPT treatment, and explained by the author as part of the research 
study. Similarly, item "D" - "inquiry re patients' expectation of psychotherapy" 
may have been addressed before sessions 1 and 2. The remaining items (F, K, 
L, and M) were more likely to be addressed at the end of the initial phase of 
• 
treatment and may have been observed if session 3 was recorded. 
Middle phase of IPT- adherence monitoring 
The goal directed activities identified in the IPT treatment manual (Kierman et al 
1984) which enable the therapist to maintain a therapeutic strategy for the 
entire problem areas (role dispute, role transition, interpersonal deficit and 
complicated bereavement) are listed in tables below. As previously used in the 
initial phase, the raters use the codes "1" =yes, "2" =no to establish if the goal 
directed activity is present or not. However, unlike the initial phase, if the goal 
directed activity is present, the raters have an opportunity to grade the quality of 
that intervention, using a likert scale with a score ranging from "1" excellent to 
"7" poor. 
Role disputes -therapist adherence monitoring 
The areas identified in the IPT treatment manual (Kierman et al 1984) which 
enable the therapist to maintain a therapeutic strategy for a role dispute are 
listed in the table below. Each rater listened to the complete IPT session on the 
audiotapes and completed the ratings below. 
Table C5-30 shows the goal directed activity for role disputes on the NIMH 
adherence rating form 
Goal directed activity for role disputes 
A Review depressive symptoms 
B Relate depressive symptom to overt or covert dispute with significant other with whom the 
patient is currently involved 
c Determine the stage of the dispute 
D Explanation of how non-reciprocal role expectations relate to the dispute 
E Exploration and discussion of differences in expectations and values 
F Exploration of parallels in other relationships 
G Exploration and discussion of options available to the patients 
H Discussion of communication patterns (structural, emotional, expectational and wish 
aspects) 
Quality of intervention 
Excellent Poor 
I 1 2 3 4 5 6 7 
Table C5-31 shows the results of the therapist adherence monitoring for 
role disputes 
193 
(a score of 1="yes" which is followed by a rating for quality; 2 = "no", item not 
evident) 
Therapist A B c D E F G 
Participants Session I Rater 
F012 12 PC/ER 1/1 1/3 1/3 2 1/3 2 1/2 
F012 13 PC/ER 1/3 1/3 1/2 1/3 1/3 2 1/2 
F011 5 PC/ER 1/2 1/3 2 2 1/4 2 1/3 
F011 6 PC/ER 1/2 1/2 1/2 1/3 1/3 1/3 1/3 
F011 7 PC/ER 1/2 1/1 1/2 1/3 1/3 2 1/2 
F011 9 PC/ER 1/1 1/2 1/3 1/3 1/2 2 2 
F011 11 PC/ER 1/2 1/3 1/2 1/3 1/3 2 1/3 
F021 6 ER/SDM 1/2 1/2 1/2 1/2 1/2 2 1/2 
mean scores quality 1.9 2.4 2.5 2.4 2.9 3 2.4 
Mean scores of qualtty are calculated for strategy rated as present. 
H 
1/3 
1/3 
1/3 
2 
2 
1/3 
1/4 
1/2 
3 
The sessions rated ranged from 6-13, which represented a fair spread of 
sessions during the middle of phase of IPT. Three of the four participants who 
agreed to have their IPT sessions audiotaped had a role dispute as a focal 
area. One participant had role dispute as a single focus (012), and another had 
two focal areas identified, the role dispute in this case was the primary focus 
(011 ). A third participant also had two focal areas, however the role dispute was 
secondary to the role transition (021) As two of the three of the participants 
above were treated by therapist PC most of the ratings concerning role disputes 
evaluated his psychotherapy sessions. Most of the goal directed activity was 
achieved and carried out to a high standard (mean score of the quality of the 
rating ranged from 1.9-3). The most common goal directed activity which least 
achieved was Item F "Exploration of parallels in other relationships". This 
however, had been addressed by the therapist (PC) with one subject (F011) 
during one session in the middle phase and would not necessarily be the focus 
of every session. 
Role transitions - therapist adherence monitoring 
The table below are the areas identify the areas which enable the therapist to 
maintain the therapeutic strategies for role transitions as directed in the 
Interpersonal Psychotherapy treatment manual (Kierman et al 1984). 
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Table C5-32 shows the goal directed activity for role transitions on the 
NIMH adherence rating form 
(a score of 1 ="yes" which is followed by a rating for quality; 2 = "no", item not evident) 
Goal directed activity for role transitions 
A Review depressive symptoms 
8 Relate depressive symptom to coping with some recent life change 
c Review positive and negative aspects of old role and possible new ones 
D Explore feelings about what is lost 
E Explore feelings about change itself 
F Explore opportunities in the new role 
G Realistic evaluation about what is lost 
H Encourage appropriate release of affect 
I Encourage development df ~ocial support system and new skills called for in new role 
The sessions were rated from 3-14. All of the participants had a role transition 
as a focal area, one of whom had role transition as a single focus throughout 
the acute and maintenance treatment (023), a second had role transition as a 
primary focal area or two foal areas (role dispute and role transition), and the 
last participant had moved from a focal area of role dispute to role transition. 
Nearly all of goal directed activity was achieved and carried out to a high 
standard (mean score of quality of the rating ranged from 1.7-2.9). The 2 items 
which were not achieved were item F "Explore opportunities in the new role" 
and item I "Encourage development of social support system and new skills 
called for in new role" (Participant 021; session 3). As this was very early into 
the middle phase of treatment•this goal directed activity would not usually be 
addressed at this early stage; later sessions with the same participant 
demonstrate that this goal directed activity was achieved. 
Table C5-33 shows the results of the therapist adherence monitoring for 
role transitions 
(a score of 1 ='yes" which is followed by a rating for quality; 2 = "no", item not evident) 
Participants Session Therapist A B c D E F G H I 
/Rater 
F012 14 PC/ER 1/2 1/3 1/2 2 1/2 1/3 2 1/3 1/2 
F011 9 PC/ER 1/1 1/2 1/3 1/3 1/2 1/3 2 1/3 1/3 
F011 10 PC/ER 1/2 1/3 1/3 1/3 1/3 1/3 1/3 1/2 1/2 
F021 3 ER/SDM 1/1 1/2 1/2 1/2 1/2 2 1/2 1/2 2 
F021 4 ER/SDM 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2 
F021 5 ER/SDM • 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2 
M023 3 ER 1/2 1/1 1/2 1/2 1/2 1/2 1/2 1/2 1/2 
Mean score quality 1 ~7 2.1 2.9 2.3 2.~ 2.1 1.6 2.3 1.9 
s 
Mean scores of qualtty are calculated for strategy rated as present. 
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Complicated bereavement and interpersonal deficit were not the focus of IPT 
' for any of the participants used in this study; therefore the strategies to be 
employed by the therapists for these problem areas could not be evaluated. 
Therapist strategy in IPT 
The rating scale developed for the NIMH study included a section evaluating 
the overall strategy of the approach used in psychotherapy. Specifically, items 
G and H are approaches used in CBT and psychodynamic psychotherapy. This 
is included to ensure the therapist adheres to the model of IPT and does not 
drift into alternate psychotherapeutic approaches. As was the case with the 
monitoring of the interpersonal problem areas (role transition, role dispute, 
complicated bereavement and interpersonal deficit) the adherence raters 
continue to use the codes "1" ::t yes, "2" =no. When the goal directed activity is 
present, the quality of the therapists' interventions is also rated, from "1" 
excellent to "7" poor. 
Table CS-34 shows the therapist strategy for goal directed activity 
(interpersonal focus) the on the NIMH adherence rating form 
(a score of 1 ="yes" which is followed by a rating for quality; 2 = "no", item not evident) 
Therapist strategy rating form Goal directed activity 
A Exploration of recent and remote losses and reactions to these losses 
B Facilitation of mourning 
c Exploration of ways patient can develop and/or resume relationships and activities 
D Information gathering and exploration re: nature of disputes and/or role transition 
E Exploration and discussion of possible changes that could be made 
F Review of past and current relationships in detail 
G Review of self concept, with emphasis on self destructive, unrealistic 
attitudes/expectations 
H Careful attention to the positive and negative elements of the patient/therapist 
relationship 
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Table CS-35 shows the results for the therapist adherence monitoring for 
therapist strategy 
(a score of 1="yes" which is followed by a rating for quality; 2 ="no", item not evident) 
Participants Session Therapist Focus A B c D E F G H 
I Rater 
F012 12 PC/ER ' RD 2 2 1/3 1/3 1/3 2 2 2· 
F012 13 PC/ER RD 2 2 1/3 1/3 1/3 2 2 2 
F012 14 PC/ER RT 2 2 1/3 1/3 1/3 2 2 2 
F011 3 PC/ER RD 2 2 1/3 1/4 2 2 2 2 
F011 5 PC/ER RD 1/3 1/3 1/2 1/3 1/2 1/3 1/3 2 
F011 6 PC/ER RD 2 2 1/3 1/3 1/3 1/3 2 2 
F011 7 PC/ER RD 1/2 1/2 1/2 1/2 1/2 2 1/3 2 
F011 9 PC/ER RD/RT 1/3 1/3 1/2 1/2 1/3 1/4 2 2 
F011 10 PC/ER RT 1/2 2 1/3 1/3 2 2 2 2 
F011 11 PC/ER RD 1/3 1/3 1/2 1/3 2 2 2 2 
F021 3 ER/SDM RT 1/2 1/2 2 1/2 2 2 2 2 
F021 4 ER/SDM RT 1/2 1/2 1/2 1/2 1/2 2 2 2 
F021 5 ER/SDM RT 1/2 1/2 1/2 1/2 1/2 2 2 2 
F021 6 ER/SDM RD 2 2 1/2 1/2 1/2 1/3 2 2 
M023 3 ER/SDM RT 1/2 1/2 1/2 1/2 1/2 1/3 2 2 
Mean scores quality 2.3 2.4 2.4 2.6 2.4 3.2 3 
-
Mean scores of quality (Jre calculated for strategy rated as present. 
Excluding Items G and H which are not IPT approaches, the analysis of the 
results demonstrate that two thirds of the goal directed strategies were met by 
the therapists, and that the quality of the intervention was good (mean score for 
the quality of the goal directed activity 2.3-3.2). However, further analysis needs 
to address the fact that each session was rated individually for goal directed 
activity. There are occasions when the strategies are inappropriate for the 
problem area; for example, strategies A and 8 (A- exploration of recent and 
remote losses and reactions to these losses; B - facilitation of mourning) focus 
primarily on role transitions. Furthermore, the timing of the session needs to be 
considered; for instance, Item F (Review of past and current relationships in 
detail) may typically be addressed at the early stage of treatment. Moreover,. it 
is not reasonable or practical to expect every single goal directed activity to be 
achieved at every single IPT session. 
For each participant and for Items A, 8, C, D and E the entire goal directed 
activities were addressed during the some stage of the middle phase of IPT 
treatment. Regarding Item F ("Review of past and current relationships in 
detail'), this goal directed activity was achieved for three out of four of the 
participants used in these ratings during some stage of their middle phase of 
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treatment. The taped sessions of the fourth participant were late middle phase 
treatment; hence it would be unlikely that a review of past and current 
relationships would be performed at such a late stage into IPT treatment. Item 
G (Review of self concept, with emphasis on self destructive, unrealistic 
attitudes/expectations) was noted to have occurred twice with the same 
participant (F011) and therapist (PC). The IPT focal area of dispute had led the 
therapist to explore the participants own expectations of the relationship in 
question, and assess its' impact on her depressive symptoms. This strategy 
when conceptualised in this way fits into the model of I PT. 
Therapist overall competence 
An item towards the end of the NIMH rating scale allows a general rating of the 
overall competence of the therapist during the IPT sessions. Additionally, an 
assessment by the adherence rater is made of how receptive the subject is 
during the sessions. Finally, the rater is asked if the IPT used in this study 
would be of sufficient quality to justify using the same therapist in an IPT 
outcome study in the future. 
How would you rate the clinician OVERALL in this session as an 
interpersonal psychotherapist? 
poor barely mediocre satisfactory good very good 
adequate 
0 1 2 3 4 5 
How difficult did you fee/ the patient was to work with? 
Not difficult moderately 
very difficult 
receptive 
0 1 2 3 4 5 
excellent 
6 
extremely 
difficult 
6 
If you were conducting an OUTCOME study in interpersonal 
psychotherapy, do you think you would select this therapist to participate 
at this time (assuming the session is typical?) 
i 
Definitely not Probably not Uncertain/borderline Probably yes Definitely yes 
0 1 2 3 4 
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Table CS-36 shows the scores for the therapist overall competence 
ratings 
Participants Session Therapist OveraiiiPT Outcome Patient 
I Rater study difficulty 
F011 1 PC/ER 5 4 1 
F011 3 PC/ER 5 4 1 
F012 1 PC/ER 5 3 2 
F012 2 PC/ER 4 3 3 
F012 12 PC/ER 4 3 2 
F012 13 PC/ER 4 3 2 
F012 14 PC/ER 4 3 2 
F011 5 PC/ER 4 3 1 
F011 6 PC/ER 4 3 0 
F011 7 PC/ER 5 4 0 
F011 9 PC/ER 4 3 0 
F011 10 PC/ER 5 4 0 
F011 11 PC/ER 4 3 0 
F021 3 ER/SDM 5 4 2 
F021 4 ER/SDM 5 4 2 
F021 5 ER/SDM 5 4 2 
F021 6 ER/SDM 5 4 2 
M023 3 ERJSDM 5 4 2 
M023 1 ER/SDM 5 4 2 
F021 1 ER/SDM 6 4 2 
F021 2 ER/SDM 6 4 2 
mean scores 4.71 3.57 1.42 
Both of the IPT therapists during this study adhered to the model of IPT and 
provided the treatment consistently. The ratings relating to the overall 
competence of the therapist ranged from 4 ("good") to 6 ("excellent"). The mean 
score was high 4.71 demonstrating the overall competence of the therapist to 
be somewhere between "good" and "very good". Furthermore, the adherence 
raters found that the therapists were providing IPT well enough to be 
I 
considered for another outcome study. The participants were not considered to 
be difficult to work with psychologically, only one participant was considered 
moderately difficult and the remaining participants fell just below this category. 
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Mirtazapine 
The table CS-37 lists the dose of mirtazapine prescribed for each 
I 
participant and includes the compliance to the antidepressant medication 
Participant ID WeekO Week 3 WeekS Week 16 Compliant 
Stopped 
F01 30mg 30mg 45mg mirtazapine Compliant 
(week 7) 
F05 30mg 30mg 30mg 45mg Compliant 
F11 30mg 30mg 30mg 30mg Compliant 
F12 30mg 30mg 30mg 30mg Compliant 
30mg 
F21 30mg 30mg 30mg stopped Compliant 
mirtazapine week 
30 
M06 30mg 30mg 30mg 30mg Compliant 
M04 30mg 45mg 45mg 45mg Compliant 
M15 30mg 45mg 45mg 45mg Compliant 
M16 30mg 30mg 30mg 45mg Took only half 
of the tablets 
M23 30mg 30mg 45mg 45mg Compliant 
F03 30mg 30mg 30mg 30mg Compliant 
Slopped Missed 2 
F10 30mg 30mg 45mg mirtazapine doses weekO-
(week 10) 3, 
missed 7 
doses week 3-
6 
F17 30mg 45mg 45mg 45mg Compliant 
F19 30mg 45mg 45mg 45mg 3 doses 
missed week3-
6 
F20 30mg 30mg 45mg 45mg Compliant 
30mg for 2 I 
MO? days then 45mg 45mg 45mg Compliant 
45mg 
MOB 30mg 30mg 45mg 45mg Compliant 
Missed 2 
M18 30mg 30mg 30mg 30mg doses week 0-
6 
M22 30mg 45mg 45mg 45mg Compliant 
M24 30mg 45mg 45mg 45mg Compliant 
Only four of the participants appeared to have compliance difficulties with the 
medication prescribed; three participants in the mirtazapine only group missed 
occasional doses of medication (M18, F19, and F1 0) . Only one participant in 
the combined mirtazapine and IPT group demonstrated compliance problems 
and missed more sustained periods of medication (M16). The author assess~d 
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the impact on the therapeutic dose of mirtazapine taken for each participant 
taking into account the medication returned. This is shown in the table below. 
Two of the participants in the combined group (F21 and F01) and one (F1 0) 
participant in the mirtazapine only group stopped taking their mirtazapine in 
favour of an alternative antidepressant medication. 
Table CS-38 shows the mean dose of mirtazapine in milligrams taken for 
each participant 
Participant Week 0-3 Week4-6 Week 7-16 
F01 30 30 Xx 
F05 30 30 30 
F11 30 30 30 
F12 30 30 30 
F21 
'* 30 30 30 
M06 30 30 30 
M04 30 37.5 42.2 
M15 30. 37.5 42.2 
;. 
M16 15 15 45 
M23 30 30 39.4 
" 
F03 30 30 30 
F10 27.1 20 Xx 
F17 30 37.5 45 
F19 30 38.6 45 
F20 30 30 39.4 
MO? 40.7 44.3 44.7 
M08 30 30 39.4 
M18 30 28.6 30 
M22 30 37.5 42.2 
• 
M24 30 37.5 42.2 
lt appears from the compliance monitoring that 16 out of 20 participants 
complied with their prescribed medication, two of the four participants still 
received mirtazapine at a therapeutic recommended dose (F19, M18). 
Participant F1 0 received a recommended clinica l dose between weeks 0-3 
(27 .1mg) and received a low dose at weeks 3-6, however, this wou ld still have 
some therapeutic effects. lt is unlikely that these doses would be prescribed for 
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patients with treatment resistant depression ; furthermore, the participant would 
have been likely to take the medication on an adhoc basis and th is is not 
recommended as a therapeutic strategy. There were slightly higher doses of 
mirtazapine taken for the medication only group for the first 16 weeks of the 
study. This has been presented in a table below. Two participants withdrew 
from mirtazapine treatment between week 6 and week 16. 
Table CS-39 shows the mean dose of mirtazapine (allowing for non 
• 
compliance) for the total group and each treatment group at each time 
period 
IPT and 
Total group mirtazapine Mirtazapine only 
Weeks 0-3 29.6 28.5 
Weeks 4-6 31.7 30 n 
Weeks 7-16 37.6 35.4 
*Note that the above data excludes the 2 subjects who discontinued the 
mirtazapine treatment at week 7 (F01) and week 10 (F10). 
30 .8 
33.4 
39.8 
Although there are slight differences in the mean dose of the mirtazapine only 
• group versus the combined group, it is unlikely to have a significant clinical 
effect as there is no evidence for 5mg variations yielding a differential clinical 
effect; clinical experience also bears this out. 
202 
Adverse events 
Table C5-40 shows the adverse events reported for each participant 
Participant 
F01 
F11 
F21 
F21 
M04 
M06 
M15 
M16 
M23 
F03 
F10 
MO? 
Week of study 
2 
7 
51 
7 
14 
30 
6 
4 ' 
4 
33 
5 
12 
6 
10 
Adverse event Trial medication 
stoe ed 
swollen knees 
weight gain yes 
erratic mood 
Cold 
Itchy face 
weight gain Yes 
increased anxiety 
symptoms 
Cold 
Damaged ligament to left 
knee 
Chest infection 
Flu 
Agitated and took 10 
clonazepam 
Rage/irritability attacks 
Rage/irritability attacks Yes 
and anxiety 
Low potassium level 
Three participants stopped treatment with mirtazapine due to adverse events; 
two were due to weight gain and one due to increased anxiety symptoms. 
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Concomitant medication 
Table CS-41 shows the use of concomitant medication used for each 
participant 
Subject ID Week number Trial drug medication 
stopped 
F01 7 yes Citalopram 60mg 
Epilim chrono 
F21 30 yes Venlafaxine 75mg 
F21 34 GP stopped Venlafaxlne 
M04 6 Lorazepam 1 mg nocte 
Lorazepam 0.5mg BD 
M06 6 Lemsip PRN 
M23 5 Lemsip PRN 
F03 10 Clonazepam 500mcg PRN 
10 Zimovane 7.5mg 
F10 6 Amisulpride 100mg BD 
7 Carbamazepine 1 OOmg BD 
10 yes Stop carbamezepine 
Venlafaxine 75mg then 
11 Venlafaxine 150mg 
12 Stop venlafaxine 
Start Seroxat 50mg 
18 Seroxat 60mg 
18 Diazepam 5mg BD, 2mg BD 
18 Zimovane 7.5mg 
MO? 3 Zimovane 7.5mg 4 weeks 
Lorazepam 1 mg 
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Chapter Six - Sequential dopamine 02 
recaptor mapping in treatment resistant 
~epression 
Introduction 
1123- lodobenzamide (IBZM) is a radioligand which has a strong affinity 
for the neurotransmitter dopamine, specifically the subtype dopamine 02 
receptor (Kung et al, 1989; Seibyl et al, 1992). The 1123 IBZM ligand is 
administered intravenously to an individual and binds to the dopamine 
02 receptor sites and emits radiation apparently as one gamma ray 
photon per adhered molecule per receptor, as well as from free ligand. 
Single Photon Emission Computed Tomography (SPECT) imaging then 
maps the binding of this radioligand to the dopamine 02 receptor sites in 
the brain and computes th~ir precise location. These functional brain 
scans can give us some insight into the dopaminergic activity in 
depressed patients compared to controls; they can also identify 
functional changes in the dopaminergic system in response to 
antidepressant treatment. As dopamine has been implicated in 
depressive disorder, SPECT functional brain imaging allows us to carry 
out in vivo assessments of depressed individuals to gain a greater 
awareness of the functioning of the brain in depression. 
There is a paucity of literature available examining dopamine 02 
receptors using SPECT scans in depressed patients. Of the studies 
reviewed, findings demonstrate that depressed subjects who respond to 
treatment with total sleep deprivation (Ebert et al 1994), or SSRI 
treatment (Kiimke et al, 1999) show decreased IBZM binding ratios on 
the right basal ganglia (Ebert et al 1994) compared to non responders. 
Only one study has examined depressed patients who had not 
responded to a trial of tricyclic antidepressant medication (Kiimke et al, 
1999). No study has evaluated the effect of treatment resistant 
depression using IBZM SPECT imaging. 
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Design 
This was a parallel group study of a comparison of IBZM SPECT before 
and after 6 weeks of treatment with mirtazapine alone or mirtazapine 
plus Interpersonal Psychotherapy in treatment resistant depressed 
participants. 
Method 
Twenty three participants who had been unresponsive to at least 6 
weeks of an adequate dose of an antidepressant agreed to enter the 
trial. Three subjects (largely due to "personal reasons") withdrew their 
consent before the study commenced. This clinical trial received ethical 
approval from Sunderland Ethics Committee in advance of the start of 
study. In addition, Professor David Williams, Chief Medical Physicist 
obtained the necessary consent from Administration of Radioactive 
Substances Committee (ARSAC) for the use of the IBZM SPECT scans 
at the same time. 
Before treatment started, a • baseline assessment of clinical symptoms 
was conducted by the author using the Structured Clinical Interview for 
the DSM IV (SCID). Demographic information for each participant was 
collected at the same time. 
All participants took a single oral dose of 120mg potassium iodide the 
day before each IBZM SPECT scan, a standard procedure used to 
protect the thyroid gland during scanning. Following a three day 
antidepressant washout phase, IBZM SPECT scans took place at week 
0, before either treatment had started. A psychiatric nurse who was blind 
to the subjects treatment condition rated depression and anxiety (using 
. . 
the Hamilton depression scale and the Hamilton anxiety scale) on the 
same day as the first IBZM SPECT scan. The subjects were given the 
Beck Depression Inventory and the Social Adaptation Scale at the same 
time by the blinded rater who would collect the ratings. After 6 weeks of 
randomly assigned treatment with mirtazapine or mirtazapine plus 
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' Interpersonal Psychotherapy the same process of ratings was carried 
out. This took place on the same day or one day either side of the IBZM 
SPECT scan. 
SPECT procedure 
Quality control and performance tests 
The Medical Physics Department in Sunderland Royal Hospital arranged 
a quality control programme to monitor the camera performance. This 
took place before any participants entered the trial. The quality control 
measures helped to establish the sensitivity and uniformity of the scans 
and the range of expected results. Performance tests used the ligand 1-
1123 before imaging any Jjlarticipants with 1-1123 IBZM; the camera 
uniformity of response to 1-1123 was routinely measured before scanning 
using 1-1123 IBZM. 
In order to establish the best settings for imaging with IBZM two 
performance tests were carried out. One test measured the performance 
perimeters, and the second used a phantom (or model) which simulates 
the basal ganglia (the area most concentrated with dopamine receptors). 
The images were acquired (obtained) using 2 ligands, technetium and 
1123; this helped the medical physicists establish which collimators were 
needed to achieve the best quality of the image. The tests showed that a 
' long time (1 hour) was needed to obtain a good quality SPECT image. A 
method was devised for scanning in four consecutive sections so that 
should the participant become restless or move, the data from the whole 
scan would not be lost. 
Scanning method 
The author accompanied each subject during their first IBZM SPECT 
scan, which took place at Sunderland Royal Hospital. The whole 
procedure would take about three and a half hours. The participants 
were asked to lie quietly on a bed for a few minutes, and then a 
technician administered an intravenous injection of the IBZM radioligand 
into the back of the participant's hand. Participants were requested to 
close their eyes during this procedure and for a couple of minutes 
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afterwards to allow an equal distribution and uptake of the IBZM 
radioligand. After a short period the participants was then taken to a 
comfortable waiting area for a small snack and drinks, and wait for two 
hours. During this time the participant was asked not to walk around, or 
to read any complex (such as crossword puzzles) upsetting or 
distressing material to restrict the effect this may have on the functioning 
of the brain. 
The participants were scanned two hours post injection and the scan 
took one hour, ending at three hours post injection. The MEAP 
collimators were used and the data was acquired on 128 x 128 matrix 
with a pixel size of 4.5mm. The camera made 32 steps per 180 degree 
rotation acquiring two sets of projection data at each. The camera first 
• 
rotated clockwise then anticlockwise, and then repeated the movement. 
Four rotations were given 256 projections altogether which were 
combined to give a projection data for one rotation of 64 projection. The 
acquisition times were 28 seconds per step giving a total scanning time 
of one hour. 
Reconstructions 
All the scans were reconstructed using filtered back projection. In order 
to choose a filter, a study of the basal ganglia phantom was 
reconstructed using different filters and different orders, and different cut 
off values for each filter. A Stretch Gaussian filter was chosen with 
optimum filtration and cut off. Attenuation is the process by which 
radiation is reduced in intensity when passing through matter due to 
either absorption or scatter. During reconstruction, attenuation correction 
was applied and the effects of small changes in the value of the 
attenuation co-efficient was investigated and found to be negligible. 
Analysis of Regions of Interest (ROI) using BRASS to obtain IBZM 
uptake values 
The Brain Registration and Analysis Software Suite (BRASS) is a 
quantitative analysis program for the automatic fitting of brain perfusion 
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(blood flow) scans which provides quantification and localisation of 
abnormal perfusion regions. lt was originally developed to analyse 
cerebral blood flow SPECT images (Radau et al, 2001, Slomka et al, 
2001) and later developed to analyse other images including iodine-123-
IBZM dopamine receptor images (Radau et al, 2000). The program fits 
I . 
and compares participant images to three-dimensional references 
templates created from images of normal controls (Siomka et al, 1995). 
Each participant is aligned to each other and the template. Defects are 
quantified against a database of ten normal control participant on the 
voxel level; therefore the marked voxels can be assessed statistically, 
using the standard deviation criterion. Defects can also be determined by 
analysis within a 3 dimensional map of regions of interest. 
BRASS used in this study uses anisotropic-linear scaling (linear 
transformation of areas) tending to a different shape to compensate for 
the anatomic variations betw'een the brains of various individuals. 
Results 
Overview 
A number of nuclear masses which have concentrations of dopamine 
producing cells are located in the midbrain and hypothalamus (van den 
Pal et al, 1996). Components of these masses are collectively known as 
the basal ganglia, groupings of which are known as the right or left 
striatum. IBZM is a radioligand with a strong affinity for dopamine D2 
receptors. The use of SPECT allows in vivo studies of the dopamine D2 
activity of depressed participants. Correlations of clinical variables 
• 
associated with depression can also be assessed. Radiopharmaceuticals 
including IBZM, also demonstrate non specific binding which potentially 
could confound interpretation of the results. In order to address this 
issue, functional imaging studies compare the binding of the area under 
investigation, with another unrelated region of interest. By comparing the mean 
counts in these two areas a control for the non specific binding characteristics 
of the radiopharmaceutical is introduced. As the cerebellum does not contain 
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dopaminergic pathways and had not been implicated in depression, it was 
chosen as a reference region. 
In addition to a straight forward comparison of the two treatment groups, the 
author wished to assess if there were any changes in dopamine function 
brought about in relation to a number of important variables. These included: 
responders versus non-responders, the level of treatment resistant depression, 
agitated participants versus non-agitated participants and gender. 
Treatment groups 
The mean uptake ratio, standard deviation and standard error for each 
participant in each treatment group are reported in table C6-1. 
Table C6-1 demonstrating mean uptake ratios for treatment group in the 
striatum using the cerebellum as a reference region 
WeekO Week6 
IPT and mirtazapine Right-90.98, sd 54.55, se18.19 Right-87.30, sd, 61.15, se 20.38 
Treatment N=9 Left-88.06, sd64.60, se 21.53 Left-91.73, sd 64.51, se 21.50 
group Mirtazapine orily Right-112.45, sd 50.50, se 16.83 Right-118.26, sd 45, se 15 
N=10 Left-1 08.29, sd 41.42, se 13.80 Left-114.62, sd 39.78, se 13.26 
A Treatment Group repeated measures analysis of variance (ANOVA) did not 
• 
detect any significant effects of Time (F=O.OOO, p= 0.99) or Hemisphere (F= 
0.056, p= 0.815) and there were very small effect sizes and low power for both 
variables as demonstrated by a partial eta squared 0.000, 0.004 and power of 
0.05 and 0.056 respectively. The two way interactions of Time X Group 
(F0.162, p= 0.85), Hemisphere X Group (F=0.24, p= 0.79) and Time X 
Hemisphere (F=0.20, p= 0.66) also did not detect any significant interaction and 
demonstrated similarly low effect sizes and insufficient power (partial eta 
squared 0.02, 0.029, 0.012; power 0.071, 0.081, 0.070 respectively). The three 
way interaction, Time X Group X Hemisphere yielded similar results (F=0.203, 
p= 0.819, partial eta squared 0.025, power 0.076). The failure to detect any 
significant changes using the repeated measures ANOVA model in addition to 
the small effect sizes leaves little doubt there are no differences in IBZM uptake 
binding between the two treatment groups. 
Responders I nonresponders 
The mean uptake ratio, standard deviation and standard error for responders 
and non-responders are reported in table C6-2. 
210 
Table C6-2 demonstrating mean uptake ratios in the striatum for 
responders and non-responders using the cerebellum as a reference 
region 
WeekO Week6 
Responders Right-66.36, sd 42.64, se 16.12 Right-55.69, sd 35.98, se 13.60 
Responders N=7 Left-57.40, sd 38.14, se 14.41 Left-61 .79, sd 34.44, se 13.10 
vs. non- Non-responders Right-116.41, sd 51.42, se 14.84 Right-123.61 , sd 50.70, se 14.64 
responders N=12 Left-116.14, sd 51 .86, 14.97 Left-120.73, sd 53.72, se 15.51 
The reduction in the clinical scores on the clinician rated Hamilton Depression 
Scale provided an indication of the range and level of response to treatment in 
between IBZM SPECT scans. This is presented in the table below. 
Table C6-3 shows the percent change scores in the Hamilton depression 
scale 
Responders Partial responders Poor responders Deterioration 
~40% 25-39% 0-24% Minus scores 
F05 (45%) F21 (33%)" ~ F01 (3.6%) & z; ., 
w N 
' * F11 (45%) . "' M06 (25%) M16 (21%) 
Y'! .•t l!i 
F12 (40%) "" M23 (6%~ ' 
.. • +. 
M04 (48%) "" 't ' 
m· . j@ % 
M15. (63%~ "' ' 1 ~9 
·: . ;M 8! 
•i• 
M18 (63%) F03 (33%) F17 (4%) F20 (-3%) 
M24 (40%) F10 (30%) F19 (15%) M07 (-17%) 
M08 (0%) M22 (-16%) 
N=7 N=4 N=6 N=3 
Due to small numbers the SPECT analysis compared responders (at 
least 40% red uction in Hamilton depression scores) to non-responders 
(less than a 40% reduction in scores) . SPECT analyses of the level of 
response during the six weeks of treatment using BRASS followed by 
SPSS analysis are detailed below. 
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There were 7 participants who demonstrated a minimum of 40% 
reductions in the Hamilton depression scores after 6 weeks of treatment 
and 12 who had not. A Response X Time X Hemisphere repeated 
measures ANOVA detected a significant main effect of Response 
F(1,17) = 7.67, p=0.013, indicating that there was a smaller mean uptake 
ratio in the striatum using the cerebellum as a reference region among 
responders when compared to non-responding participants (60.32 (SE 
16.92) vs. 119.23 (SE 12.92). The effect size was large as demonstrated 
by a partial eta squared 0.311, (power= 0.74). Neither of the main other 
effects of Time (week 0 vs. week 6), or Hemisphere (right vs. left 
striatum), were significant (F= 0.048, df =1, p=0.83; F = 0.20, df = 1, p= 
0.66 respectively). Further, none of the two way interactions (Time X 
Response, F 0.52, df = 1, p= 0.48; Hemisphere X Response F= 0.00, df 
. . 
= 1, p=0.98; Time X Hemisphere F= 1.64, df = 1, p=0.22) were 
significant; additionally small effect sizes were evident for each of the two 
way interactions (0.029; 0.00; 0.088 respectively). The three way 
interaction (Hemisphere X Response X Time) approached significance 
(F = 3.31, df = 1, p= 0.087), there were moderate effect sizes (partial eta 
squared 0.163) and although there was low power (0.403) in this study 
for this effect (accounting for over half the variance found for the 
significant response effect) we cannot exclude the possibility of a three 
way interactional effect superimposed on the response main effect given 
the large interaction effect size, low power, and a result approaching 
significance. Thus although responders demonstrated a significantly 
lower mean IBZM uptake than non responders this effect may be 
somewhat influenced by the combined effects of time and hemisphere. 
Level of treatment resistant depression 
The author established the different levels for treatment resistant 
depression based on the number of failed antidepressant trials, the total 
number of months depressed during the participants' lifetime and the 
duration of the current depressive episode. All of this data considered in 
combination would indicate where each participant would be classified in 
the spectrum of treatment resistance . 
• 
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The author did not use the Thase I Rush guidance on levels of treatment 
resistant depression. This was for a number of reasons: Using this 
guidance, participants must have been prescribed at least one course of 
tricyclic antidepressant treatments in order to reach the minimum level of 
treatment resistance. There ,were participants who had numerous failed 
antidepressant medications, none of which were a tricyclic 
antidepressants and therefore were not considered resistant to treatment 
according to Thase/Rush guidance. Furthermore, these guidelines were 
published in 1995, when the clinical use of the tricyclic antidepressants 
was more common. Since the introduction of the newer generation of the 
antidepressants such as the SSRI's or the SNRI's, prescription habits 
have changed. More choice and concerns about safety and tolerability 
led to a reduction in the prescriptions for tricyclic antidepressants. 
Another consideration to note is the limited evidence to date regarding 
switching classes of antidepressant medication in order to increase the 
potency of the antidepressant treatment. There are suggestions which 
support the changes within the same antidepressant class, outlining that 
there are significant pharmacokinetic and pharmacodynamic differences to 
justify this approach (Fava, 2001; Bondolfi et al, 1996). Bearing this in 
mind, the author felt it was inappropriate to exclude changes within 
classes from the assessment of the levels of TRD. 
The author considered the number of previous failed antidepressant 
treatment trials to be a baseline for establishing the level of treatment 
resistance. This was split into categories of mild (only one previous failed 
. . 
antidepressant trial), moderate (two failed antidepressant trials), or 
severe (three or more failed antidepressant trials). Furthermore, the number of 
previous months depressed during the participant's lifetime was examined 
within each basic category, this may allow for the overlap between the number 
of failed antidepressant treatments and the duration of life time depressive 
episodes. Three categories were included: 12 months or less of lifetime 
depression, 13-29 months of lifetime depression and at least 30 months of 
lifetime depression. The three levels are demonstrated in the table below. 
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Table C6-4 demonstrates the definition of the levels of treatment resistant 
depression for this study 
I MILD - 1 x failed antidepressant treatment 
a). 1 x failed antidepressant treatment plus .:::_12 months life time depression 
b) . 1 x failed antidepressant treatment plus 13 -29 months life time depression 
c) . 1 x failed antidepressaot treatment plus ~ 30 months life time depression 
I MODERATE - 2 x failed antidepressant treatment 
a) . 2 x failed antidepressant treatment plus .:::_12 months life time depression 
b) . 2 x failed antidepressant treatment plus 13 -29 months life time depression 
c). 2 x failed antidepressant treatment plus ~ 30 months life time depression 
I SEVERE - 3 x failed antidepressant treatment 
a) . 3 x failed antidepressant treatment plus .:::_12 months life time depression 
b) . 3 x failed antidepressant treatment plus 13 -29 months life time depression 
c) . 3 x failed antidepressant treatment plus .::-_ 30 months life time depression 
Table C6-5 below shows increasing treatment resistance based on the number 
of failed antidepressant trials• added to the increasing time suffering with 
depressive symptoms during the participant's lifetime. There were 7 
participants who were categorised as in the middle I upper range of mild 
treatment resistance, 5 in the combination group and 2 in the mirtazapine only 
group. A further 7 participants were categorised as moderately treatment 
resistant, only one was at the lower end of the category and the remaining 6 
bordered the severe category. Most of these participants were in the 
medication only group (5 vs. 2 in the combined treatment group). Finally, eight 
(40%) of the study group were categorised as severely resistant to treatment; 
there were more participants allocated to the combined group in this category . 
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Table C6-5 demonstrates the levels of treatment resistant depression for 
all the participants in the study 
Mild 
c 
X 
X 
8 X 
18 
Impact of the levels of treatment resistant depression (TRD) 
' 
The mean uptake ratio, standard deviation and standard error for each level of 
treatment resistant depression are reported in table C6-6. 
Table C6-6 demonstrating mean uptake ratios for TRD level in the striatum 
using the cerebellum as a reference region 
Week 0 Week6 
High TRD Right-87 .60, sd 57 .13, se 21 .59 Righl-80.54, sd 32.94, se 12.45 
N=7 Left-77.52, sd 48.97, se 18.51 Left-90.91, sd 24.85, se 9.39 
Levels of Moderate TRD Right-113.43, sd 58.19, se 23.75 Right-131 .06, sd 74.68, se 30.49 
TRD N=6 Left-111 .38, sd 68.85, se 28.11 Left-129.04, sd 80.95, se 33.05 
• 
LowTRD Right-94.62, sd 49.60, se 20.25 Right-87.16, sd 50.30, se 20.54 
N=6 Left-97.45, sd 48.36, se 19.74 Left-78.44, sd 43.26, se 17.66 
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Participants were separated into three levels of resistant depression, low (n=6) , 
moderate (n=6) and high (n=7) . A TRD Level X Time X Hemisphere repeated 
measures of variance analysis detected a significant 3 way interaction F (2 , 16) 
= 5.46, p= 0.016. The TRD effect was large accounting for over 40% of the 
variance (partial eta squared 0.406, power of 0.771) . To explore the interaction, 
separate repeated measures ANOVA's were conducted for each level of TRD. 
No effects were found for the low and moderate TRD levels (although the Time 
X Hemisphere interaction for the moderate TRD group was approaching 
significance F (1 , 5) = 5.194, df, 5, p=0.072 with a large effect size of 0.51 but 
inadequate power 0.451) . The graphs below (C6-5 and C6-6) demonstrate the 
non-significant pattern of change in the right and left striatum in participants 
with low and moderate levels of treatment resistant depression . 
• 
Graph C6-7 showing IBZM uptake for week 0 and week 6 for low TRD 
participants 
~ 
~ 
i 
::l 
~ 
Graph showing IBZM uptake for week 0 and 
week 6 for low TRD participants 
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Although there are decreased binding patterns in the low TRD group and 
increased IBZM binding in the moderate TRD group, the degree of change was 
not statistically significant, but may have been contributing to the significant 
three-way interaction effect. 
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Graph C6-8 showing IBZM uptake for week 0 and week 6 for moderate 
TRD participants 
IBZM uptake ratios for moderate TRD 
participants 
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A significant interaction between time and hemisphere was detected among the 
high TRD participants F (1, 16). = 31 .593, p= 0.001 . There was both a large 
effect size of 0.84 and high power (0.99) . No differences between the mean 
uptake ratios were detected for either the right or left striatum using the 
cerebellum as a reference region at week 0 (t=1 .61 , p=0.158) and week 6 (t=-
1.86, p=0.113) however significant differences (t=5.62, p=0.001) were observed 
in the change scores in both the right (7.06, SE 11 .19) and left (-13.39 SE 
11.41) striatum (7.06 vs. -13.39). Thus there was an asymmetrical IBZM 
binding in high TRD participants with a decreased binding on the right and an 
increased binding on the left which can be clearly seen on graph C6-7 below. 
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Graph C6-8 showing IBZM uptake for week 0 and week 6 for high TRD 
participants 
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Graph showing IBZM uptake in high TRD 
participants at weekl 0 and week 6 
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Although the 7 high TRD participants were analysed as a group as described 
above, inspection of individual response data showed that three of these 
participants had in fact responded to 6 weeks of antidepressant treatment with 
• 
IPT and mirtazapine (n=2) or mirtazapine alone (n=1) . 
There were no plans at the start of the trial to investigate this further as one 
consequence of multiple testing is to increase the risk of a type I error. 
However, the author considered that the retrospective data collection approach 
may have incorrectly identified participants to be high TRD, and having 
responded to just 6 weeks of antidepressant therapy these participants may not 
be as severely resistant to treatment. 
A subsequent analysis splitting this small group of seven on response in order 
to address any response interaction effects was conducted. There was a 
significant effect of Time X Hemisphere (F (1 ,5)=79.53, p= 0.0001) which 
accounted for 94% of the varia~ce (partial eta 0.941) with a high power (1 .0) . 
There was a significant three way interaction for Time X Hemisphere X 
Response (F(1 ,5)=8.97, p=0.03) with a partial eta of 0.642 and power of 0.671 . 
There was no significant interaction for Time (F (1, 5) = 0.205, p=0.671) or Time 
X Response (F (1 ,5)=1.29, p=0.307) detected. The table below shows the 
mean IBZM uptake ratio in the right and left striatum using the cerebellum as a 
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reference region in the high TRD responders (n=3) and the high TRD non-
responders (n=4). 
Graph C6-10 showing IBZM uptake for week 0 and week 6 for high TRD 
responding participants 
IBZM uptake at week 0 and week 6 in high 
TRD responders 
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Graph C6-11 showing IBZM uptake for week 0 and week 6 for high TRD 
non-responding participants 
• 
Graph showing IBZM uptake at week 0 and 
week 6 in high TRD nonresponders 
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Agitation 
The author wished to examine the impact of agitation on the IBZM 
uptake in the participants studied. This could be examined using Item 9 
on the Hamilton depression scale (agitation) to assess high levels of 
agitation (a minimum score of 2) . There were 13 subjects however who 
remained significantly agitated on item 9 of the Hamilton depression scale at 
both weeks 0 and 6. This data is listed on the table below. 
Table C6-12 demonstrates significant symptoms of agitation at weeks 0 
and 6 in each treatment group 
Week 0 and 6 IPT group F01, F11, F12, M04, 
Week 0 and 6 mirtazapine grOUJi> F03, F10, F17, F19, F20, MOB, M18, M22, M24 
The mean uptake ratio, standard deviation and standard error for are reported 
for agitation in tab le C6-13. 
Table C6-13 demonstrating mean uptake ratios for agitated participants in 
the striatum using the cerebellum as a reference region 
Week 0 Week 6 
Agitated Right-1 16.10, sd 53.39, se 14.80 Right-114.72, sd 58.14, se 16.13 
N=13 Left-112 .1 0, sd 56.06, se 15.55 Left-111.47, sd 59 .06, se 16.39 
Agitation Non-ag itated Right-58 .72, sd 25.87 , se 10.56 Right-63 .62, sd 32 .1 0, se 13.10 
N=6 Left-56.38, sd 24.93, se 10.18 Left-72.04, sd 34.65, se 14.15 
There were 13 participants in tnis study who obtait:Jed high scores (above 2) on 
the Hamilton depression scale and 6 non-agitated participants. An Ag itation X 
Time X Hemisphere repeated measures ANOVA detected a significant main 
effect of agitation F (1 , 17) = 4.67, p= 0.045, indicating there was a larger mean 
uptake ratio in the striatum using the cerebellum as a reference region among 
agitated part icipants (113.60 (SE 13.24) vs. 62.69 (SE 19.49). This difference 
corresponded to a large effect size as demonstrated by a partial eta squared 
0.215; however, power was barely adequate (0.531 ). Neither of the other main 
effects of time (week 0 vs. week 6) or hemisphere (right vs. left striatum) were 
significant (F = 0.51, df =1 , p= 0.48; F = 0.97, df = 1, p= 0.93 respectively) . 
Further, none of the two way interactions (Time X Agitation, F = 0.76, df=1 , p= 
0.40; Hemisphere X Agitation, f=0.97, df = 1, p= 0.34; Time X Hemisphere, F= 
1.14, df = 1, p= 0.30) nor the three way interaction were significant (F=0.87, p= 
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0.36). Small to medium effect sizes were evident which at this point probably 
cannot be attributed to anything other than natural variance in a trial given that 
the agitation main effect is more than 4 times greater (partial eta squared 
results for Time = 0.029, Hemisphere = 0.000, Time X Agitation = 0.043, 
Hemisphere X Agitation = 0.054, Time X Hemisphere = 0.063). Given these 
effect sizes and sample sizes, there was low power to detect any of the 
interactions under analysis (0.104, 0.13, and 0.14 respectively). 
The agitation effect was large, accounting for approximately 21% of the 
variance (partial eta squared 0.215 power of 0.531) whereas none of the other 
effects accounted for more than 6%. This indicates that the agitation effect 
accounted for between three and four times more the variance than any other 
effects. Consequently, given both the low absolute effect sizes of these other 
effects and the fact that agitation accounts for a great deal more variance, it is 
unlikely that the other non significant effects would be of interest. Thus it _is 
concluded that more agitated participants showed greater IBZM uptake than 
less agitated participants. 
Gender 
The mean uptake ratio, standard deviation and standard error for are reported 
for gender in table C6-14. 
Table C6-14 demonstrating sex differences in the mean uptake ratios in the 
striatum using the cerebellum as a reference region 
WeekO Week6 
Male Right-67.06, sd 43.48, se 14.49 Right-67.96, sd 46.54, se 15.51 
Gender N=9 Lefl-66.50, sd 41.59, se 13.86 Lefl-67.27, sd 34.90, se 11.63 
' Female Right-125.80, sd 46.66, se 14.76 Right-126.14, sd 50.64, 16.01 
N=10 Lefl-119.71, sd 54.07, se 17.10 Left-127.59, sd 55.03, se 17.40 
A Gender X Time X Hemisphere repeated measures ANOVA detected a 
significant effect of gender F (1,17) = 7.4, p= 0.015, indicating that there 
was a larger mean uptake ratio in the striatum among females when 
compared to males (124.24 (SE 14.47) vs. 67.37 (SE 15.46)). Neither of 
the other main effects of Time (week 0 versus week 6), or Hemisphere 
(right versus left striatum) were significant (F=0.16, df =1, p=0.69; F = 
0.65, df =1, p= 0.65 respectively). Further, none of the two way 
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interactions (Time X Gender F = 0.071, df =1, p= 0.79; Hemisphere X 
Gender F = 0.069, df =1, p= 0.79; Time X Hemisphere F = 0.59, df=1, 
p=0.47) nor the three way interaction were significant (F = 0.58, df=1, 
p=0.54). The gender main effect was large, accounting for approximately 
30% of the variance (partial eta squared 0.302, power 0.705) whereas 
none of the other effects •accounted for more than 3% (partial eta 
squared, Time = 0.01, Hemisphere = 0.03). This indicates that the 
gender effect accounted for ten times more variance than hemisphere 
and 20 times more than any of the other interaction effects ( Time X 
Gender= 0.002, Hemisphere X Gender= 0.023, Time X Hemisphere= 
0.033, Time X Hemisphere X Group = 0.033). Consequently, given both 
the low absolute effect sizes and the fact that gender accounts for a 
great deal more variance, it is unlikely that other non significant effects 
would be of interest. lt is thus concluded that there was a significantly 
greater IBZM uptake in the striatum among women compared to men. 
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Chapter seven - Patterns of change 
Reliable Change Index 
In order to evaluate depressive symptoms during this psychotherapy trial 
the author used the clinician rated Hamilton depression scale and the 
self report Beck Depression Inventory as measures of depression. 
Typically, psychiatric research identifies percentage reductions in the 
depression rating scales, with 50% reduction demonstrating a significant 
improvement. However, there are limitations to this approach; for 
example a 50% reduction in the Hamilton depression scores from 36 
(severe) to 18 (moderate), or from 18 (moderate) to 9 (mild) yield very 
different clinical presentations. Although the scores have fallen by more 
points in the first case, this patient is still moderately depressed, in fact, 
sufficiently depressed to enter a clinical trial for depression. Hence it is 
reasonable to assume despite the 50% improvements in depression 
scores, there remains a significant debilitating effect of the depression. In 
contrast the second example has demonstrated a 50% reduction in 
scores but would be only c.onsidered mildly depressed, with limited, . if 
any impact on their social and interpersonal functioning. In addition to 
this approach the author used a reliable change index (RCI) (Jacobson 
and Truax, 1991) which is alternative strategy than that used by general 
psychiatric researchers; it is conceptually superior to percentage change 
or Clinical Global Impression ratings in that it takes into account the 
reliability of the rating scale. A RCI is computed by dividing the difference 
between the pre-treatment and post-treatment scores by the standard 
error of the difference between the two scores. A RCI of a greater score 
than 1.96 is a change of a large magnitude which cannot be attributed to 
chance (p<0.05) and so is attributed to the treatment. Indeed all 
measures are to varying degrees unreliable. A RCI score of less than 
1.96 is not considered reliable and may reflect fluctuations of an 
imprecise measuring instrument. 
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Based on data from the literature and this study a drop of 4 points on the 
Hamilton Depression scale and 11 on the Beck Depression Inventory 
would signify a reliable change in depression scores. The model is then 
extended further to identify a specific point at which the reliable change 
becomes a clinically significant improvement (Jacobson and Truax, 
1991 ). This can be difficult to conceptualise or measure in statistical 
terms, and often "rules of thumb" or published cut scores are used. 
Jacobson and Truax (1984) approached this statistically by using the 
concept that at the beginning of therapy clients enter treatment as part of 
a dysfunctional population; and leave following successful treatment as 
part of a normal or functional population (Jacobson and Truax, 1984). 
This is demonstrated by post treatment levels of functioning falling 
outside of the dysfunctional population, within the range of the non-
clinical population and closer to the mean of the functional population than the 
dysfunctional population. 
In order to identify participants who have demonstrated clinically significant and 
reliable change, data needed to be obtained for the normal population and the 
dysfunctional population (i.e. TRD population). This was obtained from data 
published in previous studies and is presented in the tables below (C7 -1, C7 -2, 
C7-3, and C7-4). The individual study means and standard deviations were 
weighted by the sample size. Larger numbers of treatment resistant depression 
studies of the Hamilton Depression Scale were published than for the Beck 
Depression Inventory. Similarly, there were more data available for non-clinical 
participants on the Hamilton Depression Scale than the Beck Depression 
Inventory. 
Jacobson and Truax (1991) suggest that when these data are available the 
point which lies at the intersection between the two distributions is the 
recommended cut off point (cut score C) for clinically significant change. This 
would be a Hamilton depression score of 12 and a Beck Depression Inventory 
score of 16. 
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Table C7-1demonstrating Hamilton De11,ression scores taken from clinical 
11,opulation in 11,revious TRD studies 
Study n m sd 
Avery et al 05 35 23.50 3.90 
Avery et al 05 33 23.50 2.90 
Carpenter 02 13 21.90 3.80 
Carpenter 02 13 22.50 5.80 
Dannon and Grunhaus 01 17 22.50 8.00 
deMontigny 99 159 25.60 
Dinan and Moybayed 92 13 25.00 7.20 
Fava 94 41 18.10 2.30 
Fava 02 101 20.70 2.90 
Gitlin 1987 16 23.10 4.00 
Grunhaus 03 20 25.50 5.90 
Grunhaus 03 20 24.40 3.90 
Huang 05 11 26.90 6.00 
Joffe 93 17 20.20 5.40 
Joffe 93 17 18.80 3.50 
Joffe 93 16 18.70 4.50 
Karp 05 46 22.30 3.70 
Katona 95 17 18.30 3.80 
Katona 95 16 18.70 3.30 
Katona 95 12 17.30 3.10 
Katona 95 17 19.90 4.30 
Kauffmann 04 12 21.86 2.31 
Kennedy 2003 21 23.10 3.90 
Kennedy 2003 23 24.20 5.20 
Little 98 19 22.20 4.20 
MCKewan 88 114 26.70 
Nelsen and Dunner 95 26 22.70 5.20 
Neirenberg 94 41 26.60 
Neirenberg 94 43 30.00 
Papakostas 2003 92 21.30 3.90 
Perez 99 80 20.50 4.10 
Perry 2004 21 29.00 7.00 
Perry 2004 17 30.00 7.00 
Petersen 01 92 21.30 3.90 
Rush 05 210 28.80 5.70 
Sackheim 01 60 36.80 5.80 
Thase 02 117 24.60 6.40 
Thase 02 50 25.00 6.00 
Thase 1997 106 21.00 3.50 
Whyte 04 25 21.20 3.50 
Whyte 04 28 17.50 3.50 
TOTAL 1847 23.21 4.58 
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Table C7-2 demonstrating results of Hamilton Depression scores taken 
from non-clinical population studies 
The data in the table below was obtained from a review conducted by 
Zimmerman et al (2004). 
Study n m sd 
Atmaca 02 16 5.10 2.10 
Blackburn 86 31 2.20 2.30 
Bungener96 14 1.90 1.60 
Bungener96 34 5.50 4.20 
Ceulemens 84 20 4.10 4.40 
Fassino 02 80 2.90 1.60 
Fasseno 02 80 3.20 1.70 
Fava 82 40 6.10 5.00 
Georgotas 86 25 1.90 
Gorand 95 10 3.00 0.70 
Grundy 96 44 2.70 2.40 
Gur 02 20 3.60 3.50 
Hu 00 47 8.40 5.50 
Kish 94 24 1.30 2.20 
Lanquillon 00 15 0.60 1.10 
Martin 94 31 4.10 4.00 
Naranjo 84 16 0.80 1.30 
Noder 90 13 1.50 1.80 
Rehm and O'Hara 85 17 3.40 3.20 
Rothrock 02 40 3.30 5.60 
Rubin 02 20 0.20 0.40 
Salctu 96 29 2.90 2.40 
Scanlan 98 92 2.00 2.30 
Szelenberger 01 14 0.50 1.20 
Wahby 90 43 1.50 0.60 
White 00 15 2.90 0.40 
Williams 91 84 3.30 
Zorzon 01 110 3.10 3.60 
TOTAL 1014 3.2 3.2 
Table C7-3 demonstrating Beck Depression Inventor~ scores taken from 
clinical population in previous TRD studies 
Study n m sd 
Avery 2005 35 28.10 8.70 
Avery 2005 33 28.40 8.00 
Gitlin 1987 16 29.10 6.70 
Kaplan and Klinetob 2000 20 25.00 
Kennedy 2003 21 30.00 10.10 
Kennedy 2003 23 28.50 9.30 
Triggs 1999 10 32.00 8.00 
TOTAL 158 28.7 6.7 
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Table C7-4 demonstrating results of Beck Depression Inventory scores 
taken from non-clinical population studies 
Study n m sd 
Dent and Salkovskis, 1986 243 6.26 5.33 
Lightfoot and Oliver, 1985 204 6.71 6.48 
TOTAL 447 6.47 5.9 
Using the approach suggested by Jacobson and Truax (1991) data for the 
normal population and a treatment resistant depressed population was 
gathered by the author (Hamilton depression scores; non clinical -mean 3.20, 
range 0.2-8.4, SO 3.20; treatment resistant depression data, mean 23.21, range 
17.3-36.8, SO 4.58. Beck Depression Inventory scores; non clinical - mean 
6.47, range 6.26-6.71, SO 5.9; treatment resistant depression data, mean 28.7, 
range 25-32, SO 6.47). There were more data available for the Hamilton 
Depression Scores for both the clinical and non-clinical scores compared to the 
Beck Depression Inventory. A total of 28 studies recruited 1847 TRD patients 
who were evaluated with the Hamilton Depression Scale, whereas only 5 
studies of 158 TRD patients were rated using the Beck Depression Inventory. 
Although there were more subjects per study (n=447) reported in two studies 
• 
for the non-clinical data using the Beck Depression Inventory; a review by 
Zimmerman and colleagues (2004) using the Hamilton Depression Scale 
reported data on 1014 subjects from 26 studies. The statistical formula used 
for computation of cut score C providing the point lies between the two groups 
is presented below. 
Where 
c = (S2 X M1) + (S1 X M2) 
S1 + S2 
• M1 =mean of the clinical/ dysfunctional population 
• M2 =mean of the non-clinical/ normal population 
• S1 = standard de"iation of the clinical/ dysfunctional population 
• S2 = standard deviation of non-clinical/ dysfunctional population 
Using the above formula the cut scores for the Hamilton Depression (12) 
and Beck Depression Inventory (16) were identified which could be used 
to demonstrate clinically significant change. 
227 
Results section for the reliable change index (RCI) scores 
Ten participants from each treatment group were measured over four 
time points (week 6, 16, 26 and 52) . The differences from baseline to 
each of the four time points was calculated and compared to the RCI 's 
for the Hamilton Depression scores and Beck Depression Inventory 
scores respectively . There were twice as many reliable improvements 
noted in the IPT group (n=36/40) compared to mirtazapine only group 
(n=18/40) on the Hamilton Depression Scale. Virtually identical results 
were observed in the Beck Depression Inventory. The column labelled 
52-16 highlighted participants who had reliably deteriorated from week 
16 by the end of the trial (I PT group, n=2; mirtazapine only group, n=4) . 
A similar pattern was evident on the Beck Depression Inventory 
measurements although on this measure fewer participants deteriorated 
from between week 16- week 52 in the IPT group versus mirtazapine (1 
vs . 6 respectively) . Participants who demonstrated reliable change in 
Hamilton Depression and Beck Depression Inventory scores are listed in the 
table below (table C7 -5) 
Table C7-5 demonstrating reliable change in Hamd and BD/ scores 
HamD Dl 
6 16 26 '52 52- 6 16 26 52 52 .. 
16 16 
F01 X X X X X 
FOS X X X X X X X X 
F11 X X X X X X X X 
F12 X X X X X .% X X 
F21 X X X X X X X X 
M04 X X X X X X X X X 
M06 X X X X 
M15 X X X X X X X X 
M16 X X X X X X 
M23 X X X X X X X 
F03 X X 
F10 X X X 
F1 7 X X X X 
F19 X X X X X X X 
F20 X X X X X X 
M07 X X 
MOB • X. 
M18 X X X X X X X X X X 
M22 X X X X 
M24 X X X X X X X X 
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Participants who demonstrated reliable change on the Hamilton Depression 
Scale and the Beck Depression Inventory (table C7-5) who in addition showed 
• 
clinically significant change, i.e. their score fell below the respective cut scores, 
are highlighted in table C7-6 and C7-7. These tables identify two aspects of 
treatment; initial response, and the effects of this initial response over time. In 
terms of the initial response, participants who demonstrated changes by 6 
weeks were considered "early responders ", 16 weeks "acute responders", 26 
weeks "delayed responders" and 52 weeks were "eventual responders ". This 
last category helped to differentiate between those participants who did not 
demonstrate changes in their depression scores, that is the "non responders" of 
the group. Response to treatment was recorded in the left side of the table 
(tables C7-6, C7-6) . 
The response over time was recorded in the shaded grey area in the right hand 
side of the table and included those participants who demonstrated a sustained 
improvement, (sustained reduction in depression scores or maintenance of 
improvement in scores); a "deterioration after a response" (initial response 
followed by a deterioration), or participants who followed a "fluctuating course" 
(participants who initially responded and then relapsed over the course of a 
year) . 
Table C7-6 demonstrating clinically significant and reliable change 
response and treatment effects over time - Hamilton depression score of 
12 or below 
Treatment response 
Early Acute Oetayed Eventual Non· Sustained o:terioration Fl~ctuating 
6/52 16/52 responder responder Responder improvement after course 
reSPOnse 
F01 X 
F05 X 
F11 X 
F12 X 
F21 X 
M04 X X X 
M06 X 
M15 X 
M16 X X 
M23 X X X X 
F03 X 
F10 X 
F17 X 
F19 X X 
F20 X 
M07 X X 
MOB X IJ 
M18 X X 
M22 X 
M24 X X X 
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Five participants had a Hamilton depression score of below 12 by the end of 16 
weeks of acute treatment; two in the combined treatment group and three in the 
mirtazapine only group. By 26 weeks a further 2 participants demonstrated 
clinically significant improvements in depression scores, one from each 
treatment group. When considering the effects of treatment over time 3 
participants demonstrated reduction in scores below the cut score by the end of 
treatment and all were from the combined treatment group; additionally, one 
participant from the combined treatment group sustained their clinical 
improvement from 16 weeks onward . Only one of the participants in the 
combined group deteriorated after a response, in contrast 4 of the mirtazapine 
only group deteriorated after a response; 2 participants shortly after the 16 
week acute treatment and another 2 after six months. 
Table C7-7 demonstrating clinically significant response and reliable 
change and treatment effects over time - Beck Depression Inventory 
scores of 16 or below 
Treatment response 
Earty Acute Delayed Eventual Non· Sustained Deterioration Fluctuating 
6/52 16/52 responder responder Responder improvement ~Iter course 
res pan se 
F01 X 
F05 X 
F11 X 
F12 X 
F21 X 
M04 X 
M06 X 
M15 X 
M16 X 
M23 X + 
F03 X 
F10 X 
F17 X 
F19 X X 
F20 X 
M07 X 
M08 X 
M18 X X X 
M22 X 
M24 X 
On ly two participants demonstrated a clinically significant treatment 
response using the reliable thange index cut scores of 16 on the Beck 
Depression Inventory, both were receiving mirtazapine alone and the 
response was evident by the end of the 16 weeks of acute treatment. 
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One of these participants deteriorated after this initial response and the 
other followed a fluctuating course. Eighteen participants (90%) of the 
participants studied did not •reach clinically significant improvements in 
Beck Depression Scores at any time point. 
The reliable change index and cut scores were calculated using the data 
gathered by the author for clinical (TRD) and non-clinical populations. 
Much more data was available on the Hamilton Depression Scale than 
the Beck Depression Inventory; this suggested that the cut score used in 
this study for the Hamilton Depression Scale is likely to be more robust. 
Further, one important consideration of the reliable change index model 
is the data assumes a symmetrical distribution. This is unlikely for both 
depression scores on the non-clinical data as many subjects often score 
' 
"0", leading to a positively skewed distribution. 
Participants in this study were severely depressed as measured by the 
Hamilton Depression Scale and Beck Depression Inventory at baseline; 
additionally, most (n=15) had moderate/high levels of treatment resistant 
depression. The cut scores used in this trial for this treatment population 
were very stringent and are based on a recovery model. Taking into 
account the severity of depression, high levels of resistance and limited 
potency of antidepressant therapy, such rigorous cut score may not 
have been the best approach. An improvement model may have been 
more appropriate, i.e. where a cut score may be used to demonstrate 
when the participant has demonstrated significant improvements 
although may not be near to a full recovery. For example, the appropriate 
group reference could be those who have shown recovery from a first 
episode of depression providing scores are not used to define the 
groups. 
Alternative methods of assessing outcome could be used in difficult to 
treat groups such as treatment resistant depression, for instance 
recognising improved social, interpersonal or work functioning, or if the 
participant continues to fulfil the diagnostic criteria for the index 
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diagnosis(es). The Structured Clinical Interview (SCID) conducted at the 
start of the trial may have provided this information and given some 
indication of functioning of the participant in a broader and more clinically 
meaningful way. 
232 
Chapter eoght - Discussion 
This research is original in a number of different ways: lt is the first study 
to date to have assessed the feasibility, applicability and efficacy of IPT 
augmented to antidepressant medication in a treatment resistant 
depressed population. Furthermore, the sequential mapping of the 
dopamine D2 receptors using IBZM SPECT has never been undertaken 
in treatment resistant depression, or when addressing the potential 
effects of any psychotherapeutic approach. The statistical analysis of the 
clinical data has also been extended to include reliable change i.e. that 
which is both considered to have statistical significance taking into 
account consistency of the rating instrument and clinical meaning in 
terms of improved depression scores. 
Thesis study 1: Interpersonal Psychotherapy for treatment resistant 
depression, a parallel trial 
Twenty treatment resistant depressed participants received either 
mirtazapine alone (30-45mg) or mirtazapine at the same dose 
augmented to IPT. Up to 16 weekly IPT sessions were provided during 
the acute phase of treatment and followed by monthly maintenance 
• 
sessions. On the clinician rated Hamilton Depression Scale and the 
Hamilton Anxiety Scale both treatment groups showed an improvement 
over time. Significant differences emerged between the two groups 
favouring the IPT group at week 26 and were maintained at week 52. 
There were no significant treatment effects noted on the Beck 
Depression Inventory. 
Differences between the Hamilton Depression Scale and Beck 
Depression Inventory were unexpected. One possibility is that the raters 
used in this study were not blind to the treatment. However, neither of 
the clinical raters were working on the research unit and were 
geographically located in another department away from the research 
unit building; hence they were excluded from exposure to participants 
attending appointments. In addition, the author ensured appointments for 
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IPT were not made at a time when either of the two raters would attend 
the unit. The blind raters. were aware that all of the participants, 
regardless of their treatment group would need to attend the research 
unit for appointments; further, they were unaware of the timing of 
interviews for the research protocol. Finally, participants were informed 
by the author not to tell the rater of their treatment allocation at the start 
of the trial, and were reminded of this request at the beginning of each 
rating session by the blinded rater. Both of the raters were informed at 
the start of the study to inform the author if they became aware of the 
treatment allocation; neither of the two raters informed the author that 
this had occurred. Hence, although blindness cannot be guaranteed it is 
unlikely that the raters influenced the discrepant results. 
There have been differences between in self rated (Beck Depression 
Inventory) and clinician rated scales (Hamilton Depression Scale) which 
have been reported in other trials, including one trial of IPT (Sayer et al, 
1993; Aben et al, 2002; Enns et al, 2000; Domkin et al, 1994; Mufson et 
al, 1996). Higher neuroticism (Enns et al, 2000; Domken et al, 1994) and 
lower agreeableness (Enns et al, 2000) and lower self-esteem (Domken 
et al, 1994) have significantly correlated with discrepant scores. An 
alternative possibility is that the varying personality profiles or levels of 
self esteem for each participant may have contributed to the discrepant 
results. This cannot be C€>nfirmed as there were no measures of 
personality functioning conducted during this trial. Although both rating 
scales assess depressive symptoms, there are distinct differences in 
specific symptoms covered in each scale. The Beck Depression 
Inventory is more heavily focused on cognitive and affective aspects of 
depression and the Hamilton Depression Scale includes symptoms such 
as somatic and general anxiety, agitation, diurnal variation in mood, 
paranoia and obsessive compulsive symptoms. This may have 
accounted for the discrepant results. 
Characteristics of depression of the participants 
A quasi-systematic literature search and use of meta-analytic 
• 
approaches conducted by the author of previous studies of a TR.D 
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samples allowed an estimate of baseline moderate depression scores on 
both of these scales (HamD 24.17, BDI 28.43). This contrasted with the 
participants used in this study who were severely depressed at the start 
of the trial (HamD 29.5; BDI, 36.4) and who demonstrated strong within 
subject effect sizes for treatment (HamD ES 1.25, Cl 1.13-1.36; 801, ES 
1.00, Cl 0.87-1.13). This is an important factor as the severity of 
depression at the start of treatment has been shown to slow recovery 
rates and is also linked to a poor outcome (Keller et al, 1992; Hirshfield 
et al, 1998; O'Leary et al, 2000; Ezquiaga et al, 1998; Bromberger et al, 
1994 ). Although the effect sizes were large, the mean scores post-
treatment remain within the mild (IPT plus mirtazapine group) and 
moderate (mirtazapine group) on the Hamilton depression and moderate 
(both treatment groups) Beck Depression Inventory respectively. Thus 
large changes for severely depressed patients still result in significant 
mean residual levels of depression . 
• 
In order to establish the level of treatment resistance the author needed 
to consider a number of factors which included the number of failed 
antidepressant treatments, the duration of the current depressive 
episode and the duration of lifetime depression. There were no 
statistically significant differences between the two groups relating to 
these characteristics of depression although power to detect them have 
been low. 
In terms of the number of previous depressive episodes there were 6 of 
the 20 participants who had•entered the study with their first episode of 
depression (2 in the IPT group and 4 in the mirtazapine only group). Of 
the 6 subjects with no previous major depressive episode their current 
depressive episode ranged from >18-48 months. Only one participant in 
this group had received just one trial of an antidepressant, four had 
received 2 trials and one participant had received 3 trials of 
antidepressants. The mean number of major depressive episodes was 2 
for the IPT group and 1.5 for the mirtazapine only group; the difference 
represents small to moderate effect size of 0.35 (Cl 0.14-0.84). The 
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number of failed antidepressant trials between the two treatment groups 
(IPT and medication mean = 2.6.:!:_1.57; mirtazapine only 2.3.:!:_1.15) were 
similar, with small effect sizes demonstrated by 0.21 (Cl 0.20-.022). The 
mirtazapine only group demonstrated a longer duration (months) of 
current depressive episode (21.05.:!:_12.05 vs. 12.93.:!:_1 0.06), yielded by 
medium to large effect sizes of 0.73 (Cl 0.24-1.22). Similarly, the IPT 
group had a longer lifetime of depression than the mirtazapine only 
group (mean 67.8, sd 88.'13 vs. 41.4, sd 21.62 respectively) with 
moderate effect sizes of 0.44 (Cl 0.08-0.9). Not surprisingly, this was 
reflected in the diagnosis of the participants; 80% of the IPT group were 
diagnosed with "double depression" (major depression and dysthymic 
disorder), whereas only 40% of the mirtazapine only group were 
diagnosed double depressives. This may have impacted on the outcome 
of the study, evidence suggests that chronic forms of depression such 
as double depression, or the index episode lasting more than 2 years 
have been associated with poorer outcome in some studies (O'Leary et 
al, 2000; Corryell et al, 1990; Mynors-Wallis and Gath, 1997; Keller et al, 
1983; Keller et al, 1992; MuEtller et al, 1996; 1999); although this has not 
been confirmed in others (Stewart et al, 1989; Fava, 1997). 
On balance, the differences in characteristics of depression between the 
two groups were evenly spread and would not be likely to favour one 
particular treatment group. Larger effect sizes in favour of the 
mirtazapine group with regard to length of current episode and was offset 
by the greater number of "double depressives" in the combined group 
and the greater lifetime duration. 
Participants with a comorbid diagnosis of anxiety including generalised 
anxiety disorder and agoraphobia with or without panic symptoms were 
included in this trial as this type of comorbidity is considered to represent 
a common clinical presentation. Anxiety disorders have been associated 
with a poorer response to antidepressant treatment (Fava, 1997; Kupfer 
and Spiker, 1981) however; there was an equal spread across both 
treatment groups of eo-morbid anxiety disorders. 
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Defining TRD for this study 
In order to define the level of TRD the author used the number of failed 
antidepressant trials as a baseline, the greater the number of failed 
antidepressant trials indicates an increasing level of treatment 
resistance; a failed trial of antidepressant medication was a minimum of 
6 weeks at a therapeutic dose. Additionally, the length of time the 
participants have been depressed in months was then added which 
would provide further information regarding the level of treatment 
resistance, these two factors together would provide data on the 
spectrum of resistance to treatment in the participants used in this study 
(as shown in Chapter 6; Table C6-4 on page 217). Eight (40%) of the 
total group studied were categorised as severe TRD, a further 6 (30%) 
were in the upper bound of the moderate category; two ( 1 0%) bordered 
moderate TRD and a further three participants were assigned the mid 
range of the mild category. 
lt should be noted however that there were problems associated with 
retrospective data collection for this study; this included poor 
documentation in the medical notes, particularly with regard to recording 
depressive symptoms and t£eatment response, lack of information a11d 
poor memory of medication dose and response which underestimates 
the number of failed treatments reported in this trial. 
Clearly, the lack of a universally agreed and accepted of definition of 
TRD presented a challenge for the author. Previous definitions 
suggested in the literature are useful for theoretical considerations; 
however, they may not provide an operational tool that can be applied in 
clinical practice and research. One definition of many which had been 
suggested and is currently being used in a large multisite research trial in 
the US was the Thase/Rush definition. Although there are clear 
similarities which include the increasing number of failed antidepressant 
treatments used, there were distinct differences between this definition 
and the one used by the author for this study. 
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The Thase/Rush definition meant that all participants would have 
received at least one trial o{ a tricyclic antidepressant by stage Ill. This 
does not always happen in clinical practice, many of the participants had 
not received a trial of tricyclic antidepressants and yet have received a 
number of antidepressant medications from a different class, the author 
believed this would exclude a significant number of participants which 
should still be considered resistant to treatment. Furthermore, the 
Thase/Rush definition assumes a hierarchy of antidepressant efficacy, 
the monoamine oxidase inhibitors (MAOI's) being considered superior to 
tricyclic antidepressants (TCA's) and serotonin specific reuptake 
inhibitors (SSRI's) and the TCA's superior to SSRI's (Thase et al, 1992). 
However, this hierarchy has not been supported by meta-analyses on 
antidepressant trials (Mace, 2000). The Thase/Rush definition also 
assumes the response of two antidepressants from different classes is 
more effective than two agents from the same class. 
Whilst switching within the TCA's have not been supported by available 
data (Charney et al, 1986; Reimherr et al, 1984), there is evidence that 
patients who are unresponsive to an SSRI may respond to a second trial 
with a different SSRI (Brown and Harrison, 1992; Peselow et al, 1989; 
Joffe et al, 1996; Thase et al, 1997a; Thase et al, 2001 ). Switching from 
one agent that affects one neurotransmitter system such as an SSRI to a 
different antidepressant such as a SNRI has been suggested to be more 
effective and forms the basis of clinical practice (Fava, 2003) but has not 
been studied in clinical trials (Charney et al, 1998). Additionally, the 
Thase /Rush levels of TRD were first published over a decade ago, and 
therefore were being developed before this time. Since then prescribing 
habits of psychiatrists have changed considerably, newer generations of 
antidepressants from a number of different classes have now become 
available. Moreover, literature regarding the efficacy of particular classes 
of antidepressants used in TRD remains in its infancy, indeed, switches 
to antidepressants in the same class has been suggested when varying 
effects of pharmacokinetics and pharmacodynamics of different 
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antidepressants within the same class are considered (Bondolfi et al, 
1996). 
Demographics 
An equal number of men and women were recruited to this study. The 
geographical area of recruitment was homogenously an area of low 
socio-economic status, with, poor health and high unemployment; this 
was reflected in the participants who were recruited. Decreased 
subjective social support has been found to predict poor depression 
outcome (Bosworth et al, 2001; Hirschfield et al, 1998; O'Leary et al, 
2000; Ezquiaga et al, 1998) and poor social adjustment and 
interpersonal relationships have been associated with resistance in 
depression (Freidman et al, 1995). There were differences in the 
employment profile of the two treatment groups. There was higher 
unemployment in the combined group (70% vs. 40%) at baseline. 
Additionally, those participants who were employed were predominantly 
assigned to the mirtazapine only group (50% vs. 1 0%) and they 
consisted of professional, s1<illed or semi-skilled workers. This was in 
sharp contrast to the single participant ( 1 0%) in the I PT group who was 
an unskilled worker. Unemployment has been causally related to 
depression (Zimmerman and Katon, 2005) with twice the rates of 
depression reported (Dolley et al, 1994); in addition, unemployment can 
prolong depressive symptoms (Frese and Mohr, 1987). 
There were also differences in the educational attainment of the 
participants between the two groups. Only one (10%) of the participants 
in IPT had studied to A' level compared to 4 (40%) in the mirtazapine 
only group. 
Regular alcohol use was greater in the IPT group (70% vs. 20%). This 
could contribute to the response to treatment for the treatment groups. 
Moderate (Worthington et al, 1996) or even mild (Thase, 2003) alcohol 
·consumption has been associated with poorer response to 
antidepressant treatment (Fava, 2003). 
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The resulting differences between the groups regarding employment, 
education, and the use of alcohol is a limitation of this small study; 
however, attempts to further control for this during randomisation were 
considered inappropriate given the small numbers involved. 
About half of the total group was married and nearly half of the IPT group 
had been divorced. Divorce or being separated has been associated as 
a risk factor for the onset or maintenance of depression (Weissman, 
1987; Rounsaville et al, 197~; Bruce and Kim, 1992). 
This study recruited a small sample of participants who were randomly 
assigned to two treatment groups. The randomisation proved to be 
effective in obtaining a general balanced range of depressive symptoms 
and characteristics of depression and concurrent anxiety disorders. 
However, differences in the employment profiles, educational status and 
the use of alcohol emerged between groups which could bias treatment 
outcome in favour of the mirtazapine only group (Zimmerman and Katon, 
2005; Worthington et al, 1996; Thase et al, 2003; Fava et al, 2003). 
As the author needed to control for gender as a confounding variable 
when using the IBZM SPECT scans, further controls regarding 
demographic or clinical characteristics were considered too restrictive, 
particularly in such a small sample size. As there is clearly such a 
difference in IBZM binding between the sexes, this was considered by 
the author a priority. There are many variables which are known to 
contribute to treatment outcome and prognosis in depression; 
randomisation in larger studies may eliminate group differences which 
emerged in this small study. Alternatively, stratification or matching on 
other characteristics such as diagnosis, severity of depression and levels 
of treatment resistant depres,sion could be built in as design features. 
IPT therapists 
There were two research trained IPT therapists who provided IPT during 
this trial, one male and one female; both of whom received research 
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training prior to commencement of the study. This is strength of the 
• 
study; previous clinical trials have been criticised for not validating 
therapists before the study (Martin et al, 2001) or for using novice 
therapists (De Mello et al, 2002). The research training for each therapist 
met the criteria set by Gerald Klerman, the key originator of IPT. 
Furthermore, the research training was provided and validated by 
experienced IPT therapists I researchers who were both trained by 
Klerman and conducted research under his guidance. This demonstrates 
high quality research trained therapists and meets the standards 
previously established in clinical trials of IPT (Eikin et al, 1989; Klerman 
et al, 1974; Markowitz et al, 1994). 
Although a small study, the provision of IPT by two therapists increases 
generalisabilty and allows attribution of the results to the therapy rather 
than the therapist. The author provided IPT to more participants (n=7) 
than the male IPT therapist (PC, n=3), this was due to workload within 
the research department. An equal balance of IPT sessions by both 
therapists would enhance generalisabilty of the findings when comparing 
therapists, help increase our understanding of the specific mechanism of 
antidepressant action of I PT. 
Weekly peer supervision took place between the two therapists to 
' minimise drift; this contributes to the rigour of the study, a third therapist 
providing weekly supervision would have enhanced the quality further 
still. Although it was planned to tape all sessions, only three participants 
agreed to audio-taping of their IPT sessions; these were rated at the end 
of the trial for the purposed of formal adherence monitoring and quality 
assessments and will be discussed later. Concurrent monitoring by 
independent raters would increase the rigour of the study by ensuring 
quality was achieved throughout and detecting early signs of drift. IPT 
appeared to be well tolerated by participants with treatment resistant 
depression and none of the participants who were randomised to 
treatment refused treatment with either therapist. 
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Format and delivery of IPT 
The timing of the acute phase of the IPT was the same as recommended 
in the original treatment manual (Kierman et al, 1984), 16 IPT sessions 
were delivered weekly. Psychoeducation regarding depression is 
provided routinely in IPT f~r major depressive disorder. The therapist 
uses the sick role by framing the depression as a medical illness, and 
where problems exist with specific symptoms of depression such as poor 
drive, motivation or anhedonia, patients are encouraged to blame 
symptoms of depression and not themselves. IPT for treatment resistant 
depression emphases this approach as depressed patients often feel 
guilty and blame themselves for a lack of response; in treatment resistant 
depression this may be more evident especially if there have been 
lengthy periods of depression. In addition to strategies used in IPT for 
major depression, the IPT therapist included specific education about 
treatment resistant depression as well as major depression. 
Sixteen sessions of acute IPT were offered to all of the participants 
assigned to the psychotherapy. The mean number of acute sessions 
received by the participants was 11.3 which are below the recommended 
dose of psychotherapy. The mean number of maintenance IPT sessions 
was 5.8 which were lower than the optimum dose which would have 
been 8-10 sessions. The IPT from one therapist was delivered in 8.3 
months vs. 11 months, although there were a similar number of mean 
sessions delivered by both therapists; this has the effect of a lower dose 
of IPT for the therapist who delivered the treatment over a longer period 
of time. The difference in time is minimal and the small numbers involved 
make investigation difficult. 
The maintenance psychotherapy sessions were offered to participants in 
the study on a monthly basis, and IPT sessions were agreed at the end 
of each therapy session at a mutually convenient time. The amount of 
sessions received by the participants for both the acute and maintenance 
phases of treatment fell below the recommended optimum dose. This 
may have been due to a number of different reasons. The poor socio-
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economic status of the participants recruited to this trial may have led to 
increased difficulties on their part to commit the time for therapy; family 
commitments, financial constraints, problems with travel arrangements to 
the hospital for therapy may also have attributed to a lower attendance. 
The participant may also have felt that depressive symptoms had 
improved to a level which had improved functioning and as a result did 
not place importance on the frequency of psychotherapy treatment; 
indeed, this may have also h'ad the same effect on the therapist. 
Dose of IPT 
When designing the research protocol the author did not establish a 
system which would enforce attendance at weekly intervals for 16 weeks 
during the acute phase and then monthly sessions for the maintenance 
phase; instead the treatment with IPT was outlined to the participants as 
a model at the start of treatment and it was agreed that the 
psychotherapy sessions would be arranged at a mutually convenient 
time. This inadvertently may have led to reduced adherence to the 
specified doses. Higher doses of IPT have been provided previously in 
' 
other trials of dysthymic or partially responding patients (Scocco and 
Frank, 2002; deMello et al, 2001; Markowitz et al, 1992); and have 
ranged from 16-22 IPT sessions delivered over a shorter period of time. 
Positive outcomes have been present in most studies (Scocco and 
Frank, 2002; Markowitz et al, 1992); however, beneficial effects from one 
study took time to emerge (deMello et al, 2001 ). Lower doses of I PT, for 
example, ten sessions over 6 months, have also been provided in 
dysthymia studies (Mason et al, 1993; Browne et al, 2002). Extremely 
low doses of IPT (mean 8.6; median 1 0) were provided over a six month 
treatment phase, during the large Canadian trial of IPT in dysthymic 
patients. This perhaps led to the superior response rates of therapeutic 
doses of sertraline (50-200mg) compared to low dose IPT (59% vs. 46% 
respectively) at six months. 
Fixed dose was an a priori decision based on the recommendations from 
the original treatment manual; the dose of the antidepressant 
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mirtazapine used in this trial was set at 30-45mg. There were no 
opportunities to increase the dose of mirtazapine further or switch to 
alternate antidepressant(s). Systematic variable dose of psychotherapy, 
pharmacotherapy or their combination would require a much bigger 
study. Similarly, maximum tolerated dose could still have been used but 
would be answering a different question, and in a smaller group of 
participants introduce even greater variability. Future studies should 
evaluate the efficacy of a staged approach to increasing the potency of 
both the IPT and the antidepressant medication in a resistant depressed 
population. 
The low numbers of participants recruited to this study limit its findings 
which should be viewed as preliminary; a larger sample size may have 
detected significant differences which have not appeared in this small 
group. Although there were significant improvements from baseline at 
every time point and significant differences on the Hamilton depression 
scale between the two groups in favour of the IPT group by week 26, 
earlier changes may have been detected had the optimum dose of IPT 
been received by the participants in this study. Slower recovery rates 
have been reported in patients who have had a longer duration of 
depressive symptoms and increased severity of depressive symptoms at 
• the index episode (Keller et al, 1992; Mueller et al, 1999; Leon et al, 
2003); both of these characteristics applied to the IPT group. Further 
studies which increase the potency of IPT with the use of more frequent 
sessions would give us more insight into the efficacy of treatment in this 
difficult to treat group. 
Quality of IPT 
The quality of IPT and adherence monitoring was conducted at the end 
of the trial with the use of audiotapes of IPT sessions. Only four (40%) of 
the IPT group agreed to have their psychotherapy sessions tape 
recorded; of these only half of these sessions were recorded; 13/25 
(52%) of the sessions provided by PC and 8/18 (44%) of the sessions 
provided by the author ER. Most of the sessions taped were during the 
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acute phase (95.3%) of IPT and one session was taped during an early 
session of the maintenance phase (4.7%) treatment. Both therapists 
adhered to the model of IPT and received a high quality rating score for 
• 
the problem areas focused on during psychotherapy treatment two thirds 
of the strategies were met during the initial phase of IPT, however, the 
third session of IPT was not recorded and these strategies may have 
been met during these sessions or else when the author has interviewed 
the participants before starting psychotherapy sessions. 
There were only two focal areas of a possible four identified during 
therapy with all of the participants in the IPT group. This may be due to a 
number of reasons. Firstly, role transition and role dispute are typically 
the most common of focal areas used in IPT (Markowitz et al, 2000), 
interpersonal deficit is usually recommended as a focal area only if there 
are no other focal areas to concentrate on during therapy sessions, and 
complicated bereavement is usually less common a focal area compared 
to both role dispute and role transitions. A second consideration is the 
relatively young age group of the participants used in this study. The 
oldest participant was 52 and it is unlikely that participants with a mean 
age of 39.5 would have experienced much bereavement; this is a more 
common focal area in a study of elderly depressed subjects (Wolfson et 
al, 1997). Thirdly, the small numbers of participants receiving IPT limit 
the likelihood of less common focal areas being present. 
There was good agreement on the focal area identified with each 
therapist, both during weekly peer supervision and during the formal 
adherence monitoring with the use of the NIMH rating scale. Although 
there is little data on therapists agreement on focal areas in IPT one inter 
rater reliability study has demonstrated close agreement between IPT 
therapists in identifying problem areas and potential treatment foci 
(Markowitz et al, 2000). 
Most of the taped sessions evaluating role dispute were from the 
therapist PC. 83% of the goal directed strategies were met and were of a 
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high quality (role dispute = 1.9-3 out of a possible score of 7; where "1" 
represents excellent and "7" is poor). The strategies which were not met 
(17%) included strategies which were not appropriate for the timing of 
the IPT sessions. There were nearly equal numbers of sessions from 
each therapist rated for role transition and most of the strategies were 
achieved (93.7%) with a hi~h quality rating (1.7-2.9 out of a possible 
score of 7). The overall strategy rating demonstrated that both therapist 
adhered to the model of IPT and did not use alternative 
psychotherapeutic approaches such as CBT. 
There were potentially serious limitations of the results of the adherence 
monitoring which reduce generalisabilty of the findings; under half of the 
participants agreed to the sessions being taped and only half of these 
sessions were recorded. Nearly all of these sessions were during the 
acute phase of therapy, and only two of possible four problems areas 
were evident in therapy. 
Although the taped sessions demonstrated that both IPT therapists were 
adherent to the model and maintained a high quality of interventions, we 
cannot confirm this was the case in the sessions which were not taped. 
Previous psychotherapy trials have recorded all psychotherapy sessions, 
randomly selected tapes and rated a segment of the study (Eikin et al, 
1989; Frank et al, 1991 ). Due to the limited number of tapes available, 
every tape was rated, this excludes the random selection of sessions for 
rating. However, the whole of the 50 minute session was rated for 
adherence monitoring, which is strength of this smaller study. Future 
trials should record all of the IPT sessions and systematically sample 
. . 
from each phase of treatment and include acute, intermediate and end 
phase of IPT as well as IPT as the maintenance treatment. This may 
help provide the data to address questions regarding the specific 
mechanism of action of I PT. 
The most common focal areas of role transition and role dispute were the 
only problem areas identified for all of the participants in the study, 
246 
reflecting what is seen in clinical practice. The brain imaging component 
of this trial led to recruitment restrictions, specifically, there were smaller 
numbers of participants recruited and there was a tight age range (28-
55). A larger number of participants recruited to the trial may have 
extended the focal areas and increase our understanding of the 
applicability an efficacy of IPT in treatment resistant depression. 
Research unit 
The participants for this study were all treated in the single research site 
• 
at Cherry Knowle Hospital, Sunderland. This was a two storey building 
which included a pleasantly decorated waiting room and conservatory 
with pleasant views of the countryside. The staff aimed to provide a 
peaceful and aesthetic environment. There were comfortable easy 
chairs, relaxing music, and tea, coffee, soft drinks, biscuits and sweets 
were provided. Staff were all friendly and approachable and all 
participants were seen at the appointment time given. The IBZM SPECT 
brain imaging scans were conducted at Sunderland Royal Infirmary. This 
medical physics department was a purpose built department and building 
works had just been completed at the start of the study. The staff aimed 
to be as approachable as• in the research department and offered 
participants tea, coffee, sandwiches and biscuits. None of the 
participants were kept waiting for their appointment. The author each 
participant at medical physics department to introduce the medical 
physics staff and deal with any additional questions they may have. 
Participants made their own way to the follow up scan 6 weeks later. 
The attention received by each participant at the start of the trial may 
have had an impact on the depression scores at the start of treatment. In 
fact Markowitz (personal communication) reports sharp reductions in 
Hamilton depression scores at the start of research trial after 
• 
psychologists use a Structured Clinical Interview for Diagnostic and 
Statistical Manual (SCID DSM IV, APA 2000). If a long and relatively 
tedious interview such as the SCID can contribute to a reduction in 
Hamilton depression scores, it is reasonable to assume that the impact 
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of a brain scan in addition to clinical assessments with SCID and 
depression rating scales ma.y also contribute to reduction in depression 
scores. However, the research protocol at the start of the trial included 
more than the brain scans. There was a comprehensive assessment of 
physical, psychological and social factors, including: the SCID, routine 
blood tests, clinical ratings of depression, anxiety and social functioning, 
and finally the first of two brain scans. Feedback from some participants 
at the time included comments such as "they felt their depression was 
taken seriously". The brain scanning as part of the research is likely to 
have reinforced a biological component of depression which reinforced 
the approach used in IPT for depression when providing the sick role. All 
of these interventions in combination help to provide hope that things will 
improve. 
Furthermore, the facilities on offer both at the research unit and medical 
physics department and the prompt, friendly and professional service 
may also have had an impact on depressive symptoms. This treatment is 
in sharp contrast to the usual care offered in an NHS outpatient 
department and may have contributed to the very low attrition rates of 
the study. Participants from both treatment groups received care at the 
same settings. 
The attrition rates in both tr~atment groups of this study were low and 
were much lower than rates reported in other studies (Browne et al, 
2002; deMello et al, 2001; Frank et al, 2000). This may be due in part to 
the quality of the service and the attention participants received from 
both departments throughout the course of treatment. Indeed, 
recruitment and retention of subjects to the research unit for other clinical 
trials during the same time was excellent, which would suggest the 
environment of the Unit has contributed to the retention rates. The 
environment of the research unit would be in sharp contrast to the usual 
care on the NHS, particularly when taking into account the catchment 
area for the study. Although this would limit the generalisabilty of the 
• findings, the physical and psychological environment provided from this 
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research site is an interesting area which warrants further study, 
particularly if there is potentially a positive treatment outcome as a result 
of increased engagement and compliance with therapy. 
Conclusion 
There is a paucity of literature reviewing psychotherapy generally in 
treatment resistant depression, and there are suggestions that 
psychotherapy should be reviewed in this area (NICE, 2004; Fava et al, 
2003; Rush et al, 2004; Wisniewski et al, 2004). This is the first and only 
study of IPT in this population. IPT appears to be well tolerated and has 
demonstrated promising initial results. This is especially important when 
considering the participants were recruited from an area of high social 
deprivation. 
After random allocation to a treatment group there were no differences 
between the groups regarding depression scores, anxiety scores and 
social functioning; although the study is not powered for detect any small 
to moderate differences .. At baseline, the IPT group demonstrated 
differences to the mirtazapine only group in education, employment 
profile and alcohol use. Furthermore, nearly all (80%) of the IPT group 
had a concurrent diagnosis of dysthymic disorder compared to 40% of 
the mirtazapine only group. All of these variables have been shown to 
have a negative effect on treatment outcome. 
Significant differences emerged between the groups after 6 months 
which was sustained at 12 months. These delayed antidepressant 
• 
effects of IPT have been reported in previous trials (Kierman et al, 1979; 
Mufson et al, 1996). What is particularly relevant is that IPT was 
potentially disadvantaged at the start of the study, demonstrating more 
baseline factors that are negative prognostic indicators. In addition, the 
mean dose of IPT received by each participant was moderate as was the 
dose of mirtazapine. This provides promising initial data on the efficacy 
of IPT in TRD, even at a moderate dose; although it appears the 
beneficial effects take time to emerge. 
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The participants in this study had their levels of treatment resistant 
depression assessed retrospectively. There are various problems 
associated with retrospective data collection which include incorrect 
assessment of the degree of response due to the patients recall biases, 
misclassification of non response of patients who have relapsed after an 
initial response and inaccurate documentation (Fava et al 2003). 
However, when reviewing the data in medical notes the author 
maintained a high thresholq for including previous treatment trials and 
episodes of depression, which would reduce the likelihood of assigning a 
diagnosis of treatment resistant depression inappropriately, if anything 
an underestimation of failed previous trials was likely. 
The sequenced treatment alternatives to relieve depression study 
(STAR*D) is currently reviewing CBT as part of a sequential strategy and 
when the current protocol is complete the authors plan to review 
alternative antidepressant psychotherapies (Fava et al, 2003). This will 
be helpful as the STAR*D study only evaluates CBT as a 
psychotherapeutic intervention, alongside a specific sequential strategy 
for antidepressant therapy (either alone or in combination). This study, 
like others will only answer some of the questions raised in relation to 
treatment resistant depression; the prospective data collection will allow 
us an insight into the incidence of TRD, in the U.S. at least. The 
treatment will be provided over a number of sites, albeit all in the U.S. 
which increases the generalisabilty of the findings. Moreover, we will 
gain at least some insight into the efficacy of a staged approach in 
managing treatment resistant depression. 
Evaluation of the effects of the dose of IPT and also antidepressant 
medication should be ass~ssed in future trials; this should include 
increasing dose of either therapy alongside combination and 
augmentation strategies. In addition, studies comparing alternative 
antidepressant psychotherapies such as cognitive behaviour therapy or 
cognitive behavioural analysis system of psychotherapy (McCullough et 
al, 2000) should be included in future studies. 
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Evaluation of treatments should include health and social care costs and 
include a longer period of follow up. This is particularly important given 
the evidence that health and social care cost increase with greater levels 
of TRD (Greenberg et al, 2004), and studies of major depression have 
found that increased treatment effectiveness is positively correlated with 
significant reductions in treatment costs (Simon et al, 2000; Mitchell et al, 
1997; Thompson et al, 1997). Similarly, poor psychosocial functioning 
has been found in patients with TRD (Petersen et al, 2004) and 
impairments in work and social functioning, both feature of TRD (Hays 
et al, 1995; Greden et al, 2001) have been found to worsen outcome in 
treatment resistant depression (Corey-Lisle et al, 2004; Petersen et al, 
2004; Mintz et al, 1992; Fawcett, 1994). 
Future studies should use the reliable change index and clinically 
significant change as outcome measurements as this would enhance the 
quality of the data and help with interpretation of results. For example a 
clinically significant change explicitly tells us the participant has 
improved to an extent that their new level of functioning falls within the 
healthy population, whereas percent reductions in depression scores 
does not provide this critical information . 
• 
Perhaps the most important issue raised by this study, is the lack of 
universally agreed and accepted definition of treatment resistant 
depression. This is urgently needed for further studies for work in both 
research and clinical practice. The lack of a universally acceptable 
definition in the TRD literature makes interpretation of literature difficult. 
The author selected the most basic and common definition in terms of 
failure of an antidepressant trial. There are still short comings in the 
literature regarding a practical and workable definition. Little attention 
has been given to combination or augmentation strategies, and 
interestingly no definition acknowledges any psychotherapy with proven 
antidepressant efficacy as a failed trial. An agreed definition as part of 
the Diagnostic and Statistical Manual for Mental Disorders and the 
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International Classification of Disorders for use in a clinical and research 
setting is needed and would improve interpretation of research findings. 
Thesis study 2: Sequential dopamine 02 receptor scanning with the 
use of IBZM SPECT 
The clinical characteristics of the participants used in this study have 
been described earlier in this chapter. All 20 of the participants received 
both IBZM SPECT scans pre and post six weeks of treatment. This is the 
first IBZM SPECT study to have made a direct comparison of two 
treatment conditions; previous studies have compared depressed 
patients to controls (D'Haenen and Bossuyt, 1994; Ebert et al, 1994; 
Ebert et al, 1996; Klimke et al, 1999; Shah et al, 1997; Parsey et al, 
2001 ). Although one German study (Larisch et al, 1997; Klimke et al, 
1999) evaluated depressed 'patients who had been non responsive to a 
tricyclic antidepressant, this is the only IBZM SPECT study to have 
examined the specific effect of treatment resistant depression and 
dopamine 02 receptor activity. 
Cerebellum as a reference region 
Previous IBZM SPECT depression studies have chosen the frontal 
cortex or the cerebellum as a reference region in order to obtain uptake 
values allowing for non specific binding of the radioligand. The frontal 
cortex was not used as a reference region for this study for a number of 
reasons: There is a substantial body of literature which demonstrates 
• 
altered blood flow (Mayberg · et al, 1994; Sackheim et al; 1990) and 
metabolism (Martinot et al, 1990; Little et al, 1996; Buschbaum et al, 
1997) in major depression. Reduced cerebral blood flow has been shown 
to have an effect on the IBZM uptake (Larisch et al, 1997). Additionally, 
the frontal cortex contains dopamine d2 receptors (Doucet et al, 1986); 
the counts in this region would be an indication of both the non-specific 
and specific binding which would confound the mean ratio of counts in 
the striatum. Finally, we cannot exclude the possibility that low dopamine 
02 densities are increased in major depression. In contrast the 
cerebellum is not reported to have any post synaptic dopamine 02 
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receptors and the cerebellum has not been shown to be altered in mood 
disorders (Larisch et al, 1997). 
Treatment groups 
1123 IBZM is a benzamide derivative with a high affinity for 02/3 receptor 
selectivity (Verhoeff et al, 1992); IBZM counts reflect the binding of the 
• 
ligand to dopamine 02 and 03 receptors with at least partial 
displacement of endogenous dopamine by the ligand and any dopamine 
antagonists (Laruelle et al, 1995). Repeated measures ANOVA revealed 
no differences in the IBZM binding ratios between the two treatment 
groups using the cerebellum as a reference region. These results were 
not surprising given the two treatment groups contained both treatment 
responders and treatment non responders; five (50%) of the participants 
in the IPT group and one (10%) of the participants in the mirtazapine 
only group were responders (minimum of a 40% reduction in Hamilton 
depression scores between scans). 
There have been reports of differences in uptake ratios of responders 
versus non responders (Ebert et al, 1994; Ebert et al, 1996 Klimke et al, 
1999) which could confound the situation and may have led to the 
negative results. 
Another consideration is that there was only one pharmacological 
treatment which was provided to both treatment groups during this trial, 
the antidepressant mirtazapine. The direct action of mirtazapine is to 
enhance noradrenergic and serotonergic function neurotransmission, 
additionally; mirtazapine may also have an indirect action on the 
mesolimbic dopaminergic system (Rogoz et al, 2002). An alternative 
pharmacological agent with direct specific dopaminergic effects used as 
a comparison may give us more insight into the distinct pharmacological 
actions of antidepressant medication and the role of dopamine function. 
Although functional imaging studies in major depression have shown that 
response to either IPT or antidepressant medication led to regional 
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activation of blood flow with HMPAO SPECT (Martin et al, 2001) and 
glucose metabolism with a PET study (Brody et al, 2001) no other 
studies have demonstrated or suggested changes in neurotransmitter 
function, particularly in such a complex condition as treatment resistant 
depression. The limited time in between the first and second scan may 
also account for negative findings, particularly as IPT has been shown to 
take longer to have an antidepressant effect than antidepressant 
medication (Kierman et al, 197 4; Frank et al, 1991 ) . 
• Responders versus nonresponders 
30% of the total sample responded to treatment after six weeks 
demonstrated by at least a 40% reduction in the Hamilton depression 
scores. Of this group 83.3% had been treated with IPT and mirtazapine, 
and only one participant (16.6%) was treated in the mirtazapine only 
group. 
There was a smaller mean uptake ratio in responders versus non-
responders using the cerebellum as a reference region. Furthermore, 
responding participants demonstrated decreased IBZM striatal binding 
after six weeks of antidepressant treatment. Numerous in vivo studies 
with benzamides have shown that reduced receptor occupancy is an 
acute result of increased dopamine release (Hall et al, 1990; Dewey et 
al, 1993; Laruelle et al, 1995; Smith et al, 1995; Laruelle et al, 2000; 
Ebert et al, 1996). The decreased binding of IBZM in responders may 
reflect increases in post synaptic dopamine release which is competing 
with the IBZM ligand for receptor occupancy (Logan et al, 1991; Rognan 
et al, 1990). 
These results are in good agreement with three previous German studies 
which have reported similar changes in IBZM uptake ratios in responders 
versus nonresponders. In the first IBZM SPECT study of depression 
Ebert and colleagues (1994) found that total sleep deprivation (TSD) 
responders demonstrated significantly reduced IBZM binding compared 
to non responders and controls. The same group (Ebert et al, 1996) 
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conducted a second trial comparing 10 depressed patients after three 
weeks of tricyclic antidepressant medication. After antidepressant 
therapy the relative 02 dopamine receptor occupancy significantly 
decreased in 5 responders and remained unchanged or increased in 5 
non responders. Finally, Klimke and colleagues (1999) compared 15 
hospitalised depressed patients to 17 controls. Nine responders 
demonstrated lower baseline IBZM uptake ratios compared to 6 
nonresponders and 17 controls (p< 0.05). In contrast to the Ebert's study 
(1996), responders to six weeks of SSRI treatment demonstrated 
increased IBZM binding; however, the baseline IBZM uptake ratios were 
low in the responders in the Klimke but not the Ebert group. One of the 
German studies recruited a homogeneous sample of DSM IV major 
• 
depressed patients, who were similar to the group reported in this thesis 
in that they had not responded to a trial of a tricyclic antidepressant. 
Furthermore the level of depression was also in the severe range (HamD 
27.3), another similarity with participants reported in this thesis. 
However, different patterns of change have been reported in response to 
antidepressant therapy. Klimke et al (1999) demonstrated increased 
binding in responders and Ebert and colleagues during both studies 
(1994, 1996) reported decreased binding in responders and increased 
binding or no change in non responders. Chronic administration of 
antidepressants, has been shown to enhance dopamine function, and 
may account for the patterns of change in two studies (Ebert et al, 1994; 
1996) but not a third (Kiimke et al, 1999). There is an emerging 
hypothesis which suggests that the pathogenesis of depression is likely 
to involve the plasticity of neuronal pathways (Vaidya and Duman, 2001). 
Stress and antidepressants have been shown to have reciprocal 
interactions on neuronal growth, vulnerability and synaptic plasticity 
(Reid and Stewart, 2001). Hence the increased binding in responders 
(Kiimke et al, 1999) and decreased binding (Ebert et al, 1994; 1996) 
reported in these studies may reflect the ability of responders to change, 
a concept that neuroplasticity might be characteristic of responders. 
Furthermore, differences in scanning methods and patient groups may 
• 
also have contributed to the discrepant results. 
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Negative findings to a pharmacological challenge have been recently 
published from a group in New York (Parsey et al, 2001) when they 
compared the dopamine 02 receptor availability and amphetamine 
induced dopamine release in nine untreated depressed patients and 10 
controls. No differences were detected between patients and controls in 
the dopamine 02 receptor availability either before or after the 
amphetamine challenge. A number of factors, different to previous 
studies may have led to these negative results. IBZM was administered 
by continuous infusion, which consisted of one single scan, lasting 360 
minutes which was used to measure two clinical states (pre and post 
amphetamine challenge). Additionally, patients were less depressed 
(mean HamO 21±5), and the authors were measuring transient 
improvements in specific symptoms of depression rather than substantial 
and sustained improvements in depressive symptoms as evaluated in 
previous studies. 
The patients studied in Parsey's group were completely drug na·ive 
whereas previous studies involved patients who had a history of 
antidepressant use; this is an important difference as there is a 
substantial body of literature which demonstrates that chronic treatment 
with antidepressants, notably tricyclic antidepressants, increases 
responsiveness of dopamine 02/03 receptors in the mesolimbic system 
(Oemonstis et al, 1990; Asakura et al, 1992). 
One negative study reported no differences in the dopamine 02 activity 
after an amphetamine chatlenge (Parsey et al, 2001 ). A number of 
factors may have led to the discrepant results. A general criticism of 
these studies will be found later, however, one factor which has not been 
discussed in previous studies is the time passed in between scans. This 
has varied greatly from one study to the next. Klimke et al (1999) took 
40.1 (sd 8.8) days, 3 weeks was reported for Ebert et al (1996), 2 days 
for Ebert's sleep deprivation study (1994) and just 5 hours for the 
amphetamine challenge where data was analysed for the first 240 
minutes and compared to the last 120 minutes. IBZM SPECT has a high 
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affinity for dopamine 02/03 receptors thus reflecting the number of 
receptor sites. There is evidence that although antidepressant therapy 
may immediately increase monoamine neurotransmitters such as 
serotonin, subsequent down-regulation of post synaptic receptors takes 
2-3 weeks (Preskorn, 1993). Immediate receptor action does not 
correspond with clinical change but receptor downregulation over a small 
number of weeks does (Bauman and Rochat, 1995; Laifenfeld et al, 
2005) as reuptake inhibition ~s immediate but clinical response takes 2.,3 
weeks. Limited time in between scans may not account for this and will 
not demonstrate changes which may be in process. Furthermore, 
regional cerebral blood flow changes have been demonstrated in 
depression (Bench et al, 1992; Austin et al, 1992; Mayberg et al, 1994; 
Sackheim et al, 1990), which activate with treatment (Martin et al, 2001; 
Mayberg et al, 2004); Larisch et al (1997) have found that IBZM images 
correlate highly with regional cerebral blood flow as measured with 
HMPAO SPECT, hence may have contributed to the lack of response 
given the limited time. 
The studies published to date including data in this thesis have all been 
limited by small sample sizes. Although samples selected may be 
homogenous in relation to diagnosis (Kiimke et al, 1999; Parsey et al, 
2001; Ebert et al, 1996) other studies have included depression with 
melancholic features, bipolar disorder and psychotic depression (Ebert et 
al, 1994; Shah et al, 1997). Dopamine dysfunction demonstrated by 
lower HVA levels (Roy et al, 1985; Asberg et al, 1984), and PET studies 
(Baxter et al, 1985; Buschbaum et al, 1986) and have been reported in 
melancholic depression in all of these clinical areas. Additionally, there 
have been studies which evaluate patients with severe depression (Ebert 
et al, 1994; Ebert et al, 1996; Klimke et al, 1999) and those who have 
studied less severe depression (Parsey et al, 2001; D'haenen and 
Bossuyt, 1994). 
Gender 
Women in this study demonstrated a higher IBZM uptake in the striatum 
compared to men. This supports the findings of Shah et al (1997) who 
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compared 9 male and 6 fem'ale depressed patients to the same number 
and sex distribution of controls. There have not been other IBZM 
depression studies reporting gender differences in binding. There are 
limited studies which have reviewed dopamine activity using IBZM 
SPECT in depression, moreover, of these studies some groups have 
recruited all male (Ebert et al, 1994; 1996), predominantly male (Parsey 
et al, 2001) or predominantly female patients (D'Haenen et al, 1994). 
Although Klimke's group did not report differences they made no 
references to the earlier work of Shah's (1997) group which may mean 
that this was not evaluated by Klimke and colleagues (1999) during this 
study. In a SPECT study Pilpwsky and colleagues (1994) have reported 
increased right striatal IBZM uptake in women versus men in healthy 
volunteers. 
Despite the limited data on gender differences in dopamine function 
measured by IBZM SPECT, there have been reports of differences in 
dopaminergic transmission between sexes using alternative 
measurements of dopamine function. One post mortem study reported 
lower dopamine levels in women in the putamen compared to men 
(Konradi et al, 1992). A number of studies report higher plasma HVA 
levels (Sumiyoshi et al, 1997) in women including schizophrenic patients 
(Koreen et al, 1994), and women who were post-menopausal or who had 
undergone hysterectomies or oophorectomies (Di Paolo et al, 1989). 
Animal studies (Kazandjian et al, 1987; Hafner et al, 1993) support the 
role of hormones and dopamine function and have suggested modulation 
of dopamine function by oestrogen. 
In addition, gender differences have been reported in the 
pharmacokinetics and pharmacodynamic properties of psychotropic 
medications (Frackiewitcz et al, 2000; Yonkers et al, 1992). Women have 
demonstrated higher plasma concentrations of tricyclic antidepressants 
(Hildebrandt et al, 2003) or, may have an enhanced response to non-
tricyclic antidepressants (Yonkers et al, 1992). This may have accounted 
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for the differences in IBZM binding between men and women in this 
study. 
Agitation 
Agitated participants demonstrated a higher mean IBZM uptake in the 
striatum compared to non-agitated participants. Although this is the first 
IBZM SPECT study in depression to identify altered dopamine function in 
depressed patients with agitation, there is evidence in the literature that 
agitation, which can be present in depression as well as other psychiatric 
conditions, may be mediated by dysregulation of dopaminergic, 
serotonergic, noradrenergic and GABAergic systems (Lindenmayer, 
2000). Slightly elevated cerebral spinal fluid HVA levels (Lykouras et al, 
1995) have been demonstrated in agitated patients compared to non 
agitated patients. Furthermore, a study of psychotic patients have found 
I ' 
that CSF HVA levels were elevated in those with delusions and agitation, 
but normal in those with just delusions (Lykouras et al, 1994 ). In addition, 
agents which reduce dopaminergic tone alleviate symptoms of agitation 
(Lindenmayer, 2000; Sachs, 2006). Although limited, there is evidence 
that dopamine abnormalities exist in agitation. The finding of increased 
IBZM uptake in the participants in this study extends these limited data. 
Further studies are warranted to replicate and substantiate the findings 
of this study; and may help with the management of agitation in the 
future. For example, the use of dopaminergic antidepressants in agitated 
depression may provide superior results to an SSRI; these are important 
questions which need to tle addressed with the use of randomised 
controlled trials. 
Levels of TRD 
Having separated participants into levels of treatment resistant 
depression (low, n=6; moderate, n=6; high, n=7) statistically significant 
effects of IBZM binding was only evident in the high TRD group. IBZM 
binding showed non significant decreases in the low TRD participants 
and non significant increases in the moderate TRD participants; both the 
left and the right striatum demonstrated the same pattern of response 
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after six weeks of treatment. This was in sharp contrast to the high TRO 
group where significant differences in the change scores of the right and 
left striatum which was demonstrated by marked asymmetrical binding 
patterns; increased binding in the left striatum and decreased binding in 
the right striatum. 
Although the 7 high TRO pa'rticipants were analysed using the repeated 
measures ANOVA model as described above, three of these participants 
had in fact responded to 6 weeks of antidepressant treatment with IPT 
and mirtazapine (n=2) or mirtazapine alone (n=1 ). This response may be 
predictable as both treatments are potent antidepressant therapies; 
additionally, the attention received during the clinical trial may also 
contribute to positive effects (Benetti et al, 2005). However, one 
alternative possibility is that the retrospective data collection may have 
inadvertently identified some patients as a high level of TRO when in fact 
they may have been less resistant to treatment. Further analysis of this 
small group yielded the sap1e pattern of asymmetrical binding in the 
responders and single non responding participant. The responding 
participants demonstrated statistically significant increases in binding in 
the left striatum after six weeks of treatment. Although there were 
extremely strong effect sizes (partial eta squared 0.98 & 0.84; and good 
power 0.99 & 0.78 respectively) the small sample size used in this 
analysis would restrict these findings which should therefore be viewed 
with caution. 
One possibility which could explain the changes is that the receptors in 
the responding participants may have changed from a low to a high 
affinity state (Ebert et al,' 1994) or alternatively participants have 
increases in the density of dopamine 02 receptors (Kiimke et al, 1999) 
and/or an increased affinity for the ligand (O'Haenen and Bossuyt, 1994; 
Klimke et al, 1999). 
The examination of dopamine 02 function in treatment resistant 
depression with the use of IBZM SPECT has never previously been 
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assessed. There were statistically significant changes in dopamine 
function which were evident only in the high level of TRO group. 
Statistically significant changes in IBZM binding after antidepressant 
therapy apparently occurred in both the left and the right striatum; a 
finding which has been reported in a previous study (Larisch et al, 1997). 
The asymmetrical changes in IBZM uptake demonstrated by decreased 
binding in the right and increased binding in the left striatum in the 7 
high TRO participants was unexpected and has never been reported in 
previous IBZM SPECT depression studies. IBZM binding has previously 
• 
appeared to follow the same direction in the right and left striatum 
(Kiimke et al, 1999; Ebert et al, 1994; Ebert et al, 1996). 
There are known factors which have been shown to alter dopamine 
function which would have impacted on a TRO group. Chronic treatment 
with antidepressant medication increases the sensitivity of the dopamine 
02/03 receptors; the participants in the high level TRO group had also 
suffered from depressive symptoms for longer and would have had a 
greater exposure to antidepressants over time. Studies in animals have 
shown that chronic stress leads to changes in dopamine 02 receptor 
function (Papp et al, 1994;. Oziedzicka et al, 1997). Moreover, the 
hypothesis of transmitter/receptor neuroplasticity in depression should be 
considered. Antidepressant medication does not involve only the critical 
site of action, studies in humans and animals demonstrate that 
interaction between the dopaminergic, serotonergic and noradrenergic 
neurotransmitters occur (Smith et al, 1995; Oewey et al, 1995; 
Baldessarini and Marsh, 1990; Awouters et al, 1990; Ainsworth et al, 
1998; Carbonari et al, 1998). IBZM binding may not be due to primary 
changes in dopamine function but may also reflect the possibility of 
improved participants' ability to respond to pharmacological stimuli such 
as antidepressants. Alternatively, the increasing levels of severity and 
. 
chronicity of the level of TRO may lead to an inability to respond in a 
healthy way. Asymmetrical changes in dopamine d2 uptake as measured 
by IBZM SPECT have been reported in studies of schizophrenia 
(Pilowsky et al, 1994). 
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There are limitations in the ~tudies reported. Different scanning methods 
involving slightly different preparations of the IBZM radiotracers, different 
delivery of the radioligand (single injection versus continuous infusion), 
different region of interest to compare as a reference region and finally 
the use of a single headed, double headed and triple headed gamma 
camera may have contributed to resolution differences in all of the above 
studies. 
Conclusion 
This study is innovative in a number of ways: lt is the first IBZM SPECT 
study to explore dopamine 02 receptor function in a treatment resistant 
depressed population; no previous IBZM SPECT study has compared mote 
than one antidepressant treatment at the same time or examined the potential 
effect of antidepressant psychotherapy on dopamine function. Although one of 
the largest IBZM SPECT depression studies, like other studies the limited size 
restricts findings which should be viewed as preliminary. However, sizable 
effect sizes and power, especially in the high TRD group, were evident. The 
analytical strategy used enabled a better balance of type I and type 11 errors. 
The repeated measures approach across both hemispheres and time allowed a 
greater power (and hence reduced type 11 error) to examine the between group 
differences which comprised of responders, agitation, gender and levels of 
TRD. The approach that followed up only significant interaction minimised the 
number of tests and so provided a degree of control over a type I errqr. 
Although there were no significant differences between the treatment groups at 
baseline, most of the responders (83%) significantly, were from the combined 
IPT and medication group. Significant differences were noted in responders vs. 
nonresponders; agitated vs. non-agitated participants; men and women, and 
participants with a high level of TRD. 
To further investigate the role of dopamine, additional studies consisting of 
homogenous groups are necessary. The evaluation of dopaminergic function 
with different classes of antidepressants should include medication which 
specifically targets the dopaminergic system such as amisulpride or bupropion. 
Alternative assessments of dopamine function such as measures of the 
• dopamine metabolite HVA in the plasma or urine could be taken in isolation or 
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concurrently with a functional brain imaging scan. This may also help us build a 
clearer picture of the evidence for dopamine abnormalities in depression. 
Neuroimaging studies in depression have largely focused on response to 
pharmacotherapy; although there are a small number reviewing non-
pharmacological approaches such as total sleep deprivation and I PT. 
Neuroimaging techniques such as SPECT, PET and functional MRI with 
antidepressant psychotherapy would help us to understand the relationship 
between psychological approaches and physiological response; furthermore, 
this would allow researchers to study drug free participants allowing a greater 
understanding of functioning of the brain in depression without any potential 
confounding variables. 
A number of studies examining brain function across a range of clinical 
presentations of depression is needed which should cover the spectrum of 
response, partial response and non-response to antidepressant treatment. This 
should range from first episode drug free major depression to those patients 
. . 
who are highly resistant to numerous antidepressant treatments. Although this 
particular study assessed brain dopamine function after 6 weeks, longer term 
evaluation in the management of chronic and disabling conditions such as 
treatment resistant depression would be helpful to appreciate comprehensively 
the variation over time of dopamine in depression. Given the current radiation 
ethical restrictions of a maximum of two scans per year, these data has to be 
obtained through a separate study. This reinforces the need for standardised 
imaging techniques including the use of camera, radiopharmaceuticals and 
analysis. 
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